{
  "symbol": "BSGM",
  "company_name": "Biosig Technologies",
  "ir_website": "https://ir.biosig.com/",
  "structured_data": [
    {
      "section_name": "Latest News",
      "links": [
        {
          "title": "BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement",
          "url": "http://ir.biosig.com/news/detail/367/biosig-regains-compliance-with-nasdaqs-minimum-bid-price-requirement",
          "content": "**Your web browser (Chrome 91) has a serious security vulnerability!** Update your browser for more security, speed and the best experience on this site. [Update browser](https://browser-update.org/update-browser.html#3.3.55:ir.biosig.com) Ignore\n\n[ ![BioSig Technologies, Inc.](https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/files/theme/images/logo_3x.svg) ](/)\n\nInvestors\n\n# Press Releases\n\n## BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement\n\n[ Download as PDF](https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/news/2024-11-13_BioSig_Regains_Compliance_with_Nasdaq_s_Minimum_367.pdf \"PDF: BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement\")\n\nNovember 13, 2024\n\nLos Angeles, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “Company\"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced that it has received notice from the Nasdaq Listing Qualifications staff (\"Nasdaq\") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the \"Rule\").\n\nTo regain compliance with the Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days; on November 13, 2024, Nasdaq informed the Company it achieved compliance with this Rule. Therefore, Nasdaq considers the prior bid price deficiency matter now closed.\n\nBioSig’s CEO, Anthony Amato stated, “We are thrilled with the outpour of support and enthusiasm for our Company’s relisting to the Nasdaq and for its continued success. We greatly appreciate the opportunities we have been given and we will continually make great efforts toward increasing shareholder value.”\n\nAbout BioSig Technologies, Inc. (BSGM)\n\nBioSig Technologies is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. By leveraging a first of its kind software, we deliver unprecedented cardiac signal clarity, ending the reliance on ‘mixed signals’ and ‘reading between the lines.’ Our platform technology is addressing some of healthcare’s biggest challenges—saving time, saving costs, and saving lives.\n\nThe Company’s FDA 510(k) cleared PURE EP™ Platform, provides superior, real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words \"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\" \"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with BioSig’s ability to conduct its business and raise capital in the future when needed; BioSig’s inability to manufacture its products and product candidates on a commercial scale on its own, or in collaboration with third parties; difficulties in obtaining financing on commercially reasonable terms; changes in the size and nature of BioSig’s competition; loss of one or more key executives or scientists; and difficulties in securing regulatory approval to market BioSig’s products and product candidates. For a discussion of other risks and uncertainties, and other important factors, any of which could cause BioSig’s actual results to differ from those contained in forward-looking statements, see BioSig’s filings with the Securities and Exchange Commission (“SEC”), including the section titled “Risk Factors” in BioSig’s Annual Report on Form 10-K, filed with the SEC on April 16, 2024. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise, except as required by law.\n\n```\nTodd Adler BioSig Technologies, Inc. Investor Relations 12424 Wilshire Blvd Ste 745 Los Angeles, CA 90025 tadler@biosigtech.com 203-409-5444 ext. 104 Anthony Amato Chief Executive Officer aamato@biosigtech.com 203-409-5444 ext. 102 \n```\n\n[![Primary Logo](https://ml.globenewswire.com/media/1dac0368-d181-4bc1-af5d-f95010be6bdc/small/biosig-rgb-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/1dac0368-d181-4bc1-af5d-f95010be6bdc)\n\nSource: BioSig Technologies, Inc. \n\nReleased November 13, 2024\n\n![Award](https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/files/theme/images/award-logo.png)\n\n[![BioSig Technologies, Inc.](https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/files/theme/images/logo_3x.svg)](/)\n\n[Sign Up for BioSig Updates](https://ir.biosig.com/email-alerts) [Contact Us](/contact-biosig)\n\n[ ![x formerly known as twitter icon](https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/files/theme/images/x-logo-gray.webp) X formerly known as Twitter ](https://twitter.com/BioSig_Tech)\n\n[ linkedin](https://www.linkedin.com/company/8247196) [ Facebook](https://www.facebook.com/BioSig-Technologies-1431615447130625/)\n"
        }
      ]
    },
    {
      "section_name": "Upcoming Events",
      "links": [
        {
          "title": "2024 Annual Meeting of Stockholders",
          "url": "https://ir.biosig.com/ir-calendar/detail/3251/2024-annual-meeting-of-stockholders",
          "content": "[ ![BioSig Technologies, Inc.](https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/files/theme/images/logo_3x.svg) ](/)\n\nInvestors\n\n# IR Calendar\n\n## 2024 Annual Meeting of Stockholders\n\nDec 31, 2024 • 10:00am EST\n\n[ Webcast](https://www.virtualshareholdermeeting.com/BSGM2024)\n\n![Award](https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/files/theme/images/award-logo.png)\n\n[![BioSig Technologies, Inc.](https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/files/theme/images/logo_3x.svg)](/)\n\n[Sign Up for BioSig Updates](https://ir.biosig.com/email-alerts) [Contact Us](/contact-biosig)\n\n[ ![x formerly known as twitter icon](https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/files/theme/images/x-logo-gray.webp) X formerly known as Twitter ](https://twitter.com/BioSig_Tech)\n\n[ linkedin](https://www.linkedin.com/company/8247196) [ Facebook](https://www.facebook.com/BioSig-Technologies-1431615447130625/)\n"
        }
      ]
    },
    {
      "section_name": "Latest Financial Results",
      "links": [
        {
          "title": "10-Q",
          "url": "https://ir.biosig.com/all-sec-filings/content/0001493152-24-045687/form10-q.htm",
          "content": "false Q3 --12-31 0001530766 P5Y6M P5Y6M 0001530766 2024-01-01 2024-09-30 0001530766 2024-11-14 0001530766 2024-09-30 0001530766 2023-12-31 0001530766 us-gaap:RelatedPartyMember 2024-09-30 0001530766 us-gaap:RelatedPartyMember 2023-12-31 0001530766 BSGM:SeriesCNinePercentageConvertiblePreferredStockMember 2024-09-30 0001530766 BSGM:SeriesCNinePercentageConvertiblePreferredStockMember 2023-12-31 0001530766 us-gaap:SeriesAPreferredStockMember 2024-09-30 0001530766 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001530766 us-gaap:SeriesBPreferredStockMember 2024-09-30 0001530766 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2024-09-30 0001530766 us-gaap:SeriesCPreferredStockMember 2023-12-31 0001530766 us-gaap:SeriesDPreferredStockMember 2024-09-30 0001530766 us-gaap:SeriesDPreferredStockMember 2023-12-31 0001530766 us-gaap:SeriesEPreferredStockMember 2024-09-30 0001530766 us-gaap:SeriesEPreferredStockMember 2023-12-31 0001530766 us-gaap:SeriesFPreferredStockMember 2024-09-30 0001530766 us-gaap:SeriesFPreferredStockMember 2023-12-31 0001530766 2024-07-01 2024-09-30 0001530766 2023-07-01 2023-09-30 0001530766 2023-01-01 2023-09-30 0001530766 us-gaap:ServiceMember 2024-07-01 2024-09-30 0001530766 us-gaap:ServiceMember 2023-07-01 2023-09-30 0001530766 us-gaap:ServiceMember 2024-01-01 2024-09-30 0001530766 us-gaap:ServiceMember 2023-01-01 2023-09-30 0001530766 us-gaap:CommonStockMember 2023-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001530766 us-gaap:RetainedEarningsMember 2023-12-31 0001530766 us-gaap:NoncontrollingInterestMember 2023-12-31 0001530766 us-gaap:CommonStockMember 2024-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001530766 us-gaap:RetainedEarningsMember 2024-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2024-03-31 0001530766 2024-03-31 0001530766 us-gaap:CommonStockMember 2024-06-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001530766 us-gaap:RetainedEarningsMember 2024-06-30 0001530766 us-gaap:NoncontrollingInterestMember 2024-06-30 0001530766 2024-06-30 0001530766 us-gaap:CommonStockMember 2022-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001530766 us-gaap:RetainedEarningsMember 2022-12-31 0001530766 us-gaap:NoncontrollingInterestMember 2022-12-31 0001530766 2022-12-31 0001530766 us-gaap:CommonStockMember 2023-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001530766 us-gaap:RetainedEarningsMember 2023-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2023-03-31 0001530766 2023-03-31 0001530766 us-gaap:CommonStockMember 2023-06-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001530766 us-gaap:RetainedEarningsMember 2023-06-30 0001530766 us-gaap:NoncontrollingInterestMember 2023-06-30 0001530766 2023-06-30 0001530766 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001530766 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001530766 2024-01-01 2024-03-31 0001530766 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001530766 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001530766 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001530766 2024-04-01 2024-06-30 0001530766 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001530766 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001530766 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001530766 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001530766 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001530766 2023-01-01 2023-03-31 0001530766 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001530766 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001530766 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001530766 2023-04-01 2023-06-30 0001530766 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001530766 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001530766 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001530766 us-gaap:CommonStockMember 2024-09-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001530766 us-gaap:RetainedEarningsMember 2024-09-30 0001530766 us-gaap:NoncontrollingInterestMember 2024-09-30 0001530766 us-gaap:CommonStockMember 2023-09-30 0001530766 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001530766 us-gaap:RetainedEarningsMember 2023-09-30 0001530766 us-gaap:NoncontrollingInterestMember 2023-09-30 0001530766 2023-09-30 0001530766 BSGM:AttheMarketOfferingMember 2023-07-01 2023-09-30 0001530766 BSGM:ViralClearMember 2019-01-01 2019-12-31 0001530766 BSGM:ViralClearMember 2020-01-01 2020-12-31 0001530766 BSGM:ViralClearMember 2024-09-30 0001530766 BSGM:ViralClearMember 2023-12-31 0001530766 BSGM:BioSigAIMember 2024-06-30 0001530766 BSGM:BioSigAIMember 2023-12-31 0001530766 BSGM:WorkforceReductionMember 2024-01-28 2024-01-28 0001530766 BSGM:WorkforceReductionMember 2024-02-20 2024-02-20 0001530766 srt:MinimumMember 2024-03-05 0001530766 srt:MinimumMember 2024-03-05 2024-03-05 0001530766 2024-03-12 0001530766 us-gaap:SubsequentEventMember 2024-10-18 0001530766 srt:MinimumMember us-gaap:SubsequentEventMember 2024-10-23 0001530766 2024-01-31 2024-01-31 0001530766 2022-01-01 2022-12-31 0001530766 BSGM:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001530766 BSGM:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001530766 BSGM:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001530766 BSGM:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001530766 BSGM:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001530766 BSGM:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001530766 BSGM:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001530766 BSGM:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001530766 srt:MinimumMember 2024-09-30 0001530766 srt:MaximumMember 2024-09-30 0001530766 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001530766 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001530766 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001530766 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001530766 us-gaap:PatentsMember 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2023-12-31 0001530766 BSGM:BioSigAISciencesIncMember 2024-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2023-12-31 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2023-12-31 0001530766 BSGM:BioSigAISciencesIncMember 2024-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2023-12-31 0001530766 us-gaap:ServiceMember 2023-12-31 0001530766 us-gaap:ServiceMember 2024-09-30 0001530766 us-gaap:ServiceMember 2022-12-31 0001530766 us-gaap:ServiceMember 2023-09-30 0001530766 us-gaap:SeriesCPreferredStockMember 2024-01-01 2024-09-30 0001530766 us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-09-30 0001530766 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001530766 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001530766 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001530766 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001530766 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001530766 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001530766 us-gaap:ComputerEquipmentMember 2024-09-30 0001530766 us-gaap:ComputerEquipmentMember 2023-12-31 0001530766 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001530766 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001530766 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001530766 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001530766 BSGM:TestingAndDemoEquipmentMember 2024-09-30 0001530766 BSGM:TestingAndDemoEquipmentMember 2023-12-31 0001530766 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001530766 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001530766 2023-01-01 2023-12-31 0001530766 BSGM:LeaseOneMember 2023-01-01 2023-12-31 0001530766 BSGM:LeaseTwoMember 2023-01-01 2023-12-31 0001530766 BSGM:ContractAssetsCurrentMember 2023-12-31 0001530766 BSGM:ContractAssetsCurrentMember 2024-01-01 2024-09-30 0001530766 BSGM:ContractAssetsCurrentMember 2024-09-30 0001530766 BSGM:ContractAssetsNoncurrentMember 2023-12-31 0001530766 BSGM:ContractAssetsNoncurrentMember 2024-01-01 2024-09-30 0001530766 BSGM:ContractAssetsNoncurrentMember 2024-09-30 0001530766 BSGM:ContractAssetsCurrentMember 2022-12-31 0001530766 BSGM:ContractAssetsCurrentMember 2023-01-01 2023-09-30 0001530766 BSGM:ContractAssetsCurrentMember 2023-09-30 0001530766 BSGM:ContractAssetsNoncurrentMember 2022-12-31 0001530766 BSGM:ContractAssetsNoncurrentMember 2023-01-01 2023-09-30 0001530766 BSGM:ContractAssetsNoncurrentMember 2023-09-30 0001530766 BSGM:PromissoryNoteMember 2024-03-07 0001530766 BSGM:PromissoryNoteMember 2024-03-07 2024-03-07 0001530766 us-gaap:SeriesCPreferredStockMember srt:MaximumMember 2024-09-30 0001530766 us-gaap:SeriesCPreferredStockMember srt:MinimumMember 2024-09-30 0001530766 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001530766 us-gaap:InvestorMember 2024-01-12 2024-01-12 0001530766 us-gaap:InvestorMember 2024-01-12 0001530766 us-gaap:InvestorMember 2024-05-01 2024-05-01 0001530766 us-gaap:InvestorMember 2024-05-01 0001530766 us-gaap:InvestorMember 2024-05-29 2024-05-29 0001530766 us-gaap:InvestorMember 2024-05-29 0001530766 2024-05-29 0001530766 2024-05-29 2024-05-29 0001530766 us-gaap:EmployeeStockOptionMember BSGM:TwoThousandTwentyThreeLongTermIncentivePlanMember 2022-12-27 0001530766 2022-12-27 2022-12-27 0001530766 us-gaap:EmployeeStockOptionMember BSGM:TwoThousandTwentyThreeLongTermIncentivePlanMember 2024-09-30 0001530766 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001530766 us-gaap:InvestorMember us-gaap:WarrantMember 2024-09-30 0001530766 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001530766 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001530766 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001530766 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001530766 us-gaap:WarrantMember 2024-09-30 0001530766 BSGM:KeyConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2024-03-01 2024-03-01 0001530766 BSGM:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-04-01 0001530766 BSGM:EmployeesMember 2024-05-01 2024-05-01 0001530766 BSGM:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2024-05-01 2024-05-01 0001530766 us-gaap:RestrictedStockMember BSGM:ConsultantsMember 2024-05-30 2024-05-30 0001530766 us-gaap:RestrictedStockMember BSGM:ConsultantsMember 2024-07-03 2024-07-03 0001530766 us-gaap:RestrictedStockMember BSGM:ConsultantsMember us-gaap:SubsequentEventMember 2024-10-04 2024-10-04 0001530766 BSGM:ConsultantsMember 2024-06-01 2024-06-01 0001530766 BSGM:EmployeesAndBoardMembersMember 2024-06-07 2024-06-07 0001530766 BSGM:EmployeesAndBoardMembersMember 2024-07-26 2024-07-26 0001530766 us-gaap:RestrictedStockUnitsRSUMember BSGM:SteveChaussyMember 2024-07-26 2024-07-26 0001530766 2024-07-26 2024-07-26 0001530766 us-gaap:RestrictedStockUnitsRSUMember BSGM:SteveChaussyMember 2024-07-26 0001530766 2024-09-11 2024-09-11 0001530766 2024-09-11 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001530766 us-gaap:EmployeeStockOptionMember BSGM:TwoThousandNineteenLongTermIncentivePlanMember 2019-09-24 2019-09-24 0001530766 2019-09-24 2019-09-24 0001530766 BSGM:TwoThousandNineteenLongTermIncentivePlanMember us-gaap:EmployeeStockOptionMember 2019-09-24 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-01-01 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-07-01 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2023-07-01 2023-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2023-01-01 2023-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember BSGM:ViralClearPharmaceuticalsIncMember 2024-07-01 2024-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember BSGM:ViralClearPharmaceuticalsIncMember 2024-01-01 2024-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember BSGM:ViralClearPharmaceuticalsIncMember 2023-07-01 2023-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember BSGM:ViralClearPharmaceuticalsIncMember 2023-01-01 2023-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember BSGM:ViralClearPharmaceuticalsIncMember 2024-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2024-01-01 2024-09-30 0001530766 BSGM:OptionsUnder999Member 2024-01-01 2024-09-30 0001530766 BSGM:OptionsUnder999Member 2024-09-30 0001530766 BSGM:Options1000To1999Member 2024-01-01 2024-09-30 0001530766 BSGM:Options1000To1999Member 2024-09-30 0001530766 BSGM:Options2000To2999Member 2024-01-01 2024-09-30 0001530766 BSGM:Options2000To2999Member 2024-09-30 0001530766 BSGM:Options3000To3999Member 2024-01-01 2024-09-30 0001530766 BSGM:Options3000To3999Member 2024-09-30 0001530766 BSGM:Options4000To4999Member 2024-01-01 2024-09-30 0001530766 BSGM:Options4000To4999Member 2024-09-30 0001530766 BSGM:Options5000To5999Member 2024-01-01 2024-09-30 0001530766 BSGM:Options5000To5999Member 2024-09-30 0001530766 BSGM:Options6000To6999Member 2024-01-01 2024-09-30 0001530766 BSGM:Options6000To6999Member 2024-09-30 0001530766 BSGM:Options7000To7999Member 2024-01-01 2024-09-30 0001530766 BSGM:Options7000To7999Member 2024-09-30 0001530766 BSGM:WarrantsAt1398Member 2024-06-30 0001530766 BSGM:WarrantsAt1398Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt1780Member 2024-06-30 0001530766 BSGM:WarrantsAt1780Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt23875Member 2024-06-30 0001530766 BSGM:WarrantsAt23875Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt3364Member 2024-06-30 0001530766 BSGM:WarrantsAt3364Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt3573Member 2024-06-30 0001530766 BSGM:WarrantsAt3573Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt4066Member 2024-06-30 0001530766 BSGM:WarrantsAt4066Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt4455Member 2024-06-30 0001530766 BSGM:WarrantsAt4455Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt4466Member 2024-06-30 0001530766 BSGM:WarrantsAt4466Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt46626Member 2024-06-30 0001530766 BSGM:WarrantsAt46626Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt49252Member 2024-06-30 0001530766 BSGM:WarrantsAt49252Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt4929Member 2024-06-30 0001530766 BSGM:WarrantsAt4929Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt51358Member 2024-06-30 0001530766 BSGM:WarrantsAt51358Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt7181Member 2024-06-30 0001530766 BSGM:WarrantsAt7181Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt7502Member 2024-06-30 0001530766 BSGM:WarrantsAt7502Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt7963Member 2024-06-30 0001530766 BSGM:WarrantsAt7963Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt9000Member 2024-06-30 0001530766 BSGM:WarrantsAt9000Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt9596Member 2024-06-30 0001530766 BSGM:WarrantsAt9596Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt100992Member 2024-06-30 0001530766 BSGM:WarrantsAt100992Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt1026Member 2024-06-30 0001530766 BSGM:WarrantsAt1026Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt104678Member 2024-06-30 0001530766 BSGM:WarrantsAt104678Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt1130Member 2024-06-30 0001530766 BSGM:WarrantsAt1130Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt1328Member 2024-06-30 0001530766 BSGM:WarrantsAt1328Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt1400Member 2024-06-30 0001530766 BSGM:WarrantsAt1400Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt4800Member 2024-06-30 0001530766 BSGM:WarrantsAt4800Member 2024-01-01 2024-06-30 0001530766 BSGM:WarrantsAt6160Member 2024-06-30 0001530766 BSGM:WarrantsAt6160Member 2024-01-01 2024-06-30 0001530766 BSGM:RangeOneMember BSGM:ViralClearPharmaceuticalsIncMember 2024-09-30 0001530766 BSGM:RangeOneMember BSGM:ViralClearPharmaceuticalsIncMember 2024-01-01 2024-09-30 0001530766 BSGM:RangeTwoMember BSGM:ViralClearPharmaceuticalsIncMember 2024-09-30 0001530766 BSGM:RangeTwoMember BSGM:ViralClearPharmaceuticalsIncMember 2024-01-01 2024-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2024-09-30 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember BSGM:ViralClearPharmaceuticalsIncMember 2023-12-31 0001530766 BSGM:BioSigAISciencesIncMember 2023-06-01 2023-06-30 0001530766 BSGM:BioSigAISciencesIncMember 2023-07-01 2023-07-31 0001530766 BSGM:BioSigAIMember 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-07-01 2024-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2024-07-01 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2023-07-01 2023-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2023-07-01 2023-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-01-01 2024-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2024-01-01 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2023-01-01 2023-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2023-01-01 2023-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2023-12-31 0001530766 BSGM:BioSigAISciencesIncMember 2023-12-31 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2024-09-30 0001530766 BSGM:TwentyTwentySeventeenKnowHowLicenseAgreementMember srt:MinimumMember 2017-03-15 2017-03-15 0001530766 BSGM:TwentyTwentySeventeenKnowHowLicenseAgreementMember srt:MaximumMember 2017-03-15 2017-03-15 0001530766 BSGM:TwentyTwentySeventeenKnowHowLicenseAgreementMember 2024-06-30 0001530766 BSGM:TwentyTwentySeventeenKnowHowLicenseAgreementMember 2023-12-31 0001530766 BSGM:EPSoftwareAgreementMember 2019-11-20 0001530766 BSGM:EPSoftwareAgreementMember 2024-09-30 0001530766 BSGM:EPSoftwareAgreementMember 2023-12-31 0001530766 BSGM:ToolsAgreementMember 2021-01-01 2021-12-31 0001530766 BSGM:ToolsAgreementMember 2019-11-20 0001530766 BSGM:ToolsAgreementMember 2024-09-30 0001530766 BSGM:ToolsAgreementMember 2023-12-31 0001530766 BSGM:ViralClearPatentAgreementMember 2019-11-20 0001530766 BSGM:ViralClearPatentAgreementMember 2021-01-01 2021-12-31 0001530766 BSGM:ViralClearPatentAgreementMember 2024-09-30 0001530766 BSGM:ViralClearPatentAgreementMember 2023-12-31 0001530766 BSGM:TrekTherapeuticsMember 2024-01-01 2024-09-30 0001530766 BSGM:TrekTherapeuticsMember BSGM:FirstCountryMember 2024-01-01 2024-09-30 0001530766 BSGM:TrekTherapeuticsMember BSGM:SecondCountryMember 2024-01-01 2024-09-30 0001530766 BSGM:TrekTherapeuticsMember 2024-09-30 0001530766 BSGM:TrekTherapeuticsMember 2023-12-31 0001530766 BSGM:ConsultingAgreementMember 2023-06-17 2023-06-17 0001530766 BSGM:ConsultingAgreementMember 2024-09-30 0001530766 BSGM:ConsultingAgreementMember 2023-12-31 0001530766 BSGM:NeuroKinesisCorporationMember srt:MinimumMember 2024-07-01 0001530766 BSGM:NeuroKinesisCorporationMember srt:MaximumMember 2024-07-01 0001530766 2024-01-01 2024-06-30 0001530766 2023-12-04 2023-12-04 0001530766 2024-02-22 2024-02-22 0001530766 2024-03-22 2024-03-22 0001530766 us-gaap:CorporateMember 2024-07-01 2024-09-30 0001530766 us-gaap:CorporateMember 2023-07-01 2023-09-30 0001530766 us-gaap:CorporateMember 2024-01-01 2024-09-30 0001530766 us-gaap:CorporateMember 2023-01-01 2023-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-07-01 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2023-07-01 2023-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-01-01 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2023-01-01 2023-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2024-07-01 2024-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2023-07-01 2023-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2024-01-01 2024-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2023-01-01 2023-09-30 0001530766 us-gaap:CorporateMember 2024-09-30 0001530766 us-gaap:CorporateMember 2023-12-31 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2024-09-30 0001530766 BSGM:ViralClearPharmaceuticalsIncMember 2023-12-31 0001530766 BSGM:BioSigAISciencesIncMember 2024-09-30 0001530766 BSGM:BioSigAISciencesIncMember 2023-12-31 0001530766 2024-06-05 2024-06-05 0001530766 BSGM:FrederickDHrkacMember 2024-03-01 2024-03-01 0001530766 srt:ChiefExecutiveOfficerMember BSGM:AnthonyAmatoMember 2024-03-01 2024-03-01 0001530766 srt:ChiefExecutiveOfficerMember BSGM:AnthonyAmatoMember 2024-06-07 2024-06-07 0001530766 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember 2024-10-01 2024-10-01 0001530766 us-gaap:SubsequentEventMember 2024-10-17 0001530766 us-gaap:SubsequentEventMember 2024-10-17 2024-10-17 0001530766 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-10-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares BSGM:Integer xbrli:pure\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM 10-Q**\n\n**(Mark One)**\n\n☒ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  \n---|---  \n  \n**For the quarterly period ended September 30, 2024**\n\n☐ | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  \n---|---  \n  \n**For the transition period from to**\n\n**Commission file number: 001-38659**\n\n**BIOSIG TECHNOLOGIES, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n**Delaware** | **26-4333375**  \n---|---  \n(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.)  \n**12424 Wilshire Blvd Suite 745** **Los Angeles , CA** | **90025**  \n(Address of principal executive office) | (Zip Code)  \n  \n**(203) 409-5444**\n\n(Registrant’s telephone number, including area code)\n\n**Securities registered pursuant to Section 12(b) of the Act:**\n\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered  \n---|---|---  \nN/A | N/A | N/A  \n  \nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated filer | ☐ | Accelerated filer | ☐  \n---|---|---|---  \nNon-accelerated filer | ☒ | Smaller reporting company | ☒  \nEmerging growth company | ☐  \n  \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\nAs of November 14, 2024, there were 17,234,929 shares of the registrant’s common stock, $0.001 par value per share, outstanding.\n\n**TABLE OF CONTENTS**\n\n**[PART I. FINANCIAL INFORMATION](#a_001)**  \n---  \nITEM 1. | [Financial Statements](#a_002)  \n[Condensed consolidated balance sheets as of September 30, 2024 (unaudited) and December 31, 2023](#a_003) | 3  \n[Condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023 (unaudited)](#a_004) | 4  \n[Condensed consolidated statement of changes in equity for the three and nine months ended September 30, 2024 (unaudited)](#a_005) | 5  \n[Condensed consolidated statement of changes in equity for the three and nine months ended September 30, 2023 (unaudited)](#a_006) | 6  \n[Condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 (unaudited)](#a_007) | 7  \n[Notes to condensed consolidated financial statements (unaudited)](#a_009) | 8-29  \nITEM 2. | [Management’s Discussion and Analysis of Financial Condition and Results of Operations](#b_001) | 30-37  \nITEM 3. | [Quantitative and Qualitative Disclosures about Market Risk](#b_002) | 38  \nITEM 4. | [Controls and Procedures](#b_003) | 38  \n**[PART II. OTHER INFORMATION](#b_004)**  \nITEM 1. | [Legal Proceedings](#b_005) | 40  \nITEM 1A. | [Risk Factors](#b_006) | 41  \nITEM 2. | [Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities](#b_007) | 42  \nITEM 3. | [Defaults Upon Senior Securities](#b_008) | 42  \nITEM 4. | [Mine Safety Disclosures](#b_009) | 42  \nITEM 5. | [Other Information](#b_010) | 42  \nITEM 6. | [Exhibits](#b_011) | 43  \n[SIGNATURES](#b_012) | 44  \n  \n2  \n---  \n  \n**PART I** – **FINANCIAL INFORMATION**\n\n**ITEM 1. FINANCIAL STATEMENTS**\n\n**BIOSIG TECHNOLOGIES, INC.**\n\n**CONDENSED CONSOLIDATED BALANCE SHEETS**\n\n**(In Thousands, Except Par Value and Share Amounts)**\n\n**September 30,** | **December 31,**  \n---|---  \n**2024** | **2023**  \n**(unaudited)**  \nASSETS  \nCurrent assets:  \nCash | $| 615 | $| 190  \nAccounts receivable | 81 | 24  \nEmployee advance | - | 5  \nNet investment in leases, short term | 39 | 103  \nPrepaid expenses and vendor deposits | 113 | 206  \nTotal current assets | 848 | 528  \nProperty and equipment, net | 111 | 509  \nRight-to-use assets, net | 137 | 412  \nOther assets:  \nNet investment in leases, long term | 4 | 17  \nPatents, net | 274 | 288  \nOther assets | 44 | 44  \nTotal assets | $| 1,418 | $| 1,798  \nLIABILITIES AND EQUITY (DEFICIT)  \nCurrent liabilities:  \nAccounts payable and accrued expenses, including $0 and $30 to related parties as of September 30, 2024 and December 31, 2023, respectively | $| 1,448 | $| 4,116  \nCustomer deposits | - | 16  \nDividends payable | 108 | 101  \nLease liability, short term | 145 | 349  \nTotal current liabilities | 1,701 | 4,582  \nLong term liabilities:  \nLease liability, long term | - | 103  \nTotal long-term liabilities | - | 103  \nTotal liabilities | 1,701 | 4,685  \nCommitments and contingencies (Note 12) | - | -  \nSeries C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of September 30, 2024 and December 31, 2023 | 105 | 105  \nDeficit  \nPreferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. 105 shares of Series C outstanding as of September 30, 2024 and December 31, 2023 (see above) | - | -  \nCommon stock, $0.001 par value, authorized 200,000,000 shares, 16,617,096 and 9,040,043 issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 17 | 9  \nAdditional paid-in-capital | 253,824 | 241,988  \nAccumulated deficit | (254,246| ) | (245,015| )  \nTotal stockholders’ deficit attributable to BioSig Technologies, Inc. | (405| ) | (3,018| )  \nNon-controlling interest | 17 | 26  \nTotal deficit | (388| ) | (2,992| )  \nTotal liabilities and equity | $| 1,418 | $| 1,798  \n  \nThe accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements\n\n3  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**\n\n**(In Thousands, Except Par Value and Share Amounts)**\n\n**_(unaudited)_**\n\n2024 | 2023 | 2024 | 2023  \n---|---|---|---  \nThree months ended September 30, | Nine months ended September 30,  \n2024 | 2023 | 2024 | 2023  \nRevenue:  \nService | $| - | $| 1 | $| 27 | $| 6  \nTotal revenue | - | 1 | 27 | 6  \nOperating expenses:  \nResearch and development | 156 | 1,145 | 736 | 3,916  \nGeneral and administrative | 2,763 | 2,815 | 10,559 | 18,167  \nImpairment of long term assets | - | - | 253 | -  \nDepreciation and amortization | 31 | 92 | 158 | 268  \nTotal operating expenses | 2,950 | 4,052 | 11,706 | 22,351  \nLoss from operations | (2,950| ) | (4,051| ) | (11,679| ) | (22,345| )  \nOther income (expense)  \nInterest income, net | - | 1 | (8| ) | 8  \nGain on settlement and forgiveness of accounts payable | 1,021 | - | 2,409 | -  \nOther income (expense), net: | 15 | - | 38 | (225| )  \nLoss before income taxes | (1,914| ) | (4,050| ) | (9,240| ) | (22,562| )  \nIncome taxes (benefit) | - | - | - | -  \nNet loss | (1,914| ) | (4,050| ) | (9,240| ) | (22,562| )  \nNon-controlling interest | - | (517| ) | 9 | (430| )  \nNet loss attributable to BioSig Technologies, Inc. | (1,914| ) | (4,567| ) | (9,231| ) | (22,992| )  \nPreferred stock dividend | (2| ) | (2| ) | (7| ) | (7| )  \nPreferred stock deemed dividend | (24| ) | - | (157| ) | -  \nNET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | (1,940| ) | $| (4,569| ) | $| (9,395| ) | $| (22,999| )  \nNet loss per common share, basic and diluted | $| (0.12| ) | $| (0.61| ) | $| (0.72| ) | $| (3.33| )  \nWeighted average number of common shares outstanding, basic and diluted | 16,200,928 | 7,537,237 | 13,002,868 | 6,907,790  \n  \nThe accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements\n\n4  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**\n\n**THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024**\n\n**(In Thousands, Except Par Value and Share Amounts)**\n\nShares | Amount | Capital | Deficit | Interest | Total  \n---|---|---|---|---|---  \n**Additional** | **Non-**  \n**Common stock** | **Paid in** | **Accumulated** | **controlling**  \n**Shares** | **Amount** | **Capital** | **Deficit** | **Interest** | **Total**  \nBalance, December 31, 2023 | 9,040,043 | $|  9 | $| 241,988 | $| (245,015| ) | $|  26 | $| (2,992| )  \nCommon stock issued for services | 1,862,744 | 2 | 1,249 | - | - | 1,251  \nSale of common stock and warrants | 260,720 | -* | 1,040 | - | - | 1,040  \nStock based compensation | 1,500 | -* | (190| ) | - | - | (190| )  \nAccretion of deemed preferred stock dividend | - | - | 133 | - | - | 133  \nDeemed preferred stock dividend | - | - | (133| ) | - | - | (133| )  \nPreferred stock dividend | - | - | (2| ) | - | - | (2| )  \nNet loss | - | - | - | (3,402| ) | (13| ) | (3,415| )  \nBalance, March 31, 2024 _(unaudited)_ | 11,165,007 | $| 11 | $| 244,085 | $| (248,417| ) | $| 13 | $| (4,308| )  \nCommon stock issued for services | 278,000 | -* | 420 | - | - | 420  \nSale of common stock and warrants, net transactional costs | 434,782 | 1 | 635 | - | - | 636  \nCommon stock issued in exchange for principal and accrued interest on a note payable | 348,624 | -* | 509 | - | - | 509  \nSale of common stock and warrants, net transactional costs | 1,570,683 | 2 | 2,532 | - | - | 2,534  \nStock issued as forgiveness of accounts payable | 75,000 | -* | 122 | - | - | 122  \nStock based compensation | 1,238,750 | 1 | 4,011 | - | - | 4,012  \nPreferred stock dividend | - | - | (3| ) | - | - | (3| )  \nNet loss | - | - | - | (3,915| ) | 4 | (3,911| )  \nBalance, June 30, 2024 _(unaudited)_ | 15,110,846 | $| 15 | $| 252,311 | $| (252,332| ) | $| 17 | $| 11  \nStock based compensation | 1,506,250 | 2 | 1,515 | - | - | 1,517  \nAccretion of deemed preferred stock dividend | - | - | 24 | - | - | 24  \nDeemed preferred stock dividend | - | - | (24| ) | - | - | (24| )  \nPreferred stock dividend | - | - | (2| ) | - | - | (2| )  \nNet loss | - | - | - | (1,914| ) | - | (1,914| )  \nBalance, September 30, 2024 _(unaudited)_ | 16,617,096 | $| 17 | $| 253,824 | $| (254,246| ) | $| 17 | $| (388| )  \n* | - less than $1  \n---|---  \n  \nThe accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements\n\n5  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**\n\n**THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023**\n\n**(In Thousands, Except Par Value and Share Amounts)**\n\n**Additional** | **Non-**  \n---|---  \n**Common stock** | **Paid in** | **Accumulated** | **controlling**  \n**Shares** | **Amount** | **Capital** | **Deficit** | **Interest** | **Total**  \nBalance, December 31, 2022 | 5,505,068 | $|  5 | $| 216,282 | $| (215,974| ) | $|  (21| ) | $| 292  \nCommon stock issued for services | 116,750 | -* | 1,097 | - | - | 1,097  \nCommon stock issued in settlement of accounts payable | 8,800 | -* | 105 | - | - | 105  \nSale of common stock and warrants, net transactional costs of $482 | 850,030 | 1 | 6,747 | - | - | 6,748  \nStock based compensation | 249,125 | -* | 1,047 | - | 5 | 1,052  \nPreferred stock dividend | - | - | (2| ) | - | - | (2| )  \nNet loss | - | - | - | (7,332| ) | (50| ) | (7,382| )  \nBalance, March 31, 2023 (unaudited) | 6,729,773 | $| 6 | $| 225,276 | $| (223,306| ) | $| (66| ) | $| 1,910  \nCommon stock issued for services | 385,434 | -* | 4,811 | - | - | 4,811  \nSale of common stock and warrants, net transactional costs of $201 | 259,090 | 1 | 3,245 | - | - | 3,245  \nSale of subsidiary stock | - | - | 1,379 | - | 188 | 1,567  \nCommon stock issued for exercise of warrants cashless | 4,360 | -* | - | - | - | -  \nStock based compensation | 11,083 | -* | (73| ) | - | 4 | (69| )  \nPreferred stock dividend | - | - | (3| ) | - | - | (3| )  \nNet loss | - | - | - | (11,093| ) | (37| ) | (11,130| )  \nBalance, June 30, 2023 (unaudited) | 7,389,740 | $| 7 | $| 234,635 | $| (234,399| ) | $| 89 | $| 331  \nBalance | 7,389,740 | $| 7 | $| 234,635 | $| (234,399| ) | $| 89 | $| 331  \nCommon stock issued for services | 150,300 | -* | 937 | - | - | 937  \nSale of common stock and warrants, net transactional costs of $237 | 391,737 | -* | 2,624 | - | - | 2,624  \nSale of common stock and warrants, net transactional costs | 391,737 | -* | 2,624 | - | - | 2,624  \nSale of common stock under at-the-market offerings, net of transactional expenses of $164 | 29,861 | -* | (3| ) | - | - | (3| )  \nSale of subsidiary stock | - | - | 296 | - | 108 | 404  \nStock based compensation | 6,750 | -* | (687| ) | - | (609| ) | (1,296| )  \nPreferred stock dividend | - | - | (2| ) | - | - | (2| )  \nNet loss | - | - | - | (4,567| ) | 517 | (4,050| )  \nBalance, September 30, 2023 (unaudited) | 7,968,388 | $| 7 | $| 237,799 | $| (238,966| ) | $| 105 | $| (1,055| )  \nBalance | 7,968,388 | $| 7 | $| 237,799 | $| (238,966| ) | $| 105 | $| (1,055| )  \n* | - less than $1  \n---|---  \n  \nThe accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements\n\n6  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**\n\n**(In Thousands, Except Par Value and Share Amounts)**\n\n**_(unaudited)_**\n\n2024 | 2023  \n---|---  \n**Nine months ended September 30,**  \n**2024** | **2023**  \nCASH FLOWS FROM OPERATING ACTIVITIES:  \nNet loss | $| (9,240| ) | $| (22,562| )  \nAdjustments to reconcile net loss to cash used in operating activities:  \nDepreciation and amortization | 158 | 268  \nNon-cash lease expense | 275 | 216  \nNon-cash inventory write-down | - | 1,307  \nImpairment of long-term assets | 253 | -  \nGain on settlement and forgiveness of accounts payable | 2,409 | -  \nEquity based compensation | 7,010 | 6,532  \nChanges in operating assets and liabilities:  \nAccounts receivable | (57| ) | (5| )  \nLease receivables | 77 | 75  \nEmployee advances | 5 | (16| )  \nInventory | - | (49| )  \nPrepaid expenses and other | 93 | (625| )  \nDeferred expense | - | (4| )  \nDeferred revenue | - | (5| )  \nCustomer deposits | (7| ) | 4  \nAccounts payable and accrued expenses | (4,953| ) | 724  \nOperating lease liabilities | (307| ) | (231| )  \nNet cash used in operating activities | (4,284| ) | (14,371| )  \nCASH FLOWS FROM INVESTING ACTIVITIES:  \nPurchase of property and equipment | - | (182| )  \nNet cash used in investing activity | - | (182| )  \nCASH FLOWS FROM FINANCING ACTIVITIES:  \nProceeds from issuance of related party note payable | 500 | -  \nProceeds from sale of common stock and warrants, net of issuance costs | 4,209 | 12,617  \nProceeds from sale of common stock under at-the-market offerings, net of issuance costs | - | (3| )  \nProceeds from the sale of subsidiary stock to non-controlling interest, net of issuance costs | - | 1,971  \nNet cash provided by financing activities | 4,709 | 14,585  \nNet increase in cash and cash equivalents | 425 | 32  \nCash, beginning of the period | 190 | 357  \nCash, end of the period | $| 615 | $| 389  \nSupplemental disclosures of cash flow information:  \nCash paid during the period for interest | $| - | $| -  \nCash paid during the period for income taxes | $| - | $| -  \nNoncash investing and financing activities:  \nCommon stock issued in settlement of accounts payable | $| 122 | $| 105  \nCommon stock issued in settlement of accrued severance | $| 46 | -  \nDividend payable on preferred stock charged to additional paid in capital | $| 7 | $| 7  \nSeries C convertible preferred stock deemed dividend | $| 157 | $| -  \nCommon stock issued for conversion of note payable and accrued interest | $| 509 | $| -  \n  \nThe accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements\n\n7  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n**NOTE 1** – **NATURE OF OPERATIONS AND BASIS OF PRESENTATION**\n\n_Business and organization_\n\nBioSig Technologies, Inc. was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the standard care in electrophysiology with our PURE EP System’s enhanced signal acquisition, digital signal processing, and analysis during ablation of cardiac arrhythmias. The Company has generated minimal revenue to date and consequently its operations are subject to all risks inherent in business enterprises in early commercialization stage.\n\nOn November 7, 2018, the Company formed a subsidiary under the laws of the State of Delaware originally under the name of NeuroClear Technologies, Inc. which was renamed to ViralClear Pharmaceuticals, Inc. (“ViralClear”) in March 2020. The subsidiary was established to pursue additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that showed potential for the treatment of COVID-19. Since late 2020, ViralClear had been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology.\n\nIn 2019 and 2020, ViralClear sold an aggregate of 1,965,240 shares of its common stock to investors for net proceeds of $15.6 million and issued an aggregate of 894,869 shares of its common stock in connection with acquiring assets and with know-how agreements. As of September 30, 2024 and December 31, 2023, the Company had a majority interest in ViralClear of 69.08%.\n\nOn July 2, 2020, the Company formed an additional subsidiary, NeuroClear Technologies, Inc., a Delaware corporation, which was renamed to BioSig AI Sciences, Inc. (“BioSig AI”) on May 31, 2023. The subsidiary was established to pursue clinical needs of cardiac and neurological disorders through recordings and analyses of action potentials. BioSig AI aims to contribute to the advancements of AI-based diagnoses and therapies. At September 30, 2024 and December 31, 2023, the Company had a majority interest in BioSig AI of 84.5% (see Notes 9 and 11).\n\nThe Company continues to evaluate opportunities for the two subsidiaries.\n\nOn January 28, 2024 and February 20, 2024, management of the Company commenced a workforce reduction intended to reduce significantly the annual cash burn which was completed as of February 20, 2024. The workforce reduction consisted of the departure of sixteen employees, effective as of January 31, 2024 and included the departure of John Sieckhaus, the Company’s Chief Operating Officer, and Gray Fleming, the Company’s Chief Commercial Officer and twenty-six employees effective February 20, 2024. The effect of the workforce reductions has significantly reduced operations in the short term. In connection with workforce reduction, the Company issued an aggregate of 85,244 shares of common stock with a fair value of $72,065 as severance.\n\nOn March 5, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq (the “Staff”) stating that the Company has not regained compliance with Listing Rule 5550(a)(2) because the Company’s common stock did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market LLC (“Nasdaq”), and the Company is not eligible for a second 180 day cure period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market, and that accordingly, Nasdaq would delist the Company’s common stock unless the Company requested an appeal of this determination. On March 11, 2024, the Company submitted a request for a hearing before the Nasdaq Hearings Panel to appeal the Staff’s delisting determination. On March 12, 2024, the Company received a letter from the Staff stating that based upon the Staff’s review of the Company and pursuant to Listing Rule 5101, the Staff believes that the Company no longer has an operating business and is a “public shell,” and that the continued listing of its securities is no longer warranted, in view of work force reductions and resignations of members of the board of directors and officers (see below).\n\n8  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\nThe letter further stated that the Company no longer meets the requirement of Rule 5550(b)(2) to maintain a minimum Market Value of Listed Securities of $35 million, if none of the other standards set forth in Rule 5550(b) is met. The Staff stated that the foregoing matters serve as an additional basis for delisting the Company’s common stock from Nasdaq, and that the Hearings Panel will consider this matter in rendering a determination regarding the Company’s continued listing on The Nasdaq Capital Market. The Company appealed the foregoing determinations. The requested hearing before the Hearings Panel was held on May 7, 2024.\n\nOn June 10, 2024, the Company received formal notice that the Nasdaq Hearings Panel had determined to delist the Company’s common stock from Nasdaq due to the Company’s continued non-compliance with the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(2) for continued listing on Nasdaq. As a result, trading in the Company’s common stock will be suspended on Nasdaq effective with the open of business on Wednesday, June 12, 2024. The Company’s common stock should be eligible to trade on the OTC Markets’ Pink Current Information tier under symbol “BSGM” effective with the open of trading on Wednesday, June 12, 2024. The Company seeked the Panel’s reconsideration of its decision in accordance with the Nasdaq Listing Rules.\n\nOn June 24, 2024, the Company was notified by Nasdaq that the Nasdaq Hearings Panel had declined to reconsider its decision dated June 10, 2024 to delist the Company’s common stock from Nasdaq (the “Delisting Decision”). Trading in the Company’s securities was suspended on Nasdaq effective with the open of business on June 12, 2024, at which point the Company’s common stock was eligible to trade on the OTC Market’s Pink Current Information tier.\n\nOn July 10, 2024, the Company filed a submission in support of an appeal to the Delisting Decision to the Nasdaq Listing and Hearing Review Council.\n\nOn July 23, 2024, the Company commenced trading of its common stock on the OTCQB, operated by OTC Markets Group, Inc.\n\nOn October 18, 2024, the Company received a decision from the Nasdaq Listing and Hearing Review Council granting the Company a grace period until March 7, 2025 to regain compliance with the Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”), which requires a market value of listed securities of at least $35 million.\n\nOn October 21, 2024, the Company was notified that its common stock will commence trading on The Nasdaq Capital Market on Wednesday, October 23, 2024, effective at the opening of trading.\n\nOn October 24, 2024, the Company received a letter from the Nasdaq Listing Qualifications (“Nasdaq”) notifying the Company that based upon the closing bid price of the Company’s common stock from the period of June 11, 2024 through the reinstatement date, October 23, 2024, the Company did not meet the minimum bid price of $1.00 per share required by the Nasdaq Listing Rules (“Rules”) and as a result, the Company no longer meets this requirement. However, the Rules also provides the Company a compliance period of 180 calendar days in which to regain compliance.\n\nOn November 13, 2024, the Company issued a press release announcing its Nasdaq bid price compliance.\n\nThe unaudited condensed consolidated financial statements include the accounts of BioSig Technologies, Inc., and its majority owned subsidiaries, ViralClear and BioSig AI.\n\nThe unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.\n\nThe condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements.\n\nOperating results for the three and nine months ended September 30, 2024 are not necessarily indicative of results that may be expected for the year ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2023 filed with the Company’s Form 10-K with the Securities and Exchange Commission on April 16, 2024.\n\n**NOTE 2** – **GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS**\n\nAs of September 30, 2024, the Company had cash of $0.6 million and working capital deficit of $0.9 million. During the nine months ended September 30, 2024, the Company used net cash in operating activities of $4.3 million. These balances create a liquidity concern, which in turn raises substantial doubt about the Company’s ability to continue as a going concern.\n\nThe Company’s primary source of operating funds since inception has been cash proceeds from sale of equity securities and issuance of debt. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future.\n\nThe Company’s plans include the continued commercialization of the PURE EP System and other applications of our core technology and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. The Company’s strategic shift to potentially hiring a team of an additional 4-6 persons to execute a business development strategy of finding partners for the commercialization of PURE EP, develop new products in the field of Pulse Field Ablation and to continue to integrate PURE EP into today’s lab equipment will allow the Company to significantly reduce operating expenses.\n\nThe Company will require additional financing to fund future operations. Further, although the Company began commercial operations, there is no assurance that the Company will be able to generate sufficient cash flow to fund operations. In addition, there can be no assurance that the Company’s continuing research and development will be successfully completed or that any additional products will be commercially viable.\n\n9  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\nAccordingly, the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.\n\n**NOTE 3** – **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**\n\nA summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows.\n\n_Reverse Stock Split_\n\nOn January 31, 2024, the Company filed a Reverse Stock Split Amendment with the Secretary of State of the State of Delaware, effective February 2, 2024. Pursuant to the Reverse Stock Split Amendment, the Company effected a 1-for-10 reverse stock split of its issued and outstanding shares of common stock. The Company accounted for the reverse stock split on a retrospective basis pursuant to ASC 260, Earnings Per Share. All authorized, issued and outstanding common stock, common stock warrants, stock option awards, exercise prices and per share data have been adjusted in these consolidated financial statements, on a retroactive basis, to reflect the reverse stock split for all periods presented. Authorized common and preferred stock was not adjusted because of the reverse stock split.\n\n_Use of Estimates_\n\nThe preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.\n\n_Revenue Recognition_\n\nThe Company derives its revenue primarily from the sale of its medical device, the PURE EP™ System, and well as related support and maintenance services and software upgrade rentals in connection with the system.\n\nThe Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 842, _Leases_ (“ASC 842”) for lease components and ASC 606, _Revenue from Contracts with Customers_ (“ASC 606”) for non-lease components. For medical device sales and software rentals, the Company recognizes revenue under ASC 606.\n\nThe core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.\n\nUnder ASC 606, the Company determines revenue recognition through the following five steps:\n\n● | Identify the contract with the customer;  \n---|---  \n● | Identify the performance obligations in the contract;  \n● | Determine the transaction price;  \n● | Allocate the transaction price to the performance obligation in the contract; and  \n● | Recognize revenue when, or as, the performance obligations are satisfied.  \n  \n10  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\nPerformance obligations are the units of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. If the Company determines that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Once the PURE EP Platform is delivered, installed, and accepted by the customer, our performance obligation is recognized. Support, maintenance, and software upgrade rentals are performance obligations over a defined period and are recognized rateably over the contractual service period. Customers typically purchase these services with the initial sale of the PURE EP Platform and do not have the right to terminate their contracts unless we fail to perform material obligations.\n\nThe Company may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements.\n\nThe Company records accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the contractual arrangement. Unbilled receivables, if any, include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue.\n\nThe Company’s unconditional right to consideration for goods and services transferred to the customer is included in accounts receivable, net (if any) in the Company’s consolidated balance sheet.\n\nIn 2022, the Company entered two leases for our PURE EP Platform at a rate of $4,333 per month each. The term of the leases is for 30 months with an option provided to extend for an additional one year. The leases also have an option to purchase at the end of the lease at the fair market value. The Company accounts for the leases in accordance with ASC 842 and ASC 606.\n\nIn 2023, the Company entered into a one-year lease for software upgrade. The Company accounts for the lease in accordance with ASC 606.\n\nThe Company determined the leases meet the criteria of a sales-type lease whereby the present value of the future expected revenue (less the present value of the estimated unguaranteed residual value), cost of sales and profit and loss are recognized at the lease inception. Non-lease components are recognized under ASC 606. The discount rate utilized was the contract explicit rate of 2% per annum. (See Note 6 – Lease Receivables).\n\nA reconciliation of contract liabilities with customers for the nine months ended September 30, 2024 and 2023, are presented below:\n\nSCHEDULE OF RECONCILIATION OF CONTRACT LIABILITIES WITH CUSTOMERS\n\n_Nine months ended September 30,2024:_\n\n**Balance at** **December 31, 2023** **(000’s)** | **Consideration Received** **(000’s)** | **Recognized in Revenue** **(000’s)** | **Balance at** **September 30,** **2024** **(000’s)**  \n---|---|---|---  \nService revenue | $| - | $| 27 | $| (27| ) | $| -  \n  \n11  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n_Nine months ended September 30, 2023:_\n\n**Balance at** **December 31, 2022** **(000’s)** | **Consideration Received** **(000’s)** | **Recognized in Revenue** **(000’s)** | **Balance at** **September 30,** **2023** **(000’s)**  \n---|---|---|---  \nService revenue | $| 5 | $| 1 | $| (6| ) | $| -  \n  \nThe Company had one customer which accounts for 96% and 100% of our revenue in the nine months ended September 30, 2024 and 2023, respectively.\n\nAt September 30, 2024, the Company had three customers representing 40.7%, 37.2% and 16% of the outstanding accounts receivable and had three customers which accounts for approximately 62.3%, 19.6% and 18.0% of our outstanding accounts receivable at December 31, 2023.\n\nThe Company utilized one contract manufacturer for the manufacture and supply of the PURE EP Platform for the three and nine months ended September 30, 2024 and 2023.\n\n_Deferred Costs (Contract acquisition costs)_\n\nThe Company capitalizes initial and renewal sales commissions in the period the commission is earned, which generally occurs when a customer contract is obtained, and amortize deferred commission costs on a straight-line basis over the expected period of benefit, which we have deemed to be the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs would have been one year or less.\n\n_Allowance for Doubtful Accounts_\n\nThe Company adjusts accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for doubtful accounts for estimated losses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon historical collection experience, financial condition of the customer and the status of any open or unresolved issues with the customer preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. The allowance for doubtful accounts was $0 at September 30, 2024 and December 31, 2023. The Company believes that its reserve is adequate, however results may differ in future periods. For the three and nine months ended September 30, 2024 and 2023, bad debt expense totaled $0.\n\n_Concentrations of Credit Risk_\n\nFinancial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At September 30, 2024 and December 31, 2023, deposits in excess of FDIC limits were $0.37 million and nil, respectively.\n\n_Fair Value of Financial Instruments_\n\nAccounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.\n\n12  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\nThe Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and ASC 825-10, which permits entities to choose to measure many financial instruments and certain other items at fair value.\n\n_Prepaid Expenses and Vendor Deposits_\n\nPrepaid expenses and vendor deposits are comprised of prepaid insurance, operating expenses and other prepayments.\n\n_Leases (lessee)_\n\nThe Company determines if a contractual arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and noncurrent operating lease liabilities on the Company’s consolidated balance sheet. The Company evaluates and classifies leases as operating or finance leases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonably certain and failure to exercise such option which result in an economic penalty. All the Company’s real estate leases are classified as operating leases. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term.\n\nThe lease payments included in the present value are fixed lease payments. As most of the Company’s leases do not provide an implicit rate, the Company estimates its collateralized incremental borrowing rate, based on information available at the commencement date, in determining the present value of lease payments. The Company applies the portfolio approach in applying discount rates to its classes of leases. The operating lease ROU assets include any payments made before the commencement date. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company does not currently have subleases. The Company does not currently have residual value guarantees or restrictive covenants in its leases.\n\n_Leases (lessor)_\n\nThe Company classifies contractual lease arrangements entered as a lessor as a sales-type, direct financing or operating lease as described in ASC 842-Leases. For sales-type leases, the Company derecognizes the leased asset and recognizes the lease investment on the balance sheet.\n\n_Property and Equipment_\n\nProperty and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings.\n\n13  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n_Impairment of Long-lived Assets_\n\nThe Company recognizes an impairment of long-lived assets used in operations, other than goodwill, when events or circumstances indicate that the asset might be impaired and the estimated undiscounted cash flows to be generated by those assets over their remaining lives are less than the carrying amount of those items. The net carrying value of assets not recoverable is reduced to fair value, which is typically calculated using the discounted cash flow method.\n\nDuring the three and nine months ended September 30, 2024, the Company re-assessed its carrying amounts of certain property and equipment due to reduced manufacturing of its commercial products and determined that these carrying amounts exceeded the estimated undiscounted future cash flows. Accordingly, the Company recorded a $0 and $253 impairment charge to current operations during the three and nine months ended September 30, 2024. The Company did not recognize and record any impairments of long-lived assets used in operations during the three and nine months ended September 30, 2023.\n\n_Research and Development Costs_\n\nThe Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $0.2 million and $1.1 million for the three months ended September 30, 2024 and 2023, respectively. The Company incurred research and development expenses of $0.7 million and $3.9 million for the nine months ended September 30, 2024 and 2023, respectively.\n\n_Net Income (loss) Per Common Share_\n\nThe Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.\n\nThe computation of basic and diluted loss per share as of September 30, 2024 and 2023 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.\n\nPotentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:\n\nSCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE\n\n**September 30,** **2024** | **September 30,** **2023**  \n---|---  \nSeries C convertible preferred stock | 618,060 | 63,439  \nOptions to purchase common stock | 2,515,200 | 530,465  \nWarrants to purchase common stock | 4,951,068 | 1,234,964  \nRestricted stock units to acquire common stock | 1,965,000 | 81,250  \nTotals | 10,049,328 | 1,910,118  \n  \n_Stock Based Compensation_\n\nThe Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.\n\n14  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n_Income Taxes_\n\nThe Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.\n\n_Patents, Net_\n\nThe Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser of the legal patent term or the estimated life of the product of 20 years. During the three months ended September 30, 2024 and 2023, the Company recorded amortization of $4,752 and $4,751 to current period operations, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded amortization of $14,254 and $14,354 to current period operations, respectively.\n\n_Warranty_\n\nThe Company generally warrants its products to be free from material defects and to conform to material specifications for a period of up to two (2) years. Warranty expense is estimated based primarily on historical experience and is reflected in the consolidated financial statements.\n\n_Segment Information_\n\nOperating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s principal operating segments. (See Note 13 – Segment Reporting).\n\n_Non-controlling Interest_\n\nThe Company’s non-controlling interest represents the non-controlling shareholders ownership interests related to the Company’s subsidiaries, ViralClear and BioSig AI. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the unaudited condensed consolidated balance sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common shareholders on the face of the unaudited condensed consolidated statements of operations. The Company’s equity interest in ViralClear and BioSig AI is 69.08% and 84.48%; and the non-controlling stockholders’ interest is 30.92% and 15.52%, respectively as of September 30, 2024 and December 31, 2023. This is reflected in the consolidated statements of changes in equity.\n\n_Warrants_\n\nThe Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (ASC 480), and ASC 815, Derivatives and Hedging (ASC 815), depending on the specific terms of the warrant agreement.\n\n15  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n_Recent Accounting Pronouncements_\n\nIn December 2023, the FASB issued ASU 2023-09, _Improvements to Income Tax Disclosures,_ which requires disaggregated information about our effective tax rate reconciliation as well as information on income taxes paid. The guidance will first be effective in our annual disclosures for the year ending December 31, 2025, and should be applied on a prospective basis with the option to apply retrospectively. Early adoption is permitted. The Company is in the process of assessing the impact of ASU 2023-09 on our disclosures.\n\nIn November 2023, the FASB issued ASU No. 2023-07, _Improvements to Reportable Segment Disclosures_(Topic 280). ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the potential impact of adopting this new guidance on the consolidated financial statements and related disclosures.\n\nThere were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.\n\n**NOTE 4** – **PROPERTY AND EQUIPMENT**\n\nProperty and equipment as of September 30, 2024 and December 31, 2023 is summarized as follows:\n\nSCHEDULE OF PROPERTY AND EQUIPMENT\n\n**September 30,** **2024** **(000’s)** | **December 31,** **2023** **(000’s)**  \n---|---  \nComputer equipment | $| 531 | $| 531  \nFurniture and fixtures | 109 | 109  \nManufacturing equipment | - | 372  \nTesting/Demo equipment | 312 | 356  \nLeasehold improvements | 84 | 84  \nTotal | 1,036 | 1,452  \nLess accumulated depreciation | (925| ) | (943| )  \nProperty and equipment, net | $| 111 | $| 509  \n  \nProperty and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. Leasehold improvements are depreciated over the related expected lease term. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings.\n\nDuring the three and nine months ended September 30, 2024, the Company re-assessed its carrying amounts of certain property and equipment due to reduced manufacturing of its commercial products and determined that these carrying amounts exceeded the estimated undiscounted future cash flows. Accordingly, the Company recorded a $0 and $253,411 impairment charge to current operations during the three and nine months ended September 30, 2024.\n\nDepreciation expenses were $26,590 and $87,338 for the three months ended September 30, 2024 and 2023, respectively. Depreciation expenses were $143,804 and $253,486 for the nine months ended September 30, 2024 and 2023, respectively.\n\n**NOTE 5** – **RIGHT TO USE ASSETS AND LEASE LIABILITY**\n\nOn July 15, 2024 the Company terminated its sublease for the office space at 55 Greens Farms Road Westport, Connecticut which was set to end at December 15, 2024.\n\nAs of December 31, 2023, the Company had outstanding two leases with aggregate payments of $30,544 and $29,995 per month, respectively, expiring through July 31, 2025.\n\nAs of September 30, 2024, the Company had one lease outstanding with payments of $15,129 per month, expiring in July 31, 2025.\n\nRight to use assets is summarized below:\n\nSCHEDULE OF RIGHT TO USE ASSETS\n\n**September 30,** **2024** **(000’s)** | **December 31,** **2023** **(000’s)**  \n---|---  \nRight to use asset | $| 502 | $| 995  \nLess accumulated amortization | (365| ) | (583| )  \nRight to use assets, net | $| 137 | $| 412  \n  \nDuring the three months ended September 30, 2024 and 2023, the Company recorded $36,565 and $95,964 as lease expense to current period operations, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded $203,315 and $280,541 as lease expense to current period operations, respectively.\n\n16  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\nLease liability is summarized below:\n\nSCHEDULE OF LEASE LIABILITY\n\n**September 30,** **2024** **(000’s)** | **December 31,** **2023** **(000’s)**  \n---|---  \nTotal lease liability | $| 145 | $| 452  \nLess: short term portion | (145| ) | (349| )  \nLong term portion | $| - | $| 103  \n  \nMaturity analysis under these lease agreements are as follows (000’s):\n\nSCHEDULE OF MATURITY ANALYSIS UNDER LEASE AGREEMENTS\n\nYear ended December 31, 2024 | 45  \n---|---  \nYear ended December 31, 2025 | 106  \nTotal | 151  \nLess: Present value discount | (6| )  \nLease liability | $| 145  \n  \nLease expense for the three months ended September 30, 2024 and 2023 was comprised of the following:\n\nSCHEDULE OF LEASE EXPENSE\n\n**September 30,** **2024** **(000’s)** | **September 30,** **2023** **(000’s)**  \n---|---  \nOperating lease expense | $| 36 | $| 84  \nShort-term lease expense | - | 8  \nVariable lease expense | 1 | 4  \nTotal | $| 37 | $| 96  \n  \nLease expense for the nine months ended September 30, 2024 and 2023 was comprised of the following:\n\n**September 30,** **2024** **(000’s)** | **September 30,** **2023** **(000’s)**  \n---|---  \nOperating lease expense | $| 158 | $| 252  \nShort-term lease expense | 41 | 22  \nVariable lease expense | 4 | 7  \nTotal | $| 203 | $| 281  \n  \n**NOTE 6** – **LEASE RECEIVABLES**\n\nIn 2022, the Company entered into two leases for our PURE EP Platform at a rate of $4,333 per month each. The term of the leases is for 30 months with an option provided to extend for an additional one year. The leases also have an option to purchase at the end of the lease at the fair market value.\n\nThe Company determined the leases meet the criteria of a sales-type lease whereby the present value of the future expected revenue (less the present value of the estimated unguaranteed residual value), cost of sales and profit and loss are recognized at the lease inception. The discount rate utilized was the contract explicit rate of 2% per annum. The present value of the unguaranteed residual assets of $4 is included in net investment in leases in the balance sheet.\n\nA reconciliation of lease receivables with customers for the nine months ended September 30, 2024 and 2023 are presented below:\n\nSCHEDULE OF RECONCILIATION OF LEASE RECEIVABLES WITH CUSTOMERS\n\n_Nine months ended September 30, 2024:_\n\n**Balance at** **December 31, 2023** **(000’s)** | **Recognized in Revenue** **(000’s)** | **Invoiced to Customer** **(000’s)** | **Interest Earned** **(000’s)** | **Unguaranteed** **Residual** **Assets** **(000’s)** | **Balance at** **September 30, 2024** **(000’s)**  \n---|---|---|---|---|---  \nContract asset | $| 120 | $| - | $| (81| ) | $| - | $| 4 | $| 43  \nLess current portion | (103| ) | - | 66 | - | (2| ) | (39| )  \nNoncurrent portion | $| 17 | $| - | $| (15| ) | - | $| 2 | $| 4  \n  \n17  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n_Nine months ended September 30, 2023:_\n\n**Balance at** **December 31, 2022** **(000’s)** | **Recognized in Revenue** **(000’s)** | **Invoiced to Customer** **(000’s)** | **Interest Earned** **(000’s)** | **Unguaranteed** **Residual** **Assets** **(000’s)** | **Balance at** **September 30, 2023** **(000’s)**  \n---|---|---|---|---|---  \nContract asset | $| 221 | $| - | $| (81| ) | $| 2 | $| 3 | $| 145  \nLess current portion | (101| ) | - | (1| ) | - | - | (102| )  \nNoncurrent portion | $| 120 | $| - | $| (82| ) | 2 | $| 3 | $| 43  \n  \nFuture cash flows under this lease agreement are as follows (000’s):\n\nSCHEDULE OF FUTURE CASH FLOWS UNDER LEASE AGREEMENT\n\nYear ended December 31, 2024 | 27  \n---|---  \nYear ended December 31, 2025 | 13  \nPresent value of unguaranteed residual assets | 4  \nTotal | 44  \nLess: Present value discount | (1| )  \nNet investment in leases | $| 43  \n  \n**NOTE 7** – **ACCOUNTS PAYABLE AND ACCRUED EXPENSES**\n\nAccounts payable and accrued expenses at September 30, 2024 and December 31, 2023 consist of the following:\n\nSCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE\n\n**September 30,** **2024** **(000’s)** | **December 31,** **2023** **(000’s)**  \n---|---  \nAccrued accounting and legal | $| 256 | $| 1,277  \nAccrued reimbursements and travel | 7 | 9  \nAccrued consulting | 152 | 804  \nAccrued research and development expenses | 474 | 802  \nAccrued marketing | 36 | 333  \nAccrued office and other | 423 | 290  \nAccrued payroll | 100 | 601  \nAccounts payable and accrued expenses | $| 1,448 | $| 4,116  \n  \nDuring the three and nine months ended September 30, 2024, the company recorded a gain on settlement and forgiveness of accounts payable of approximately $1,021,000 and $2,409,000, respectively.\n\n**NOTE 8 – NOTE PAYABLE-RELATED PARTY**\n\nOn March 7, 2024, the Company issued a promissory note for $500,000 to a significant shareholder/investor due March 7, 2026. The promissory note was unsecured and bears interest of twelve percent (12%) per annum, payable at maturity. The Company had the option to prepay all or any portion of the promissory note at any time without penalty. See Note 9 – Stockholder Equity for details related to the full conversion of the promissory note for common stock on May 1, 2024.\n\n**NOTE 9** – **STOCKHOLDER EQUITY**\n\n_Preferred stock_\n\nThe Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of September 30, 2024 and December 31, 2023, the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E Preferred Stock and 200,000 shares of Series F Preferred Stock. As of September 30, 2024 and December 31, 2023, there were no outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock.\n\n_Series C Preferred Stock_\n\nAs of September 30, 2024 and December 31, 2023, the Company had 105 shares of Series C Preferred stock issued and outstanding. During the nine months ended September 30, 2024, the conversion price of the Series C Preferred stock was reset from $2.50 per share to $0.5302 per share and again to $0.4100 per share. As such, the Company recorded a noncash deemed dividend of $156,734 during the nine months ended September 30, 2024.\n\n18  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n_Common stock_\n\nOn January 31, 2024, the Company filed a Reverse Stock Split Amendment with the Secretary of State of the State of Delaware, effective February 2, 2024. Pursuant to the Reverse Stock Split Amendment, the Company effected a 1-for-10 reverse stock split of its issued and outstanding shares of common stock. The Company accounted for the reverse stock split on a retrospective basis pursuant to ASC 260, Earnings Per Share. All authorized, issued and outstanding common stock, common stock warrants, stock option awards, exercise prices and per share data have been adjusted in these consolidated financial statements, on a retroactive basis, to reflect the reverse stock split for all periods presented. Authorized common and preferred stock was not adjusted because of the reverse stock split.\n\nThe Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of September 30, 2024 and December 31, 2023, the Company had 16,617,096 and 9,040,043 shares issued and outstanding, respectively.\n\nDuring the nine months ended September 30, 2024, the Company issued an aggregate of 75,000 shares of common stock for the forgiveness of accounts payable at a fair value of $122,250.\n\nDuring the nine months ended September 30, 2024, the Company issued an aggregate of 2,140,744 shares of common stock for services at a fair value of $1,670,375.\n\nDuring the nine months ended September 30, 2024, the Company issued an aggregate of 2,322,747 shares of common stock for vested restricted stock units.\n\n_Sale of common stock._\n\nOn January 12, 2024, the Company entered into a securities purchase agreement with certain accredited and institutional investors, pursuant to which the Company sold to the investors an aggregate of 260,720 shares of the Company’s common stock and warrants to purchase up to 130,363 shares of common stock, at a purchase price of $3.989 per share and a warrant to purchase one-half of a share. The warrants have an exercise price of $3.364 per share, will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance. The gross proceeds from this offering were $1,040,000.\n\nOn May 1, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company sold to the Investors an aggregate of 783,406 shares of the Company’s common stock at a purchase price of $1.4605 per share, and warrants to purchase up to 391,703 shares of common stock at an exercise price of $1.398 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $1,144,164, including $634,999 in cash and $509,165 representing conversion of the principal balance of and accrued interest on the previously issued related party note payable. The note was not convertible by its terms, but the holder has agreed to convert it into shares of common stock and warrants under the Purchase Agreement.\n\nOn May 29, 2024, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to sell and issue to the investors (i) in a registered direct offering, 1,570,683 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company at a price of $1.91 per share and (ii) in a concurrent private placement, common stock purchase warrants to purchase up to an aggregate of 1,570,683 shares of Common Stock, at an exercise price of $1.78 per share of Common Stock. In connections with the Offering, the Company issued 109,948 warrants to its placement agent. The gross proceeds from the offering were approximately $3,000,000.\n\n19  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n**NOTE 10** – **OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS**\n\n_BioSig Technologies, Inc._\n\n_2023 Long-Term Incentive Plan_\n\nOn December 27, 2022, the Board of Directors of BioSig Technologies, Inc. approved the 2023 Long-Term Incentive Plan (the “2023 Plan”). The 2023 Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 876,595 shares, plus any prior plan awards of the Company’s common stock to officers, directors, employees and consultants of the Company. Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.\n\nHowever, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.\n\nAdditionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. At September 30, 2024, there were 15,718 shares available under the 2023 Long-Term Incentive Plan.\n\n_Options_\n\nOption valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from historical stock prices of the Company. The Company accounts for the expected life of options using the based on the contractual life of options for non-employees.\n\nFor employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.\n\nDuring the nine months ended September 30, 2024, an employee was issued stock option to purchase 2,400,000 shares of the Company’s common stock with an exercise price $0.4479 per share, with 50% of the Options vesting on the date of grant and the remaining 50% of the options vesting over a term of 3 years in equal bi-annual instalments with vesting commencing on the date of grant. The grant date fair value of the option was $965,592.\n\nThe following table presents information related to stock options at September 30, 2024:\n\nSCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS\n\nOptions Outstanding | Options Exercisable  \n---|---  \nWeighted  \nAverage | Exercisable  \nExercise | Number of | Remaining Life | Number of  \nPrice | Options | In Years | Options  \n$| Under 9.99 | 2,467,000 | 9.9 | 1,266,496  \n10.00-19.99 | 39,700 | 8.4 | 37,858  \n20.00-29.99 | - | - | -  \n30.00-39.99 | - | - | -  \n40.00-49.99 | 4,000 | 4.9 | 4,000  \n50.00-59.99 | - | - | -  \n60.00-69.99 | 3,000 | 5.3 | 3,000  \n70.00-79.99 | 1,500 | 5.9 | 1,500  \n2,515,200 | 9.89 | 1,312,854  \n  \nA summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2024 is as follows:\n\nSCHEDULE OF STOCK OPTION ACTIVITY\n\nShares | Weighted-Average Exercise Price | Weighted-Average Remaining Contractual Term | Aggregate Intrinsic Value  \n---|---|---|---  \nOutstanding at January 1, 2024 | 603,229 | $| 25.67 | 6.7 | $| -  \nIssued | 2,400,000 | 0.45  \nForfeited/expired | (488,029) | $| 28.97  \nOutstanding at September 30, 2024 | 2,515,200 | $| 0.96 | 9.89 | $| -  \nExercisable at September 30, 2024 | 1,312,854 | $| 1.41 | 9.84 | $| -  \n  \nThe aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of BioSig Technologies, Inc. of $0.34 as of September 30, 2024, which would have been received by the option holders had those option holders exercised their options as of that date.\n\nThe option value during the nine months ended September 30, 2024, was valued using the Black-Scholes option pricing model the Company used the following assumptions (i) an expected term of 5.50 years , (ii) volatility of 135.51%, (iii) risk free interest rate of 3.50% and a (iv) dividend yield rate of 0%.\n\nThe fair value of all options vesting during the three and nine months ended September 30, 2024 of $498,445 and $655,863, respectively, was charged to current period operations. The fair value of all options vesting during the three and nine months ended September 30, 2023 of $502,662 and $1,142,185, respectively, was charged to current period operations. Unrecognized compensation expense of $477,849 at September 30, 2024 which the Company expects to recognize over a weighted average period of 1.64 years.\n\n20  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n_Warrants_\n\nThe following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at September 30, 2024:\n\nSCHEDULE OF OUTSTANDING WARRANTS\n\nExercise | Number | Expiration  \n---|---|---  \nPrice | Outstanding | Date  \n$| 1.398 | 391,703 | November 2029  \n1.780 | 1,570,683 | May 2029  \n2.3875 | 109,948 | May 2029  \n3.364 | 130,363 | July 2029  \n3.573 | 1,399,386 | May 2025-November 2028  \n4.066 | 25,000 | November 2032  \n4.455 | 113,005 | June 2028  \n4.466 | 48,980 | November 2028  \n4.6626 | 64,982 | April 2029  \n4.9252 | 56,307 | March 2029  \n4.929 | 76,997 | March 2029  \n5.1358 | 116,045 | July 2028  \n7.181 | 95,761 | July 2028  \n7.502 | 9,846 | July 2028  \n7.963 | 88,324 | August 2028  \n9.000 | 21,709 | June 2027  \n9.596 | 84,390 | January 2029  \n10.0992 | 19,118 | August 2028  \n10.26 | 51,705 | September 2028  \n10.4678 | 84,296 | September 2028  \n11.30 | 40,417 | October 2028  \n13.28 | 96,198 | November 2028  \n14.00 | 174,013 | September 2025  \n48.00 | 25,000 | February 2025 to July 2026  \n61.60 | 56,892 | November 2027  \n4,951,068  \n  \n21  \n---  \n  \nDuring the nine months ended September 30, 2024, the Company issued warrants to purchase an aggregate of 2,202,697 shares of its common stock to investors at an exercise price of $2.28 per share.\n\nA summary of the warrant activity for nine months ended September 30, 2024 is as follows:\n\nSCHEDULE OF WARRANT ACTIVITY\n\nShares | Weighted-Average Exercise Price | Weighted-Average Remaining Contractual Term | Aggregate Intrinsic Value  \n---|---|---|---  \nOutstanding at January 1, 2024 | 2,748,371 | $| 7.40 | 3.7 | $| 1,717,104  \nIssued | 2,202,697 | $| 2.28 | 5.0 | -  \nOutstanding at September 30, 2024 | 4,951,068 | $| 4.92 | 3.8 | $| -  \nVested and expected to vest at September 30, 2024 | 4,559,365 | $| 5.23 | 3.7 | $| -  \nExercisable at September 30, 2024 | 4,559,365 | $| 5.23 | 3.7 | $| -  \n  \nThe aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the company’s stock price of $0.34 of September 30, 2024, which would have been received by the warrant holders had those warrants holders exercised their options as of that date.\n\nThe fair value of warrants issued for services during the three and nine months ended September 30, 2024 and 2023 of $0 and $0 and was charged to current period operations. Unrecognized compensation expense was $0 at September 30, 2024.\n\n_Restricted Stock Units_\n\nThe following table summarizes the restricted stock activity for the nine months ended September 30, 2024:\n\nSCHEDULE OF RESTRICTED STOCK ACTIVITY\n\nRestricted shares issued as of January 1, 2024 | 163,250  \n---|---  \nGranted | 4,605,000  \nVested and issued | (2,746,500| )  \nForfeited | (56,750| )  \nTotal | 1,965,000  \nComprised of:  \nVested restricted shares as of September 30, 2024 | -  \nUnvested restricted shares as of September 30, 2024 | 1,965,000  \n  \n22  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\nOn March 1, 2024, the Company granted 500,000 restricted stock units for shares of its common stock to a key consultant, vesting in substantially equal monthly installments over one year, for services rendered, valued at $352,550.\n\nOn April 1, 2024, the Company granted 200,000 restricted stock units for shares of its common stock to employees, vesting in substantially equal monthly installments over one year, for services rendered, valued at $140,000.\n\nOn May 1, 2024, the Company issued 150,000 restricted stock units for shares of its common stock to an employee for services rendered valued at $298,500 that’s fully vested on the date of issuance.\n\nOn May 1, 2024, the Company granted 50,000 restricted stock units for shares of its common stock to an employee vesting in substantially equal monthly installments over one year.\n\nOn May 30, 2024, the Company granted an aggregate of 1,500,000 restricted stock units for shares of its common stock to consultants of which 650,000 shares were fully vested at the time of grant and 650,000 shares vest on July 3, 2024 and the remaining 200,000 vest on October 4, 2024.\n\nJune 1, 2024, the Company issued 12,500 restricted stock units for shares of its common stock to a consultant for services rendered valued at $25,125.\n\nOn June 7, 2024, the Company granted an aggregate of 262,500 restricted stock units for shares of its common stock to employees and board members, the shares were fully vested at the time of grant valued at $489,563.\n\nOn July 26, 2024, the Company granted an aggregate of 280,000 restricted stock units for shares of its common stock to employees and board members, the shares were fully vested at the time of grant valued at $114,800.\n\nOn July 26, 2024, the Company paid $25,000 in cash and issued and aggregate of 112,500 shares of its common stock as a full settlement of the General Release and Severance Agreement dated January 29, 2023 by and between Steve Chaussy and BioSig Technologies, Inc. (the “Severance Agreement”). The Company granted 12,500 shares of the afore mentioned common stock in 2023 but was only issued as part of the settlement. Pursuant to the original Severance Agreement, the Company was to pay a cash bonus of $200,000 to Steve Chaussy.\n\nOn September 11, 2024, the company granted 275,000 shares of restricted common stock, with a grant date fair value of $123,173, and granted an additional 1,275,000 shares of common stock that vest biannually over the term of 3 years with a grant date fair value of $571,073.\n\nStock based compensation expense related to restricted stock grants was $1,017,858 and $4,588,379 for the three and nine months ended September 30, 2024, respectively. Stock based compensation expense related to restricted stock grants was $172,717 and $379,243 for the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, the stock-based compensation relating to restricted stock of $924,945 remains unamortized.\n\n_ViralClear Pharmaceuticals, Inc._\n\n_2019 Long-Term Incentive Plan_\n\nOn September 24, 2019, ViralClear’s Board of Directors approved the 2019 Long-Term Incentive Plan (as subsequently amended, the “ViralClear Plan”). The ViralClear Plan was approved by BioSig as ViralClear’s majority stockholder. The ViralClear Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 4,000,000 shares of ViralClear’s common stock to officers, directors, employees and consultants of the ViralClear. Under the terms of the ViralClear Plan, ViralClear may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of ViralClear only and nonqualified options. The Board of Directors of ViralClear or a committee thereof (the “Administrator”) administers the ViralClear Plan and determines the exercise price, vesting and expiration period of the grants under the ViralClear Plan.\n\nHowever, the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder. The fair market value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the Administrator in good faith.\n\nAdditionally, the vesting period of the grants under the ViralClear Plan will be determined by the Administrator, in its sole discretion, with an expiration period of not more than ten years. There are 2,650,071 shares remaining available for future issuance of awards under the terms of the ViralClear Plan.\n\n_ViralClear Options_\n\nAs of September 30, 2024, there were no options outstanding for ViralClear. The remaining 25,000 options with an exercise price of $5 were forfeited as of September 30, 2024.\n\nThe fair value of all options vesting during the three and nine months ended September 30, 2024 of $0; and $0 and $0 and $0 for the three and nine months ended September 30, 2023, respectively, was charged to current period operations. Unrecognized compensation expense of $0 at September 30, 2024 will be expensed in future periods.\n\n23  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n_Warrants (ViralClear)_\n\nThe following table presents information related to warrants (ViralClear) at September 30, 2024:\n\nSCHEDULE OF OUTSTANDING WARRANTS\n\n**Exercise** | **Number** | **Expiration**  \n---|---|---  \n**Price** | **Outstanding** | **Date**  \n$ | 5.00 | 473,772 | November 2027  \n10.00 | 6,575 | May 2025  \n480,347  \n  \n_Restricted stock units (ViralClear)_\n\nThe following table summarizes the restricted stock activity for the nine months ended September 30, 2024:\n\nSCHEDULE OF RESTRICTED STOCK ACTIVITY\n\nRestricted shares outstanding at January 1, 2024: | 1,078,679  \n---|---  \nForfeited | (400,000| )  \nTotal restricted shares outstanding at September 30, 2024: | 678,679  \nComprised of:  \nVested restricted shares as of September 30, 2024 | 678,679  \nUnvested restricted shares as of September 30, 2024 | -  \nTotal | 678,679  \n  \nStock based compensation expense related to restricted stock unit grants of ViralClear was $0 and $0 for the three and nine months ended September 30, 2024 and $(1,970,931) and $(1,941,861) for the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, the stock-based compensation relating to restricted stock of $0 remains unamortized.\n\n_BioSig AI Sciences, Inc._\n\n_Warrants (BioSig AI)_\n\nThe following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at September 30, 2024:\n\nSCHEDULE OF OUTSTANDING WARRANTS\n\n**Exercise** | **Number** | **Expiration**  \n---|---|---  \n**Price** | **Outstanding** | **Date**  \n$ | 1.00 | 130,500 | June-July 2028  \n  \n**NOTE 11** – **NON-CONTROLLING INTEREST**\n\nOn November 7, 2018, the Company formed a subsidiary, now known as ViralClear, to pursue additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that showed potential for the treatment of COVID-19. Since late 2020, ViralClear has been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology.\n\nAs of September 30, 2024 and December 31, 2023, the Company had a majority interest in ViralClear of 69.08%.\n\nOn July 2, 2020, the Company formed an additional subsidiary, now known as BioSig AI Sciences, Inc., to pursue clinical needs of cardiac and neurological disorders through recordings and analyses of action potential. BioSig AI aims to contribute to the advancements of AI-based diagnoses therapies. In June and July 2023, BioSig AI sold 2,205,000 shares of its common stock for net proceeds of $1,971,277 to fund initial operations.\n\nAs of September 30, 2024 and December 31, 2023, the Company had a majority interest in BioSig AI of 84.5%.\n\n24  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\nA reconciliation of ViralClear Pharmaceuticals, Inc. and BioSig AI Sciences, Inc. non-controlling loss attributable to the Company:\n\nNet loss attributable to the non-controlling interest for the three months ended September 30, 2024 (000’s):\n\nSCHEDULE OF NON-CONTROLLING INTEREST\n\n**ViralClear Pharmaceuticals, Inc.** **(000’s)** | **BioSig AI Sciences, Inc.** **(000’s)** | **Total** **(000’s)**  \n---|---|---  \nNet Income (loss) | $|  (0| ) | $| (0| ) | $| (0| )  \nAverage Non-Controlling interest percentage of losses | 32| % | 16| % | 15| %  \nNet income (loss) attributable to non-controlling interest | $| (0| ) | $| (0| ) | $| (0| )  \n  \nNet loss attributable to the non-controlling interest for the three months ended September 30, 2023 (000’s):\n\n**ViralClear Pharmaceuticals, Inc.** **(000’s)** | **BioSig AI Sciences, Inc.** **(000’s)** | **Total** **(000’s)**  \n---|---|---  \nNet loss | $| 1,863 | $| (389| ) | $| 1,474  \nAverage Non-Controlling interest percentage of profit/losses | 31| % | 15| % | 35| %  \nNet loss attributable to non-controlling interest | $| 576 | $| (59| ) | $| 517  \n  \nNet loss attributable to the non-controlling interest for the nine months ended September 30, 2024 (000’s):\n\n**ViralClear Pharmaceuticals, Inc.** **(000’s)** | **BioSig AI Sciences, Inc.** **(000’s)** | **Total** **(000’s)**  \n---|---|---  \nNet Income (loss) | $|  (41| ) | $| 24 | $| (17| )  \nAverage Non-Controlling interest percentage of losses | 32| % | 16| % | 52| %  \nNet income (loss) attributable to non-controlling interest | $| (13| ) | $| 4 | $| (9| )  \n  \nNet loss attributable to the non-controlling interest for the nine months ended September 30, 2023 (000’s):\n\n**ViralClear Pharmaceuticals, Inc.** **(000’s)** | **BioSig AI Sciences, Inc.** **(000’s)** | **Total** **(000’s)**  \n---|---|---  \nNet loss | $| 1,583 | $| (407| ) | $| 1,176  \nAverage Non-Controlling interest percentage of profit/losses | 31| % | 15| % | 37| %  \nNet loss attributable to non-controlling interest | $| 489 | $| (59| ) | $| 430  \n  \nThe following table summarizes the changes in non-controlling interest for the nine months ended September 30, 2024 (000’s):\n\nSCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST\n\n**ViralClear Pharmaceuticals, Inc.** **(000’s)** | **BioSig AI Sciences, Inc.** **(000’s)** | **Total** **(000’s)**  \n---|---|---  \nBalance, January 1, 2024 | $| (158| ) | $| 184 | $| 26  \nNet income (loss) attributable to non-controlling interest | (13| ) | 4 | (9| )  \nBalance, September 30, 2024 | $| (171| ) | $| 188 | $| 17  \n  \n25  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n**NOTE 12** — **COMMITMENTS AND CONTINGENCIES**\n\n**_Operating leases_**\n\nSee Note 5 for operating lease discussion.\n\n**_Licensing agreements_**\n\n_2017 Know-How License Agreement_\n\nOn March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale. The agreement expires in ten years from the effective date.\n\nThe Company is obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined. At September 30, 2024 and December 31, 2023, accounts payable due under the contract was $4.\n\n_Patent and Know-How License Agreement_ – _EP Software Agreement_\n\nOn November 20, 2019, the Company entered into a patent and know-how license agreement (the “EP Software Agreement”) with Mayo Foundation for Medical Education and Research (“Mayo”). The EP Software Agreement grants to the Company an exclusive worldwide license, with the right to sublicense, within the field of electrophysiology software and under certain patent rights as described in the EP Software Agreement (the “Patent Rights”), to make, have made, use, offer for sale, sell and import licensed products and a non-exclusive license to the Company to use the research and development information, materials, technical data, unpatented inventions, trade secrets, know-how and supportive information of Mayo to develop, make, have made, use, offer for sale, sell, and import licensed products. The EP Software Agreement will expire upon the later of either (a) the expiration of the Patent Rights or (b) the 10th anniversary of the date of the first commercial sale of a licensed product, unless earlier terminated by Mayo for the Company’s failure to cure a material breach of the EP Software Agreement, the Company’s or a sublicensee’s commencement of any action or proceedings against Mayo or its affiliates other than for an uncured material breach of the EP Software Agreement by Mayo, or insolvency of the Company.\n\nIn connection with the EP Software Agreement, the Company agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $625,000 in aggregate. At September 30, 2024 and December 31, 2023, accounts payable due under the contract was $0.\n\n_Amended and Restated Patent and Know-How License Agreement_ – _Tools Agreement_\n\nOn November 20, 2019, the Company entered into an amended and restated patent and know-how license agreement (the “Tools Agreement”) with Mayo. The Tools Agreement contains terms of license grant substantially identical to the EP Software Agreement, although it is for different patent rights and covers the field of electrophysiology systems. In June 2021, patent rights were issued (“Valid Claim”) as defined whereby the Company paid milestone one of $75,000 during the 2021 year.\n\nIn connection with the Tools Agreement, the Company agreed to pay Mayo an upfront consideration of $100,000. The Company also agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $550,000 in aggregate. At September 30, 2024 and December 31, 2023, accounts payable due under the contract was $0.\n\n_ViralClear Patent and Know-How License Agreement_\n\nOn November 20, 2019, the Company’s majority-owned subsidiary, ViralClear, entered into a patent and know-how license agreement (the “ViralClear Agreement”) with Mayo. The ViralClear Agreement contains terms of license grant substantially identical to the EP Software Agreement and the Tools Agreement, although it is for different patent rights and covers the field of stimulation and electroporation for hypotension/syncope management, renal and non-renal denervation for hypertension treatment, and for use in treatment of arrhythmias in the autonomic nervous system.\n\nIn connection with the ViralClear Agreement, ViralClear agreed to make earned royalty payments to Mayo in connection with ViralClear’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $700,000 in aggregate. In June 2021, patent rights were issued (“Valid Claim”) as defined whereby the Company paid milestone one of $75,000 during the 2021 year. At September 30, 2024 and December 31, 2023, accounts payable due under the contract was $0.\n\n_Trek Therapeutics, PBC_\n\nIn the event of sublicensing, sale, transfer, assignment or similar transaction, ViralClear agreed to pay Trek 10% of the consideration received.\n\nAs part of the acquired assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding certain formulas and compounds usage. The agreement calls for milestone payments upon marketing authorization (as amended and defined with respect of product in a particular jurisdiction in the territory, the receipt of all approvals from the relevant regulatory authority necessary to market and sell such product in any such jurisdiction, excluding any pricing approval or reimbursement authorization) in any first and second country of $10 million and $5 million, respectively, in addition to 6% royalty payments. At September 30, 2024 and December 31, 2023, accounts payable due under the contract was $0.\n\n26  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n_BioSig AI Sciences, Inc._ – _Consulting Agreement_\n\nOn June 17, 2023, BioSig AI entered into an agreement with Reified Labs LLC (“Reified”) whereby Reified will work with the BioSig AI to develop datasets for the purpose of creating a foundational artificial intelligence platform. The agreement has a one-year term from the effective date and automatically renews for successive one year terms, unless terminated. On January 1, 2024, the contract was terminated.\n\nBioSig AI is obligated to pay Reified a monthly consulting fee of $30,000. At September 30, 2024 and December 31, 2023, accounts payable due under the contract was $210,000 and $90,000.\n\n_Neuro-Kinesis Corporation_\n\nOn July 1, 2024, the Company announced the intent to acquire the assets of Neuro-Kinesis Corporation (NKC), a privately held Los Angeles-based medical technology company developing smart EP tools. A non-binding letter of intent (LOI) has been executed confirming BioSig’s preliminary interest in the proposed acquisition of the assets of NKC. The purchase price will be paid through the issuance of shares of BioSig’s common stock to the shareholders of NKC. In addition, at closing, NKC will provide a minimum of $2.5 million, but could provide up to $6 million, of unrestricted cash to BioSig. The proposed acquisition will require extensive due diligence, potentially through the first quarter of 2025. The LOI expired on October 14, 2024, and the Company entered into an amendment to extend the term of the LOI through March 31, 2025. In addition, the amendment states that any party may terminate the LOI in writing prior to the end of the term.\n\n**_Defined Contribution Plan_**\n\nEffective January 1, 2019, the Company established a qualified defined contribution plan (the “401(k) Plan”) pursuant to Section 401(k) of the Code, whereby all eligible employees may participate. Participants may elect to defer a percentage of their annual pretax compensation to the 401(k) plan, subject to defined limitations. The Company is required to make contributions to the 401(k) Plan equal to 3 percent of each participant’s eligible compensation, subject to limitations under the Code. For the three and nine months ended September 30, 2024, the Company charged operations $0 and $(25,904), respectively, for contributions under the 401(k) Plan. For the three and nine months ended September 30, 2023, the Company charged operations $56,078 and $118,815, respectively, for contributions under the 401(k) Plan.\n\n**_Purchase commitments._**\n\nAs of September 30, 2024, the Company had aggregate purchase commitments of approximately $1,849,386 for future services or products, some of which are subject to modification or cancellations.\n\n**_Litigation_**\n\n_Threatened litigation._\n\nOn December 4, 2023, the Company received a threat of litigation for the termination of employment with the Company alleging the termination of employment was in retaliation for bringing to the attention of the Company’s board of directors and executives a series of wrongful and questionable practices by members of the Company’s board of directors, Chief Executive Officer and Chief Financial Officer. The claimant sought compensation in the amount of $775,782. After an investigation conducted by the Board and guidance of legal counsel, it was concluded that the claim was without merit.\n\nOn February 22, 2024, the Company received a threat of litigation seeking restitution for losses resulting from unlawful actions taken by the Company’s board of directors. The claimant contends that he and others have sustained losses totaling $1,440,000. On March 22, 2024, the claimant sent another letter to the Company referencing the previous letter and requesting several documents. The Company believes that these claims are without merit.\n\nOn March 22, 2024, plaintiff, Michael Gray Fleming (the “Plaintiff”), filed a lawsuit in Hennepin County, Minnesota District Court naming the Company, its former Chief Executive Officer and former Chief Financial Officer as defendants. The Plaintiff contends that the Company failed to meet its obligations in issuing the Plaintiff stock certificates under the terms of a restricted stock award agreement. Plaintiff is seeking at least $288,000 in damages. The Company believes Plaintiff’s allegations are baseless, and its intent is to contest the allegations vigorously. As of the date of this report, the Company is unable to provide an evaluation of the outcome of the litigation or to provide an estimate of the amount of or a range of potential loss that might be incurred by the Company. The Company has moved to dismiss Plaintiff’s claims; a hearing was set in September 2024. The motion has been fully briefed, and the parties argued the motion to the Court. A ruling is expected in mid-December. The Company also has learned that, following expiration of the SEC Rule 144 waiting period for affiliate/control shares, Plaintiff was able to have his restrictions removed. The Company believes that these claims are without merit.\n\nWe may be subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.\n\nThere are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more than 5% of our common stock is an adverse party or has a material interest adverse to our interest.\n\n27  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n**_Stock-based compensation_**\n\nThe Company takes some tax positions, including the reporting of stock-based compensation, that may not be accepted by the Internal Revenue Service upon an examination, and we may be subject to penalties for underreporting of recipient’s income. The result of any such examination is uncertain, and any such penalties could be material to our financial position and results of operations given our current limited cash and revenues.\n\n**NOTE 13** – **SEGMENT REPORTING**\n\nIn accordance with ASC 280-10, the Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has three reportable segments: BioSig Technologies, Inc. (parent), ViralClear Pharmaceuticals, Inc. and BioSig AI Sciences, Inc.\n\nInformation concerning the operations of the Company’s reportable segments is as follows:\n\nSCHEDULE OF SEGMENT REPORTING\n\nThree Months Ended | Three Months Ended | Nine Months Ended | Nine Months Ended  \n---|---|---|---  \nSeptember 30, | September 30, | September 30, | September 30,  \n2024 | 2023 | 2024 | 2023  \n(000’s) | (000’s) | (000’s) | (000’s)  \nRevenues (from external customers)  \nBioSig | $|  - | $|  1 | $| 27 | $| 6  \nViralClear | - | - | - | -  \nBioSig AI Sciences | - | - | - | -  \nRevenues | $| - | $| 1 | $| 27 | $| 6  \nThree Months Ended | Three Months Ended | Nine Months Ended | Six Months Ended  \n---|---|---|---  \nSeptember 30, | September 30, | September 30 | September 30  \n2024 | 2023 | 2024 | 2023  \n(000’s) | (000’s) | (000’s) | (000’s)  \nOperating Expenses:  \nBioSig | $| 2,950 | $| 5,526 | $| 11,658 | $| 23,527  \nViralClear | - | (1,863| ) | 45 | (1,583| )  \nBioSig AI Sciences | - | 389 | 3 | 407  \nOperating Expenses | $| 2,950 | $| 4,052 | $| 11,706 | $| 22,351  \nThree Months Ended | Three Months Ended | Nine Months Ended | Nine Months Ended  \n---|---|---|---  \nSeptember 30, | September 30, | September 30, | September 30,  \n2024 | 2023 | 2024 | 2023  \n(000’s) | (000’s) | (000’s) | (000’s)  \nLoss from Operations:  \nBioSig | $| (2,950| ) | $| (5,525| ) | $| (11,631| ) | $| (23,521| )  \nViralClear | - | 1,863 | (45| ) | 1,583  \nBioSig AI Sciences | - | (389| ) | (3| ) | (407| )  \nLoss from Operations | $| (2,950| ) | $| (4,051| ) | $| (11,679| ) | $| (22,345| )  \n  \n28  \n---  \n  \n**BIOSIG TECHNOLOGIES, INC.**\n\n**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**\n\n**SEPTEMBER 30, 2024**\n\n**_(unaudited)_**\n\n**September 30, 2024** **(000’s)** | **December 31, 2023** **(000’s)**  \n---|---  \nTotal Assets  \nBioSig | $| 108 | $| 485  \nViralClear | - | -  \nBioSig AI Sciences | 1,310 | 1,313  \nTotal Assets | $| 1,418 | $| 1,798  \n  \n**NOTE 14** – **RELATED PARTY TRANSACTIONS**\n\nOn June 5, 2024, the Company and Mr. Ferdinand Groenewald entered into a consulting agreement (the “Agreement”) effective June 5, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s interim chief financial officer, principal accounting officer and vice president of finance. The Agreement will continue indefinitely until terminated by either party upon 30 days’ advance notice. The Agreement provides for compensation at a fixed rate of $15,000 per month and reimbursement by the Company for any usual and customary business expenses incurred by Mr. Groenewald in connection with performing services pursuant to the Agreement. In addition, the Agreement provides for the Company to indemnify Mr. Groenewald on terms customary for officers.\n\nAccounts payable and accrued expenses include due to related parties comprised primarily director fees and travel reimbursements. Due to related parties as of September 30, 2024 and December 31, 2023 was $0 and $30,000, respectively.\n\nOn March 1, 2024, the Company issued 500,000 shares of common stock to Frederick D Hrkac, director in exchange for consulting services with a fair value of $352,550, pursuant to a consulting agreement dated March 1, 2024.\n\nOn March 1, 2024, the Company issued 500,000 shares of common stock to Anthony Amato, CEO and director in exchange for services with a fair value of $352,550.\n\nOn June 7, 2024, the Company issued 50,000 shares of common stock to Anthony Amato, CEO and director in exchange for services with a fair value of $93,250.\n\nOn March 7, 2024, the company issued a promissory note to a significant shareholder for $500,000 (See Note 8.) This note was subsequently converted into shares of common stock (See Note 9).\n\n**NOTE 15** – **SUBSEQUENT EVENTS**\n\nThe Company has evaluated subsequent events from the balance sheet date through the date on which these condensed financial statements were issued. Other than as described in the notes above, the Company did not have any material subsequent events that impacted its condensed financial statements or disclosures.\n\nSubsequent to September 30, 2024, the Company issued 325,000 shares of common stock for vested restricted stock.\n\nSubsequent to September 30, 2024, the Company issued 250,000 shares of common for services provided by a consultant.\n\nOn October 17, 2024, the Company’s board of directors agreed to amend the existing 391,703 warrants that were issued under the Securities Purchase Agreement dated May 1, 2024 with an exercise price of $1.398. Per the amendment the Company agreed to reduce the exercise price of the warrants to $0.30. Since the modification, various investors requested a cashless exercise of their warrants, and the Company issued an aggregate of $42,833 shares of common stock of the Company.\n\n29  \n---  \n  \n**ITEM 2. MANAGEMENT** ’**S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**\n\n_This Management_ ’ _s Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements that reflect Management_ ’ _s current views with respect to future events and financial performance. You can identify these statements by forward-looking words such as_ “ _may,_ ” “ _will,_ ” “ _expect,_ ” “ _anticipate,_ ” “ _believe,_ ” “ _estimate_ ” _and_ “ _continue,_ ” _or similar words. Those statements include statements regarding the intent, belief or current expectations of us and members of our management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements._\n\n_Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission. Important factors currently known to Management could cause actual results to differ materially from those in forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions. Factors that could cause differences include, but are not limited to, expected market demand for our products, fluctuations in pricing for materials, and competition._\n\n**Business Overview**\n\nBioSig Technologies is a medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), we are committed to addressing healthcare’s biggest priorities — saving time, saving costs, and saving lives.\n\nOur first product, the PURE EP™ System, is an FDA 510(k) cleared non-invasive class II device consisting of a unique combination of hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals paving the way for personalized patient care. Integrating with existing systems in the EP lab, PURE EP™ is designed to accurately pinpoint even the most complex signals to maximize procedural success and efficiency.\n\nBy capturing critical cardiac signals—even the most complex, the PURE EP™ System is designed to enhance clinical decision-making and improve clinical workflow for all types of arrhythmias - even the most challenging procedures for cardiac arrhythmias, like ventricular tachycardia (VT) and atrial fibrillation (AF).\n\nOn July 1, 2024, the Company announced the intent to acquire the assets of Neuro-Kinesis Corporation (NKC), a privately held Los Angeles-based medical technology company developing smart EP tools. A non-binding letter of intent (LOI) has been executed confirming BioSig’s preliminary interest in the proposed acquisition of the assets of NKC. The purchase price will be paid through the issuance of shares of BioSig’s common stock to the shareholders of NKC. In addition, at closing, NKC will provide a minimum of $2.5 million, but could provide up to $6 million, of unrestricted cash to BioSig. The proposed acquisition will require extensive due diligence, potentially through year-end, with full disclosures in the Company’s next proxy statement for shareholder vote.\n\nOur owned patent portfolio now includes 41 issued/allowed utility patents (29 utility patents where BioSig is at least one of the applicants). Twenty-seven additional U.S. and foreign utility patent applications are pending covering various aspects of our PURE EP System for recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures (27 U.S. and foreign utility patent applications where either BioSig, Mayo, or both is at least one of the applicants). We also have one U.S. patent and one U.S. Pending application directed to artificial intelligence (AI). We also have 30 issued worldwide design patents, which cover various features of our display screens and graphical user interface for enhanced visualization of biomedical signals (30 design patents where BioSig is at least one of the applicants). Finally, we have licenses to 12 (issued/allowed) patents and 9 additional worldwide utility patent applications from Mayo Foundation for Medical Education and Research that are pending (12 issued/allowed patents and 9 applications where only Mayo is the applicant). These patents and applications are generally directed to electroporation and stimulation.\n\n30  \n---  \n  \n_Notices of Delisting_\n\nOn March 5, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq (the “Staff”) stating that the Company has not regained compliance with Listing Rule 5550(a)(2) because the Company’s common stock did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market, and the Company is not eligible for a second 180 day cure period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market, and that accordingly, Nasdaq would delist the Company’s common stock unless the Company requested an appeal of this determination. On March 11, 2024, the Company submitted a request for a hearing before the Nasdaq Hearings Panel to appeal the Staff’s delisting determination.\n\nOn March 12, 2024, the Company received a letter from the Staff stating that based upon the Staff’s review of the Company and pursuant to Listing Rule 5101, the Staff believes that the Company no longer has an operating business and is a “public shell,” and that the continued listing of its securities is no longer warranted, in view of work force reductions and resignations of members of the board of directors and officers (see below).\n\nThe letter further stated that the Company no longer meets the requirement of Rule 5550(b)(2) to maintain a minimum Market Value of Listed Securities of $35 million, if none of the other standards set forth in Rule 5550(b) is met.\n\nThe Staff stated that the foregoing matters serve as an additional basis for delisting the Company’s common stock from The Nasdaq Stock Market, and that the Hearings Panel will consider this matter in rendering a determination regarding the Company’s continued listing on The Nasdaq Capital Market.\n\nOn June 10, 2024, the Company received formal notice that the Nasdaq Hearings Panel had determined to delist the Company’s common stock from Nasdaq due to the Company’s continued non-compliance with the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(2) for continued listing on Nasdaq. As a result, trading in the Company’s common stock will be suspended on Nasdaq effective with the open of business on Wednesday, June 12, 2024. The Company’s common stock should be eligible to trade on the OTC Markets’ Pink Current Information tier under symbol “BSGM” effective with the open of trading on Wednesday, June 12, 2024. The Company sought the Panel’s reconsideration of its decision in accordance with the Nasdaq Listing Rules\n\nOn June 24, 2024, the Company was notified by Nasdaq that the Nasdaq Hearings Panel had declined to reconsider its decision dated June 10, 2024 to delist the Company’s common stock from Nasdaq (the “Delisting Decision”). Trading in the Company’s securities was suspended on Nasdaq effective with the open of business on June 12, 2024, at which point the Company’s common stock was eligible to trade on the OTC Market’s Pink Current Information tier.\n\nOn July 10, 2024, the Company filed a submission in support of an appeal to the Delisting Decision to the Nasdaq Listing and Hearing Review Council and is currently awaiting a decision.\n\nOn July 23, 2024, the Company commenced trading of its common stock on the OTCQB, operated by OTC Markets Group, Inc On October 18, 2024, the Company received a decision from the Nasdaq Listing and Hearing Review Council granting the Company a grace period until March 7, 2025 to regain compliance with the Nasdaq Listing Rule 5550(b)(2), the MVLS Rule, which requires a market value of listed securities of at least $35 million.\n\nOn October 21, 2024, the Company was notified that its common stock will commence trading on The Nasdaq Stock Market on Wednesday, October 23, 2024 effective at the opening of trading.\n\nOn October 24, 2024, the Company received a letter from the Nasdaq Listing Qualifications (“Nasdaq”) notifying the Company that based upon the closing bid price of the Company’s common stock from the period of June 11, 2024 through the reinstatement date, October 23, 2024, the Company did not meet the minimum bid price of $1.00 per share required by the Listing Rules (“Rules”) and as a result, the Company no longer meets this requirement. However, the Rules also provides the Company a compliance period of 180 calendar days in which to regain compliance.\n\nOn November 13, 2024, the Company issued a press release announcing its Nasdaq bid price compliance.\n\nIf at any time during this 180 day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary.\n\n_Private Placement:_\n\nOn May 1, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company sold to the Investors an aggregate of 783,406 shares of the Company’s common stock at a purchase price of $1.4605 per share, and warrants to purchase up to 391,703 shares of common stock at an exercise price of $1.398 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $1,144,164, including $634,999 in cash and $509,165 representing conversion of the principal balance of and accrued interest on the previously issued related party note payable. The note was not convertible by its terms, but the holder has agreed to convert it into shares of common stock and warrants under the Purchase Agreement as described above. (See Note 9).\n\nOn May 29, 2024, the Company entered into a securities purchase agreement (the “SPA”) with certain institutional investors, pursuant to which the Company agreed to sell and issue to the investors (i) in a registered direct offering, 1,570,683 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.91 per share and (ii) in a concurrent private placement, common stock purchase warrants (the “Private Placement Warrants”) to purchase up to an aggregate of 1,570,683 shares of Common Stock, at an exercise price of $1.78 per share of Common Stock.\n\n31  \n---  \n  \n_Lack of funding, workforce reductions, resignations and appointments of members of the Company’s board of directors and certain officers_\n\nOn January 28, 2024 and February 20, 2024, management of the Company commenced a workforce reduction intended to reduce significantly the annual cash burn which was completed as of February 20, 2024. The workforce reduction consisted of the departure of sixteen employees, effective as of January 31, 2024 and included the departure of John Sieckhaus, the Company’s Chief Operating Officer, and Gray Fleming, the Company’s Chief Commercial Officer and twenty six employees effective February 20, 2024. The effect of the workforce reductions had significantly reduce operations in the short-term.\n\nOn February 15, 2024, Steve Buhaly resigned from his position as the Chief Financial Officer of the Company effective as of the same date.\n\nOn February 19, 2024, David Weild IV, Donald E. Foley, Patrick J. Gallagher and James J. Barry, resigned from their positions as directors of the Company, effective as of the same date.\n\nOn February 20, 2024, James L. Klein and Frederick D. Hrkac resigned from their positions as directors of the Company, effective as of the same date.\n\nOn February 20, 2024 due to lack of funding, the company had laid off the entire workforce except for the CEO.\n\nOn February 27, 2024, the company re-appointed Frederick D. Hrkac as a director and the president and principal executive officer. Additionally, on February 27, 2024, Kenneth L. Londoner resigned from his positions as director, executive chairman and chief executive officer of the Company and from any and all committees, offices, appointments, designations, responsibilities or other capacities related to the Company or any of its subsidiaries, effective as of the same date.\n\nOn April 30, 2024, the board of directors appointed former advisory board member and consultant, Anthony Amato as a director, president, chief executive officer and principal executive officer, effective immediately. In connection with the appointment of Mr. Amato, Mr. Hrkac tendered his resignation as president and principal executive officer effective as of the same date, however, continues to serve as a director and acted as chief financial officer until June 5, 2024.\n\nOn May 2, 2024, the board of directors appointed Mr. Chris Baer as a director on the Board.\n\nOn May 3, 2024, the board of directors appointed Messrs. Steven E. Abelman and Donald F. Browne as directors on the board.\n\nOn June 5, 2024, Frederick D. Hrkac resigned as acting chief financial officer and principal accounting officer of the Company, effective as of the same date. Also on June 5, 2024, the Company and Ferdinand Groenewald entered into the Agreement effective June 5, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald currently serves as the Company’s interim chief financial officer, principal accounting officer and vice president of finance. The Agreement will continue indefinitely until terminated by either party upon 30 days’ advance notice. The Agreement provides for compensation at a fixed rate of $15,000 per month and reimbursement by the Company for any usual and customary business expenses incurred by Mr. Groenewald in connection with performing services pursuant to the Agreement. In addition, the Agreement provides for the Company to indemnify Mr. Groenewald on terms customary for officers.\n\nCurrently, the Company has 5 employees and 6 key consultants. Dependent upon funding, the Company would plan on hiring a team of 4-6 persons to execute the business development strategy of finding partners for the commercialization of PURE EP, develop new products in the field of Pulse Field Ablation and to continue to integrate PURE EP into today’s lab equipment.\n\n**Results of Operations (000** ’**s)**\n\nWe anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, such as the progress of our research and development and commercialization efforts, the timing and outcome of future regulatory submissions and uncertainty around the current pandemic. Due to these uncertainties, accurate predictions of future operations are difficult or impossible to make.\n\n32  \n---  \n  \n**_Three Months Ended September 30, 2024 Compared to Three Months September 30, 2023 (000_** ’** _s)_**\n\n_Revenues and Cost of Goods Sold_. Revenue for the three months ended September 30, 2024 was $0, comprised of recognized service revenue, as compared to $1, comprised of recognized service revenue for the three months ended September 30, 2023.\n\nWe derive our revenue primarily from the sale of our medical device, PURE EP Platform, as well as related support and maintenance services and software upgrades in connection with the device.\n\nWe recognize revenue in accordance with Accounting Standards Codification (ASC) 842, _Leases_ for lease components and ASC 606, _Revenue from Contracts with Customers_ (“ASC 606”) for non-lease components. For medical device sales, we recognize revenue under ASC 606.\n\nThe core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.\n\n_Research and Development Expenses_. Research and development expenses for the three months ended September 30, 2024 were $156, a decrease of $989, or 86.38%, from $1,145 for the three months ended September 30, 2023. The decrease is primarily due to decreases in payroll, consulting, Data/AI development and research and clinical studies and design work to $139 for the three months ended September 30, 2024 as compared to $1,066 for the three months ended September 30, 2023.\n\nResearch and development expenses were comprised of the following:\n\nThree months ended:\n\n**September 30,** **2024** | **September 30,** **2023**  \n---|---  \nSalaries and equity compensation | $|  105 | $|  815  \nConsulting expenses | - | 135  \nResearch and clinical studies and design work | 34 | 62  \nData/AI development | - | 54  \nRegulatory | 1 | 21  \nTravel, supplies, other | 16 | 58  \nTotal | $| 156 | $| 1,145  \n  \nStock based compensation for research and development personnel was $7 and $147 for the three months ended September 30, 2024 and 2023, respectively.\n\n_General and Administrative Expenses._ General and administrative expenses for the three months ended September 30, 2024 were $2,763, a decrease of $52 or 1.85%, from $2,815 incurred in the three months ended September 30, 2023. This decrease is primarily due to a decrease in employee and service provider (stock-based) performance pay in the current period as compared to the same period in the prior year and additional service provider fees paid.\n\nPayroll related expenses, including stock-based compensation expenses, increase to $1,744 in the current period from $1,302 for the three months ended September 30, 2023, an increase of $442, or 33.95%. The increase was primarily due to increase stock-based compensation in the current period compared to the prior period. We incurred $1,510 in stock-based compensation in connection with the vesting of stock and stock options issued to board members, officers, employees and consultants for the three months ended September 30, 2024 as compared to $(506) in stock-based compensation for the same period in 2023.\n\nProfessional services for the three months ended September 30, 2024 totaled $227, a decrease of $14, or 5.81%, over the $241 recognized for the three months ended September 30, 2023. Of professional services, the decrease is mainly attributed to a decrease in legal expenses and accounting fees in the current period as compared to the prior period.\n\nConsulting, public and investor relations fees for the three months ended September 30, 2024 were $527 as compared to $734 incurred for the three months ended September 30, 2023, a decrease of $207, or 28.20%. The decrease primarily related to a reduction in investor relations, marketing and consulting during the three months ended September 30, 2024 as compared to the same period, last year.\n\nTravel, meals and entertainment costs for the three months ended September 30, 2024 were $99, a decrease of $66, or 40%, from $165 incurred in the three months ended September 30, 2023. Travel, meals and entertainment costs include travel related to business development and financing. The decrease in 2024 was due to staff reductions in 2024 as compared to 2022.\n\nRent for the three months ended September 30, 2024 and 2023 was $38 and $96.\n\n_Impairment of Long Term Assets._ During the three months ended September 30, 2024, the Company re-assessed it’s carrying amounts of certain property and equipment due to reduced manufacturing of its commercial products and determined that these carrying amounts did not exceed the estimated undiscounted future cash flows. Accordingly, the Company recorded no impairment charge.\n\n33  \n---  \n  \n_Depreciation and Amortization Expense._ Depreciation and amortization expense for the three months ended September 30, 2024 totaled $31, a decrease of $61, or 66.30%, over the expense of $92 incurred in the three months ended September 30, 2023, as a result aging of equipment.\n\n_Other Income (Expense)._ Other income (expense) for the three months ended September 30, 2024 totaled $1,036, an increase in other income of $1,035, over the income of $1 incurred in the three months ended September 30, 2023, as a direct result of our gain on settlement and forgiveness of accounts payable negotiated by management during the current period.\n\n_Preferred Stock Dividend_. Preferred stock dividend for the three months ended September 30, 2024 and 2023 totaled $26 and $2, respectively. Preferred stock dividends are related to the dividends accrued on our Series C Preferred Stock issued during the period from 2013 through 2015.\n\n_Net Loss Attributable to BioSig Technologies, Inc. Common Shareholders_. As a result of the foregoing, net loss attributable to common shareholders for the three months ended September 30, 2024 was $1,940 compared to a net loss of $4,569 for the three months ended September 30, 2023.\n\n**_Nine months ended September 30, 2024 Compared to nine months ended September, 2023 (000_** ’** _s)_**\n\n_Revenues and Cost of Goods Sold_. Revenue for the nine months ended September 30, 2024 was $27, comprised of recognized service revenue, as compared to $6, comprised of recognized service revenue for the nine months ended September 30, 2023.\n\nWe derive our revenue primarily from the sale of our medical device, PURE EP Platform, as well as related support and maintenance services and software upgrades in connection with the device.\n\nWe recognize revenue in accordance with Accounting Standards Codification (ASC) 842, _Leases_ for lease components and ASC 606, _Revenue from Contracts with Customers_ (“ASC 606”) for non-lease components. For medical device sales, we recognize revenue under ASC 606.\n\nThe core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.\n\n_Research and Development Expenses_. Research and development expenses for the nine months ended September 30, 2024 were $736, a decrease of $3,180, or 81.21%, from $3,916 for the nine months ended September 30, 2023. The decrease is primarily due to decreases in payroll, consulting, Data/AI development and research and clinical studies and design work to $674 for the nine months ended September 30, 2024 as compared to $6,695 for the nine months ended September 30, 2023 primarily in the BioSig Technologies segment, a decrease of $3,021 or 81.76%.\n\nResearch and development expenses were comprised of the following:\n\nNine months ended:\n\n**September 30,** **2024** | **September 30,** **2023**  \n---|---  \nSalaries and equity compensation | $|  469 | $|  3,063  \nConsulting expenses | 120 | 203  \nResearch and clinical studies and design work | 85 | 338  \nData/AI development | - | 91  \nRegulatory | 3 | 64  \nTravel, supplies, other | 59 | 157  \nTotal | $| 736 | $| 3,916  \n  \nStock based compensation for research and development personnel was $83 and $998 for the nine months ended September 30, 2024 and 2023, respectively.\n\n_General and Administrative Expenses._ General and administrative expenses for the nine months ended September 30, 2024 were $10,559, a decrease of $7,608 or 41.88%, from $18,167 incurred in the nine months ended September 30, 2023. This decrease is primarily due to a decrease in employee and service provider (stock-based) performance pay in the current period as compared to the same period in the prior year and additional service provider fees paid.\n\nPayroll related expenses, including stock-based compensation expenses, decreased to $7,481 in the current period from $11,366 for the nine months ended September 30, 2023, a decrease of $3,885, or 34.18%. The decrease was primarily due to reduced staff in commercialization, sales and general and administration in the BioSig Technologies segment. We incurred $6,508 in stock-based compensation in connection with the vesting of stock and stock options issued to board members, officers, employees and consultants for the nine months ended September 30, 2024 as compared to $5,534 in stock-based compensation for the same period in 2023.\n\nProfessional services for the nine months ended September 30, 2024 totaled $884, a decrease of $26 or 2.88%, over the $910 recognized for the nine months ended September 30, 2023. Of professional services, legal fees totaled $556 for the nine months ended September 30, 2024; a decrease of $24, or 4.14%, from $580 incurred for the nine months ended September 30, 2023. The decrease in legal fees are primarily due to costs reduced costs incurred in 2024 for contract work and patent filings for the BioSig Technologies segment as compared to the nine months ended September 30, 2023. Accounting fees incurred in the nine months ended September 30, 2024 amounted to $139, a decrease of $17, or 10.90%, from $156 incurred in same period last year. In 2023, we incurred added accounting fees relating to financing in our BioSig Technologies segment.\n\nConsulting, public and investor relations fees for the nine months ended September 30, 2024 were $986 as compared to $2,733 incurred for the nine months ended September 30, 2023, a decrease of $1,747, or 63.92%. The decrease primarily related to a reduction in investor relations, marketing and consulting during the nine months ended September 30, 2024 as compared to the same period, last year.\n\nTravel, meals and entertainment costs for the nine months ended September 30, 2024 were $308, a decrease of $285, or 48.06%, from $593 incurred in the nine months ended September 30, 2023. Travel, meals and entertainment costs include travel related to business development and financing. The decrease in 2024 was due to staff reductions in 2024 as compared to 2022.\n\n34  \n---  \n  \nRent for the nine months ended September 30, 2024 and 2023 was $203 and $281.\n\n_Impairment of Long Term Assets._ During the nine months ended September 30, 2024, the Company re-assessed it’s carrying amounts of certain property and equipment due to reduced manufacturing of its commercial products and determined that these carrying amounts exceeded the estimated undiscounted future cash flows. Accordingly, the Company recorded a $253 impairment charge to current operations.\n\n_Depreciation and Amortization Expense._ Depreciation and amortization expense for the nine months ended September 30, 2024 totaled $158, a decrease of $110, or 41.04%, over the expense of $268 incurred in the nine months ended September 30, 2023, as a result aging of equipment.\n\n_Other Income (Expense)._ Other income (expense) for the nine months ended September 30, 2024 totaled $2,439, an increase in other income of $2,656, over the expense of $(217) incurred in the nine months ended September 30, 2023, as a direct result of our gain on settlement and forgiveness of accounts payable negotiated by management during the current period.\n\n_Preferred Stock Dividend_. Preferred stock dividend for the nine months ended September 30, 2024 totaled $164, an increase of $157 over the expense of $7 incurred in the nine months ended September 30, 2023. Preferred stock dividends are related to the dividends accrued on our Series C Preferred Stock issued during the period from 2013 through 2015. In addition, the Series C Preferred stock conversion rate reset from $2.50 to $0.41 during the nine months ended September 30, 2024, therefore we recorded a non-cash deemed preferred stock dividend of $157 in the current period.\n\n_Net Loss Attributable to BioSig Technologies, Inc. Common Shareholders_. As a result of the foregoing, net loss attributable to common shareholders for the nine months ended September 30, 2024 was $9,395 compared to a net loss of $22,999 for the nine months ended September 30, 2023.\n\n**_Segment Results_**\n\nThe Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments.\n\nSummary Statement of Operations for the three and nine months ended September 30, 2024 as compared to the three and nine months ended September 30, 2023 are detailed in Note 13 of the accompanying unaudited condensed consolidated financial statements.\n\n**Liquidity and Capital Resources and Going Concern ($000** ’**s)**\n\nAs of September 30, 2024, we had a working capital deficit of $853, comprised of cash of $615, accounts receivable of $81, current portion of net investments in leases of $39 and prepaid expenses and other current assets of $113, which was offset by $1,448 of accounts payable and accrued expenses, accrued dividends on preferred stock issuances of $108 and of current portion of lease liability of $145. For the nine months ended September 30, 2024, we used $4,284 of cash in operating activities and nil of cash in investing activities.\n\n_Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023 (000_ ’ _s)_\n\nCash provided by financing activities totaled $4,709, comprised of proceeds from the sale of our common stock and warrants, net of expenses, of $4,209 and proceeds from issuance of a related party note of $500.\n\nIn the comparable period in 2023, our aggregate cash provided by financing activities totaled $14,585 comprised of proceeds from the sale of our common stock and warrants. At September 30, 2024, we had cash of $615 compared to $389 at September 30, 2023. Our cash is held in bank deposit accounts. At September 30, 2024 and 2023, we had no convertible debentures outstanding.\n\nCash used in operations for the nine months ended September 30, 2024 and 2023 was $4,284 and $14,371, respectively, which represent cash outlays for research and development and general and administrative expenses in such periods. The decreases in cash outlays principally resulted in reduced operating costs, general and administrative expenses in 2024 and with net decreases in our operating assets of $114 and a net increase in our operating liabilities of $5,242.\n\nWe used nil cash for investing activities for the nine months ended September 30, 2024, compared to $182 for the nine months ended September 30, 2023. For the comparable period, we purchased computers and other equipment.\n\nWe had an accumulated deficit as of September 30, 2024 of $254.24 million, as well as a net loss attributable to BioSig of $9.2 million and negative operating cash flows. We expect to continue incurring losses and negative cash flows from operations until our products (primarily PURE EP Platform) reach full commercial profitability.\n\nThese conditions raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is an issue raised due to our net losses and negative cash flows from operations since inception and our expectation is that these conditions will continue for the foreseeable future. In addition, we will require additional financing to fund future operations. Although we have commercial products available for sale, we have not generated significant revenues to date, and there is no assurance that we will be able to generate cash flow to fund operations. In addition, there can be no assurance that our research and development will be successfully completed or that any additional products will be approved or commercially viable. Our ability to continue as a going concern is subject to our ability to obtain necessary funding from outside sources, including obtaining additional funding from the sale of our securities, obtaining loans from various financial institutions or being awarded grants from government agencies, where possible. Our continued net operating losses increase the difficulty in meeting such goals and there can be no assurances that such methods will prove successful. Additionally, with our reduction in staff, our planned commercialization may be further delayed.\n\nOur plans include the continued commercialization of the PURE EP System and other applications of our core technology and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. Our shift from a focus on technology development to commercialization has allowed us to reduce our annual expenses in a meaningful way. As a result of this transition, we have been able to achieve savings through reductions in executive and management compensation and a reduction of our utilization of external consultants and professional service providers. We believe these cost-saving measures combined with our expectations of positive trends in commercial activity create the potential for us to achieve a lower cash flow breakeven rate. There are no assurances, however, that we will be successful in obtaining the level of financing needed for our operations. The ongoing COVID-19 pandemic has resulted and continues to result in significant financial market volatility and uncertainty in recent months. In addition, U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine.\n\n35  \n---  \n  \nA continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital and on the market price of our common stock, and we may not be able to successfully raise capital through the sale of our securities.\n\nOur Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of (a) 120% of the stated value of $1 or (b) the product of (I) the variable weighted average price of our common stock on the trading day immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%. As of September 30, 2024, the aggregate stated value of our Series C Preferred Stock was $105. The triggering events include our being subject to a judgment of greater than $100 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred Stock occur, the holders of our Series C Preferred Stock may demand redemption, an obligation we may not have the ability to meet at the time of such demand. We will be required to pay interest on any amounts remaining unpaid after the required redemption of our Series C Preferred Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable law.\n\nWe expect to incur losses from operations for the near future. We expect to incur additional marketing and commercialization expenses related to our PURE EP system in addition to additional research and development costs relating to the PURE EP and other product candidates, including expenses related to clinical trials. We expect that our general and administrative expenses will increase in the future as we expand our business development, add infrastructure and incur additional costs related to being a public company, including incremental audit fees, investor relations programs and increased professional services.\n\nOur future capital requirements will depend on a number of factors, including the progress of our research and development of product candidates, the timing and outcome of regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing and our success in developing markets for our product candidates.\n\nFuture financing may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, existing holders of our securities may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our securities.\n\nIf additional financing is not available or is not available on acceptable terms, we may be required to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.\n\n_Equity Financing_\n\nOn January 12, 2024, we entered into a securities purchase agreement with certain accredited and institutional investors, pursuant to which we sold to the investors an aggregate of 260,720 shares of our common stock and warrants to purchase up to 130,363 shares of common stock, at a purchase price of $3.989 per share and a warrant to purchase one-half of a share. The warrants have an exercise price of $3.364 per share, will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance. The gross proceeds from this offering were $1,040,000.\n\nOn May 1, 2024, we entered into a securities purchase agreement with certain accredited investors, pursuant to which we sold to the Investors an aggregate of 783,406 shares of our common stock at a purchase price of $1.4605 per share, and warrants to purchase up to 391,703 shares of common stock at an exercise price of $1.398 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $1,144,164, including $634,999 in cash and $509,165 representing conversion of the principal balance of and accrued interest on the previously issued related party note payable. The note was not convertible by its terms, but the holder has agreed to convert it into shares of common stock and warrants under the purchase agreement as described above. (See Below).\n\nOn May 29, 2024, the Company entered into a securities purchase agreement (the “SPA”) with certain institutional investors, pursuant to which the Company agreed to sell and issue to the investors (i) in a registered direct offering, 1,570,683 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.91 per share and (ii) in a concurrent private placement, common stock purchase warrants (the “Private Placement Warrants”) to purchase up to an aggregate of 1,570,683 shares of Common Stock, at an exercise price of $1.78 per share of Common Stock.\n\n36  \n---  \n  \nOn May 30, 2024, the Company closed the registered direct offering and the concurrent private placement (collectively, the “Offering”), raising gross proceeds of approximately $3.0 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.\n\n_Issuance of Debt_\n\nOn March 7, 2024, we issued a promissory note to an investor and an affiliate (10% or more shareholder) for $500,000. We designated its 12% note due 2026, in accordance with exemptions from registration under the Securities Act of 1933, as amended (the “Securities Act”).\n\nThe note is due March 7, 2026. We promise to pay interest in cash on the unpaid principal amount of this note at a rate per annum equal to twelve percent (12%), commencing to accrue on the date hereof and payable on the maturity date or earlier prepayment as provided therein. The Note contains customary events of default.\n\nWe may prepay all or any portion of the principal amount of the Note at any time or from time to time without penalty.\n\nOn May 1, 2024, we converted the promissory note and related accrued interest of $509,165 into 348,624 shares of common stock and warrants to purchase 174,312 shares of common stock at $1.398 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance.\n\n**Critical Accounting Estimates**\n\nThe following discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S. The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements. The consolidated financial statements include estimates based on currently available information and our judgment as to the outcome of future conditions and circumstances.\n\nWe believe the following critical accounting estimates affect our more significant judgments and estimates used in the preparation of our financial statements. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Among the significant judgments made by management in the preparation of our financial statements are the following:\n\n**_Stock Based Compensation_**\n\nWe estimate the fair value of options and stock warrants granted using the Black Scholes Merton model. We estimate when and if performance-based awards will be earned. If an award is not considered probable of being earned, no amount of equity-based compensation expense is recognized. If the award is deemed probable of being earned, related equity-based compensation expense is recorded. The fair value of an award ultimately expected to vest is recognized as an expense, net of forfeitures, over the requisite service periods in our statements of operations, which is generally the vesting period of the award.\n\nThe Black Scholes Merton model requires the input of certain subjective assumptions and the application of judgment in determining the fair value of the awards. The most significant assumptions and judgments include the expected volatility, risk-free interest rate, the expected dividend yield, and the expected term of the awards. In addition, the recognition of equity-based compensation expense is impacted by our forfeitures, which are accounted for as they occur.\n\nThe assumptions used in our option pricing model represent management’s best estimates. If factors change and different assumptions are used, our equity-based compensation expense could be materially different in the future. The assumptions used in our option pricing model represent management’s best estimates. If factors change and different assumptions are used, our equity-based compensation expense could be materially different in the future.\n\n37  \n---  \n  \nAll stock-based payments to employees and to nonemployee directors for their services as directors consisted of grants of restricted stock and stock options, which are measured at fair value on the grant date and recognized in the statements of operations as compensation expense over the relevant vesting period. Restricted stock payments and stock-based payments to non-employees are recognized as an expense over the period of performance.\n\nSuch payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable, the measurement date is the date the award is issued.\n\n**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**\n\nNot required under Regulation S-K for “smaller reporting companies.”\n\n**ITEM 4. CONTROLS AND PROCEDURES**\n\n**Management** ’**s evaluation of disclosure controls and procedures.**\n\nOur management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(e) under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.\n\nBased on management’s evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are not designed at a reasonable assurance level and are not effective in providing reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.\n\n**Management** ’**s report on internal control over financial reporting.**\n\nOur management is responsible for establishing and maintaining adequate internal control over financial reporting for our company. Internal control over financial reporting is defined in Rule 13a-15(f) and 15d-15(f) promulgated under the Exchange Act, as a process designed by, or under the supervision of, a company’s principal executive and principal financial officer and effected by the our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:\n\n(1) | pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;  \n---|---  \n(2) | provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made in accordance with authorizations of management and directors of the company; and  \n(3) | provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.  \n  \nBecause of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible enhancements to controls and procedures.\n\nManagement, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023, based on the criteria in a framework developed by the Company’s management pursuant to and in compliance with the criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations (“COSO”) of the Treadway Commission. This evaluation included review of the documentation of controls, evaluation of the design effectiveness of controls, walkthroughs of the operating effectiveness of controls and a conclusion on this evaluation. Based on this evaluation, management has concluded that our internal control over financial reporting was not effective as of September 30, 2024, because management identified that i) inadequate identification, recording and reporting of stock based compensation, ii) ineffective review processes over period end financial disclosure and reporting, and (iii) inadequate segregation of duties for transaction posting and processing, amounted to a material weakness in the Company’s internal control over financial reporting.\n\n38  \n---  \n  \nThe material weaknesses did not result in any identified misstatements to the consolidated financial statements and there were no changes to previously released financial results.\n\n_Management_ ’ _s Remediation Plan_\n\nIn 2025, we have intents to add sufficient staff and oversight supervision controls to provide adequate accounting segregation. We believe these changes will remediate the underlying deficiencies as identified by us. The remediation efforts will include an ongoing review of the implementation of additional controls to ensure all risks have been addressed.\n\nAs a result of the material weaknesses discussed above or of others, we may experience negative impacts on our ability to accurately report our results of operation and financial condition in a timely manner. If we do identify a material weakness in our internal control over financial reporting and are unsuccessful in implementing or following a remediation plan, or fail to update our internal control over financial reporting as our business evolves or to integrate acquired businesses into our controls system, if additional material weaknesses are found in our internal controls in the future, or if our external auditors cannot attest to the effectiveness of our internal control over financial review, if applicable, we may not be able to timely or accurately report our financial condition, results of operations or cash flows or to maintain effective disclosure controls and procedures. If we are unable to report financial information in a timely and accurate manner or to maintain effective disclosure controls and procedures, we could be subject to, among other things, regulatory or enforcement actions by the SEC, an inability for us to be accepted for listing on any national securities exchange in the near future, securities litigation and a general loss of investor confidence, any one of which could adversely affect our business prospects and the market value of our common stock. Further, there are inherent limitations to the effectiveness of any system of controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. We could face additional litigation exposure and a greater likelihood of an SEC enforcement or other regulatory action if further restatements were to occur or other accounting-related problems emerge.\n\nThe weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.\n\n**Changes in Internal Control over Financial Reporting**\n\nThere has been no change in our internal control over financial reporting identified in connection with the evaluation referred to above that occurred during our last completed fiscal quarter that has materially negatively affected, or is reasonably likely to materially affect, our internal control over financial reporting. As discussed above, management has remediation plans that will be implemented in 2025.\n\n39  \n---  \n  \n**PART II. OTHER INFORMATION**\n\n**ITEM 1. LEGAL PROCEEDINGS**\n\nOn December 4, 2023, we received a threat of litigation for the termination of employment with the Company alleging the termination of employment was in retaliation for bringing to the attention of the Company’s board of directors and executives a series of wrongful and questionable practices by members of the Company’s board of directors, Chief Executive Officer and Chief Financial Officer. The claimant sought compensation of in the amount of $775,782. After an investigation conducted by the Board and guidance of legal counsel, it was concluded that the claim was without merit.\n\nOn February 22, 2024, we received a threat of litigation seeking restitution for losses resulting from unlawful actions taken by the Company’s board of directors. The claimant contends that he and others have sustained losses totaling $1,440,000. On March 22, 2024, the claimant sent another letter to the Company referencing the previous letter and requesting several documents. The Company believes that these claims are without merit.\n\nOn March 22, 2024, plaintiff, Michael Gray Fleming (the “Plaintiff”), filed a lawsuit in Hennepin County, Minnesota District Court naming the Company, its former Chief Executive Officer and former Chief Financial Officer as defendants. The Plaintiff contends that the Company failed to meet its obligations in issuing the Plaintiff stock certificates under the terms of a restricted stock award agreement. Plaintiff is seeking at least $288,000 in damages. The Company believes Plaintiff’s allegations are baseless, and its intent is to contest the allegations vigorously. As of the date of this report, the Company is unable to provide an evaluation of the outcome of the litigation or to provide an estimate of the amount of or a range of potential loss that might be incurred by the Company. The Company has moved to dismiss Plaintiff’s claims; a hearing is set in September 2024. The Company also has learned that, following expiration of the SEC Rule 144 waiting period for affiliate/control shares, Plaintiff was able to have his restrictions removed. In light of the pending motion and legend removal, the Company hopes that Plaintiff will simply withdraw his complaint.\n\nWe may be subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.\n\nThere are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more than 5% of our common stock is an adverse party or has a material interest adverse to our interest. \n\n40  \n---  \n  \n**ITEM 1A. RISK FACTORS**\n\nThe following description of risk factors includes any material changes to risk factors associated with our business, financial condition and results of operations previously disclosed in Item 1A. “Risk Factors” of our annual report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on April 16, 2024. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described below, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results, and stock price.\n\nThe following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding other statements in this Form 10-Q. The following information should be read in conjunction with the condensed consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q.\n\n**_Our common stock is subject to the “penny stock” rules of the SEC and the trading market in the securities is limited, which makes transactions in the stock cumbersome and may reduce the value of an investment in the stock._**\n\nRule 15g-9 under the Exchange Act, establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person’s account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.\n\nIn order to approve a person’s account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience objectives of the person and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.\n\nThe broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) confirms that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our common stock.\n\nDisclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker or dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.\n\n41  \n---  \n  \n**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES**\n\nNone.\n\n**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**\n\nNone.\n\n**ITEM 4. MINE SAFETY DISCLOSURES**\n\nNone.\n\n**ITEM 5. OTHER INFORMATION**\n\nNone.\n\n42  \n---  \n  \n**ITEM 6. EXHIBITS**\n\n**Exhibit No.** | **Description**  \n---|---  \n10.1 | [Executive Employment Agreement, dated September 11, 2024, by and between BioSig Technologies, Inc. and Anthony Amato (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on September 13, 2024)](https://www.sec.gov/Archives/edgar/data/1530766/000149315224036190/ex10-1.htm)  \n10.2 | [Form of Restricted Stock Award Agreement (incorporated by reference to Exhibit 10.2 to our Current Report on From 8-K filed with the SEC on September 13, 2024)](https://www.sec.gov/Archives/edgar/data/1530766/000149315224036190/ex10-2.htm)  \n10.3 | [Form of Stock Option Agreement (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the SEC on September 13, 2024)](https://www.sec.gov/Archives/edgar/data/1530766/000149315224036190/ex10-3.htm)  \n31.1* | [Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-1.htm)  \n31.2* | [Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-2.htm)  \n32.1** | [Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-1.htm)  \n101 INS* | Inline XBRL Instance Document  \n101 SCH* | Inline XBRL Taxonomy Extension Schema Document  \n101 CAL* | Inline XBRL Taxonomy Calculation Linkbase Document  \n101 LAB* | Inline XBRL Taxonomy Labels Linkbase Document  \n101 PRE* | Inline XBRL Taxonomy Presentation Linkbase Document  \n101 DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document  \n104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)  \n  \n* Filed herewith.\n\n** Furnished herewith.\n\n43  \n---  \n  \n**SIGNATURES**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n**BIOSIG TECHNOLOGIES, INC.**  \n---  \nDate: November 14, 2024 | By: | _/s/ Anthony Amato_  \nAnthony Amato  \nChief Executive Officer (Principal Executive Officer)  \nDate: November 14, 2024 | By: | _/s/ Ferdinand Groenewald_  \nFerdinand Groenewald  \nActing Chief Financial Officer (Principal Accounting Officer)  \n  \n44  \n---\n"
        },
        {
          "title": "Download Raw XBRL Files",
          "url": "https://ir.biosig.com/all-sec-filings/content/0001493152-24-045687/0001493152-24-045687-xbrl.zip",
          "content": null
        },
        {
          "title": "XBRL Spreadsheet",
          "url": "https://content.equisolve.net/sec/0001493152-24-045687/Financial_Report.xlsx",
          "content": null
        }
      ]
    },
    {
      "section_name": "Latest Annual Report",
      "links": [
        {
          "title": "View Annual Report",
          "url": "https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/db/359/2943/annual_report/Annual+Report_9.2.22.pdf",
          "content": "UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWASHINGTON, D.C. 20549\nFORM 10-K\nANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nFor the Fiscal Year Ended December 31, 2021\nCommission File Number 001-38659\nBIOSIG TECHNOLOGIES, INC.\n(Exact name of registrant as specified in its charter)\nDelaware 26-4333375\n(State or other jurisdiction of incorporation (IRS Employer Identification No.)\nor organization)\n55 Greens Farms Road, 1st Floor\nWestport, CT 06880 (203) 409-5444\n(Address of principal executive office) (Zip Code) (Registrant’s telephone number, Including area code)\nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class Trading Symbol(s) Name of each exchange on which registered\nCommon Stock, par value $0.001 per share BSGM The NASDAQ Capital Market\nSecurities registered pursuant to Section 12(g) of the Act: None\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. Yes ☐ No ☒\nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the\npreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90\ndays. Yes ☒ No ☐\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§\n229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth\ncompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b–2 of the Exchange\nAct.\n(Check one):\nLarge accelerated filer ☐ Accelerated filer ☐\nNon-accelerated filer ☒ Smaller reporting company ☒\nEmerging growth company ☐\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised\nfinancial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐\nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal controls over financial\nreporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\nThe aggregate market value of the voting and non-voting common equity held by non-affiliates as of June 30, 2021, based on the price at which the common stock was last\nsold on such date, is $108,511,450. For purposes of this computation, all officers, directors, and 5 percent beneficial owners of the registrant are deemed to be affiliates.\nSuch determination should not be deemed an admission that such directors, officers, or 5 percent beneficial owners are, in fact, affiliates of the registrant.\nAs of March 30, 2022, there were 38,424,059 shares of the registrant’s common stock outstanding.\nDocuments Incorporated by Reference:\nThe registrant incorporates by reference in Part III (Items 10, 11, 12, 13 and 14) of this Form 10-K portions of its Definitive Proxy Statement for the 2022 Annual\nMeeting of Stockholders, which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year.\nTABLE OF CONTENTS\nPAGE\nPART I\nItem 1. Business 4\nItem 1A. Risk Factors 24\nItem 1B. Unresolved Staff Comments 46\nItem 2. Properties 46\nItem 3. Legal Proceedings 46\nItem 4. Mine Safety Disclosures 46\nPART II\nItem 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 47\nItem 6. Reserved 47\nItem 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 47\nItem 7A. Quantitative and Qualitative Disclosures about Market Risk 55\nItem 8. Financial Statements and Supplementary Data F-1 – F-36\nItem 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures 56\nItem 9A. Controls and Procedures 56\nItem 9B. Other Information 57\nItem 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 57\nPART III\nItem 10. Directors, Executive Officers and Corporate Governance 58\nItem 11. Executive Compensation 58\nItem 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 58\nItem 13. Certain Relationships and Related Transactions, and Director Independence 58\nItem 14. Principal Accounting Fees and Services 58\nPART IV\nItem 15. Exhibits, Financial Statement Schedules 59\nItem 16. Form 10-K Summary 61\nSignatures 62\nPART I\nNote on Forward-Looking Statements\nThis Annual Report on Form 10-K (including the section regarding Management’s Discussion and Analysis of Financial Condition and Results of Operations)\ncontains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,”\n“plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to\nrepresent an all-inclusive means of identifying forward-looking statements as denoted in this Annual Report on Form 10-K. Additionally, statements concerning future\nmatters are forward-looking statements.\nAlthough forward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our management, such statements can only be based\non facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may\ndiffer materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in\nresults and outcomes include, without limitation, those specifically addressed under the heading “Risk Factors” below, as well as those discussed elsewhere in this Annual\nReport on Form 10-K. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report on Form\n10-K. We file reports with the Securities and Exchange Commission (“SEC”). The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and\ninformation statements, and other information regarding issuers that file electronically with the SEC, including us.\nWe undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this\nAnnual Report on Form 10-K. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this Annual Report on Form 10-K,\nwhich attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.\nUnless the context indicates otherwise, references in this Annual Report to “BioSig,” the “Company,” “we,” “our” and “us” mean BioSig Technologies, Inc., and\nits predecessor entities.\nITEM 1 – BUSINESS\nCorporate Structure\nWe were formed as BioSig Technologies, Inc., a Nevada corporation, in February 2009 and in April 2011 we merged with our wholly owned subsidiary, BioSig\nTechnologies, Inc., a Delaware corporation, with the Delaware corporation continuing as the surviving entity. BioSig is principally devoted to improving the standard of\ncare in electrophysiology, or EP, with our PURE EP™ System’s enhanced signal acquisition, digital signal processing, and analysis during catheter ablation of cardiac\narrhythmias. The Company has generated minimal revenue to date and consequently its operations are subject to all risks inherent in business enterprise in early\ncommercialization stage.\nOn November 7, 2018, we formed a subsidiary under the laws of the State of Delaware, originally under the name of NeuroClear Technologies, Inc., for the\npurpose of pursuing additional applications of the PURE EP™ signal processing technology outside of the field of cardiac electrophysiology. In March 2020, it was\nrenamed ViralClear Pharmaceuticals, Inc. (“ViralClear”). As of March 30, 2022, the Company retains 60.22% ownership of ViralClear. ViralClear’s Business Overview can\nbe found on pages 16.\nOn July 2, 2020, the Company formed an additional subsidiary, NeuroClear Technologies, Inc. (“NeuroClear”), a Delaware corporation, to pursue additional\napplications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. We own 100% of the outstanding shares of common stock as of March\n30, 2022 and the subsidiary is currently dormant. NeuroClear’s Business Overview can be found on page 19.\nBusiness Overview\nWe are a medical technology company that is commercializing our PURE EP™ System which is an advanced signal acquisition and processing platform designed\nto provide essential diagnostic signals with high clinical value in all types of cardiac catheter ablations. PURE EP™ is designed to address long-standing limitations that\nslow and disrupt cardiac catheter ablation procedures, such as environmental lab noise, signal saturation, slow signal recovery, and inaccurate display of fractionated\npotentials.\n4\nTable of Contents\nCardiac catheter ablation is a procedure that involves delivery of energy through the tip of a catheter that scars or destroys heart tissue to correct heart rhythm\ndisturbances (arrhythmias). In August 2018, we received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) to market our PURE (Precise\nUninterrupted Real-time evaluation of Electrograms) EP™ System.\nPURE EP™ is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable\nelectrophysiologists to see more signals and analyze them in real-time. The device aims to minimize noise and artifacts from cardiac recordings and acquire high-fidelity\ncardiac signals. Improving fidelity of acquired cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and\nefficiency of the EP studies and ablation procedures.\nPURE EP™’s initial focus is on improving intracardiac signal acquisition and enhancing diagnostic information for catheter ablation procedures for complex\narrhythmias like ventricular tachycardia (“VT”), a potentially life-threatening arrhythmia, and atrial fibrillation (“AF”), the most common cardiac arrhythmia associated\nwith a fivefold risk of stroke.\nClinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas,\nMayo Clinic in Jacksonville, Florida, and Massachusetts General Hospital in Boston, Massachusetts was published in September 2021 in the Journal of Cardiovascular\nElectrophysiology and is available electronically with open access via the Wiley Online Library1. Study results showed 93% consensus across the blinded reviewers with a\n75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals over conventional sources. AF accounted for over 40% of\nenrollments.\nWe continue to install PURE EP™ Systems at centers of excellence for clinical evaluation under our market development plan. The PURE EP™ System has been\nutilized at numerous institutions, including Mayo Clinic campuses in Arizona, Florida and Minnesota; the University of Pennsylvania Hospital in Philadelphia,\nPennsylvania; Overland Park Regional Medical System in Overland Park, Kansas; Deborah Heart and Lung Center in Browns Mills, New Jersey; St. Elizabeth’s Medical\nCenter in Boston, Massachusetts; Medical City Heart Hospital in Dallas, Texas; Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, a teaching\nhospital of Harvard Medical School; Methodist Hospital in San Antonio, Texas; Houston Methodist Hospital; Medical City North Hills in North Richland Hills; and\nWestside Regional Medical Center in Plantation, Florida.\nTo date, more than 2,160 patient procedures have been conducted with the PURE EP™ System by more than 76 electrophysiologists across seventeen different\nclinical sites in the United States.\nIn addition to clinical evaluation, we have conducted pre-clinical evaluation with the PURE EP™ System under several protocols. At Mayo Clinic in Rochester,\nMinnesota, we have performed twenty-seven experiments (including novel research programs such as Artificial Intelligence, or AI, and repolarization) in various animal\nmodels; we also conducted a pre-clinical study at the Mount Sinai Hospital in New York, New York, with an emphasis on the VT model; and six experiments to date during\na study at the University of Pennsylvania. We intend to continue additional research and development studies with our technology at Mayo Clinic, the University of\nPennsylvania and other national centers.\nIn September 2021, we announced that we entered into a manufacturing and professional services agreement with Plexus Corp (“Plexus”) (Nasdaq: PLXS). Under\nthe terms of the agreement, Plexus will manufacture the PURE EP™ System and develop a new product pipeline for our subsidiary, ViralClear.\nWe have made progress towards obtaining a European CE marking certificate for medical devices. In Q1 2022, we completed the quality management system audit\nfor the International Organization for Standardization (“ISO”) 13485:2016 with the expectation to obtain the ISO 13485:2016 certification in the first half of 2022 and\nproceed to the application for the European CE Marking clearance in the first half of 2023, subject to the guidance and availability from the European Notified Body.\nIn January 2022, U.S. patent claims for our PURE EP™ noise-filtering technology which address computer-implemented systems and methods for filtering noise\nfrom input cardiac signals were approved, and the resulting patent issued on March 1, 2022. We now have 48 issued or allowed worldwide patents covering our novel\ntechnology for arrhythmia care.\nIn December 2020, we announced that three PURE EP™ Systems were contracted for purchase by St. David’s Healthcare in Austin, Texas and were subsequently\nsold in February 2021. We also sold three PURE EP™ Systems to Mayo Foundation for Medical Education and Research in 2021 for use in Mayo Clinic campuses in\nRochester, Minnesota, Jacksonville, Florida and Phoenix, Arizona. We are in active discussions with several accounts about the acquisition of the PURE EP™ System.\n1Evaluation of a novel cardiac signal processing system for electrophysiology procedures: The PURE EP 2.0 study - Al‐Ahmad - 2021 - Journal of Cardiovascular Electrophysiology - Wiley Online Library\n5\nTable of Contents\nRecent Developments\nTechnion Research & Development Foundation (TRDF) Ltd. Feasibility Study Agreement\nOn November 16, 2021, we announced the launch of a new Artificial Intelligence development program with Technion – Israel Institute of Technology. Based in\nHaifa, Israel, Technion – Israel Institute of Technology is a public research university offering degrees in science, engineering, and related fields, such as medicine,\nindustrial management, and education. Over the years, Technion established itself as a leading academic institution in Artificial Intelligence (AI).\nThe research program is led by Asst. Prof. Joachim Behar, Head of the Artificial Intelligence in Medicine Laboratory (AIMLab) at the Technion. Under the terms\nof the program, the ECG signals supplied by the PURE EP™ System are being analyzed in the context of developing AI-powered algorithms for atrial fibrillation ablation\nprocedures.\nMayo Clinic Artificial Intelligence (AI) Research Agreement\nIn January 2021, we entered into a research agreement with Mayo Clinic regarding a Novel AI Program for our Novel Signal Recording System. The program is a\nstrategic collaboration with Mayo to develop a next-generation AI- and machine learning-powered software for our PURE EP™ System. The new collaboration includes an\nR&D program that is expected to expand our proprietary hardware and software with advanced signal processing capabilities and aim to develop novel technological\nsolutions by combining the electrophysiological signals delivered by PURE EP™ and other data sources.\nThe development program is under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director,\nElectrophysiology Laboratory. We entered into a 10-year collaboration agreement with Mayo Clinic in March 2017 and in November 2019, we signed a patent and know-\nhow license agreement with Mayo Foundation for Medical Education and Research in which such terms apply to this program. On April 9, 2021 and October 22, 2021 we\nconducted first pre-clinical data collection studies to advance our AI program at Mayo Clinic.\nAppointment of Chief Operating Officer\nEffective March 21, 2022, we appointed John Sieckhaus as our chief operating officer. Mr. Sieckhaus brings to the Company 30 years in the healthcare industry,\nincluding 21 years at St. Jude Medical and Abbott Laboratories. Mr. Sieckhaus’s annual base salary is $280,000, less applicable payroll deductions and tax withholdings. In\naddition, Mr. Sieckhaus is eligible to receive an annual discretionary bonus as determined by the Compensation Committee of our board of directors in its sole discretion.\nOur Industry\nPharmacological, or medicine-based, therapies have traditionally been used as initial treatments for cardiac arrhythmias, but they often fail to adequately control\nthe arrhythmia and may have significant side effects. Catheter ablation is now often recommended for an arrhythmia that medicine cannot control. Catheter ablation\ninvolves advancing several flexible catheters into the patient’s blood vessels, usually either in the femoral vein, internal jugular vein or subclavian vein. The catheters are\nthen advanced towards the heart. Electrical impulses are then used to induce the arrhythmia and local heating or freezing is used to ablate (destroy) the abnormal tissue that\nis causing it. Catheter ablation for most of arrhythmias has a high success rate. For patients with complex arrhythmias like AF and VT, it is often necessary to perform\nmultiple procedures to achieve success.\nCatheter ablation is performed by an electrophysiologist (a specially trained cardiologist) in a specialized room in an EP lab. According to Health Research\nInternational, it is estimated that there are 8,163 global EP lab rooms performing catheter ablations, each typically with an EP recording system costing an average of\n$160,000. According to Global Market Insights, global cardiac ablation market value is projected to exceed $8.4 billion by 2028. The growing geriatric population is more\nsusceptible to cardiovascular diseases and is expected to contribute to the number of ablation procedures in forthcoming years. According to the World Health Organization,\nthe number of individuals aged 65 years and over is projected to increase from 524 million in 2010 to 1.5 billion by 2050. Aging typically leads to several changes in heart\nand blood vessels, which result in an increased risk of cardiac disorders. Accordingly, as cardiac ablation is a safe and highly effective treatment for irregular heart rhythm,\nwe believe population aging will drive the product demand in future. Along with the expected increased disease burden, we believe that product advancements will\nsignificantly drive the industry expansion. Industry players operating in the market are continuously developing newer technologies to offer more successful outcomes, and\nthe expected significant investment in research and development activities by these players is anticipated to lead to new product launches, thereby expanding the product\navailability.\n6\nTable of Contents\nCatheter Ablation of AF and VT\nAccurate recording of electrograms is critical to efficient mapping and ablation of complex arrhythmias. We believe that the clearer recordings and the very small\namplitude of intracardiac signals--high frequency, small amplitude components in midst of large physiologic signals; signals important to characterize critical substrate,\nsuch as fractionated atrial and ventricular electrograms; and high-frequency, low-amplitude signals such as the Purkinje potentials—provided by the PURE EP™ System\nmay improve outcomes during EP studies and ablation procedures for a variety of arrhythmias.\nFor patients who are candidates for ablation, an EP study is necessary to define the targeted sites for the ablation procedure. Two common, yet complex, conditions\nfor which ablation procedures are performed are AF and VT. Most cardiac arrhythmias are well understood, and ablation simply requires destroying a small area of heart\ntissue possessing electrical abnormality. In contrast, complex arrhythmias, such as AF and VT, have complex pathophysiology and, because knowledge of their origins and\nmechanisms are incomplete, ablation treatments for these arrhythmias are largely empirical. Furthermore, the length of these procedures, which typically last from 3-6\nhours, exposes the physician and staff to extensive radiation, requiring them to wear heavy lead vests. Consequently, ablating AF and VT has been regarded as being\nextremely difficult. Therefore, access to these procedures has traditionally been limited to being performed by only especially well-trained cardiologists and high-volume\ncenters. Particularly during ablations for persistent (chronic) AF, long procedures and extensive ablation are often required. These procedures could result in significant\nscarring and damage to heart tissue, although a study from a French Bordeaux group found “recovery of atrial contractile function” (the heart goes back to beating and\ncontracting normally) in 98% of patients in sinus rhythm after six months of follow-up. However, less experienced centers that do extensive ablations do run the risk of\ncompromising the pumping ability and transport function of the left atrium.\nAF is the most common heart rhythm disorder in the world and increases the risk for stroke 5-fold. In 2017, there were a reported 37.57 million prevalent cases and\n3.05 million incident cases of AF globally, contributing to over 287,000 deaths worldwide (Global, regional, and national prevalence, incidence, mortality, and risk factors\nfor atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017). In 2020, the Centers for Disease Control and Prevention stated that it is estimated\nthat 12.1 million people in the United States will have AF in 2030, more than 454,000 patients hospitalized annually as the primary diagnosis, and AF contributes to an\nestimated 158,000 deaths each year. An increasing proportion of diagnosed AF cases are now being treated via ablation, as both physician confidence and the devices used\nin these procedures improve. A growing amount of positive clinical data has demonstrated the efficacy of AF ablation when compared to the traditional first-line treatment\nof anti-arrhythmic drugs.\nRecent studies suggest that COVID-19 may increase the risk of certain arrhythmias. In a meta-analysis of 19 observational studies with 21,653 patients\nhospitalized with COVID-19, the prevalence of AF was 11%. According to the studies, AF was higher in patients with severe versus non-severe COVID-19 (19% versus\n3%)2.\nIn 2021, a meta-analysis of 6 randomized clinical trials involved 1,212 patients with AF (609 were randomized to AF ablation and 603 to drug therapy (AADs);\nmean age, 56 years). Compared with AADs, catheter ablation use was associated with reductions in recurrent atrial arrhythmia (32.3% vs 53%; risk ratio (RR), 0.62; 95%\nCI, 0.51-0.74; P < .001; I2 = 40%), with a number needed to treat with ablation to prevent 1 arrhythmia of 5. Use of ablation was also associated with reduced symptomatic\natrial arrhythmia (11.8% vs 26.4%; RR, 0.44; 95% CI, 0.27-0.72; P = .001; I2 = 54%) and hospitalization (5.6% vs 18.7%; RR, 0.32; 95% CI, 0.19-0.53; P < .001) with no\nsignificant difference in serious adverse events between the groups (4.2% vs 2.8%; RR, 1.52; 95% CI, 0.81-2.85; P = .19). In this meta-analysis of randomized clinical trials\nincluding first-line therapy of patients with paroxysmal AF, catheter ablation compared with antiarrhythmic drugs was associated with reductions in recurrence of atrial\narrhythmias and hospitalizations, with no difference in major adverse events.\nThe AF Ablation Long Term Registry is an international registry of 3,630 patients who underwent AF ablation between 2012 and 2015 – the study reported a 41%\nrate of repeat ablation at 3 years post ablation. At 12-month follow-up, the outcome was judged to have been successful in 74% of patients. However, almost 50% of the\npatients were still taking an antiarrhythmic drug. AF recurrences were less common in patients with paroxysmal (31%) than with persistent (40%) or long-standing\npersistent (44%) AF.\nAccording to the Heart Rhythm Society, VT is the most dangerous arrhythmia since it may result in ventricular fibrillation, a rapid chaotic heartbeat in the lower\nchambers of the heart which can often result in sudden cardiac death. Because the fibrillating muscle cannot contract and pump blood to the brain and vital organs,\nventricular fibrillation is the number one cause of sudden cardiac death which accounts for approximately 300,000 deaths in the U.S. each year. VT is typically treated with\nimplantable cardioverter defibrillators, or ICDs, or a combination of ablation along with an ICD.\n2https://www.uptodate.com/contents/covid-19-arrhythmias-and-conduction-system-disease\n7\nTable of Contents\nCatheter ablation of VT has historically been used primarily for drug refractory ventricular arrhythmias in patients with ICDs. However, advances in electro-\nanatomical mapping systems, techniques to identify ablation sites during sinus rhythm, and the use of hemodynamic support devices has broadened the applicability of\ncatheter ablation for ventricular arrhythmias. When performed in centers with high procedural volumes, the rates of complications remain relatively low. However, success\nrates have historically been quite variable and highly dependent on the specific ablation approach adopted. Additionally, catheter ablation has evolved into an important\ntreatment option for patients with scar-related heart disease presenting with VT or VF. An individual’s success rate of catheter ablation for VT is determined by the amount\nof infarct-related scar burden, represented as low-voltage signals; the experience of the team and center will influence outcomes. In patients with recurrent VT or VF despite\ncomplete revascularization and optimal medical treatment, radiofrequency catheter ablation should be considered. Recurrent VF episodes may be triggered by PVCs arising\nfrom partially injured Purkinje fibers or ventricular myocardium injured by ischemia and/or reperfusion. Precise catheter mapping and successful ablation of triggers for VT\nor VF, or myocardial substrate sustaining VT or VF, is a complex and demanding procedure according to the 2015 ESC Guidelines for the management of patients with\nventricular arrhythmias and the prevention of sudden cardiac death The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of\nSudden Cardiac Death of the European Society of Cardiology (ESC).\nWe believe that ablation will continue to be a preferred treatment for AF and VT. This increase in demand for ablation procedures has also increased the demand\nfor technological advances in medical devices essential to ablation procedures. Improvements are needed to help reduce the periprocedural complications and decrease\ncostly lengths of stay in patients undergoing catheter ablation procedures, adding focus to improving outcomes at low volume hospitals and among patients at high risk due\nto comorbidities. We believe that the PURE EP™ System may have a meaningful impact on assisting ablation strategies especially for repeat ablations and for those with\nsignificant scarring as it was developed to reveal the high frequency and very small amplitude of intracardiac signals important for identifying ablation targets.\nEP Lab Environment and EP Recording Systems\nThe EP lab environment and recording systems create significant amounts of noise and artifacts during EP procedures. Current surface and intracardiac recording\nsystems typically consist of large workstations interconnected by a complex set of cables that contribute to significant amounts of noise during signal acquisition. Additional\nnoise and artifacts generated from the EP lab equipment further hamper recordings of small electrophysiological potentials. Preserving spaciotemporal (space and time)\ncharacteristics of the signal in a very challenging EP recording environment is a difficult task. To remove noise and artifacts, recorders that are currently on the market offer\na family of low pass, high pass and notch filters, but these filters alter signal information context.\nThe shape and amplitude of electrocardiograms, unipolar and bipolar electrograms, and, consequently, reconstructed endocardial and epicardial maps, are\ninfluenced not only by electrophysiological and structural characteristics of the myocardial tissue involved, but with characteristics of the recording system. Amplitude and\nmorphology of electrocardiogram and intracardiac signals are significantly affected by filters used to remove noise. Because of the number of amplitude and interval\nmeasurements made during an EP study, it is imperative that the recording system faithfully acquires surface electrocardiogram and intracardiac electrograms. We believe\nthat the recording systems that are currently available on the market are ineffective in preserving the optimal amount of original information contained in the cardiac signals.\nIn addition, the EP lab consists of sophisticated equipment that requires an electrophysiologist to mentally integrate information from a number of sources during\nprocedures. There are numerous monitors in an EP lab that provide and display this variety of information. An electrophysiologist needs to evaluate the acquired cardiac\nsignals and the patient’s responses to any induced arrhythmias during the procedure. However, it can be difficult for an electrophysiologist to synthesize the disparate\ninformation produced by the numerous monitors in the lab and calculate the real-time, three-dimensional orientation of the anatomy and the location of the recording and\nablation catheters. As the number of EP procedures increase, a variety of diagnostic, therapeutic and highly specialized ablation catheters are widely available and continue\nto be developed. In addition, remote robotic and magnetic navigation systems have been developed to address limitations of dexterity in controlling the catheter tip,\nespecially during complex arrhythmia ablation procedures. We believe that, considering the improvements being made with respect to other equipment used in the EP lab\nand the continual increase of ablation procedures, the EP recorders currently available on the market are not sufficiently advanced with respect to the quality of their\nrecordings to deliver adequate results. We believe that the PURE EP™ System will be able to deliver superior quality of recordings that will allow it to successfully\nintegrate with the other advanced equipment found in the EP lab.\n8\nTable of Contents\nGenerally, some current electrophysiology recording systems can effectively support the treatment of arrhythmias such as atrial flutter and supraventricular\ntachycardia, which show up as large-amplitude, low-frequency signals. However, more complex and prevalent arrhythmias, such as AF and VT, which are characterized by\nlow-amplitude, high-frequency signals, have not found an effective evaluation of all relevant signals. This signal detection, acquisition, and isolation can be further\ncomplicated by equipment line noise and pacing signals. Current EP recorders use low-pass, high-pass, and notch filters to remove noise and artifacts from the various\nelectrical signal information. Unfortunately, conventional filtering techniques can alter signals and make it difficult or impossible to see low-amplitude, high-frequency\nsignals that can be inherent in cardiac monitoring, the visualization of which signals could help treat atrial fibrillation and ventricular tachycardia. It has been recently\nrecognized that the assurance of waveform integrity, such as for the noise-free acquisition of intracardiac and ECG signals in an EP environment, had not been previously\naccomplished due to contamination of various signals by artifacts and noise.\nThe requirement for optimal signal integrity is amplified during ablation treatments of AF and VT. One of the main objectives of the AF ablation procedure is to\nprecisely identify, ablate and eliminate pulmonary vein potentials and one of the main objectives of the VT procedure is to map the arrhythmia substrate and precisely\nidentify, ablate and eliminate small abnormal potentials. The information provided by recorders is essential for an electrophysiologist to determine ablation strategy during\ntermination of both pulmonary vein potentials and VT. Therefore, it is important that the recording system’s noise removal technique does not alter the appearance and\nfidelity of these potentials. As a result, it is necessary that any new signal processing technology preserves signal fidelity as much as possible during EP recordings;\notherwise, the signals that are needed to guide the ablation procedures will be difficult to distinguish due to noise interference.\nOur Product\nThe patented PURE EP™ System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as\nenvironmental lab noise, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP™ is a signal processing platform that combines\nadvanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-\ntime. The device aims to minimize noise and artifacts from cardiac recordings and acquire high-fidelity cardiac signals. Improving fidelity of acquired cardiac signals may\npotentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and ablation procedures.\nCardiac catheter ablation is a procedure that involves delivery of energy through the tip of a catheter that scars or destroys heart tissue to correct heart rhythm\ndisturbances. In August 2018, we received 510(k) clearance from the FDA to market our PURE EP™ System.\nOur PURE EP™ System can record raw (unaltered) cardiac and other physiologic signals with multiple display options, low noise, and a large input signal\ndynamic range. This is achieved using a low-noise amplifier topology with minimal filtering to band-limit the signal and a high-resolution A/D converter. In addition, the\nPURE EP™ System can provide large-signal (e.g., from a defibrillator) input protection and radio frequency (RF) signal (e.g., from ablation) noise suppression. There is no\nneed for gain switching in this architecture, and the full range of input signals is digitized with high resolution.\nOur PURE EP™ System was designed to be useful in arrhythmia diagnosis. For example, in atrioventricular reentrant tachycardia (AVRT) & AV nodal reentrant\ntachycardia (AVNRT), EP physicians often look for a slow pathway potential or accessory pathway potentials that are not easy to detect. Furthermore, during pacing\nmaneuvers, important diagnostic signals may be buried inside the saturation artifact from the pacing electrode. The wide dynamic range of the PURE EP™ System may\nallow for better differentiation of those signals, as there is no system saturation and a quicker recovery to baseline.\nWe are focused on improving intracardiac signal acquisition and enhancing diagnostic information for catheter ablation procedures for all arrhythmias, especially\ncomplex types like VT and AF. VT is a fast, abnormal heart rate in the heart’s lower chambers. VT does not give your heart enough time to fill with blood before it contracts\nagain. This can affect blood flow to the rest of your body and is potentially life-threatening. AF is the most common cardiac arrhythmia associated with a fivefold risk of\nstroke. AF occurs when the upper chambers of the heartbeat irregularly, and do not pump all of the blood to the lower chambers, causing some blood to pool and potentially\nform clots. If a clot breaks loose, it can travel through the bloodstream to the brain and lead to a stroke. Strokes related to AF are often more severe compared to strokes\nwith other underlying causes.\n9\nTable of Contents\nWe believe that the PURE EP™ System and its advanced signal processing tools may contribute to improvements in patient outcomes in connection with catheter\nablation due to the following advantages over currently available devices on the market:\n● Less noise: PURE EP™’s low-noise proprietary architecture was engineered to enable acquisition of high-fidelity signals in the original, unfiltered format.\nPURE EP’s Main System Unit (MSU) topology incorporates advanced shielding and very low noise front-end components.\n● Wider range: PURE EP™’s wide dynamic range was developed to retain cardiac signal details and reduce saturation. PURE EP™ combines a low-noise signal\narchitecture with a fixed range up to 500mV, so signals are rarely clipped or limited by quantization noise.\n● Higher fidelity: PURE EP™’s large frequency bandwidth and linear signal acquisition helps to accurately display complex fractionated signals, even at lower\namplitudes and higher frequencies. This unique system capability minimizes signal attenuation and maintains original signal amplitude – especially critical for\nidentifying and interpreting complex arrhythmogenic substrates.\n● Clear, stable unipolar signals: The PURE EP™ System uses an innovative approach to acquiring unipolar signals. The Wilson Central Terminal (WCT+™)\nrelies on a common front-end circuitry similar to how bi-polar intracardiac signals are acquired. This enables clear, stable unipolar signals, without the need for\nan internal reference catheter.\n● Customizable software and filters: PURE EP™ offers software modules and specialty digital filters, so electrophysiologists can customize their interface and\noptimize signals for mapping, signal interpretation and during therapy delivery.\n● Seamless integration: PURE EP™ integrates with existing EP labs and workflows. It is compatible and complementary with EP recording systems, mapping\nsystems, robotic equipment, and multi-display panels.\nIn April 2021, we released PURE EP™ Software Version 4. The latest release builds on the main system capabilities of the PURE EPTM while improving the\noverall user experience. The software upgrade has been rolled out to all existing customers. The latest software represents the most advanced software version of the PURE\nEPTM System. We believe the update adds valuable tools to shorten system set up time and bring innovative features for faster real-time signal analysis, potentially\nimproving the efficiency and accuracy of EP procedures.\nAdvances in the new PURE EPTM Software Version 4 include user interface enhancements for a more compelling assessment of arrhythmia morphologies, clinical\ntemplate management for an efficient case setup process, and other software functionalities for real-time signal visualization, such as the “Differential Analysis” allowing\nthe simultaneous display of a channel using various filter settings to assess specific characteristics of a signal or the enhanced “Digital Zoom” permitting to instantly focus\non important physiologic details while preserving a high signal-to-noise ratio.\nWe believe that PURE EP™’s features may allow physicians to better determine precise ablation targets, strategy, and end point of procedures with the objective of\nreducing the need for patients to undergo multiple procedures, and to allow for less experienced EP physicians to perform more complex procedures. The PURE EP™\nSystem is intended to operate in conjunction with the existing EP lab equipment.\nInitial Analysis\nAccording to S. J. Asirvatham, MD, et. al. (“Signals and Signal Processing for the Electrophysiologist,” Circ Arrhythm Electrophysiol. (2011) 4:965-973),\nrecording environments in a typical electrophysiology laboratory presents challenging situations. S. J. Asirvatham, MD, et. al., state, “Successful mapping and ablation in\nthe electrophysiology laboratory is critically dependent on acquiring multiple, low-amplitude, intracardiac signals in the presence of numerous sources of electric noise and\ninterference and displaying these signals in an uncomplicated and clinically relevant fashion, with minimal artifacts. This represents a significant engineering challenge and,\nin real-life electrophysiology laboratory, is not always successful.”\nTo determine and validate the state of present electrophysiology recording technology in the field, we completed a detailed analysis of the effect of filters used by\nexisting EP recorders to reduce noise on spaciotemporal characteristics of electrocardiograms and intracardiac electrograms. We evaluated the signal quality (amplitude,\nmorphology and duration) of the different recorders, along with the ability of the recorders to reduce noise level and remove baseline wander, which are the cardiac signals\nthat have shifted from the isoelectric line (the base line of the signal tracing). The electrocardiogram and intracardiac signals subjected to the PURE EP System’s signal\nprocessing showed less baseline wander, noise and artifacts compared to the conventional electrophysiology recorders. Further, spaciotemporal characteristics of signals\nwere greatly distorted by the conventional electrophysiology system, particularly when a notch filter was used, as compared to the recording of the same spaciotemporal\ncharacteristics by the PURE EP System.\n10\nTable of Contents\nProof of Concept Testing\nIn the second and third quarters of 2013, we performed and finalized testing of our proof of concept unit by initially using an electrocardiogram/intracardiac\nsimulator at our lab, and subsequently by obtaining pre-clinical recordings from the lab at the University of California at Los Angeles. We believe that our proof of concept\nunit performed well as compared to GE’s CardioLab recording system, in that the electrocardiogram and intracardiac signals displayed on our proof of concept unit showed\nless baseline wander, noise and artifacts compared to signals displayed on GE’s CardioLab recording system. Subsequently, we determined the final design of the PURE EP\nSystem prototype to use for end-user preference studies, additional pre-clinical studies and research studies.\nPrototype Testing\nAfter conducting research of peer-reviewed EP publications (see Initial Analysis in Our Products section above), we contacted Samuel J. Asirvatham. M.D. (who\nwe believed to be an expert in the field of signal-based catheter ablation), at Mayo Clinic in Rochester, Minnesota. Since the end of 2014, we have collaborated with Dr.\nAsirvatham and other physicians affiliated with Mayo Clinic in Rochester, Minnesota and Jacksonville, Florida. We have performed pre-clinical studies at Mayo Clinic\nsince 2015 to validate technology within the PURE EP System prototype. These studies have been designed to determine clinical effectiveness for features within the PURE\nEP System. Since March 2016, we have published nine manuscripts in collaboration with the physicians from Mayo Clinic evidencing our pre-clinical findings. To date, we\nhave conducted a total of twenty-four pre-clinical studies with the PURE EP System, twenty-one of which were conducted at Mayo Clinic in Rochester, Minnesota. We also\nconducted a pre-clinical study at the Mount Sinai Hospital in New York, NY with emphasis on the VT model; and two pre-clinical studies at the University of Pennsylvania\nin preparation for clinical studies to be conducted there.\nClinical Evaluations\nIn February 2019, we conducted the first clinical cases with our PURE EP™ System. The observational patient cases were performed by Andrea Natale, M.D.,\nF.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas. In April 2019, we announced\nthe completion of our second set of observational patient cases, which were performed at Prisma Health at Greenville Health System in South Carolina by Andrew Brenyo,\nMD, FHRS. Dr. Brenyo used the PURE EP™ System during procedures on patients with ischemic ventricular tachycardias, AF, PVC, and atypical flutters.\nIn May 2019, we announced the completion of our third set of observational patient cases at Indiana University under the leadership of Prof. John M. Miller, M.D.,\nand Dr. Mithilesh K. Das, MBBS. Drs. Miller and Das used the PURE EP™ System during procedures on patients with atypical flutter, atrioventricular nodal reentry\ntachycardia (AVNRT), AF, supraventricular tachycardia, premature ventricular contractions, and a rare case of dual septal pathway. In August 2019, observational patient\ncases at Santa Barbara Cottage Hospital in California were performed by Brett Andrew Gidney, M.D. The initial experience across these early evaluation centers showed the\nPURE EP™ System functions as designed with positive feedback from EP users about the improved signal detection and fidelity.\nIn November 2019, we commenced our first clinical study for the PURE EP™ System titled, “Novel Cardiac Signal Processing System for Electrophysiology\nProcedures (PURE EP 2.0 Study).” The PURE EP 2.0 Study was conducted at three U.S. hospitals: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in\nAustin, Texas, Mayo Clinic in Jacksonville, Florida and Massachusetts General Hospital in Boston, Massachusetts.\nIn April 2021, we announced the completion of the enrollment in the PURE EP 2.0 Study. Intracardiac signal data of clinical interest were collected during 51\ncardiac ablation procedures using the PURE EP™ System, the signal recording system, and the 3D mapping system at the same time stamps. The samples were randomized\nand subjected to blinded, head-to-head evaluation by three independent electrophysiologists to determine the overall quality and clinical utility of PURE EP™ signals when\ncompared to conventional sources. Each reviewer responded to the same 235 signal comparisons using a 10-point rating scale.\nResults showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE\nEP signals over the signals from conventional sources. Further analysis of the responses from the blinded reviewers showed an 83% (p-value <0.001) improved confidence\nwhen interpreting complex multi-component signals, leading to a better understanding of the catheter position in relation to the ablation target. Additionally, there was a\n73% (p-value <0.001) improved visualization of small, fractionated potentials increasing the proper analysis of scar and abnormal conduction tissue characteristics.\n11\nTable of Contents\nThe study manuscript, “Evaluation of a novel cardiac signal processing system for electrophysiology procedures: the PURE EP 2.0 study\" has been published in\nthe Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. The manuscript is co-authored by Amin Al-\nAhmad, M.D., FHRS, Bradley Knight, M.D., FHRS, Wendy Tzou, M.D., FHRS, Robert Schaller, D.O., FHRS, Omar Yasin, M.D, Deepak Padmanabhan, M.D., Jason\nZagrodsky, M.D., FHRS, Mohammed Bassiouny, M.D., J David Burkhardt, M.D., FHRS, Joseph Gallinghouse Jr., M.D., FHRS, Moussa Mansour, M.D., FHRS,\nChristopher McLeod, MBChB, Ph.D., FHRS and Andrea Natale, M.D., FHRS, the Principal Investigator of the study. The independent, blinded reviewers were Bradley P.\nKnight, M.D. (Northwestern University), Wendy Tzou, M.D. (University of Colorado), and Robert Schaller, M.D. (University of Pennsylvania).\nIn July, we discussed the completion of enrollment in the Re-Do Atrial Fibrillation Ablation Study. This study enrolled 20 patients undergoing repeat atrial\nfibrillation ablation at Texas Cardiac Arrhythmia Institute in Austin, TX. The study aims to determine if the PURE EP™ signals can demonstrate different ablation targets\nand improve procedural efficiency. The results of the study are expected to be announced in early 2022.\nWe continue to install PURE EP™ Systems at centers of excellence for clinical evaluation under our market development plan. The PURE EP™ System has been\nutilized at numerous institutions, including Mayo Clinic campuses in Arizona, Florida and Minnesota; the University of Pennsylvania Hospital in Philadelphia,\nPennsylvania; Overland Park Regional Medical System in Overland Park, Kansas; Deborah Heart and Lung Center in Browns Mills, New Jersey; St. Elizabeth’s Medical\nCenter in Boston, Massachusetts; Medical City Heart Hospital in Dallas, Texas; Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, a teaching\nhospital of Harvard Medical School; Methodist Hospital in San Antonio, Texas; and Westside Regional Medical Center in Plantation, Florida.\nTo date, more than 2,160 patient procedures have been conducted with the PURE EP™ System by more than 76 electrophysiologists across seventeen different\nclinical sites in the United States. Our initial focus is on a targeted commercial launch of the PURE EP™ System in the Northeast, Texas, and Florida. The technology is\nregularly used in some of the states’ highest-ranked hospitals, including St. David’s Medical Center in Austin, Houston Methodist Hospital, Medical City North Hills in\nNorth Richland Hills in Texas and Mayo Clinic Florida Campus in Jacksonville, Florida.\nIn addition to clinical evaluation, we have conducted pre-clinical evaluation with the PURE EP™ System under several protocols. At Mayo Clinic in Rochester,\nMinnesota, we have performed twenty-seven experiments (including novel research program such as AI and repolarization) in various animal models; we also conducted a\npre-clinical study at the Mount Sinai Hospital in New York, New York, with an emphasis on the VT model; and six experiments to date during a study at the University of\nPennsylvania. We intend to continue additional research and development studies with our technology at Mayo Clinic, the University of Pennsylvania and other national\ncenters of excellence.\nThe current PURE EP System\n12\nTable of Contents\nExamples of PURE EP Signals\nCommercialization of the PURE EP™ System\nWe have developed a marketing strategy to introduce and support our PURE EP™ System. The strategy includes our presence (in-person and virtually) at leading\nindustry events and scientific sessions, both nationally and internationally, for the purposes of physician education, PURE EP System’s demonstrations and select\npresentations of advanced R&D product pipeline.\nWe have begun implementing a market development program to commercially launch our PURE EP System. We have installed PURE EP™ Systems at several\nmedical centers of excellence throughout the U.S. during 2021 and will continue to do so in 2022 for clinical evaluation - whereby these systems are installed on a trial basis\nfor system evaluations; data collection for our clinical trials; to gather and publish data in peer-reviewed journals and for presentations at cardiology conferences; and for\npotential demonstrations to other physicians to observe the technology.\nHealth systems, facilities, and physicians that have conducted or observed cases performed with our technology may potentially acquire the system. Sales of our\nsystems would potentially consist of hardware, software, and a recurring revenue feature through a technical service contract, including software upgrades, and down the\nline, include the AI-driven algorithms and applications. In December 2020, we announced that three PURE EP™ Systems were contracted for purchase by St. David’s\nHealthcare in Austin, Texas and were subsequently sold in February 2021. These units were our first commercial sale. We also sold three PURE EP™ Systems to Mayo\nFoundation for Medical Education and Research in 2021, and we are in active discussions with several accounts about the acquisition of the PURE EP™ System. We\nanticipate our following customers will be medical centers of excellence and other healthcare facilities that operate EP labs within our targeted commercial launch markets\nin the Northeast, Florida, and Texas.\nWe intend to support our commercial activities by growing clinical validation and educational and training programs, including establishing training hubs at our\nearly hospital partners’ facilities. With the increased commercialization activity planned, we also plan to continue to grow our clinical account management team to support\nthe initial use of the system and assist with ongoing product training and education, and plan to develop an agile regional sales team to escalate our commercialization\nefforts along with a technical support team.\n13\nTable of Contents\nOur commercial and clinical activities are led by our Chief Commercial Officer, Gray Fleming, an experienced EP sales professional who previously spent 17 years\nat Abbott Laboratories and St. Jude Medical; Zachary Koch, CCDS, CEPS Clinical Director who spent 16 years at St. Jude Medical and Abbott EP, holding numerous\npositions across the company’s clinical, sales, training, and commercial teams; Olivier Chaudoir, Senior Director of Marketing from Biosense Webster and DePuy Synthes,\nJohnson & Johnson companies with 15 year of electrophysiology marketing and sales/clinical support experience. Our team is further complemented by Access Strategy\nPartners, Inc. (ASPI), a Boston-based consulting firm with a deep expertise in commercialization, contract management, execution, and value proposition optimization. The\nASPI team is led by co-founder and president, Jim Walker, a healthcare executive with more than 30 years of experience in sales, marketing, sales operations, and national\naccounts management in some of the leading companies in the medical device sector, including Boston Scientific Corporation (BSC) and Johnson & Johnson. His\nexperience spans domestic and international responsibilities, focusing on strategic market development and key customer management.\nWe believe we will have ample inventory to meet planned commercial placement requirements in 2022. We have made progress towards obtaining a European CE\nmarking certificate for medical devices. In Q1 2022, we completed the quality management system audit for the International Organization for Standardization (“ISO”)\n13485:2016 with the expectation to obtain the ISO 13485:2016 certification in the first half of 2022 and proceed to the application for the CE Marking clearance in the first\nhalf of 2023, subject to the guidance and availability from the European Notified Body.\nTechnology and Development Plan\nOur technology team consists of engineers and consultants with expertise in digital signal processing, low power analog and digital circuit design, software\ndevelopment, embedded system development, electromechanical design, testing and system integration, and the regulatory requirements for medical devices. We have also\nentered into collaboration agreements with advisors and medical institutions in the fields of cardiology and electrophysiology, including Mayo Clinic and the Texas Cardiac\nArrhythmia Institute in Austin, Texas. Currently, we are transitioning contract manufacturing of the complete PURE EP™ System from Minnetronix Medical to Plexus. We\nare not expecting any significant production delays due to the contract manufacturing change.\nWe intend to continue additional research studies with our technology at Mayo Clinic. On November 20, 2019, we entered into licensing agreements with Mayo\nClinic under newly reached terms to establish a new product pipeline to complement the PURE EP System and develop solutions for novel ways to treat autonomic nervous\nsystem disease. The new research and development pipeline contemplated pursuant to these agreements includes hardware, software, and algorithmic solutions to be\nintegrated into the PURE EP platform technology.\nIn January 2021, we entered into a research agreement with Mayo Clinic regarding a new AI research Program for our Novel Signal Recording System. The\nprogram is a strategic collaboration with Mayo to develop a next-generation AI- and machine learning-powered software for our PURE EP™ System. The new\ncollaboration includes an R&D program that will expand our proprietary hardware and software with advanced signal processing capabilities and aim to develop novel\ntechnological solutions by combining the electrophysiological signals delivered by PURE EP™ and other data sources. The development program is under the leadership of\nSamuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory. We entered into a 10-year collaboration\nagreement with Mayo Clinic in March 2017 and in November 2019, we signed a patent and know-how license agreement with Mayo Foundation for Medical Education and\nResearch in which such terms apply to this program. On April 9, 2021, and October 22, 2021, we conducted first pre-clinical data collection studies to advance our AI\nprogram at Mayo Clinic.\nOn November 16, 2021, we announced the launch of a new Artificial Intelligence development program with Technion – Israel Institute of Technology. Based in\nHaifa, Israel, Technion – Israel Institute of Technology is a public research university offering degrees in science, engineering, and related fields, such as medicine,\nindustrial management, and education. Over the years, the Technion established itself as a leading academic institution in Artificial Intelligence (AI). It is currently ranked\nas number one in AI in Europe and 15th in the world, with 100 faculty members engaged in areas across the AI spectrum.\nThe research program is led by Asst. Prof. Joachim Behar, Head of the Artificial Intelligence in Medicine Laboratory (AIMLab) at the Technion. Under the terms\nof the program, the ECG signals supplied by the PURE EP(tm) System are being analyzed in the context of developing AI-powered algorithms for atrial fibrillation ablation\nprocedures.\n14\nTable of Contents\nCompetition\nWe are marketing the PURE EP™ System as an additional information system for the EP lab. In general, the EP market is characterized by intense competition.\nThere are currently four large companies that share the majority of the EP recording market share in the US. They produce the following electrophysiology recording\nsystems, with an average selling price of approximately $160,000 (source: DRG Medtech 360 Millennium report on EP Devices, issued in June 2019):\n● GE Healthcare’s family of CardioLab Recording Systems were initially developed in the early 1990s by Prucka Engineering, which was acquired by General\nElectric Company in 1999.\n● The LabSystem PRO EP Recording System was originally designed in the late 1980s by C.R. Bard. C.R. Bard’s electrophysiology business was acquired by\nBoston Scientific Corporation in 2013.\n● HeNan HuaNan Medical Science and Technology Co., LTD. offers the GY-6000 multi-channel physiological recorder (not FDA approved).\n● St. Jude Medical, Inc.’s EP-WorkMate Recording System was acquired from EP MedSystems, Inc. in 2008, which had received clearance for the product from the\nFDA in 2003. In January 2017, Abbott Laboratories acquired St Jude Medical, Inc.\n● CathVision is developing an EP recording system, ECGenius System™ which is not yet cleared for sale in the US and not authorized for sale in Europe.\nBased upon our analysis of data taken from patent applications filed with the U.S. Patent and Trademark Office (“USPTO”) and 510(k) approval applications filed\nwith the FDA, and various publications, we believe that the above recording systems are built on relatively old technologies and all use similar approach in applying\nhardware and digital filters to remove noise and artifacts. We reasonably believe that such an approach sacrifices cardiac signal fidelity, and in the case of ablation, has a\ndirect impact on the ablation strategy of an electrophysiologist. The method to remove noise and artifacts used by the conventional recorders could be a contributing factor\nto the multiple (or repeated) ablation procedures that are frequently required in order to completely cure patients from complex arrhythmias. We are not currently aware of\nany other companies that are developing similar signal processing technologies for electrophysiology laboratories.\nCustomers\nIn December 2020, we announced that three PURE EP™ Systems were contracted for purchase by St. David’s Healthcare in Austin, Texas and were subsequently\nsold in February 2021. These units were our first commercial sales. We also sold three PURE EP™ Systems to Mayo Foundation for Medical Education and Research in\n2021 and we are in active discussions with several accounts about the acquisition of the PURE EP™ System. We anticipate our following customers will be medical centers\nof excellence and other healthcare facilities that operate EP labs within our targeted commercial launch markets in the Northeast, Florida, and Texas.\nSuppliers\nThe PURE EP™ System contains proprietary hardware and software modules that are assembled into the system. Hardware boards contain components that are\navailable from different distributors. The parts used to manufacture analog and digital boards are readily available from several distributors or manufacturers. Plexus is our\nmanufacturing partner for the complete PURE EP System.\nResearch and Development Expenses\nResearch and development expenses for the fiscal years ended December 31, 2021, and 2020 were $5,601,508 and $18,135,862, respectively.\n15\nTable of Contents\nViralClear Business Overview\nViralClear Pharmaceuticals, Inc.\nViralClear Pharmaceuticals, Inc. (“ViralClear”) is a majority-owned subsidiary of the Company originally known as NeuroClear Technologies, Inc. The subsidiary\nwas established November 2018 to pursue additional applications of the PURE EP™ signal processing technology outside of EP. In March 2020, it was renamed ViralClear\nin connection with its prior objective to develop merimepodib, a broad-spectrum anti-viral agent that showed potential to treat COVID-19. We currently do not intend to\nfurther develop merimepodib and have discontinued our pharmaceutical operations. Since late 2020, ViralClear has been realigned with its original objective of pursuing\nadditional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology with an initial emphasis on developing a novel nerve recording\nsystem. As of March 30, 2022, the Company retains 60.22% ownership of ViralClear.\nCurrently, ViralClear is an early stage medical device company that is developing N-SENSE™, a novel sensing technology platform for high-speed\nelectroneurogram (ENG) recordings. The specifications for this new product were based on the core competencies of the PURE EP™ signal processing technology, such as\nbroad dynamic range of recorded signals and low signal-to-noise ratio and adapted to address disorders of the autonomic nervous systems through recordings and analysis\nof action potentials, the impulses along the membrane of a muscle cell or a nerve cell. These impulses are considered to carry valuable clinical information but may be\ndifficult to detect through conventional recording platforms.\nViralClear aims to address what we believe to be the two main challenges of bioelectronic medicine devices: achieving accurate and targeted stimulation of specific\nnerves in a nerve bundle and implementing an effective feedback loop that can self-adjust for the optimal amount and timing of stimulation. We believe that advancements\nin overcoming these challenges will improve the safety and efficacy of current treatments and contribute to the developments of new therapy lines.\nOn December 18, 2020, we signed a research agreement with the University of Minnesota launching a program to develop novel therapies to treat sympathetic\nnervous system disease. The program studies are expected to form a foundation for developing a new platform technology to address disorders of the autonomic nervous\nsystem. We intend to develop new intellectual properties and products, including new hardware, software, and algorithmic solutions, with the support of Plexus, a tier 1 US-\nbased manufacturing partner and take it through FDA approval, manufacturing, and commercialization. The R&D program is led by Richard W. Bianco, Ph.D., Professor,\nDirector of Experimental Surgical Services (ESS), Department of Surgery in the University of Minnesota Medical School, John W. Osborn, Ph.D., Professor, Department of\nSurgery and Director of the Minnesota Consortium for Autonomic Neuromodulation (MCAN) in the University of Minnesota Medical School.\nIn February 2021, we conducted our first preclinical experiment at the University of Minnesota. Further studies to record and evaluate relevant nerve activity were\nconducted in April and November 2021.\nWe have partnered with Plexus to design, develop, and manufacture N-SENSE™, a novel sensing and stimulation platform technology.\nOur new product pipeline will focus on improving therapies through clearer ENG recordings – methods used to visualize directly recorded electrical activities of\nneurons in the central nervous system (brain, spinal cord) and/or the peripheral nervous system (nerves, ganglions). ENGs are usually obtained by placing an electrode\ndirectly in the neural tissue. ENGs consist of small, high frequency, low amplitude signals, which have been proven hard to detect with conventional signal recording\nsystems.\nOur business strategy is to utilize our core signal processing technology to develop superior ENG recording and processing systems and includes the following:\n• Develop N-SENSE™, a novel nerve sensing and stimulation platform technology to be used in product candidates which qualify for a nerve mapping and\nstimulation treatments including, but not limited to, renal denervation, deep brain stimulation and vagus nerve stimulation.\no The N-SENSE™ is intended to be used as a value add-on to the existing neurostimulation technologies or act as a standalone platform.\n• Pursue licensing opportunities and partnerships to leverage our expertise in high-fidelity signal processing for feedback loop systems for development of products\nfor commercial success.\n16\nTable of Contents\nWe believe that the following clinical areas may benefit the most through the advancements in achieving accurate and targeted stimulation and implementation of\nan effective self-adjusting feedback loop:\n• Renal denervation (“RDN”): RDN has been shown to reduce blood pressure and can be an effective treatment for resistant hypertension sufferers who have failed\ndrug therapy. The technique has proven to be effective, but clinical endpoints are still suboptimal. RDN device market is expected to reach $7B by 2027 (CAGR 23.7%).1\no Potential Application: A device that can measure sympathetic nerve activity will inform the need and potential benefit for performing a procedure.\nAdditionally, a device that can stimulate and elicit a sympathetic response, such as blood pressure, will aid in the assessment of nerve denervation\nsuccess, and help determine if additional ablation is necessary. Therefore, a device that can perform stimulation on a number of channels, and record\nnerve activity is needed.\n• Deep Brain Stimulation (“DBS”): DBS is a treatment that involves implanting electrodes (leads) within certain areas of the brain to deliver electrical pulses,\nwhich has demonstrated improvements in the treatment of movement disorders, such as the Parkinson’s disease, tremors and dystonia.\no Potential Application: a new high-speed board-based platform for improved accuracy in lead implantation. Precise positioning of the electrodes during\nthe surgical procedure is important in the success of lead implantation, and highly accurate signal readers can aid in the prediction of the activation of\naxons surrounding the implanted lead.\no We believe that DBS may also be applicable to a substantial number of neurological and psychiatric disorders correlated with dysfunctional circuitry;\ncomparable to a heart pacemaker that uses electric pulses to ultimately regulate brain activity.\no Other applications under our investigation include chronic pain management, ADHD, eating disorders, Alzheimer’s, addiction, epilepsy. Alzheimer’s as\nan application for DBS is currently undergoing clinical trials at several national and international institutions that target the hippocampal outflow\npathways by increasing ACh availability, influencing the limbic system, and improving lead placements.\nWe may seek additional research collaborations with other academic centers active in one or more fields of clinical interests described above.\nIndustry and Market Overview\nThe global neurostimulation devices market is predicted to grow at 15.23% CAGR during the forecast period with the market size reaching $18.667 billion by\n2025 from $7.974 billion in 2019. North America is dominating the neurostimulation devices market with highest market share due to robust healthcare infrastructure,\ngrowing R&D activity and presence of major healthcare players. The neurostimulation market is primarily driven by deep brain and spinal cord stimulation. The overall\nneurostimulation market is expected to grow due to societal factors such as an increase in the geriatric population, as well as the associated increase in the prevalence of\nchronic diseases.\nThe segment of the neurostimulation market for central nervous system (CNS), which include nVNS and DBS, is projected to exceed $14.5 billion in 2029 from a\nmarket value of $5 billion in 2019.2\nNon-invasive Vagus Nerve Stimulation\nWe believe there is a significant opportunity for nVNS based on the potential market size for the treatments for the diseases that nVNS may be applicable.\nCurrently, approximately 1,500 million people worldwide suffer from chronic pain while 1,100 million people worldwide suffer from migraines.\n1Source: iHealthcareAnalyst, Inc. Feb. 2020\n2Source: Bioelectronic Medicine 2019 – 2029. IDTechEx report, Dr. Nadia Tsao.\n17\nTable of Contents\nMost of the currently available VNS products have achieved limited commercial success to date. LivaNova currently sells VNS devices that operate in 3 modes,\nincluding a non-rechargeable implantable pulse generator (IPG), SenTiva, which uses a limited closed-loop technology and comes with a wrist-worn magnet and a wireless\nprogramming wand. Cerbomed has commercialized a transcutaneous auricular VNS device, NEMOS, which consists of a handheld stimulation unit and an ear electrode\nworn as an earphone. Cerbomed received the European clearance (CE mark) for the VNS treatment of epilepsies and depression in 2010 and for the treatment of pain in\n2012. NEMOS has been commercially available in Germany and Austria since 2013 and has expanded to Great Britain, France, and Spain.\nThe VNS patent domain is currently dominated by U.S. companies such as Medtronic, LivaNova, and Boston Scientific. Medtronic holds certain patents in closed-\nloop DBS technology, Medtronic currently markets IPGs such as RestoreSensor SureScan MRI, which is indicted for spinal cord stimulation as an aid in the management of\nchronic, intractable pain of the trunk and/or limbs and which automatically adjusts stimulation based on the patient's needs and preferences in different body positions, and\nActiva PC, which is a deep brain stimulator, for investigational loop.\nWe believe that digital health wearable markets present potential opportunities for our technology. We plan to develop technology that can provide a signaling\nfeedback loop designed to deliver appropriate stimulation to the vagus nerve through audio and to seek licensing opportunities with consumer electronic market players.\nDeep Brain Stimulation:\nDeep brain stimulator market is one of the fastest growing sectors in the neurostimulation market worldwide, growing at 9.3% annually and expected to reach $2.3\nbillion in worldwide market size by 2028. According to the World Health Organization, globally, 264 million people suffer from depression while 50 million people suffer\nfrom epilepsy. Parkinson’s disease and essential tremor are FDA-approved indications for DBS, and the deep brain stimulator market is largely dominated by Medtronic,\nAbbott, and Boston Scientific. These companies have been working on innovations in their electrodes to avoid stimulation of adjacent structures (electric field shaping)\nwhich are the root cause of unwanted side effects of DBS. The industry is working on decreasing the size of the implant of the DBS device, which may lead to a skull-\nmounted implant. Medtronic’s Activa systems consist of dual-channel or single channel IPGs. Abbott sells two devices known as the Infinity DBS IPG and Brio\nRechargeable IPG. The Infinity DBS IPG is designated to manage movement disorders including Parkinson’s disease, essential tremor, and dystonia. It utilizes the\nBluetooth technology to communicate with a controller and can receive updates through an application. The system allows for currents to be steered towards target areas\nwhile avoiding peripheral stimulation. The Brio Rechargeable IPG delivers constant currents to maintain the desired stimulation level. It has shown clinical efficacy in\nParkinson’s disease and dystonia. Boston Scientific offers the Vercise directional lead in unison with their Neural Navigator systems ranging from 8 to 16 electrode leads\nand a directional system. Medtronic’s Percept PC Deep Brain Stimulation (“DBS”) system includes their BrainSense technology making it the first and only DBS\nneurostimulation system that has the ability to chronically capture and record brain signals while providing therapy to patients with neurologic disorders associated with\nParkinson’s Disease (“PD”), among others.\nAccording to the National Institute of Health, future technical innovation in deep brain stimulators will focus on improving the practicability the device, including\nextension of battery life, reduced size of the devices and development of a device for delivering more tailored and adaptive stimulation and the integration of wireless\ntechnology. Clinically, the main challenge will be meeting the needs of an ageing population worldwide and expanding indications for DBS to circuitopathies other than\nParkinson’s disease, including depression and Alzheimer disease. Even within established indications such as Parkinson’s disease, key questions remain unanswered\nbecause biomarkers that predict clinical responses and aid in patient selection and stimulation parameter settings are still largely lacking.\nWe believe that our technology may help advance clinical response to DBS due to more precise stimulation and improve overall safety of the DBS procedures.\nOn March 5, 2021, we announced that the U.S. Patent Office had allowed a utility patent which has been exclusively licensed from the Mayo Foundation for\nMedical Education and Research. The patent application number 16/805,017 entitled, \"Systems and Methods for Electroporation\" was filed on February 28, 2020. The\npatent describes and claims methods and materials for improving the treatment of hypertension via electroporation of nerves in the renal area. Electroporation is an\nemerging technique that has demonstrated efficacy in treatments for several critical conditions and is currently being evaluated for the treatments of autonomic nervous\ndisorders, including hyper- and hypotension / syncope.\n18\nTable of Contents\nNeuroClear Business Overview\nNeuroClear Technologies, Inc.\nOn July 2, 2020, the Company formed an additional subsidiary, NeuroClear Technologies, Inc. (“NeuroClear”), a Delaware corporation, to pursue additional\napplications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. We own 100% of the outstanding shares of common stock as of March\n30, 2022 and the subsidiary is currently dormant.\nOur intention is to move the neurotech assets from ViralClear into NeuroClear where the current and future neurotech assets would be housed. We intend to further\ndevelop our nerve recording system and ultimately bring the technology to market under NeuroClear Technologies, Inc.\nViralClear will continue to have cash and a shareholder base. Given its corporate history and almost four years of segregated operations, we believe that this entity\ncan be of great value to the shareholders as we evaluate emerging growth businesses across various industry segments that aim for a Nasdaq listing.\nIntellectual Property\nPatents\nOur success depends in large part on our ability to establish and maintain the proprietary nature of our technology. We filed a patent application with the USPTO in\nDecember 2013, “Systems and Methods for the Evaluation of Electrophysiology Systems.” In December 2014, we filed this patent application under the Patent Cooperation\nTreaty (PCT) with the U.S. Receiving Office. This patent application describes a system that can show comparative output of any two cardiac signal systems—such as the\nPURE EP System as compared to a competitor system. We received notice of allowance on June 5, 2019, and on October 29, 2019, U.S. Patent No. 10,456,057 was issued.\nIn November 2017, we engaged 3LP Advisors LLC, now Sherpa Technology Group LLC as our intellectual property advisor. We have also retained Sterne Kessler\nGoldstein & Fox P.L.L.C., a patent firm based in Washington DC, to help develop and execute a strategy for the development of our patent portfolio. On May 9, 2018, we\nfiled one “omnibus” hardware and software patent application with multiple claim sets, and several multiple feature-set graphical user interface (“GUI”) design patents. The\nomnibus patent application covers the core hardware and software technology associated with our PURE EP System, which technology includes a cardiac signal system that\nreads cardiac signals and filters such cardiac signals from noise such as non-cardiac signals or other body-generated artifacts. We also filed a second omnibus application in\nMay 2019 capturing innovations in software with Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology\nLaboratory, as an inventor. Mayo Clinic’s interest in this jointly owned patent application is exclusively licensed to us for all applications.\nOur owned patent portfolio now includes sixteen allowed/issued patents. Seventeen additional worldwide utility patent applications are pending covering various\naspects of our PURE EP System for recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures. We also have two pending\nU.S. patent applications directed to artificial intelligence (AI). We also have 30 allowed/issued worldwide design patents, which cover various features of our display\nscreens and graphical user interface for enhanced visualization of biomedical signals. Finally, we have licenses to 3 patents and 14 additional worldwide utility patent\napplications from Mayo Foundation for Medical Education and Research that are pending. These patents and applications are generally directed to electroporation and\nstimulation.\nBioSig and ViralClear signed three patent and know-how license agreements with Mayo Foundation for Medical Education and Research in November 2019.\nUnder the terms of such agreements, BioSig exclusively licensed additional patents and applications of the Mayo Clinic related to novel ways for ablation therapy and to\ntreat autonomic nervous system disease including hardware, software and algorithmic solutions to be integrated into the PURE EP platform technology. BioSig intends to\ntake the licensed intellectual properties and products, which have been developed by Mayo Clinic over the last decade, through FDA approval, manufacturing, and\ncommercialization. The development program is run under the leadership of Dr. Asirvatham. On March 5, 2021, we announced that the U.S. Patent Office had allowed a\nutility patent that ViralClear has exclusively licensed from the Mayo Foundation for Medical Education and Research. The patent application number 16/805,017\nentitled, \"Systems and Methods for Electroporation\" was filed on February 28, 2020. The patent describes and claims methods and materials for improving the treatment of\nhypertension via electroporation of nerves in the renal area. Electroporation is an emerging technique that has demonstrated efficacy in treatments for several critical\nconditions and is currently being evaluated for the treatments of autonomic nervous disorders, including hyper- and hypotension / syncope.\n19\nTable of Contents\nTrademarks\nOur trademark for “BIOSIG TECHNOLOGIES” was registered on April 25, 2017. Our trademark for “PURE EP” was registered on January 26, 2016. Our\ntrademark for the standard mark, “BIOSIG” was registered January 1, 2019, and our stylized/design trademark mark for the BioSig Technologies’ logo was registered\nFebruary 12, 2019.\nOn October 7, 2019, we filed a standard mark trademark application for “SEE MORE, CLEARLY” and was published for opposition on May 26, 2020.\nOn April 22, 2020, we filed a standard mark trademark application for “DECIBEL” and was published for opposition on July 21, 2020.\nOn September 20, 2020, we filed a standard mark trademark application for “SMARTFINDER” and was published for opposition on March 16, 2021.\nOn September 20, 2020, we filed a standard mark trademark application for “COMBIO” and was published for opposition on March 16, 2021.\nOn October 22, 2020, we filed a standard mark trademark application for “WCT+” and was published for opposition on March 16, 2021.\nOn October 22, 2020, we filed a standard mark trademark application for “ACCUVIZ.”\nOn November 5, 2018, we filed a standard mark trademark application for “NEUROCLEAR”,and was registered on September 7, 2021. On January 29, 2019,\nNeuroClear filed a stylized/design trademark application for the NeuroClear logo and was registered on January 25, 2022.\nOn October 4, 2019, we filed a stylized/design trademark application for “ALLIANCE FOR ADVANCING BIOELECTRONIC MEDICINE” and was published\nfor opposition on March 16, 2021.\nOn May 26, 2020, we filed a standard mark trademark application for “N-SENSE” ” and received a notice of allowance on June 2, 2020.\nOn May 26, 2020, we filed a standard mark trademark application for “N-SENSE TECHNOLOGIES” and received a notice of allowance on November 24, 2020.\nIn July 2021, we received EU certificates of registration for the following trademarks: ACCUVIZ, WCT+, and COMBIO.\nIn July 2021, we received UK certificates of registration for the following trademarks: SMARTFINDER, ACCUVIZ, WCT+, and COMBIO.\nOn May 27, 2021, we filed a standard mark trademark application for “SHOWING THE WAY TO BETTER.”\nGovernment Regulation\nThe U.S. government regulates healthcare and related products through various agencies, including but not limited to the following: (i) the U.S. Food and Drug\nAdministration (FDA), which enforces the federal Food, Drug and Cosmetic Act (FDCA) and related laws; (ii) the Centers for Medicare & Medicaid Services (CMS),\nwhich administers the Medicare and Medicaid programs; (iii) the Office of Inspector General (OIG), which enforces various laws aimed at curtailing fraudulent or abusive\npractices, including by way of example, the Anti-Kickback Statute, the Physician Self-Referral Law, commonly referred to as the Stark law, the Civil Monetary Penalty Law\n(including the beneficiary inducement prohibition) (CMP), and the laws that authorize the OIG to exclude healthcare providers and others from participating in federal\nhealthcare programs; and (iv) the Office of Civil Rights (OCR), which administers the privacy aspects of the Health Insurance Portability and Accountability Act of 1996\n(HIPAA). All of the aforementioned are agencies within the Department of Health and Human Services (HHS). Healthcare is also provided or regulated, as the case may be,\nby the Department of Defense through its TRICARE program, the Department of Veterans Affairs, especially through the Veterans Health Care Act of 1992, the Public\nHealth Service within HHS under Public Health Service Act § 340B (42 U.S.C. § 256b), the Department of Justice through the Federal False Claims Act and various\ncriminal statutes, and state governments under the Medicaid and other state sponsored or funded programs. Various states also have state laws equivalent to certain\nhealthcare fraud and abuse laws, including but not limited to state equivalents of the Anti-Kickback Statute and the Stark law, as well as more general state laws regulating\nall healthcare activities and certain healthcare products, including medical devices.\n20\nTable of Contents\nIn addition to being regulated by the FDA, advertising and promotion of certain types of medical devices in the United States is also regulated by the Federal Trade\nCommission (FTC) and by state regulatory and enforcement authorities. Recently, promotional activities for FDA-regulated products of other companies have been the\nsubject of enforcement action brought under healthcare laws and consumer protection statutes. Further, competitors can initiate litigation relating to advertising claims under\nthe federal Lanham Act and similar state laws.\nFDA Regulation\nOur solutions include software and hardware which will be used for patient diagnosis and, accordingly, are subject to regulation by the FDA and other regulatory\nagencies. FDA regulations govern, among other things, the following activities that we perform and will continue to perform in connection with:\n● Product design and development;\n● Product testing;\n● Product manufacturing;\n● Product labeling and packaging;\n● Product handling, storage, and installation;\n● Pre-market clearance or approval;\n● Advertising and promotion; and\n● Product sales, distribution, and servicing.\nFDA Pre-market Clearance and Approval Processes\nThe FDA classifies all medical devices into one of three classes based on the risks associated with the medical device and the controls deemed necessary to\nreasonably ensure the device’s safety and effectiveness. Those three classes are:\n● Class I devices present a low risk and are not life-sustaining or life-supporting. The majority of Class I devices are subject only to “general controls” (e.g.,\nprohibition against adulteration and misbranding, registration and listing, good manufacturing practices, labeling, and adverse event reporting. General controls\nare baseline requirements that apply to all classes of medical devices.)\n● Class II devices present a moderate risk and are devices for which general controls alone are not sufficient to provide a reasonable assurance of safety and\neffectiveness. Devices in Class II are subject to both general controls and “special controls” (e.g., special labeling, compliance with performance standards, and\npost market surveillance. Unless exempted, Class II devices typically require FDA clearance before marketing, through the premarket notification (510(k))\nprocess).\n● Class III devices present the highest risk. These devices generally are implantable, life-sustaining, life-supporting, or for a use that is of substantial importance\nin preventing impairment of human health, and/or they present a potential unreasonable risk of illness or injury. Class III devices are devices for which general\ncontrols, by themselves, are insufficient and for which there is insufficient information to determine that application of special controls would provide\na reasonable assurance of safety and effectiveness. Class III devices are subject to general controls and typically require FDA approval of a premarket approval\n(“PMA”) application before marketing.\nUnless it is exempt from premarket review requirements, a medical device must receive marketing authorization from the FDA prior to being commercially\nmarketed, distributed, or sold in interstate commerce in the United States. The most common pathways for obtaining marketing authorizations are 510(k) and PMA. With\nthe enactment of the Food and Drug Administration Safety and Innovation Act (FDASIA), the de novo pathway was made available for certain low-to-moderate risk\ndevices that do not qualify for 510(k) clearance due to the absence of a predicate device.\n21\nTable of Contents\n510(k) Clearance Process\nThe 510(k) review process compares a new device to an existing legally marketed device (or, “predicate device”). “Substantial equivalence” means that the\nproposed new device: (i) has the same intended use as the predicate device; (ii) has the same or similar technological characteristics as the predicate device; (iii) is as safe\nand effective as the predicate device, as shown by the supporting information submitted within the 510(k); and (iv) does not raise different questions of safety and\neffectiveness than the predicate device.\nTo obtain 510(k) clearance, one must submit a 510(k) containing sufficient information and data to demonstrate that the proposed device is substantially equivalent\nto a legally marketed predicate device. This data generally includes non-clinical performance testing (e.g., software validation, bench testing electrical safety testing), but\nmay also include clinical data. Typically, it takes approximately three-to-six months for the FDA to complete its review of a 510(k) submission; however, it can take\nsignificantly longer and not all 510(k) submissions are accepted by the FDA for review, and not all are cleared following FDA review. During its review of a 510(k), the\nFDA may request additional information, including clinical data, which may significantly prolong the review process. After completing its review of a 510(k), the FDA may\nissue an order, in the form of a letter (i) finding the proposed device to be substantially equivalent to the predicate device and stating that the device can be marketed in the\nU.S., or (ii) finding the proposed device not substantially equivalent to the predicate device and stating that device cannot be marketed in the U.S. We received 510(k)\nclearance for the PURE EP™ System on August 8, 2018.\nAfter a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its\nintended use, will require a new 510(k) clearance or could require a pre-market approval, which requires more data and is generally a significantly longer process than the\n510(k) clearance process. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a\nmanufacturer’s determination. If the FDA disagrees with a manufacturer’s determination, it can require the manufacturer to cease marketing and/or recall the modified\ndevice until 510(k) clearance or a pre-market approval is obtained.\nA device that reaches market through the 510(k) process is not considered to be “approved” by the U.S. Food and Drug Administration. They are generally referred\nto as “cleared” or “510(k) cleared” devices. Nevertheless, it can be marketed and sold in the U.S.\nThe Premarket Approval Pathway\nThe PMA process is the most stringent type of device marketing application required by the FDA. Whether PMA is granted is based on a determination by the\nFDA that the PMA application contains sufficient valid scientific evidence to ensure that the device is safe and effective for its intended use(s). A PMA application\ngenerally includes extensive information about the device including the results of clinical testing conducted on the device and a detailed description of the manufacturing\nprocess.\nAfter a PMA application is accepted for review, the FDA begins an in-depth review of the submitted information. FDA regulations provide 180 days to review the\nPMA application and make a determination; however, in practice, the review time is typically longer (e.g., 1-3 years). During this review period, the FDA may request\nadditional information or clarification of information already provided. Also, during the review period, an advisory panel of experts from outside the FDA may be convened\nto review and evaluate the data supporting the application and provide recommendations as to whether the data provide a reasonable assurance that the device is safe and\neffective for its intended use. In addition, the FDA generally will conduct a preapproval inspection of the manufacturing facility to ensure compliance with the quality\nsystem regulation (QSR), which imposes comprehensive development, testing, control, documentation and other quality assurance requirements for the design and\nmanufacturing of a medical device.\nBased on its review, the FDA may (i) issue an order approving the PMA, (ii) issue a letter stating the PMA is “approvable” (e.g., minor additional information is\nneeded), (iii) issue a letter stating the PMA is “not approvable,” or (iv) issue an order denying PMA. A company may not market a device subject to PMA review until the\nFDA issues an order approving the PMA application. As a condition to approval, the FDA may impose post-approval requirements intended to ensure the continued safety\nand effectiveness of the device including, among other things, restrictions on labeling, promotion, sale and distribution, and requiring the collection of additional clinical\ndata. Failure to comply with the conditions of approval can result in materially adverse enforcement action, including withdrawal of the approval.\nMost modifications to a PMA approved device, including changes to the design, labeling, or manufacturing process, require prior approval before being\nimplemented. Prior approval is obtained through submission of a PMA supplement. The type of information required to support a PMA supplement and the FDA’s time for\nreview of a PMA supplement vary depending on the nature of the modification.\n22\nTable of Contents\nWe obtained FDA clearance related to the PURE EP System via the 510(k) process in 2018 and we do not anticipate a PMA for it or other devices at this time.\nPervasive and continuing FDA regulation\nAfter a medical device is placed on the market, numerous FDA regulatory requirements apply, including, but not limited to, the following:\n● Quality System Regulation (QSR), which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures during\nthe manufacturing process;\n● Establishment Registration, which requires establishments involved in the production and distribution of medical devices intended for commercial distribution in\nthe U.S. to register with the FDA;\n● Medical Device Listing, which requires manufacturers to list the devices they have in commercial distribution with the FDA;\n● Labeling regulations, which prohibit “misbranded” devices from entering the market, as well as mandate the inclusion of certain content in device labels and\nlabeling and prohibit the promotion of products for unapproved or “off-label” uses and impose other restrictions on labeling; and\n● Medical Device Reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious\ninjury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur.\nFailure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include one or more of the following sanctions:\n● Fines, injunctions, and civil penalties;\n● Mandatory recall or seizure of our products;\n● Administrative detention or banning of our products;\n● Operating restrictions, partial suspension or total shutdown of production;\n● Refusing our request for 510(k) clearance or pre-market approval of new product versions;\n● Revocation of 510(k) clearance or pre-market approvals previously granted; and\n● Criminal penalties.\nWe are subject to unannounced device inspections by the FDA, as well as other regulatory agencies overseeing the implementation of, and compliance with,\napplicable state public health regulations. These inspections may include our suppliers’ facilities.\n23\nTable of Contents\nU.S. Healthcare Laws and Regulations\nIn the United States, there are various healthcare fraud and abuse laws that apply to medical device manufacturers, such as us, with respect to our financial\nrelationships with hospitals, physicians, patients, marketers and sales agents, and other potential purchasers or acquirers of our products or those who are in a position to\nrefer or recommend our products. Federal and state anti-kickback laws prohibit the payment or receipt of kickbacks, bribes or other remuneration intended to induce the\npurchase or recommendation of healthcare products and services. The U.S. government has published regulations that identify exemptions or “safe harbors,” which describe\nvarious payment and business practices that, although they potentially implicate the federal Anti-Kickback Statute, are not treated as offenses under the statute, and thereby,\nprotected from enforcement actions under the federal Anti-Kickback Statute. To qualify, the activity must fit squarely within the safe harbor. Arrangements that do not meet\na safe harbor are not necessarily illegal but will be evaluated on a case-by-case basis, and the federal safe harbors may not apply to state anti-kickback laws. Other\nprovisions of state and federal law impose civil and criminal penalties for presenting, or causing to be presented, to third-party payors (including the government) for\nreimbursement claims that are false or fraudulent, or for items or services that were not provided as claimed. False claims allegations under federal, and some state, laws\nmay be brought on behalf of the government by private persons, or “whistleblowers,” who could then receive a share of any recovery. In addition, the federal Health\nInsurance Portability and Accountability Act of 1996 (HIPAA) imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or\nknowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for\nhealthcare benefits, items or services. The Physician Self-Referral Law, commonly referred to as the Stark law, is a strict liability statute that prohibits physicians from\nreferring patients to receive certain services defined as “designated health services” payable by Medicare or Medicaid from entities with which the physician or an\nimmediate family member has a financial relationship, unless a specific exception applies. Violations of these laws can lead to civil and criminal penalties, including but not\nlimited to punitive sanctions, damage assessments, money penalties, imprisonment, denial of payment, exclusion from participation in federal healthcare programs, or some\ncombination thereof.\nInternational Regulation\nInternational sales of medical devices are subject to foreign government regulations, which vary substantially from country to country. The time required to obtain\napproval by a foreign country may be longer or shorter than that required for FDA approval, and the requirements may differ significantly.\nThe European Union has adopted legislation, in the form of directives to be implemented in each member state, concerning the regulation of medical devices\nwithin the European Union. The directives include, among others, the Medical Device Directive that establishes standards for regulating the design, manufacture, clinical\ntrials, labeling, and vigilance reporting for medical devices. Our PURE EP system may be affected by this legislation. Under the European Union Medical Device Directive,\nmedical devices are classified into four classes, I, IIa, IIb, and III, with class I being the lowest risk and class III being the highest risk. Under the Medical Device Directive,\na competent authority is nominated by the government of each member state to monitor and ensure compliance with the Medical Device Directive. The competent authority\nof each member state then designates a notified body to oversee the conformity assessment procedures set forth in the Medical Device Directive, whereby manufacturers\ndemonstrate that their devices comply with the requirements of the Medical Device Directive and are entitled to bear the CE mark. CE is an abbreviation for Conformité\nEuropéenne (or European Conformity) and the CE mark, when placed on a product, indicates compliance with the requirements of the applicable directive. Medical devices\nproperly bearing the CE mark may be commercially distributed throughout the European Union. Failure to obtain the CE mark will preclude us from selling the PURE EP\nSystem and related products in the European Union.\nEmployees\nAs of March 30, 2022, we had 50 full-time employees. Additionally, we use consultants as needed to perform various specialized services. None of our employees\nare represented under a collective bargaining agreement.\nITEM 1A – RISK FACTORS\nRISK FACTORS\nThere are numerous and varied risks, known and unknown, that may prevent us from achieving our goals. You should carefully consider the risks described below\nand the other information included in this Annual Report on Form 10-K, including the consolidated financial statements and related notes. If any of the following risks, or\nany other risks not described below, actually occur, it is likely that our business, financial condition, and/or operating results could be materially adversely affected. The\nrisks and uncertainties described below include forward-looking statements and our actual results may differ from those discussed in these forward-looking statements.\n24\nTable of Contents\nRisk Factor Summary\nBelow is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that\nwe face. Additional discussion of risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading “Risk Factors” and\nshould be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC before making investment decisions\nregarding our common stock.\n● There is substantial doubt about our ability to continue as a going concern.\n● Because we are an early commercialization stage company with one product in commercialization process, we expect to incur substantial additional\noperating losses.\n● Our PURE EP System and other product candidates are in continued development and may not be successfully developed or commercialized.\n● We expect to derive our revenue from sales of our PURE EP System and other products we may develop. If we fail to generate revenue from these sources,\nour results of operations and the value of our business will be materially and adversely affected.\n● We may need to finance our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing\narrangements. Any additional funds that we obtain may not be on terms favorable to us or our stockholders and may require us to relinquish valuable\nrights.\n● We may be unable to develop our existing or future technology.\n● We may experience delays in any phase of the preclinical or clinical development of a product, including during its research and development.\n● We have not completed a clinical trial of our product. The results of additional clinical studies may not support the usefulness of our technology.\n● The medical device industry is subject to stringent regulation and failure to obtain regulatory approval will prevent commercialization of our products.\n● We, and our third-party manufacturer(s), are, and will be, subject to extensive regulation by the FDA.\n● The market for our technology and revenue generation avenues for our products may be slow to develop, if at all.\n● Our estimate of the size of our addressable market may prove to be inaccurate.\n● The EP market is highly competitive.\n● If we do not effectively manage changes in our business, these changes could place a significant strain on our management and operations.\n● Our strategic business plan may not produce the intended growth in revenue and operating income.\n● We currently have limited sales, marketing or distribution operations and will need to expand our expertise in these areas.\n● Our product development program depends upon third-party researchers, including Mayo, who are outside our control and whose negative performance\ncould materially hinder or delay our pre-clinical testing or clinical trials.\n● We may face risks associated with future litigation and claims.\n● If we do not obtain protection for our intellectual property rights, our competitors may be able to take advantage of our research and development efforts to\ndevelop competing products.\n● If we infringe upon the rights of third parties, we could be prevented from selling products and forced to pay damages and defend against litigation.\n● We depend on our collaboration with Mayo Clinic for the research and development of additional advanced features of PURE EP™ System. If this\ncollaboration is not successful, we may not be able to realize the market potential of such features and may not have rights to use any such developed\nadvanced features.\n● The market price for our common stock may fluctuate significantly, which could result in substantial losses by our investors.\n● Although our shares of common stock are now listed on The Nasdaq Capital Market, we currently have a limited trading volume, which results in higher\nprice volatility for, and reduced liquidity of, our common stock.\n● If we cannot continue to satisfy the continuing listing criteria of the Nasdaq Capital Market, the exchange may subsequently delist our common stock.\n● Future sales of our common stock in the public market or other financings could cause our stock price to fall.\n● If we sell additional equity or debt securities to fund our operations, it may impose restrictions on our business.\n25\nTable of Contents\nRisks Related to Our Business and Industry\nThere is substantial doubt about our ability to continue as a going concern.\nOur independent registered public accounting firm has issued an opinion on our consolidated financial statements included in this Annual Report on Form 10-K\nthat states that the consolidated financial statements were prepared assuming we will continue as a going concern. Our consolidated financial statements have been prepared\nusing accounting principles generally accepted in the United States of America applicable for a going concern, which assume that we will realize our assets and discharge\nour liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of\nand for the year ended December 31, 2021, we had a net loss of $32.9 million and net cash used in operating activities of $26.4 million. Our consolidated financial\nstatements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as\na going concern. We also cannot be certain that additional financing, if needed, will be available on acceptable terms, or at all, and our failure to raise capital when needed\ncould limit our ability to continue our operations. There remains substantial doubt about our ability to continue as a going concern for the next twelve months from the date\nthe consolidated financial statements were issued.\nTo date, we have experienced negative cash flow from development of our technology, as well as from the costs associated with building a sales force to market\nour product and services. We expect to incur substantial net losses for the foreseeable future in order to further develop and commercialize our product. We also expect that\nour selling, general and administrative expenses will continue to increase due to the additional costs associated with market development activities and expanding our staff\nto sell and support our product. Our ability to achieve or, if achieved, sustain profitability is based on numerous factors, many of which are beyond our control, including the\nmarket acceptance of our products, competitive product development and our market penetration and margins. We may never be able to generate sufficient revenue to\nachieve or, if achieved, sustain profitability.\nBecause of the numerous risks and uncertainties associated with further development and commercialization of our technology and any future tests, we are unable\nto predict the extent of any future losses or when we will become profitable, if ever. We may never become profitable, and you may never receive a return on an investment\nin our securities. An investor in our securities must carefully consider the substantial challenges, risks and uncertainties inherent in the development and commercialization\nin the medical device industry. We may never successfully commercialize our technology and our business may fail.\nBecause we are an early commercialization stage company with one product in commercialization process, we expect to incur substantial additional operating losses.\nWe are an early commercialization stage company and we expect to incur substantial additional operating expenses over the next several years as our marketing,\ncommercialization, and customer development along with additional research and development increase for our PURE EP System and other product candidates. The\namount of our future losses and when, if ever, we will achieve profitability are uncertain. Our products that have generated minimal commercial revenue, and, although we\nexpect to generate revenues this year from the commercial sale of our PURE EP System, may not be able to generate sufficient revenues to fund our operating expenses, if\nany. Our ability to generate revenue and achieve profitability will depend on, among other things, the following:\n● successful completion of the pre-clinical and clinical development of our products;\n● obtaining necessary regulatory approvals from the FDA or other regulatory authorities;\n● establishing manufacturing, sales, and marketing arrangements, either alone or with third parties; and\n● raising sufficient funds to finance our activities.\nWe might not succeed at all, or at any, of these undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of\noperations may be materially adversely affected.\n26\nTable of Contents\nOur PURE EP System and other product candidates are in continued development and may not be successfully developed or commercialized.\nAlthough our main product candidate, the PURE EP System, received FDA 510(k) clearance from FDA, we are currently conducting clinical trials and may\nconduct additional clinical trials, which may require substantial further capital expenditure, to establish the safety and efficacy data needed to obtain acceptance by the\nmedical community and coverage by third-party payors. The continued development of the PURE EP System, and/or any other product candidates we may develop, is\ndependent upon our ability to obtain sufficient additional financing. However, even if we are able to obtain the requisite financing to fund our development program, we\ncannot assure you that our current or future product candidates will be successfully developed or commercialized. Our failure to develop, manufacture, receive regulatory\napproval for, or successfully commercialize any of our product candidates could result in the failure of our business and a loss of all of your investment in our company.\nWe expect to derive our revenue from sales of our PURE EP System and other products we may develop. If we fail to generate revenue from these sources, our results\nof operations and the value of our business will be materially and adversely affected.\nAs of December 31, 2021, our cash and cash equivalents were approximately $11.7 million. Based on our currently expected level of operating expenditures, we\nexpect that our existing cash and cash equivalents will be sufficient to fund our operations through at least the next 7 months, or July 2022. Our revenue is generated from\nsales of our PURE EP System, for which we made first commercial sale in February 2021, and other products we may develop. Future sales of these products, if any, will be\nsubject to, among other things, commercial and market uncertainties that may be outside our control. If we fail to generate our intended revenues from these products, our\nresults of operations and the value of our business and securities would be materially and adversely affected.\nWe may need to finance our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements. Any\nadditional funds that we obtain may not be on terms favorable to us or our stockholders and may require us to relinquish valuable rights.\nUntil PURE EP System or another product of ours become commercially viable, we will have to fund all of our operations and capital expenditures from cash on\nhand, public or private equity offerings, debt financings, bank credit facilities or corporate collaboration and licensing arrangements. . However, we may need to raise\nadditional funds more quickly if one or more of our assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we\npresently anticipate. We also may decide to raise additional funds before we require them if we are presented with favorable terms for raising capital.\nIf we seek to sell additional equity or debt securities, obtain a bank credit facility or enter into a corporate collaboration or licensing arrangement, we may not\nobtain favorable terms for us and/or our stockholders or be able to raise any capital at all, all of which could result in a material adverse effect on our business and results of\noperations. The sale of additional equity or debt securities, if convertible, could result in dilution to our stockholders. The incurrence of indebtedness would result in\nincreased fixed obligations and could also result in covenants that would restrict our operations. Raising additional funds through collaboration or licensing arrangements\nwith third parties may require us to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or to grant licenses on\nterms that may not be favorable to us or our stockholders. In addition, we could be forced to discontinue product development, reduce or forego sales and marketing efforts\nand forego attractive business opportunities, all of which could have an adverse impact on our business and results of operations.\nWe may be unable to develop our existing or future technology.\nOur product, the PURE EP System, may not deliver the levels of accuracy and reliability needed to make it a successful product in the marketplace, and the\ndevelopment of such accuracy and reliability may be indefinitely delayed or may never be achieved. In addition, we may experience delays in the development of our\ntechnology for other reasons, including failure to obtain necessary funding and failure to obtain all necessary regulatory approvals. Failure to develop this or other\ntechnology could have an adverse material effect on our business, financial condition, results of operations and future prospects.\n27\nTable of Contents\nWe may experience delays in any phase of the preclinical or clinical development of a product, including during its research and development.\nWe may experience delays in any phase of the preclinical or clinical development of a product, including during its research and development. The completion of\nany of these studies may be delayed or halted for numerous reasons, including, but not limited to, the following:\n● successful completion of the pre-clinical and clinical development of our products;\n● the FDA or other regulatory authorities do not approve a clinical study protocol or place a clinical study on hold;\n● patients do not enroll in a clinical study or results from patients are not received at the expected rate;\n● patients discontinue participation in a clinical study prior to the scheduled endpoint at a higher than expected rate;\n● patients experience adverse events from a product we develop;\n● third-party clinical investigators do not perform the studies in accordance with the anticipated schedule or consistent with the study protocol and good\nclinical practices or other third-party organizations do not perform data collection and analysis in a timely or accurate manner;\n● third-party clinical investigators engage in activities that, even if not directly associated with our studies, result in their debarment, loss of licensure, or\nother legal or regulatory sanction;\n● regulatory inspections of manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend the preclinical or\nclinical studies;\n● changes in governmental regulations or administrative actions;\n● the interim results of the preclinical or clinical study, if any, are inconclusive or negative; and\n● the study design, although approved and completed, is inadequate to demonstrate effectiveness and safety.\nIf the preclinical and clinical studies that we are required to conduct to gain regulatory approval are delayed or unsuccessful, we may not be able to market any\nproduct that we develop in the future. Preclinical studies and clinical trials are expensive and difficult to design and implement and any delays or prolongment in our\npreclinical and clinical studies will require additional capital. There is no assurance that we will be able to acquire additional capital to support our studies. The failure to\nobtain additional capital would have a material adverse effect on the Company.\nWe have completed one clinical trial of our product. The results of additional clinical studies may not support the usefulness of our technology.\nIn November 2019, we commenced our first clinical study with PURE EP System and completed the clinical trial as of September 2021. Conducting clinical trials\nis a long, expensive, and uncertain process that is subject to delays and failure at any stage. Clinical trials can take months or years. The commencement or completion of\nany of our subsequent clinical trials may be delayed or halted for numerous reasons, including:\n● the FDA may not approve a clinical trial protocol or a clinical trial, or may place a clinical trial on hold;\n● subjects may not enroll in clinical trials at the rate we expect, or we may not follow up on subjects at the rate we expect;\n● subjects may experience unexpected adverse events;\n● third-party clinical investigators may not perform our clinical trials consistent with our anticipated schedule or the clinical trial protocols and good clinical\npractices, or other third-party organizations may not perform data collection and analysis in a timely or accurate manner;\n28\nTable of Contents\n● interim results of any of our clinical trials may be inconclusive or negative;\n● regulatory inspections of our clinical trials may require us to undertake corrective action or suspend or terminate the clinical trials if investigators find us to be in\nviolation of regulatory requirements; or\n● governmental regulations or administrative actions may change and impose new requirements, particularly with respect to reimbursement.\nResults of pre-clinical studies do not necessarily predict future clinical trial results and previous clinical trial results may not be repeated in subsequent clinical\ntrials. We may experience delays, cost overruns and project terminations despite achieving promising results in pre-clinical testing or early clinical testing. In addition, the\ndata obtained from clinical trials may be inadequate to support a device’s approval or clearance, or to demonstrate safety and efficacy to the extent required to obtain third-\nparty coverage and/or reimbursement. The FDA may disagree with our interpretation of the data from our clinical trials, or may find the clinical trial design, conduct, or\nresults inadequate to demonstrate the safety and effectiveness of the product candidate. The FDA may also require additional pre-clinical studies or clinical trials that could\nfurther delay clearance or approval of any product candidates we may develop in the future and/or the PURE EP System to the extent we seek clearance/approval for\ndifferent indications than that for which it is currently cleared. If we are unsuccessful in receiving FDA clearance approval of a future product candidate, or a product’s\nclearance or approval is withdrawn, we would not be able to commercialize the product(s) in the U.S., which could seriously harm our business. Moreover, we face similar\nrisks in other jurisdictions in which we may sell or propose to sell our products.\nThe medical device industry is subject to stringent regulation and failure to obtain regulatory approval will prevent commercialization of our products.\nMedical devices are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act, by comparable agencies in\nforeign countries and by other regulatory agencies and governing bodies. Under the Federal Food, Drug, and Cosmetic Act and associated regulations, manufacturers of\nmedical devices must comply with certain regulations that cover the composition, labeling, testing, clinical study, manufacturing, packaging and distribution of medical\ndevices. In addition, medical devices must receive FDA clearance or approval before they can be commercially marketed in the U.S., and the FDA may require testing and\nsurveillance programs to monitor the effects of approved products that have been commercialized and can prevent or limit further marketing of a product based on the\nresults of these post-market evaluation programs. The process of obtaining marketing clearance or approval from the FDA for new products could take a significant period\nof time, require the expenditure of substantial resources, involve rigorous pre-clinical and clinical testing, require changes to the products and result in limitations on the\nindicated uses of the product. In addition, if we seek regulatory approval in non-U.S. markets, we will be subject to further regulatory approvals that may require additional\ncosts and resources. There is no assurance that we will obtain necessary regulatory approvals in a timely manner, or at all.\nTo obtain 510(k) clearance for a medical device, a pre-market notification must be submitted to the FDA demonstrating that the device is “substantially equivalent”\nto a previously cleared “predicate” device. A new device is substantially equivalent to a predicate device “at least as safe and effective” as the predicate. The FDA considers\na device substantially equivalent to a predicate if it has the same intended use as the predicate and has either: (i) the same technological characteristics as the predicate or (ii)\ndifferent technological characteristics from the predicate, but the information submitted to the FDA does not raise new questions of safety or effectiveness or demonstrates\nthat the device is at least as safe and effective as the predicate.\nWe received 510(k) clearance to market our current lead product, the PURE EP System in the U.S. However, if we intend to market the PURE EP System for\nadditional medical uses or indications, we may need to submit additional 510(k) applications to the FDA that are supported by satisfactory clinical trial results specifically\nfor the additional indication. Clinical trials necessary to support 510(k) clearance or PMA approval for any future product candidates, or any new indications for use for our\nPURE EP System, would be expensive and could require the enrollment of large numbers of suitable patients who could be difficult to identify and recruit. Delays or\nfailures in any necessary clinical trials could prevent us from commercializing any modified product or new product candidate and could adversely affect our business,\noperating results and prospects.\nThe results of our initial clinical trials may not provide sufficient evidence to allow the FDA to grant us such additional marketing clearances and even additional\ntrials requested by the FDA may not result in our obtaining 510(k) marketing clearance for our product. The failure to obtain FDA marketing clearance for any additional\nindications for the PURE EP System or any other of our future products would have a material adverse effect on our business.\n29\nTable of Contents\nWe, and our third-party manufacturer(s), are, and will be, subject to extensive regulation by the FDA.\nIn addition to the pre-market regulations, once a device is approved or cleared for the applicable indications for use, numerous FDA regulations apply, including\nbut not limited to those relating to manufacturing, labeling, packaging, advertising, and record keeping. Notably, these regulations apply to us, as well as our contract\nmanufacturer(s). Even if regulatory approval or clearance of a product is obtained, the approval or clearance may be subject to limitations on the uses for which the product\nmay be marketed or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Any such requirements could\nreduce our revenues, increase our expenses, and render the product not commercially viable. If we fail to comply with the applicable regulatory requirements, or if\npreviously unknown problems with any approved commercial products, manufacturers, or manufacturing processes are discovered, we could be subject to administrative or\njudicially imposed sanctions or other negative consequences, including:\n● restrictions on our products, manufacturers or manufacturing processes;\n● warning letters and untitled letters;\n● civil penalties and criminal prosecutions and penalties;\n● fines;\n● injunctions;\n● product seizures or detentions;\n● import or export bans or restrictions;\n● voluntary or mandatory product recalls and related publicity requirements;\n● suspension or withdrawal of regulatory approvals;\n● total or partial suspension of production; and\n● refusal to approve pending applications for marketing approval of new products or of supplements to approved applications.\nRegulations are constantly changing, and in the future our business may be subject to additional regulations that increase our compliance costs.\nWe believe we understand the current laws and regulations to which our products will be subject in the future. However, federal, state and foreign laws and\nregulations relating to the sale of our products are subject to future changes, as are administrative interpretations of regulatory agencies. If we fail to comply with such\nfederal, state or foreign laws or regulations, we may fail to obtain regulatory approval for our products and, if we have already obtained regulatory approval, we could be\nsubject to enforcement actions, including injunctions preventing us from conducting our business, withdrawal of clearances or approvals and civil and criminal penalties. In\nthe event that federal, state, and foreign laws and regulations change, we may incur additional costs to seek government approvals, in addition to the clearance from the\nFDA in order to sell or market our products. If we are slow or unable to adapt to changes in existing regulatory requirements or the promulgation of new regulatory\nrequirements or policies, we or our licensees may, following approval, lose marketing approval for our products which will impact our ability to conduct business in the\nfuture.\nThe market for our technology and revenue generation avenues for our products may be slow to develop, if at all.\nThe market for our products may be slower to develop or smaller than estimated or it may be more difficult to build the market than anticipated. The medical\ncommunity may resist our products or be slower to accept them than we anticipate. Revenues from our products may be delayed or costs may be higher than anticipated\nwhich may result in our need for additional funding. We anticipate that our principal route to market will be through commercial distribution partners. These arrangements\nare generally non-exclusive and have no guaranteed sales volumes or commitments. The partners may be slower to sell our products than anticipated. Any financial,\noperational or regulatory risks that affect our partners could also affect the sales of our products. In the current economic environment, hospitals and clinical purchasing\nbudgets may exercise greater restraint with respect to purchases, which may result in purchasing decisions being delayed or denied. If any of these situations were to occur\nthis could have a material adverse effect on our business, financial condition, results of operations and future prospects.\n30\nTable of Contents\nOur estimate of the size of our addressable market may prove to be inaccurate.\nWhile our addressable market size estimate for the EP market was made in good faith and is based on assumptions and estimates we believe to be reasonable, this\nestimate may not be accurate. If our estimates of the size of our addressable market are not accurate, our potential for future growth may be less than we currently anticipate,\nwhich could have a material adverse effect on our business, financial condition, and results of operations.\nIf we seek to market our products in foreign jurisdictions, we may need to obtain regulatory approval in these jurisdictions.\nIn order to market our products in the European Union and many other foreign jurisdictions, we may need to obtain separate regulatory approvals and comply with\nnumerous and varying regulatory requirements. Approval procedures vary among countries (except with respect to the countries that are part of the European Economic\nArea) and can involve additional clinical testing. The time required to obtain approval may differ from that required to obtain FDA approval. Should we decide to market\nour products abroad, we may fail to obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities\nin other countries, and approval by one foreign regulatory authority, including obtaining CE Mark approval, does not ensure approval by regulatory authorities in other\nforeign countries or by the FDA. We may be unable to file for, and may not receive, necessary regulatory approvals to commercialize our products in any foreign market,\nwhich could adversely affect our business prospects. In addition, a new Medical Device Regulation was published in 2017, which includes additional premarket and post-\nmarket requirements, as well as potential product reclassifications or more stringent commercialization requirements that could delay or otherwise adversely affect our\nclearances and approvals.\nThe EP market is highly competitive.\nThere are a number of groups and organizations, such as healthcare, medical device and software companies in the EP market that may develop a competitive\noffering to our products. The largest companies in the EP market are GE, Johnson & Johnson, Boston Scientific, Siemens, Medtronic, and Abbott. All of these companies\nhave significantly greater resources, experience and name recognition than we possess. There is no assurance that they will not attempt to develop similar or superior\nproducts, that they will not be successful in developing such products or that any products they may develop will not have a competitive advantage over our products.\nMoreover, our product may not be viewed as superior to existing technology or new technology from our competitors and as a result we may not be able to justify expected\nselling price our product, which may have a material adverse effect on market acceptance of our product. In addition, if we experience delayed regulatory approvals or\ndisputed clinical claims, we may not have a commercial or clinical advantage over competitors’ products that we believe we currently possess. Should a superior offering\ncome to market, this could have a material adverse effect on our business, financial condition, results of operations and future prospects.\nWe rely on key officers, consultants and scientific and medical advisors, and their knowledge of our business and technical expertise would be difficult to replace.\nWe are highly dependent on our officers, consultants and scientific and medical advisors because of their expertise and experience in medical device\ndevelopment. We do not have “key person” life insurance policies for any of our officers. Moreover, if we are unable to obtain additional funding, we will be unable to\nmeet our current and future compensation obligations to such employees and consultants. In light of the foregoing, we are at risk that one or more of our consultants or\nemployees may leave our company for other opportunities where there is no concern about such employers fulfilling their compensation obligations, or for other\nreasons. The loss of the technical knowledge and management and industry expertise of any of our key personnel could result in delays in product development, loss of\ncustomers and sales and diversion of management resources, which could adversely affect our results of operations.\nWe may fail to attract and retain qualified personnel.\nWe expect to rapidly expand our operations and grow our sales, research and development and administrative operations. This expansion is expected to place a\nsignificant strain on our management and will require hiring a significant number of qualified personnel. Accordingly, recruiting and retaining such personnel in the future\nwill be critical to our success. There is intense competition from other companies, research and academic institutions, government entities and other organizations for\nqualified personnel in the areas of our activities. Many of these companies, institutions and organizations have greater resources than we do, along with more prestige\nassociated with their names. If we fail to identify, attract, retain and motivate these highly skilled personnel, we may be unable to continue our marketing and development\nactivities, and this could have a material adverse effect on our business, financial condition, results of operations and future prospects.\n31\nTable of Contents\nIf we do not effectively manage changes in our business, these changes could place a significant strain on our management and operations.\nOur ability to grow successfully requires an effective planning and management process. The expansion and growth of our business could place a significant strain\non our management systems, infrastructure and other resources. To manage our growth successfully, we must continue to improve and expand our systems and\ninfrastructure in a timely and efficient manner. Our controls, systems, procedures and resources may not be adequate to support a changing and growing company. If our\nmanagement fails to respond effectively to changes and growth in our business, including acquisitions, there could be a material adverse effect on our business, financial\ncondition, results of operations and future prospects.\nOur strategic business plan may not produce the intended growth in revenue and operating income.\nOur strategies ultimately include making significant investments in sales and marketing programs to achieve revenue growth and margin improvement targets. If\nwe do not achieve the expected benefits from these investments or otherwise fail to execute on our strategic initiatives, we may not achieve the growth improvement we are\ntargeting and our results of operations may be adversely affected. We may also fail to secure the capital necessary to make these investments, which will hinder our growth.\nIn addition, as part of our strategy for growth, we may make acquisitions and enter into strategic alliances such as joint ventures and joint development agreements.\nHowever, we may not be able to identify suitable acquisition candidates, complete acquisitions or integrate acquisitions successfully, and our strategic alliances may not\nprove to be successful. In this regard, acquisitions involve numerous risks, including difficulties in the integration of the operations, technologies, services and products of\nthe acquired companies and the diversion of management’s attention from other business concerns. Although we will endeavor to evaluate the risks inherent in any\nparticular transaction, there can be no assurance that we will properly ascertain all such risks. In addition, acquisitions could result in the incurrence of substantial additional\nindebtedness and other expenses or in potentially dilutive issuances of equity securities. There can be no assurance that difficulties encountered with acquisitions will not\nhave a material adverse effect on our business, financial condition and results of operations.\nWe currently have limited sales, marketing or distribution operations and will need to expand our expertise in these areas.\nWe currently have limited sales, marketing or distribution operations. We have begun implementing a market development program and are in the process of\nbuilding such operations in connection with the commercialization of PURE EP System, and we are expanding our expertise in sales, marketing and distribution operations\nfor commercial growth. To increase internal sales, distribution and marketing expertise and be able to conduct these operations, we have begun to invest in and will have to\ninvest significant amounts of financial and management resources. In developing these functions ourselves, we could face a number of risks, including:\n● we may not be able to attract and build an effective marketing or sales force;\n● the cost of establishing, training and providing regulatory oversight for a marketing or sales force may be substantial; and\n● there are significant legal and regulatory risks in medical device marketing and sales that we have never faced, and any failure to comply with applicable legal and\nregulatory requirements for sales, marketing and distribution could result in an enforcement action by the FDA, European regulators or other authorities that could\njeopardize our ability to market our planned products or could subject us to substantial liability.\n32\nTable of Contents\nOur product development program depends upon third-party researchers, including Mayo, who are outside our control and whose negative performance could\nmaterially hinder or delay our pre-clinical testing or clinical trials.\nWe do not have the ability to conduct all aspects of pre-clinical testing or clinical trials ourselves. We depend upon independent investigators and collaborators,\nsuch as commercial third-parties, government, universities and medical institutions, to conduct our pre-clinical and clinical trials under agreements with us. For our first\nclinical trial for the PURE EP System, titled “Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study)” which commenced in\nNovember 2019, we rely on third parties, including TCARF and Mayo Clinic to conduct the patient cases. In addition, we are party to various license agreements with\nMayo, pursuant to which we rely on research and development information, materials, technical data, unpatented inventions, trade secrets, know-how and supportive\ninformation of Mayo to develop, make, have made, use, offer for sale, sell, and import licensed products. These collaborators are not our employees and we cannot control\nthe amount or timing of resources that they devote to our programs. These investigators may not assign as great a priority to our programs or pursue them as diligently as\nwe would if we were undertaking such programs ourselves. The failure of any of these outside collaborators to perform in an acceptable and timely manner in the future,\nincluding in accordance with any applicable regulatory requirements, such as good clinical and laboratory practices, or pre-clinical testing or clinical trial protocols, could\ncause a delay or otherwise adversely affect our pre-clinical testing or clinical trials, our success in obtaining regulatory approvals and, ultimately, the timely advancement of\nour development programs. In addition, these collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our\ncollaborators assist our competitors at our expense, our competitive position would be harmed.\nIf healthcare providers are unable to obtain sufficient reimbursement or other financial incentives from third-party healthcare payers related to the use of our products,\ntheir adoption and our future product sales will be materially adversely affected.\nWidespread adoption of the PURE EP System, and any other products we may develop in the future, by the medical community is unlikely to occur without a\nfinancial incentive from third-party payors for the use of these products. Third-party payors include but are not limited to governmental programs such as Medicare and\nMedicaid, commercial health insurers and private payors, workers’ compensation programs, and other organizations. Currently, the PURE EP System does not receive\nseparate reimbursement from any third-party payor. Instead, healthcare providers typically receive reimbursement for the procedure in which our product is used. Future\nregulatory action by CMS or other governmental agencies, or unfavorable clinical data, among other things, may impact coverage and/or reimbursement policies for\nprocedures performed using our products. If healthcare providers are unable to obtain adequate coverage of, or reimbursement for, procedures performed using our products,\nor if managed care organizations do not receive improved capitated payments due to more accurate patient risk assessment using our products, we may be unable to sell our\nproducts at levels that are sufficient to allow us to achieve and maintain profitability, and our business would suffer significantly.\nWe may face risks associated with future litigation and claims.\nWe may, in the future, be involved in one or more lawsuits, claims or other proceedings. These suits could concern issues including contract disputes, employment\nactions, employee benefits, taxes, environmental, health and safety, personal injury and product liability matters. Due to the uncertainties of litigation, we can give no\nassurance that we will prevail on any claims made against us in any such lawsuit. Also, we can give no assurance that any other lawsuits or claims brought in the future will\nnot have an adverse effect on our financial condition, liquidity or operating results.\nThe risk that we may be sued on product liability claims is inherent in the development and commercialization of medical devices. Specifically, we believe we will\nbe subject to product liability claims or product recalls, particularly in the event of false positive or false negative reports, because we plan to develop and manufacture\nmedical diagnostic products. Once a product is approved for sale and commercialized, the likelihood of product liability lawsuits increases. Product liability claims could be\nasserted directly by consumers, health-care providers or others. We have obtained product liability insurance coverage; however such insurance may not provide full\ncoverage for our current or future clinical trials, products to be sold, and other aspects of our business. A product recall or a successful product liability claim or claims that\nexceed our planned insurance coverage could have a material adverse effect on us. In addition, insurance coverage is becoming increasingly expensive and we may not be\nable to maintain current coverage, or expand our insurance coverage to include future clinical trials or the sale of new products or existing products in new territories, at a\nreasonable cost or in sufficient amounts to protect against losses due to product liability or at all. A successful product liability claim or series of claims brought against us\ncould result in judgments, fines, damages and liabilities that could have a material adverse effect on our business, financial condition and results of operations. In the event\nof an award against us during a time when we have no available insurance or insufficient insurance, we may sustain significant losses of our operating capital. We may incur\nsignificant expense investigating and defending these claims, even if they do not result in liability. Moreover, even if no judgments, fines, damages or liabilities are imposed\non us, our reputation could suffer, which could have a material adverse effect on our business, financial condition and results of operations, as well as impair our reputation\nin the medical and investment communities.\n33\nTable of Contents\nOur business is subject to cybersecurity risks.\nOur operations are increasingly dependent on information technologies and services. Threats to information technology systems associated with cybersecurity risks\nand cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters, terrorist attacks, utility outages, theft, viruses, phishing,\nmalware, design defects, human error, and complications encountered as existing systems are maintained, repaired, replaced, or upgraded. Risks associated with these\nthreats include, among other things:\n● theft or misappropriation of funds;\n● loss, corruption, or misappropriation of intellectual property, or other proprietary, confidential or personally identifiable information (including supplier, or\nemployee data);\n● disruption or impairment of our and our business operations and safety procedures;\n● damage to our reputation with our potential customers and the market;\n● exposure to litigation;\n● increased costs to prevent, respond to or mitigate cybersecurity events.\nAlthough we utilize various procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving and\nunpredictable. Moreover, we have no control over the information technology systems of our suppliers, and others with which our systems may connect and communicate.\nAs a result, the occurrence of a cyber incident could go unnoticed for a period time.\nWe presently maintain insurance coverage to protect against cybersecurity risks. However, we cannot ensure that it will be sufficient to cover any particular losses\nwe may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect on our business, financial condition and results of operations.\nWe may be subject, directly or indirectly, to U.S. federal and state healthcare laws, including fraud and abuse, false claims, and privacy laws and regulations.\nProsecutions under such laws have increased in recent years and we may become subject to such litigation and enforcement. If we are unable to, or have not fully\ncomplied with such laws, we could face substantial penalties.\nWe are subject, directly or indirectly, to various U.S. federal and state healthcare laws and regulations. These laws include fraud and abuse laws, such as the federal\nAnti-Kickback Statute, federal False Claims Act, and federal Foreign Corrupt Practices Act. These laws may impact, among other things, our proposed sales, marketing and\neducation programs. In addition, we may be subject, directly or indirectly, to patient privacy regulations by both the federal government and the states in which we conduct\nour business. The healthcare laws that may affect our ability to operate include, but are not limited to, the following.\n● The federal Anti-Kickback Statute, which prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration\n(including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in exchange for or to induce either the\nreferral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program,\nsuch as the Medicare and Medicaid programs.\n● The federal physician self-referral law, commonly referred to as the Stark Law, which prohibits a physician from making a referral for certain\ndesignated health services covered by the Medicare program, if the physician or an immediate family member has a financial relationship with the\nentity providing the designated health services, unless the financial relationship falls within an applicable exception to the prohibition.\n● Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which prohibits persons from\nknowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from, the federal government.\nSuits may be filed under the federal False Claims Act by the government or by an individual on behalf of the government (known as “qui\ntam” actions). Such individuals, commonly known as “relators” or “whistleblowers,” may share in any amounts paid by the entity to the\ngovernment in fines or settlement.\n34\nTable of Contents\n● The federal transparency requirements under the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act,\nincluding the provision known as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical\nsupplies covered under Medicare, Medicaid, or the Children’s Health Insurance Program (CHIP) to record any information related to payments and\nother transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate\nfamily members, and to report this data annually to CMS for subsequent public disclosure. Manufacturers must also disclose investment interests\nheld by physicians and their family members.\n● The federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state\nhealthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider,\npractitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies.\n● Federal criminal statutes created through the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which prohibit knowingly and\nwillfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent\npretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program,\nregardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material\nfact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to\nhealthcare matters.\n● HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and their respective implementing\nregulations, which imposes requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their\nrespective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information,\nrelating to the privacy, security and transmission of individually identifiable health information.\n● Other federal and state fraud and abuse laws, prohibitions on self-referral and kickbacks, fee-splitting restrictions, prohibitions on the provision of\nproducts at no or discounted cost to induce physician or patient adoption, and false claims acts, transparency, reporting, and disclosure\nrequirements, which may extend to services reimbursable by any third-party payer, including private insurers.\n● State and federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that could\npotentially harm consumers.\nAdditionally, we may be subject to state equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and\nmay apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for\nhealthcare services reimbursed by any source, not just governmental payors, including private insurers. Several states impose marketing restrictions or require medical\ndevice companies to make marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements, and if we fail to\ncomply with an applicable state law requirement we could be subject to penalties.\nBecause of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our future business\nactivities could be subject to challenge under one or more of such laws. In addition, healthcare reform legislation has strengthened these laws. For example, the Affordable\nCare Act, among other things, amended the intent requirement of the federal Anti-Kickback and criminal healthcare fraud statutes. As a result of such amendment, a person\nor entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. Moreover, the Affordable Care\nAct provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or\nfraudulent claim for purposes of the False Claims Act.\nViolations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspension from federal and\nstate healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to\nbring actions on behalf of the U.S. government under the False Claims Act as well as under the false claims laws of several states.\n35\nTable of Contents\nEfforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is\npossible that governmental authorities will conclude that our existing or future business practices do not comply with current or future statutes, regulations or case law\ninvolving applicable fraud and abuse or other healthcare laws and regulations. Any such actions instituted against us could have a significant adverse impact on our\nbusiness, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare,\nMedicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of\nwhich could adversely affect our ability to operate our business and our results of operations. Even if we are successful in defending against such actions, we may\nnonetheless be subject to substantial costs, reputational harm and adverse effects on our ability to operate our business. In addition, the approval and commercialization of\nany of our products outside the United States will also likely subject us to non-U.S. equivalents of the healthcare laws mentioned above, among other non-U.S. laws.\nIf any of our employees, agents, or the physicians or other providers or entities with whom we do business are found to have violated applicable laws, we may be\nsubject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, or, if we are not subject to such actions, we may\nsuffer reputational harm for conducting business with persons or entities found, or accused of being, in violation of such laws. Any such events could adversely affect our\nability to operate our business and our results of operations.\nIn addition, to the extent we commence commercial operations overseas, we will be subject to the federal Foreign Corrupt Practices Act and other countries’ anti-\ncorruption/anti-bribery regimes, such as the U.K. Bribery Act. The federal Foreign Corrupt Practices Act prohibits improper payments or offers of payments to foreign\ngovernments and their officials for the purpose of obtaining or retaining business. Safeguards we implement to discourage improper payments or offers of payments by our\nemployees, consultants, sales agents or distributors may be ineffective, and violations of the federal Foreign Corrupt Practices Act and similar laws may result in severe\ncriminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation, business, financial condition and results of\noperations.\nWe could be adversely affected if healthcare legislation or reform measures substantially change the market for medical care or healthcare coverage in the U.S.,\nnegatively affecting our business or revenue for PURE EP or future products.\nThe Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, commonly referred to as the\n“Healthcare Reform Law,” includes a number of rules regarding health insurance, the provision of healthcare, conditions to reimbursement for healthcare services provided\nto Medicare and Medicaid patients, and other healthcare policy reforms. Through the law-making process, substantial changes have been and continue to be made to the\ncurrent system for paying for healthcare in the U.S., including changes made to extend medical benefits to certain Americans who lacked insurance coverage and to contain\nor reduce healthcare costs (such as by reducing or conditioning reimbursement amounts for healthcare services and medical devices, and imposing additional taxes, fees,\nand rebate obligations on medical device companies). This legislation was one of the most comprehensive and significant reforms ever experienced by the U.S. in the\nhealthcare industry and has significantly changed the way healthcare is financed by both governmental and private insurers. This legislation has impacted the scope of\nhealthcare insurance and incentives for consumers and insurance companies, among others. Additionally, the Healthcare Reform Law’s provisions were designed to\nencourage providers to find cost savings in their clinical operations. Medical devices represent a significant portion of the cost of providing care. This environment has\ncaused changes in the purchasing habits of consumers and providers and resulted in specific attention to the pricing negotiation, product selection and utilization review\nsurrounding medical devices. This attention may result in our products we may commercialize or promote, including our current commercial products, being chosen less\nfrequently or the pricing being substantially lowered. At this stage, it is difficult to estimate the full extent of the direct or indirect impact of the Healthcare Reform Law on\nus.\nThese structural changes could entail further modifications to the existing system of private payors and government programs (such as Medicare, Medicaid, and the\nState Children’s Health Insurance Program), creation of government-sponsored healthcare insurance sources, or some combination of both, as well as other changes.\nRestructuring the coverage of medical care in the U.S. could impact the reimbursement for medical devices, including our current commercial products, those we and our\ndevelopment or commercialization partners are currently developing or those that we may commercialize or promote in the future. If reimbursement for our approved\nmedical devices, products we currently commercialize or promote, or any product we may commercialize or promote is substantially reduced or otherwise adversely\naffected in the future, or rebate obligations associated with them are substantially increased, it could have a material adverse effect on our reputation, business, financial\ncondition or results of operations.\n36\nTable of Contents\nExtending medical benefits to those who currently lack coverage will likely result in substantial costs to the U.S. federal government, which may force significant\nadditional changes to the healthcare system in the U.S. Much of the funding for expanded healthcare coverage may be sought through cost savings. While some of these\nsavings may come from realizing greater efficiencies in delivering care, improving the effectiveness of preventive care and enhancing the overall quality of care, much of\nthe cost savings may come from reducing the cost of care and increased enforcement activities. Cost of care could be reduced further by decreasing the level of\nreimbursement for medical services or products (including those products currently being developed by us or our development or commercialization partners or any product\nwe may commercialize or promote, including our current commercial products), or by restricting coverage (and, thereby, utilization) of medical services or products. In\neither case, a reduction in the utilization of, or reimbursement for, any medical device or any product we may commercialize or promote, including our current commercial\nproducts, or for which we receive marketing approval in the future, could have a material adverse effect on our reputation, business, financial condition or results of\noperations.\nFurther, the healthcare regulatory environment has seen significant changes in recent years and is still in flux. Legislative initiatives to modify, limit, replace, or\nrepeal the Healthcare Reform Law and judicial challenges continue. Congress has enacted legislation that repeals certain portions of the Healthcare Reform Law, including\nbut not limited to the Tax Cuts and Jobs Act, passed in December 2017, which included a provision that eliminates the penalty under the Healthcare Reform Law’s\nindividual mandate, effective January 1, 2019, as well as the Bipartisan Budget Act of 2018, passed in February 2018, which, among other things, repealed the Independent\nPayment Advisory Board (which was established by the Healthcare Reform Law and was intended to reduce the rate of growth in Medicare spending). Additionally, in\nDecember 2018, a district court in Texas held that the individual mandate is unconstitutional and that the rest of the Healthcare Reform Law is, therefore, invalid. On\nappeal, the Fifth Circuit Court of Appeals affirmed the holding on the individual mandate but remanded the case back to the lower court to reassess whether and how such\nholding affects the validity of the rest of the Healthcare Reform Law. The Fifth Circuit’s holding has been appealed to the U.S. Supreme Court, and a decision on the case is\npending. Substantial uncertainty remains as to the future of the Healthcare Reform Law. We cannot predict the impact on our business of future legislative and legal\nchallenges to the Healthcare Reform Law or other changes to the current laws and regulations. However, it is possible that such initiatives could have an adverse effect on\nour ability to obtain approval and/or successfully commercialize products in the U.S. in the future. For example, any changes that reduce, or impede the ability of healthcare\nproviders to obtain reimbursement for medical procedures in which the products we currently, or intend to, commercialize are used, or that reduce medical procedure\nvolumes, could adversely affect our operations and/or future business plans. The financial impact of U.S. healthcare reform legislation over the next few years will depend\non a number of factors, including the policies reflected in implementing regulations and guidance and changes in sales volumes for medical devices affected by the\nlegislation. From time to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory provisions governing coverage,\nreimbursement, pricing, and marketing of medical device products. In addition, third-party payor coverage and reimbursement policies are often revised or interpreted in\nways that may significantly affect our business and our products.\nThe ongoing COVID-19 pandemic may adversely affect our business.\nIn an effort to contain and mitigate the spread of COVID-19, many countries, including the United States, have imposed unprecedented restrictions on travel,\nquarantines, and other public health safety measures. Such government-imposed precautionary measures may have been relaxed in certain countries or states, but there is no\nassurance that more strict measures will be put in place again due to a resurgence in COVID-19 cases. The COVID-19 pandemic may adversely impact our business plan as\nour clinical studies may be delayed as hospitals in the impacted regions may shift their resources to patients affected by the disease. The rapidly evolving nature of the\ncircumstances is such that it is impossible, at this stage, to determine the full and overall impact the COVID-19 pandemic may have, but it could disrupt production and\ncause delays in the supply and delivery of products used in our research and development efforts, adversely affect our employees, and disrupt our operations, all of which\nmay have a material adverse effect on our business. In addition, the pandemic may have an adverse effect on the ability of regulatory bodies to review submissions in a\ntimely manner, grant approvals or supervise our candidates and products, and may further divert the attention and efforts of the medical community to coping with the\ncoronavirus and disrupt the marketplace in which we operate and may have a material adverse effects on our operations. Patient enrollment in future clinical trials could be\nslowed, delayed, or suspended due to the pandemic as well.\nMoreover, the COVID-19 pandemic has created significant economic uncertainty and volatility in the credit and capital markets. Management plans to secure the\nnecessary financing through the issue of new equity and/or the entering into of strategic partnership arrangements; however, there is no assurance that our management will\nbe able to obtain such financing on reasonable terms or at all. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have\nan adverse effect on our ability to access capital and on the market price of our common stock, and we may not be able to successfully raise capital through the sale of our\nsecurities. If we are unsuccessful in commercializing our products or raising capital, we may need to reduce activities, curtail or cease operations.\n37\nTable of Contents\nIn addition, a significant resurgence of COVID-19 or other infectious diseases could result in a widespread health crisis that could adversely affect the economies\nand financial markets worldwide, resulting in an economic downturn that could impact our business, financial condition and results of operations.\nAs a smaller reporting company, we are subject to scaled disclosure requirements that may make it more challenging for investors to analyze our results of operations\nand financial prospects.\nCurrently, we are a “smaller reporting company,” as defined by Rule 12b-2 of the Exchange Act. As a “smaller reporting company,” we are able to provide\nsimplified executive compensation disclosures in our filings and have certain other decreased disclosure obligations in our filings with the SEC, including being required to\nprovide only two years of audited financial statements in annual reports. Consequently, it may be more challenging for investors to analyze our results of operations and\nfinancial prospects.\nFurthermore, we are a non-accelerated filer as defined by Rule 12b-2 of the Exchange Act, and, as such, are not required to provide an auditor attestation of\nmanagement’s assessment of internal control over financial reporting, which is generally required for SEC reporting companies under Section 404(b) of the Sarbanes-Oxley\nAct. Because we are not required to, and have not, had our auditor’s provide an attestation of our management’s assessment of internal control over financial reporting, a\nmaterial weakness in internal controls may remain undetected for a longer period.\nThere are inherent limitations in all control systems, and misstatements due to error or fraud may occur and not be detected.\nThe ongoing internal control provisions of Section 404 of the Sarbanes-Oxley Act of 2002 require us to identify material weaknesses in internal control over\nfinancial reporting, which is a process to provide reasonable assurance regarding the reliability of financial reporting for external purposes in accordance with accounting\nprinciples generally accepted in the United States. Our management, including our chief executive officer and chief financial officer, does not expect that our internal\ncontrols and disclosure controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not\nabsolute, assurance that the objectives of the control system are met. In addition, the design of a control system must reflect the fact that there are resource constraints and\nthe benefit of controls must be relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that\nall control issues and instances of fraud, if any, in our company have been detected. These inherent limitations include the realities that judgments in decision-making can be\nfaulty and that breakdowns can occur because of simple errors or mistakes. Further, controls can be circumvented by individual acts of some persons, by collusion of two or\nmore persons, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future\nevents, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may be inadequate\nbecause of changes in conditions, such as growth of the company or increased transaction volume, or the degree of compliance with the policies or procedures may\ndeteriorate. Because of inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.\nIn addition, discovery and disclosure of a material weakness, by definition, could have a material adverse impact on our financial statements. Such an occurrence\ncould discourage certain customers or suppliers from doing business with us and adversely affect how our stock trades. This could in turn negatively affect our ability to\naccess equity markets for capital.\nRisks Related to Our Intellectual Property\nIf we do not obtain protection for our intellectual property rights, our competitors may be able to take advantage of our research and development efforts to develop\ncompeting products.\nWe intend to rely on a combination of patents, trade secrets, and nondisclosure and non-competition agreements to protect our proprietary intellectual property. Our\nowned patent portfolio now includes sixteen allowed/issued patents. Seventeen additional worldwide utility patent applications are pending covering various aspects of our\nPURE EP System for recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures. We also have two pending U.S. patent\napplications directed to artificial intelligence (AI). We also have 30 allowed/issued worldwide design patents, which cover various features of our display screens and\ngraphical user interface for enhanced visualization of biomedical signals. Finally, we have licenses to 3 patents and 14 additional worldwide utility patent applications from\nMayo Foundation for Medical Education and Research that are pending. These patents and applications are generally directed to electroporation and stimulation.\n38\nTable of Contents\nWe plan to file additional patent applications in the U.S. and in other countries as we deem appropriate for our products. Our applications have and will include\nclaims intended to provide market exclusivity for certain commercial aspects of the products, including the methods of production, the methods of usage and the\ncommercial packaging of the products. However, we cannot predict:\n● the degree and range of protection any patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise\ncircumvent our patents;\n● if and when such patents will be issued, and, if granted, whether patents will be challenged and held invalid or unenforceable;\n● whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or\n● whether we will need to initiate litigation or administrative proceedings which may be costly regardless of outcome.\nOur success also depends upon the skills, knowledge and experience of our scientific and technical personnel, our consultants and advisors as well as our licensors\nand contractors. To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, we rely on trade secret\nprotection and confidentiality agreements. To this end, it is our policy to require all of our employees, consultants, advisors and contractors to enter into agreements which\nprohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions\nimportant to our business. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any\nunauthorized use or disclosure or the lawful development by others of such information. If any of our trade secrets, know-how or other proprietary information is disclosed,\nthe value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.\nGiven the fact that we may pose a competitive threat, competitors, especially large and well-capitalized companies that own or control patents relating to\nelectrophysiology recording systems, may successfully challenge our current and planned patent applications, produce similar products or products that do not infringe our\nfuture patents, or produce products in countries where we have not applied for patent protection or that do not respect our patents.\nIf any of these events occurs, or we otherwise lose protection for our trade secrets or proprietary know-how, the value of our intellectual property may be greatly\nreduced. Patent protection and other intellectual property protection are important to the success of our business and prospects, and there is a substantial risk that such\nprotections will prove inadequate.\nIf we infringe upon the rights of third parties, we could be prevented from selling products and forced to pay damages and defend against litigation.\nIf our products, methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantial costs and we may be required\nto:\n● obtain licenses, which may not be available on commercially reasonable terms, if at all;\n● abandon an infringing product candidate;\n● redesign our product candidates or processes to avoid infringement;\n● cease usage of the subject matter claimed in the patents held by others;\n● pay damages; and/or\n● defend litigation or administrative proceedings which may be costly regardless of outcome, and which could result in a substantial diversion of our financial and\nmanagement resources.\nAny of these events could substantially harm our earnings, financial condition and operations.\n39\nTable of Contents\nWe depend on our collaboration with Mayo Clinic for the research and development of additional advanced features of PURE EP™ System. If this collaboration is not\nsuccessful, we may not be able to realize the market potential of such features and may not have rights to use any such developed advanced features.\nOn March 15, 2017, we entered into a know-how license agreement with Mayo Foundation for Medical Education and Research (“Mayo Clinic”), effective\nDecember 2, 2016, and as amended whereby we were granted an exclusive license, with the right to sublicense, certain know how and patent applications in the fields of\nsignal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale. The agreement\nexpires ten years from the effective date. In furtherance of this collaboration, we subsequently entered into four additional agreements whereby we were granted exclusive\nlicenses, with the right to sublicense additional Mayo Clinic patents and know-how. Pursuant to these agreements, Mayo Clinic retains ownership of the licensed intellectual\nproperty and any developed intellectual property. Mayo Clinic also retains the right to prosecute and enforce the developed intellectual property. If our agreements with\nMayo Clinic terminate, our access to technology and intellectual property licensed to us by Mayo Clinic may be restricted or terminate entirely, which may delay our\ncontinued development of such advanced features utilizing the Mayo Clinic’s technology or intellectual property or require us to stop development of those product\ncandidates completely. Additional risks posed by this collaboration include:\n● Mayo Clinic may not properly obtain, maintain, enforce, or defend intellectual property or proprietary rights relating to our advanced features or may use our\nproprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings\nchallenging the scope, ownership, validity, and enforceability of our intellectual property;\n● Mayo Clinic may own or co-own intellectual property covering our advanced features that results from our collaboration with them, and in such cases, we\nmay not have the exclusive right or any right to commercialize such intellectual property or such product candidates or research programs; or\n● We may be prevented from enforcing or defending any intellectual property that we contribute to or that arises out of the collaboration, if Mayo Clinic\nrefuses to cooperate with such action.\nOur collaboration with Mayo Clinic is made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual\nproperty was developed under a funding agreement between Mayo Clinic and the U.S. government. Additionally, to the extent there is any conflict between our agreements\nwith Mayo Clinic and applicable laws or regulations, applicable laws and regulations will prevail. Some, and possibly all, of the developed intellectual property rights\nrelating to our advanced features may have been developed in the course of research funded by the U.S. government. As a result, the U.S. government may have certain\nrights to intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. Government rights in certain inventions developed under a\ngovernment-funded program include a nonexclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S.\ngovernment has the right to require us, or an assignee or exclusive licensee to such inventions, to grant licenses to any of these inventions to a third party if the U.S.\ngovernment determines that adequate steps have not been taken to commercialize the invention, that government action is necessary to meet public health or safety needs,\nthat government action is necessary to meet requirements for public use under federal regulations, or that the right to use or sell such inventions is exclusively licensed to an\nentity within the U.S. and substantially manufactured outside the U.S. without the U.S. government’s prior approval. Additionally, we may be restricted from granting\nexclusive licenses for the right to use or sell our inventions created pursuant to such agreements unless the licensee agrees to additional restrictions (e.g., manufacturing\nsubstantially all of the invention in the U.S.). The U.S. government also has the right to take title to these inventions if we fail to disclose the invention to the government\nand fail to file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title in any country in which a\npatent application is not filed within specified time limits. Additionally, certain inventions are subject to transfer restrictions during the term of these agreements and for a\nperiod, thereafter, including sales of products or components, transfers to foreign subsidiaries for the purpose of the relevant agreements, and transfers to certain foreign\nthird parties. If any of our intellectual property becomes subject to any of the rights or remedies available to the U.S. government or third parties pursuant to the Bayh-\nDole Act of 1980, this could impair the value of our intellectual property and could adversely affect our business. The U.S. government has not exercised any of these rights\nor provided us with any notice of its intent to exercise any of these rights with respect to any of the intellectual property licensed to us by Mayo Clinic. We are not aware of\nany instance in which the U.S. government has ever exercised any such rights with respect to any technologies or other intellectual property developed under funding\nagreements with the U.S. government.\n40\nTable of Contents\nRisks Related to our Common Stock\nThe market price for our common stock may fluctuate significantly, which could result in substantial losses by our investors.\nThe stock market in general, and Nasdaq in particular, as well as biotechnology companies, have experienced extreme price and volume fluctuations that have\noften been unrelated or disproportionate to the operating performance of small companies. The market price of our common stock may fluctuate significantly in response to\nnumerous factors, some of which are beyond our control, such as:\n• announcements of technological innovations, new products or product enhancements by us or others;\n• actual or anticipated quarterly increases or decreases in revenue, gross margin or earnings, and changes in our business, operations or prospects;\n• announcements of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments by us or our competitors;\n• conditions or trends in the biotechnology industry;\n• changes in the economic performance or market valuations of other biotechnology companies;\n• general market conditions or domestic or international macroeconomic and geopolitical factors unrelated to our performance or financial condition;\n• purchase or sale of our common stock by stockholders, including executives and directors;\n• volatility and limitations in trading volumes of our common stock;\n• changes in our capital structure or dividend policy, future issuances of securities, sales or distributions of large blocks of our common stock by stockholders;\n• our cash position;\n• announcements and events surrounding financing efforts, including debt and equity securities;\n• changes in earnings estimates or recommendations by security analysts, if our common stock is covered by analysts;\n• the addition or departure of key personnel;\n• disputes and litigation related to intellectual property rights, proprietary rights, and contractual obligations;\n• changes in applicable laws, rules, regulations, or accounting practices and other dynamics; and\n• other events or factors, many of which may be out of our control.\nThese factors and any corresponding price fluctuations may materially and adversely affect the market price of our common stock and result in substantial losses\nby our investors.\nFurther, the stock market in general, and the market for technology companies in particular, has experienced extreme price and volume fluctuations in the past.\nContinued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock.\nMoreover, the COVID-19 pandemic has resulted in significant financial market volatility and uncertainty in recent months. A continuation or worsening of the\nlevels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, on our business, results of operations and\nfinancial condition, and on the market price of our common stock.\n41\nTable of Contents\nPrice volatility of our common stock might be worse if the trading volume of our common stock is low. In the past, following periods of market volatility,\nstockholders have often instituted securities class action litigation. If we were involved in securities litigation, it could have a substantial cost and divert resources and\nattention of management from our business, even if we are successful. Future sales of our common stock could also reduce the market price of such stock.\nMoreover, the liquidity of our common stock is limited, not only in terms of the number of shares that can be bought and sold at a given price, but by delays in the\ntiming of transactions and reduction in security analysts’ and the media’s coverage of us, if any. These factors may result in lower prices for our common stock than might\notherwise be obtained and could also result in a larger spread between the bid and ask prices for our common stock. In addition, without a large float, our common stock is\nless liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our common stock may be more volatile. In the absence of an\nactive public trading market, an investor may be unable to liquidate its investment in our common stock. Trading of a relatively small volume of our common stock may\nhave a greater impact on the trading price of our stock than would be the case if our public float were larger. We cannot predict the prices at which our common stock will\ntrade in the future.\nAlthough our shares of common stock are now listed on The Nasdaq Capital Market, we currently have a limited trading volume, which results in higher price volatility\nfor, and reduced liquidity of, our common stock.\nAlthough our shares of common stock are now listed on The Nasdaq Capital Market under the symbol “BSGM,” trading volume in our common stock has been\nlimited and an active trading market for our shares of common stock may never develop or be maintained. The absence of an active trading market increases price volatility\nand reduces the liquidity of our common stock. As long as this condition continues, the sale of a significant number of shares of common stock at any particular time could\nbe difficult to achieve at the market prices prevailing immediately before such shares are offered.\nIf we cannot continue to satisfy the continuing listing criteria of the Nasdaq Capital Market, the exchange may subsequently delist our common stock.\nNasdaq requires us to meet certain financial, public float, bid price and liquidity standards on an ongoing basis in order to continue the listing of our common\nstock. Generally, we must maintain a minimum amount of stockholders’ equity and a minimum number of holders of our securities. If we fail to meet any of the continuing\nlisting requirements, our common stock may be subject to delisting. If our common stock is delisted and we are not able to list our common stock on another national\nsecurities exchange, we expect our securities would be quoted on an over-the-counter market. If this were to occur, our stockholders could face significant material adverse\nconsequences, including limited availability of market quotations for our common stock and reduced liquidity for the trading of our securities. In addition, we could\nexperience a decreased ability to issue additional securities and obtain additional financing in the future. There can be no assurance that an active trading market for our\ncommon stock will develop or be sustained.\nFuture sales of our common stock in the public market or other financings could cause our stock price to fall.\nSales of a substantial number of shares of our common stock in the public market, the perception that these sales might occur or other financings, could depress the\nmarket price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. A substantial majority of the outstanding\nshares of our common stock are freely tradable without restriction or further registration under the Securities Act unless these shares are owned or purchased by “affiliates”\nas that term is defined in Rule 144 under the Securities Act. In addition, shares of common stock issuable upon exercise of outstanding options, restricted stock units and\nshares reserved for future issuance under our incentive stock plan will be eligible for sale in the public market to the extent permitted by applicable vesting requirements\nand, in some cases, subject to compliance with the requirements of Rule 144. As a result, these shares can be freely sold in the public market upon issuance, subject to\nrestrictions under the securities laws.\nIf we sell additional equity or debt securities to fund our operations, it may impose restrictions on our business.\nIn order to raise additional funds to support our operations, we may sell additional equity or debt securities, which may impose restrictive covenants that adversely\nimpact our business. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on\nour ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely\nimpact our ability to conduct our business. If we are unable to expand our operations or otherwise capitalize on our business opportunities due to such restrictions, our\nbusiness, financial condition and results of operations could be materially adversely affected.\n42\nTable of Contents\nOur stockholders may experience substantial dilution as a result of the exercise of outstanding options or warrants to purchase shares of our common stock, or upon\nconversion of our Series C preferred stock into shares of our common stock.\nAs of March 30, 2022, we have outstanding options to purchase 4,869,484 shares of common stock, 82,500 restricted stock units and have reserved 2,582,522\nshares of our common stock for further issuances pursuant to our 2012 Equity Incentive Plan. In addition, as of March 30, 2022, we may be required to issue 159,822 shares\nof our common stock for issuance upon conversion of outstanding convertible Series C preferred stock which includes accrued dividends as of March 30, 2022, and\n3,432,040 shares of our common stock for issuance upon exercise of outstanding warrants. Should all of these shares be issued, you would experience dilution in ownership\nof our common stock and the price of our common stock will decrease unless the value of our company increases by a corresponding amount.\nThe interests of our controlling stockholders may not coincide with yours and such controlling stockholders may make decisions with which you may disagree.\nAs of March 30, 2022, five of our stockholders beneficially owned over 17.4% of our common stock. As a result, these stockholders may be able to influence the\noutcome of matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. In addition, this concentration of\nownership may delay or prevent a change in control of our company and make some future transactions more difficult or impossible without the support of our controlling\nstockholders. The interests of our controlling stockholders may not coincide with our interests or the interests of other stockholders.\nDelaware law and our Amended and Restated Certificate of Incorporation and By-laws contain anti-takeover provisions that could delay or discourage takeover\nattempts that stockholders may consider favorable.\nOur board of directors is authorized to issue shares of preferred stock in one or more series and to fix the voting powers, preferences and other rights and\nlimitations of the preferred stock. Accordingly, we may issue shares of preferred stock with a preference over our common stock with respect to dividends or distributions\non liquidation or dissolution, or that may otherwise adversely affect the voting or other rights of the holders of common stock. Issuances of preferred stock, depending upon\nthe rights, preferences and designations of the preferred stock, may have the effect of delaying, deterring or preventing a change of control, even if that change of control\nmight benefit our stockholders. In addition, we are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware\ncorporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person\nbecame an interested stockholder, unless (i) prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the\ntransaction which resulted in the stockholder becoming an interested stockholder; (ii) the interested stockholder owned at least 85% of the voting stock of the corporation\noutstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors\nand also officers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject\nto the plan will be tendered in a tender or exchange offer; or (iii) on or subsequent to the date of the transaction, the business combination is approved by the board and\nauthorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is\nnot owned by the interested stockholder.\nSection 203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire\nus even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.\nRisks Related to our Series C Preferred Stock\nOur Series C Preferred Stock contains covenants that could limit our financing options and liquidity position, which would limit our ability to grow our business.\nCovenants in the certificate of designation for our Series C Preferred Stock impose operating and financial restrictions on us. These restrictions prohibit or limit our\nability to, among other things:\n● incur additional indebtedness;\n● permit liens on assets;\n● repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;\n43\nTable of Contents\n● pay cash dividends to our stockholders; and\n● engage in transactions with affiliates.\nThese restrictions may limit our ability to obtain financing, withstand downturns in our business or take advantage of business opportunities. Moreover, debt\nfinancing we may seek may contain terms that include more restrictive covenants, may require repayment on an accelerated schedule or may impose other obligations that\nlimit our ability to grow our business, acquire needed assets, or take other actions we might otherwise consider appropriate or desirable.\nIn addition, the certificate of designation for our Series C Preferred Stock requires us to redeem shares of our Series C Preferred Stock, at each holder’s option and\nfor an amount greater than their stated value, upon the occurrence of certain events, including our being subject to a judgment of greater than $100,000 or our initiation of\nbankruptcy proceedings.\nThe holders of our Series C Preferred Stock are entitled to receive a dividend, which may be increased if we do not comply with certain covenants.\nThe holders of the Series C Preferred Stock are entitled to a 9% annual dividend on the $1,000 per share stated value of our Series C Preferred Stock, which is\npayable in cash or, subject to the satisfaction of certain conditions, in pay-in-kind shares. The dividend may be increased to a 18% annual dividend if we fail to comply with\ncertain covenants, including our being subject to a judgment of greater than $100,000 or our initiation of bankruptcy proceedings. As a result of the payment of dividends\nrelated to our Series C Preferred Stock, we may be obligated to pay significant sums of money or issue a significant number of shares of our common stock, which could\nnegatively affect our operations or result in the dilution of the holders of our common stock, respectively.\nThe terms of our Series C Preferred Stock contain anti-dilution provisions that may result in the reduction of the conversion prices in the future.\nThe terms of our Series C Preferred Stock contain anti-dilution provisions, which provisions require the lowering of the conversion price to the purchase price of\nfuture offerings. If in the future we issue securities for less than the conversion of our Series C Preferred Stock then in effect, we will be required to further reduce the\nrelevant conversion prices.\nThe terms of our Series C Preferred Stock prohibit us from paying dividends in the future on our common stock. As a result, any return on investment may be limited to\nthe value of our common stock.\nThe terms of our Series C Preferred Stock prohibit us from paying dividends in the future on our common stock, absent consent from the holders representing a\nsuper-majority of the outstanding shares of our Series C Preferred Stock and a certain investor. Because we will likely not pay dividends, our common stock may be less\nvaluable because a return on an investment in our common stock will only occur if our stock price appreciates.\n44\nTable of Contents\nGeneral Risk Factors\nThe liability of our directors and officers is limited.\nThe applicable provisions of the Delaware General Corporation Law and our Amended and Restated Certificate of Incorporation and By-laws limit the liability of\nour directors to us and our stockholders for monetary damages for breaches of their fiduciary duties, with certain exceptions, and for other specified acts or omissions of\nsuch persons. In addition, the applicable provisions of the Delaware General Corporation Law and of our Amended and Restated Certificate of Incorporation and By-laws\nprovide for indemnification of such persons under certain circumstances. In the event we are required to indemnify any of our directors or any other person, our financial\nstrength may be harmed.\nNegative publicity or unfavorable media coverage could damage our reputation and harm our operations.\nIn the event that the marketplace perceives our products as not offering the benefits which we believe they offer, we may receive negative publicity. This publicity\nmay result in litigation and increased regulation and governmental review. If we were to receive such negative publicity or unfavorable media attention, whether warranted\nor unwarranted, our ability to market our products would be adversely affected. We may be required to change our products and services and become subject to increased\nregulatory burdens, and we may be required to pay large judgments or fines and incur significant legal expenses. Any combination of these factors could further increase\nour cost of doing business and adversely affect our financial position, results of operations and cash flows.\nIf securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could\ndecline.\nThe trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We\ncurrently have new research coverage by securities and industry analysts. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or\nunfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of us or fails to publish reports on us\nregularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline.\nWe are subject to financial reporting and other requirements that place significant demands on our resources.\nWe are subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended, including the requirements of Section 404 of the\nSarbanes-Oxley Act of 2002. Section 404 requires us to conduct an annual management assessment of the effectiveness of our internal controls over financial reporting.\nThese reporting and other obligations place significant demands on our management, administrative, operational, internal audit and accounting resources. Any failure to\nmaintain effective internal controls could have a material adverse effect on our business, operating results and stock price. Moreover, effective internal control is necessary\nfor us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may not be able to manage our business as\neffectively as we would if an effective control environment existed, and our business and reputation with investors may be harmed.\n45\nTable of Contents\nITEM 1B – UNRESOLVED STAFF COMMENTS\nNot applicable.\nITEM 2 – PROPERTIES\nWe maintain our principal executive office at 55 Greens Farms Road, Westport, Connecticut, where we sublease approximately 6,590 square feet of office\nspace. This lease runs until December 31, 2024, with monthly payments of $14,828 from January 1, 2022 through December 31, 2022, $15,377 per month from January 1,\n2023 through December 31, 2023 and $15,926 from January 1, 2024 through December 31, 2024 plus any additional utility expenses. In connection with the lease, we paid\na security deposit of $14,828. There is no option to extend the lease past its initial term.\nIn addition, we maintain our engineering offices at 12424 Wilshire Boulevard, Los Angeles, California, where we lease approximately 4,000 square feet of office\nspace. This lease runs until June 30, 2022, with monthly payments of $13,702. In connection with the lease, we paid a security deposit of $32,852. Although we do not\nhave an option to extend past its lease term, we are currently in negotiations to replace our expiring existing lease.\nIn October 2021, we exercised our option to extend our lease agreement for approximately 1,400 square feet of office space in Rochester Minnesota commencing\nNovember 1, 2021, and expiring on October 31, 2023, at a rate of $3,513 per month through October 31, 2023. This lease agreement includes an option to extend the lease\nfor one additional period of two years each its existing term.\nWe believe we may need to expand our current facilities to meet our future needs.\nITEM 3 – LEGAL PROCEEDINGS\nAurigene Pharmaceutical Services LTD vs. ViralClear Pharmaceuticals Inc. and BioSig Technologies, Inc.\nOn January 8, 2021, Aurigene Pharmaceutical Services, LTD (“Aurigene”) filed a complaint with the United States District Court for the District of Connecticut\nclaiming the Company is in default of certain milestone payments for manufacturing and services under contracts dated June 23, 2020 and July 16, 2020 in aggregate\namount of $1,530,000.\nOn September 23, 2021, we entered into a settlement agreement with Aurigene for a sum of $1,000,000 payable in three installments of $400,000, $300,000, and\n$300,000 on September 30, 2021, December 31, 2021, and March 31, 2022, respectively, with no admission or concession by either party. Balance due under the settlement\nis $300,000 as of March 30, 2022.\nFrom time to time, we may become involved in other various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is\nsubject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any\nsuch legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating\nresults.\nThere are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more than 5% of our common\nstock is an adverse party or has a material interest adverse to our interest.\nITEM 4 – MINE SAFETY DISCLOSURES\nNot applicable.\n46\nTable of Contents\nPART II\nITEM 5 – MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY\nSECURITIES\nMarket for Common Stock\nOn October 29, 2014, our common stock commenced trading on OTCQB under the symbol “BSGM” and on September 21, 2018 we commenced trading on the\nNasdaq Capital Market exchange under the same ticker symbol. Prior to October 29, 2014, there was no established trading price for our common stock. The last reported\nsales price of our common stock on the Nasdaq Capital Market on March 29, 2022, was $1.30 per share.\nHolders of Record\nAs of March 30, 2022, there were approximately 290 holders of our common stock, as determined by counting our record holders and the number of participants\nreflected in a security position listing provided to us by the Depository Trust Company. Because the “DTC participants” are brokers and other institutions holding shares of\nour common stock on behalf of their customers, we do not know the actual number of unique shareholders represented by these record holders.\nDividends\nWe have never paid cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future but intend to retain our capital\nresources for reinvestment in our business.\nITEM 6 – RESERVED\nITEM 7 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS\nManagement’s Discussion and Analysis of Financial Condition and Results of Operations is intended to provide a reader of our financial statements with a\nnarrative from the perspective of our management on our financial condition, results of operations, liquidity, and certain other factors that may affect our future results. You\nshould read the following discussion and analysis of our financial condition and results of operations in conjunction with our financial statements and the related notes\nthereto that are included in this Form 10-K. In addition to historical information, the following discussion and analysis includes forward-looking statements that reflect our\nplans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to\nthese differences include those discussed below and elsewhere in this prospectus, particularly in the section entitled “Risk Factors.” See “Special Note Regarding Forward-\nLooking Statements.”\nOverview\nWe are a medical technology company that is commercializing our PURE EP™ System which is an advanced signal acquisition and processing platform designed\nto provide essential diagnostic signals with high clinical value in all types of cardiac catheter ablations. PURE EP™ is designed to address long-standing limitations that\nslow and disrupt cardiac catheter ablation procedures, such as environmental lab noise, signal saturation, slow signal recovery, and inaccurate display of fractionated\npotentials.\nCardiac catheter ablation is a procedure that involves delivery of energy through the tip of a catheter that scars or destroys heart tissue to correct heart rhythm\ndisturbances (arrhythmias). In August 2018, we received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) to market our PURE (Precise\nUninterrupted Real-time evaluation of Electrograms) EP™ System.\nPURE EP™ is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable\nelectrophysiologists to see more signals and analyze them in real-time. The device aims to minimize noise and artifacts from cardiac recordings and acquire high-fidelity\ncardiac signals. Improving fidelity of acquired cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and\nefficiency of the EP studies and ablation procedures.\nPURE EP™’s initial focus is on improving intracardiac signal acquisition and enhancing diagnostic information for catheter ablation procedures for complex\narrhythmias like ventricular tachycardia (“VT”), a potentially life-threatening arrhythmia, and atrial fibrillation (“AF”), the most common cardiac arrhythmia associated\nwith a fivefold risk of stroke.\n47\nTable of Contents\nClinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas,\nMayo Clinic in Jacksonville, Florida, and Massachusetts General Hospital in Boston, Massachusetts was published in September 2021 in the Journal of Cardiovascular\nElectrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a\n75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals over conventional sources. AF accounted for over 40% of\nenrollments.\nWe continue to install PURE EP™ Systems at centers of excellence for clinical evaluation under our market development plan. The PURE EP™ System has been\nutilized at numerous institutions, including Mayo Clinic campuses in Arizona, Florida and Minnesota; the University of Pennsylvania Hospital in Philadelphia,\nPennsylvania; Overland Park Regional Medical System in Overland Park, Kansas; Deborah Heart and Lung Center in Browns Mills, New Jersey; St. Elizabeth’s Medical\nCenter in Boston, Massachusetts; Medical City Heart Hospital in Dallas, Texas; Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, a teaching\nhospital of Harvard Medical School; Methodist Hospital in San Antonio, Texas; Houston Methodist Hospital; Medical City North Hills in North Richland Hills; and\nWestside Regional Medical Center in Plantation, Florida.\nTo date, more than 2,160 patient procedures have been conducted with the PURE EP™ System by more than 76 electrophysiologists across seventeen different\nclinical sites in the United States.\nIn addition to clinical evaluation, we have conducted pre-clinical evaluation with the PURE EP™ System under several protocols. At Mayo Clinic in Rochester,\nMinnesota, we have performed twenty-seven experiments (including novel research programs such as Artificial Intelligence, or AI, and repolarization) in various animal\nmodels; we also conducted a pre-clinical study at the Mount Sinai Hospital in New York, New York, with an emphasis on the VT model; and six experiments to date during\na study at the University of Pennsylvania. We intend to continue additional research and development studies with our technology at Mayo Clinic, the University of\nPennsylvania and other national centers.\nIn September 2021, we announced that we entered into a manufacturing and professional services agreement with Plexus Corp (“Plexus”) (Nasdaq: PLXS). Under\nthe terms of the agreement, Plexus will manufacture the PURE EP™ System and develop a new product pipeline for our subsidiary, ViralClear.\nWe have made progress towards obtaining a European CE marking certificate for medical devices. In Q1 2022, we completed the quality management system audit\nfor the International Organization for Standardization (“ISO”) 13485:2016 with the expectation to obtain the ISO 13485:2016 certification in the first half of 2022 and\nproceed to the application for the European CE Marking clearance in the first half of 2023, subject to the guidance and availability from the European Notified Body.\nIn January 2022, we were awarded U.S. patent claims for our PURE EP™ noise-filtering technology which address computer-implemented systems and methods\nfor filtering noise from input cardiac signals. We now have 49 issued or allowed worldwide patents covering our novel technology for arrhythmia care.\nIn December 2020, we announced that three PURE EP™ Systems were contracted for purchase by St. David’s Healthcare in Austin, Texas and were subsequently\nsold in February 2021. We also sold three PURE EP™ Systems to Mayo Foundation for Medical Education and Research in 2021 for use in Mayo Clinic campuses in\nRochester, Minnesota, Jacksonville, Florida and Phoenix, Arizona. We are in active discussions with several accounts about the acquisition of the PURE EP™ System.\nCritical Accounting Estimates\nThe following discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been\nprepared in accordance with generally accepted accounting principles in the U.S. The preparation of consolidated financial statements in accordance with generally accepted\naccounting principles in the U.S. requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements. The consolidated\nfinancial statements include estimates based on currently available information and our judgment as to the outcome of future conditions and circumstances.\nAmong the significant judgments made by management in the preparation of our financial statements are the following:\nWe believe the following critical accounting estimates affect our more significant judgments and estimates used in the preparation of our financial statements.\n48\nTable of Contents\nRevenue Recognition\nWe derive our revenue primarily from the sale of our medical device, the PURE EP™ System, as well as related support and maintenance services and software\nupgrades in connection with the system.\nWe recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (“ASC 606”). The core\nprinciple of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to\nwhich the entity expects to be entitled in exchange for those goods or services.\nWe determine revenue recognition through the following five steps:\n●Identify the contract with the customer;\n●Identify the performance obligations in the contract;\n●Determine the transaction price;\n●Allocate the transaction price to the performance obligation in the contract; and\n●Recognize revenue when, or as, the performance obligations are satisfied.\nPerformance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer.\nIf we determine that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Support,\nmaintenance, and software upgrades are performance obligations over a defined period and are recognized ratably over the contractual service period. Customers typically\npurchase these services with the initial sale of the PURE EP System and do not have the right to terminate their contracts unless we fail to perform material obligations.\nWe may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single objective,\nwhether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised\nin the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and\nthe timing of revenue recognition related to those arrangements.\nWe estimate the transaction price based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. The\nconsideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, we evaluate the\namount of the potential payments and the likelihood that the payments will be received. If it is probable that a significant revenue reversal would not occur, the variable\nconsideration is included in the transaction price.\nWe record accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the\ncontractual arrangement. Unbilled receivables, if any, include amounts related to our contractual right to consideration for completed performance obligations not yet\ninvoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on an\nindividual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the\ncustomer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue.\nResearch and Development\nWe account for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC\n730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are\nexpensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved.\nCompany-sponsored research and development costs related to both present and future products are expensed in the period incurred.\n49\nTable of Contents\nStock Based Compensation\nAll stock-based payments to employees and to nonemployee directors for their services as directors consisted of grants of restricted stock and stock options, which\nare measured at fair value on the grant date and recognized in the statements of operations as compensation expense over the relevant vesting period. Restricted stock\npayments and stock-based payments to nonemployees are recognized as an expense over the period of performance.\nSuch payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for\nawards that vest immediately and are non-forfeitable, the measurement date is the date the award is issued.\nUse of Estimates\nThe preparation of our consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the\nreported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of\nrevenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, fair value of acquired assets, stock-\nbased compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.\nAcquisition of Intellectual Property\nIntellectual property acquired are accounted for under the acquisition method of accounting. This method requires the recording of acquired assets, including\nseparately identifiable intangible assets, and assumed liabilities at their acquisition date fair values. Any excess consideration transferred over fair value is allocated on a\nrelative fair value basis to the identifiable net assets.\nThe acquired intellectual property from the Trek acquisition was considered unproven compounds, the success of which was uncertain at the time of the\nacquisition. Accordingly, the fair value of the consideration paid was charged as acquired research and development to current period operations.\nResults of Operations (000’s)\nWe anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, such as the progress of our research and development\nefforts and the timing and outcome of regulatory submissions. Due to these uncertainties, accurate predictions of future operations are difficult or impossible to make.\nTwelve Months Ended December 31, 2021, Compared to Twelve Months Ended December 31, 2020\nRevenues and Cost of Goods Sold. Revenue for the year ended December 31, 2021, totaled $441 comprised of product sales of $414 and recognized service\nrevenue of $27 as compared to nil for the year ended December 31, 2020.\nWe derive our revenue primarily from the sale of our medical device, PURE EP™ system, as well as related support and maintenance services and software\nupgrades in connection with the system.\nCost of sales for the year ended December 31, 2021, was $199 comprised of the delivered product and cost of services as compared to nil for the year ended\nDecember 31, 2020.\nGross profit from the year ended December 31, 2021, was $242 or 54.9% as compared to nil for the year ended December 31, 2020.\nResearch and Development Expenses. Research and development expenses for the twelve months ended December 31, 2021, were $5,602, a decrease of $12,534 or\n69.1%, from $18,136 for the twelve months ended December 31, 2020. This decrease is primarily due to ceasing development of merimepodib in 2020, which led to a\nreduction of $13,116 from 2020 to 2021 in the ViralClear segment, net with a $614 increase in the BioSig segment research and development from $4,399 for the twelve\nmonths ended December 31, 2020, to $5,013 for the twelve months ended December 31, 2021.\n50\nTable of Contents\nResearch and development expenses were comprised of the following:\n2021 2020\nSalaries and equity compensation $ 2,833 $ 3,030\nConsulting expenses 725 2,374\nResearch, clinical studies, and design work 1,159 2,068\nRegulatory 142 68\nData/AI development 307 505\nProduct development and formulation 15 4,910\nAcquired research and development 150 4,883\nTravel, supplies, other 271 298\nTotal $ 5,602 $ 18,136\nStock-based compensation for research and development personnel was $759 and $1,253 for the twelve months ended December 31, 2021, and 2020, respectively.\nOn March 24, 2020, ViralClear entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Trek Therapeutics, PBC (“Trek”). Pursuant to the\nAsset Purchase Agreement, Trek sold to ViralClear all right, title and interest of Trek and its affiliates to certain assets (the “Purchased Assets”). As consideration for the\nPurchased Assets, ViralClear agreed to pay Trek in upfront and milestone payments a combination of cash, shares of ViralClear’s common stock, which common stock may\nequal up to 10% of ViralClear’s outstanding equity, and sublicense fees in the event ViralClear sublicenses the Purchased Assets. On March 30, 2020, pursuant to the Asset\nPurchase Agreement, ViralClear paid $350,000 in cash and issued 634,910 shares of ViralClear’s common stock to Trek at a fair of $3,174,550. The Purchased Assets were\nrecorded as acquired research and development.\nOn April 8, 2020, ViralClear entered into a know-how license agreement (the “Agreement”) with Mayo. The Agreement grants to ViralClear (i) an exclusive\nworldwide license, with the right to sublicense, within the field of anti-viral agents to target COVID-19 (the “Field”) to certain patent rights for the development and\ncommercialization of products, methods, and processes for public use and benefit (the “Licensed Products”) and (ii) a non-exclusive worldwide license, with the right to\nsublicense, within the Field, to use the know-how of Mayo that is necessary to develop the Licensed Products.\nThe Agreement will expire upon the later of either (a) the expiration of the licensed patent rights or (b) the 7th anniversary of the date of the first commercial sale\nof a Licensed Product, unless earlier terminated by Mayo for ViralClear’s failure to cure a material breach of the Agreement, ViralClear’s or a sublicensee’s commencement\nof any action or proceedings against Mayo or its affiliates other than for an uncured material breach of the Agreement by Mayo, or insolvency ViralClear.\nIn connection with the Agreement, ViralClear issued to Mayo 259,959 shares of ViralClear’s common stock. ViralClear also agreed to make earned royalty\npayments to Mayo in connection with ViralClear’s sales of the Licensed Products along with certain milestone payments.\nGeneral and Administrative Expenses. General and administrative expenses for the twelve months ended December 31, 2021, were $27,853, a decrease of $13,101,\nor 32.0%, from $40,954 incurred in the twelve months ended December 31, 2020. This decrease is primarily due to reduction in equity-based and other compensation,\nprofessional services, consulting fees and travel, meals and entertainment costs.\nPayroll related expenses (including equity compensation) decreased to $17,360 in the twelve months ended December 31, 2021, from $31,080 for the twelve\nmonths ended December 31, 2020, a decrease of $13,720, or 44.1%. This decrease is due to the value of the stock-based compensation decreasing to $9,062 in 2021, as a\nresult of the vesting of stock and stock options issued to board members, officers, and employees, as compared to $23,911 of stock-based compensation in 2020, net with\nadded additional personnel in 2021, a decrease of $14,849 or 62.1%.\nProfessional services for the twelve months ended December 31, 2021, totaled $1,261, a decrease of $687, or 35.3%, over the $1,948 recognized for the twelve\nmonths ended December 31, 2020. Of professional services, legal fees totaled $943 for the twelve months ended December 31, 2021, a decrease of $560, or 37.3%, from\n$1,503 incurred for the twelve months ended December 31, 2020. The significant decrease in legal fees in 2021 is due to reduction in legal work in asset acquisitions,\nfinancing and in developing and registering patents. Accounting fees incurred in the twelve months ended December 31, 2021, amounted to $179, a decrease of $79 or\n30.6%, from $258 incurred for the same period in 2020. The significant decrease is due to reduction in 2021 work relating to internal control audit, design and monitoring,\naudit work relating to ViralClear segment.\n51\nTable of Contents\nConsulting fees and marketing totaled $4,763 for the twelve months ended December 31, 2021, a decrease of $2,106 or 30.7%, from $6,869 for the twelve months\nended December 31, 2020. The decrease primarily relates to reductions in fund raising and investor relations to support our efforts in market research and potential investor\nidentification and key consultants in connection with our commercialization efforts, net increases in marketing activities.\nTravel, meals and entertainment costs for the twelve months ended December 31, 2021, were $1,010, an increase of $637, or 170.8%, from $373 incurred during\nthe twelve months ended December 31, 2020. The significant increase in 2021 was due to lifting of various restrictions imposed by the COVID-19 pandemic-related\nmeasures as compared to 2020.\nRent for the twelve months ended December 31, 2021, totaled $466, a decrease of $18, or 3.7%, from $484 incurred during the same period in 2020. In 2021, we\nincurred a rent reduction with our relocation of our corporate offices in Connecticut and our lease extension in our Los Angeles facility.\nDepreciation and Amortization Expense. Depreciation and amortization expense for the twelve months ended 2021 totaled $198 as compared to $94 incurred\nduring the same period in 2020. The increase is due primarily to additional equipment purchased in 2021.\nInterest Income. Interest income for the twelve months ended December 31, 2021, totaled $2 as compared to $45 earned during the twelve months ended\nDecember 31, 2020. The decrease in 2021 was due reduction of interest rates earned with cash balances in our interest-bearing accounts.\nGain on Settlement of Debt. On September 23, 2021, we negotiated a lawsuit settlement with Aurigene relating to certain milestone payments for manufacturing\nand services under a contract with our ViralClear subsidiary. In connection with the settlement, we recognized a gain on settlement of debt of $553 during the twelve months\nended December 31, 2021, as compared to nil for the twelve months ended December 31, 2020.\nPreferred Stock Dividend. Preferred stock dividend for the twelve months ended December 31, 2021, totaled $9, a decrease of $5, or 35.7% from $14 incurred\nduring the twelve months ended December 31, 2020. Preferred stock dividends are related to the issuance of our Series C Preferred Stock from 2013 through 2015. The\nsignificant decrease in 2021 as compared to 2020 is the result of 2020 conversions of the Series C Preferred Stock.\nNoncontrolling Interest. In 2019 and 2020, ViralClear sold shares of its common stock to fund its initial and ongoing operations. As of December 31, 2021, we had\na majority interest in ViralClear of 68.4%. The proportionate loss attributed to noncontrolling interests for the twelve months ended December 31, 2021, was $939 as\ncompared to $6,922 for 2020.\nNet Loss Available to BioSig Technologies, Inc. Net loss available to common stockholders for the twelve months ended December 31, 2021, was $31,926,\ncompared to a net loss of $52,232 for the twelve months ended December 31, 2020, a decrease of $20,306 or 38.9%. The primary reasons for the decrease, as described\nabove, are the decreases in research and development costs and general and administrative expenses from 2020 to 2021.\nSegment Results\nThe Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by\nmanagement for making decisions and assessing performance as the source of the Company’s reportable segments.\nSummary Statement of Operations for the year ended December 31, 2021, as compared to the year ended December 31, 2020, are detailed in Note 12 of the\naccompanying consolidated financial statements.\nCOVID-19\nThe full public-health impact of the ongoing COVID-19 pandemic is currently indeterminable and rapidly evolving, and the related health crisis has adversely\naffected and may continue to adversely affect the global economy, resulting in possibly delaying our commercialization objectives of the PURE EP Systems due to limited\nresources and accessibility of hospitals as they cope with the pandemic.\n52\nTable of Contents\nLiquidity and Capital Resources\nWe had an accumulated deficit as of December 31, 2021, of approximately $189 million, as well as a net loss of approximately $32 million and negative operating\ncash flows. We expect to continue incurring losses and negative cash flows from operations until our products (primarily PURE EP System) reach commercial profitability.\nWe have incurred net losses and negative cash flows from operations since inception and our expectation is that these conditions will continue for the foreseeable\nfuture. In addition, we will require additional financing to fund future operations. Although we have commercial products available for sale, we have not generated\nsignificant revenues to date, and there is no assurance that we will be able to generate cash flow to fund operations. In addition, there can be no assurance that our research\nand development will be successfully completed or that any additional products will be approved or commercially viable. Our ability to continue as a going concern is\nsubject to our ability to obtain necessary funding from outside sources, including obtaining additional funding from the sale of our securities, obtaining loans from various\nfinancial institutions or being awarded grants from government agencies, where possible. Our continued net operating losses increase the difficulty in meeting such goals\nand there can be no assurances that such methods will prove successful.\nOur plans include the continued commercialization of the PURE EP System and other applications of our core technology and raising capital through the sale of\nadditional equity securities, debt or capital inflows from strategic partnerships. Our shift from a focus on technology development to commercialization has allowed us to\nreduce our annual expenses in a meaningful way. As a result of this transition, we have been able to achieve savings through reductions in executive and management\ncompensation and a reduction of our utilization of external consultants and professional service providers. We believe these cost-saving measures combined with our\nexpectations of positive trends in commercial activity create the potential for us to achieve a lower cash flow breakeven rate. There are no assurances, however, that we will\nbe successful in obtaining the level of financing needed for our operations. The ongoing COVID-19 pandemic has resulted and continues to result in significant financial\nmarket volatility and uncertainty in recent months. In addition, U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical\ntensions and the start of the military conflict between Russia and Ukraine.\nA continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital and\non the market price of our common stock, and we may not be able to successfully raise capital through the sale of our securities.\nOur Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of (a) 120% of the stated\nvalue of $1 or (b) the product of (I) the variable weighted average price of our common stock on the trading day immediately preceding the date of the triggering event and\n(II) the stated value divided by the then conversion price or (ii) in shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided\nby 75%. As of June 30, 2021, the aggregate stated value of our Series C Preferred Stock was $105. The triggering events include our being subject to a judgment of greater\nthan $100 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred Stock occur, the holders of our Series C Preferred\nStock may demand redemption, an obligation we may not have the ability to meet at the time of such demand. We will be required to pay interest on any amounts\nremaining unpaid after the required redemption of our Series C Preferred Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable\nlaw.\nWe expect to incur losses from operations for the near future. We expect to incur increasing marketing and commercialization expenses related to our PURE EP\nsystem in addition to additional research and development costs relating to the PURE EP and other product candidates, including expenses related to clinical trials. We\nexpect that our general and administrative expenses will increase in the future as we expand our business development, add infrastructure and incur additional costs related\nto being a public company, including incremental audit fees, investor relations programs and increased professional services.\nOur future capital requirements will depend on a number of factors, including the progress of our research and development of product candidates, the timing and\noutcome of regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property\nrights, the status of competitive products, the availability of financing and our success in developing markets for our product candidates.\n53\nTable of Contents\nFuture financing may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. Even if we are able to raise the\nfunds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek alternative\nfinancing. Furthermore, if we issue additional equity or debt securities, existing holders of our securities may experience additional dilution or the new equity securities may\nhave rights, preferences or privileges senior to those of existing holders of our securities.\nIf additional financing is not available or is not available on acceptable terms, we may be required to delay, reduce the scope of or eliminate our research and\ndevelopment programs, reduce our commercialization efforts or obtain funds through arrangements with collaborative partners or others that may require us to relinquish\nrights to certain product candidates that we might otherwise seek to develop or commercialize independently.\nEquity Financing\nOn July 2, 2021, we entered into an underwriting agreement (the “Underwriting Agreement”) with Laidlaw & Company (UK) Ltd. (the “Underwriter”), relating to\nan underwritten public offering of 2,500,000 shares of the Company’s common stock, $0.001 par value per share. The public offering price of the shares was $4.00 per\nshare, and the Underwriter agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $3.68 per share. After the underwriting discount,\noffering and other related expenses, we received net proceeds from the offering of approximately $9.0 million. Pursuant to the Underwriting Agreement, we also granted the\nUnderwriter an option to purchase up to 375,000 additional shares of common stock, or 15% of the number of Shares sold in the offering, at a price of $3.68 per share, for a\nperiod of 30 days from the date of the Underwriting Agreement, of which none were exercised.\nPursuant to the Underwriting Agreement, we issued to the Underwriter or its designees warrants to purchase up to an aggregate 125,000 shares of common stock,\nor 5% of the number of shares sold in the offering (the “Underwriter Warrants”). The Underwriter Warrants are exercisable following the date of issuance, July 7, 2021, and\nending five years from the date of the execution of the Underwriting Agreement, July 2, 2026, at a price per share equal to $4.80 per share (120% of the public offering\nprice per share) and are exercisable on a “cashless” basis.\nThe shares were sold and issued pursuant to our shelf registration statement on Form S-3 (Registration Statement No. 333-251859) previously filed with the\nSecurities and Exchange Commission and declared effective by the Securities and Exchange Commission on January 12, 2021. A preliminary prospectus supplement and\nprospectus supplement and the accompanying prospectus relating to the offering were filed with the Securities and Exchange Commission. The offering closed on July 7,\n2021.\nOn March 22, 2022, we closed a registered direct offering (the “Offering”) of an aggregate of 2,613,130 shares of our common stock, at an offering price of $1.15\nper share and (ii) warrants to purchase up to 2,613,130 shares of our common stock, at an exercise price of $1.40 per share, that will become exercisable six months after the\ndate of issuance and will expire three and one-half years following the date of issuance, for gross proceeds of approximately $3.0 million before the deduction of fees and\noffering expenses.\nThe common stock and warrants were offered by us pursuant to a shelf registration statement on Form S-3 (File No. 333-251859) (the “Shelf Registration\nStatement”), previously filed with the SEC on December 31, 2020, and declared effective by the SEC on January 12, 2021, and a prospectus supplement, dated March 21,\n2022, to the Shelf Registration Statement, filed with the SEC on March 22, 2022.\nAt-the-Market Offering\nOn August 28, 2020, we entered into an Open Market Sale Agreement (the “Sales Agreement”) with Jefferies LLC to act as our sales agent and/or principal\n(“Jefferies” or the “Agent”), with respect to the issuance and sale of up to $45,000,000 of our shares of common stock, par value $0.001 per share (the “Shares”), from time\nto time in an at-the-market offering (the “Offering”).\nJefferies sold the Shares by an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities\nAct”). We sold the Shares in amounts from time to time subject to the terms and conditions of the Sales Agreement, and we had no obligation to sell any of the Shares under\nthe Sales Agreement. We or Jefferies were able to suspend or terminate the offering of Shares upon notice to the other party and subject to other conditions. Jefferies acted\nas sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and\nthe rules of Nasdaq.\n54\nTable of Contents\nWe paid the Agent a commission equal to 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company has also agreed to\nprovide Jefferies with customary indemnification and contribution rights.\nFrom January 15, 2021, through February 16, 2021, the Company sold 251,720 shares of its common stock through the Open Market Sales Agreement for net\nproceeds of $1,300,135, after transactional costs of $40,365.\nThe Shares were sold and issued pursuant the Company’s shelf registration statement on Form S-3 (File No. 333-230448), which was previously declared effective\nby the Securities and Exchange Commission, and a related prospectus. On March 25, 2021, the Sales Agreement was terminated with approximately $41M remaining\navailable under the Shelf registration.\nOn March 25, 2021, the Company delivered written notice to Jefferies to terminate the Sales Agreement effective as of April 8, 2021, pursuant to Section 7(b)(i)\nthereof. The Company was not subject to any termination penalties related to the termination of the Sales Agreement.\nTwelve Months Ended December 31, 2021, Compared to Twelve Months Ended December 31, 2020\nAs of December 31, 2021, we had a working capital of $11,318, comprised of cash of $11,659, inventory of $1,881 and prepaid expenses of $354, which was offset\nby $2,179 of accounts payable and accrued expenses, accrued dividends on preferred stock issuances of $82, short term deferred revenue of $32 and short term lease\nliabilities of $283. For the twelve months ended December 31, 2021, cash provided by financing activities totaled $10,332, comprised of proceeds from the sale of our\ncommon stock of $9,004, proceeds from At-the-market sale of our common stock of $1,300 and proceeds from the exercise of options of $28. In the comparable period in\n2020, $25,215 was raised through the sale of our common stock, sale of subsidiary stock to non-controlling interests of $10,592, proceeds from At-the-market sale of our\ncommon stock of $2,228 and proceeds of $4,812 from the exercise of options and warrants. At December 31, 2021, we had cash of $11,659 compared to $28,268 at\nDecember 31, 2020. Our cash is held in bank deposit accounts. At December 31, 2021 and 2020, we had no convertible debentures outstanding.\nCash used in operations for the twelve months ended December 31, 2021, and 2020 was $26,399 and $26,601, respectively, which represent cash outlays for\nresearch and development and general and administrative expenses in such periods. The decrease in cash outlays principally resulted from reduced research and\ndevelopment and general and administrative expenses from 2020 to 2021.\nCash used in investing activities for the twelve months ended December 31, 2021, was $542, compared to $87 for the twelve months ended December 31,\n2020. During the twelve months ended December 31, 2021, we purchased office furniture, manufacturing equipment, computer equipment and leasehold improvements.\nFor the twelve months ended December 31, 2020, we incurred $87 purchases of office furniture and computer equipment.\nOur Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of (a) 120% of the stated\nvalue of $1,000 or (b) the product of (I) the variable weighted average price of our common stock on the trading day immediately preceding the date of the triggering event\nand (II) the stated value divided by the then conversion price or (ii) in shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above\ndivided by 75%. As of December 31, 2020, the aggregate stated value of our Series C Preferred Stock was $105,000. The triggering events include our being subject to a\njudgment of greater than $100,000 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred Stock occur, the holders of\nour Series C Preferred Stock may demand redemption, an obligation we may not have the ability to meet at the time of such demand. We will be required to pay interest on\nany amounts remaining unpaid after the required redemption of our Series C Preferred Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted\nby applicable law.\nRecent Accounting Pronouncements\nThere were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are\nnot expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.\nITEM 7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK\nNot applicable.\n55\nTable of Contents\nITEM 8 – FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA\nBIOSIG TECHNOLOGIES, INC.\nCONSOLIDATED FINANCIAL STATEMENTS\nTABLE OF CONTENTS\nReports of Independent Registered Public Accounting Firm (PCAOB ID 711) F-2\nConsolidated Balance Sheets as of December 31, 2021 and 2020 F-4\nConsolidated Statements of Operations for the Years Ended December 31, 2021 and 2020 F-5\nConsolidated Statement of Changes in Equity for the Years Ended December 31, 2021 and 2020 F-6\nConsolidated Statements of Cash Flows for the Years Ended December 31, 2021 and 2020 F-8\nNotes to Consolidated Financial Statements F-9\nF-1\nTable of Contents\nREPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM\nTo the Board of Directors and\nStockholders of BioSig Technologies, Inc.\nOpinion on the Consolidated Financial Statements\nWe have audited the accompanying consolidated balance sheets of BioSig Technologies, Inc. and subsidiaries (the “Company”) as of December 31, 2021 and 2020, and the\nrelated consolidated statements of operations, changes in equity, and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes\n(collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial\nposition of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the two year period ended December\n31, 2021, in conformity with accounting principles generally accepted in the United States of America.\nThe Company’s Ability to Continue as a Going Concern\nThe accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated\nfinancial statements, the Company’s accumulated deficit and operating losses raise a substantial doubt about its ability to continue as a going concern. Management’s\nevaluation of the events and conditions and management’s plans regarding those matters are also described in Note 2. The consolidated financial statements do not include\nany adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to that matter.\nBasis for Opinion\nThese consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated\nfinancial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and\nare required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and\nExchange Commission and the PCAOB.\nWe conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about\nwhether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to\nperform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting,\nbut not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.\nOur audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and\nperforming procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated\nfinancial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall\npresentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.\nCritical Audit Matter\nThe critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to\nbe communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our\nespecially challenging, subjective, or complex judgments. The communication of critical audit matter does not alter in any way our opinion on the consolidated financial\nstatements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts\nor disclosures to which it relates.\nF-2\nTable of Contents\nRecognition and Disclosure of Research and Development Costs\nDescription of the Matter\nAs described in Note 3 of the consolidated financial statements, research and development costs are expensed as incurred. Significant estimates include assessment of work\nin progress of multiple third-party contracts and evaluation whether milestones and contingent payments are probable in estimating the research and development costs to\naccrue or disclose in the reporting period. Recognition and disclosure of research and development costs were considered a critical audit matter due their material impact on\ndisclosures in the consolidated financial statements and the nature and extend of audit effort required to evaluate the results of audit procedures.\nHow We Addressed the Matter in Our Audits\nWe reviewed third-party contracts, statements of work and purchase orders, discussed with personnel and obtained confirmations with external service providers as to the\nprogress or stage of completion of services, the agreed-upon fee to be paid for such services, and probability of milestones and contingent payments.\n/s/ Friedman LLP\nWe have served as the Company’s auditor since 2020.\nMarlton, New Jersey\nMarch 31, 2022\nF-3\nTable of Contents\nBIOSIG TECHNOLOGIES, INC.\nCONSOLIDATED BALANCE SHEETS\n(In Thousands, Except Par Value and Share Amounts)\nDecember 31,\n2021 2020\nASSETS\nCurrent assets:\nCash $ 11,659 $ 28,268\nInventory 1,881 768\nPrepaid expenses and vendor deposits 354 301\nTotal current assets 13,894 29,337\nProperty and equipment, net 652 289\nRight-to-use assets, net 604 306\nOther assets:\nPatents, net 326 346\nTrademarks 1 1\nPrepaid expenses, long term - 5\nDeposits 42 102\nTotal assets $ 15,519 $ 30,386\nLIABILITIES AND EQUITY\nCurrent liabilities:\nAccounts payable and accrued expenses, including $86 and $317 to related parties as of December 31, 2021 and 2020,\nrespectively $ 2,179 $ 4,722\nDeferred revenue, short term 32 -\nDividends payable 82 73\nLease liability, short term 283 313\nTotal current liabilities 2,576 5,108\nDeferred revenue, long term 5 -\nLease liability, long term 373 1\nTotal long-term liabilities 378 1\nTotal liabilities 2,954 5,109\nCommitments and contingencies (Note 11)\nSeries C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares\nissued and outstanding: liquidation preference of $105 as of December 31, 2021 and 2020 105 105\nEquity:\nPreferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series\nB, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred\nStock, none issued - -\nCommon stock, $0.001 par value, authorized 200,000,000 shares, 35,567,180 and 30,764,792 issued and outstanding as\nof December 31, 2021 and 2020, respectively 36 31\nAdditional paid in capital 201,127 181,344\nAccumulated deficit (188,922) (157,005)\nTotal stockholders' equity attributable to BioSig Technologies, Inc. 12,241 24,370\nNon-controlling interest 219 802\nTotal equity 12,460 25,172\nTotal liabilities and equity $ 15,519 $ 30,386\nSee the accompanying notes to the consolidated financial statements.\nF-4\nTable of Contents\nBIOSIG TECHNOLOGIES, INC.\nCONSOLIDATED STATEMENTS OF OPERATIONS\n(In Thousands, Except Par Value and Share Amounts)\nYear ended December 31,\n2021 2020\nRevenue:\nProduct sales $ 414 $ -\nService 27 -\nTotal revenue 441 -\nCost of goods sold 199 -\nGross profit 242 -\nOperating expenses:\nResearch and development 5,602 18,136\nGeneral and administrative 27,853 40,954\nDepreciation and amortization 198 94\nTotal operating expenses 33,653 59,184\nLoss from operations (33,411) (59,184)\nOther income (expense):\nInterest income, net 2 45\nGain on settlement of debt 553 -\nLoss on foreign currency translation - (1)\nLoss before income taxes (32,856) (59,140)\nIncome taxes (benefit) - -\nNet loss (32,856) (59,140)\nNon-controlling interest 939 6,922\nNet loss attributable to BioSig Technologies, Inc. (31,917) (52,218)\nPreferred stock dividend (9) (14)\nNET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (31,926) $ (52,232)\nNet loss per common share, basic and diluted $ (0.95) $ (1.87)\nWeighted average number of common shares outstanding, basic and diluted 33,511,941 27,906,584\nSee the accompanying notes to the consolidated financial statements.\nF-5\nTable of Contents\nBIOSIG TECHNOLOGIES, INC.\nCONSOLIDATED STATEMENT OF CHANGES IN EQUITY\nYEARS ENDED DECEMBER 31, 2021 AND 2020\n(In Thousands, Except Par Value and Share Amounts)\nAdditional Non-\nCommon stock Paid in Accumulated controlling\nShares Amount Capital Deficit Interest Total\nBalance, December 31, 2019 23,323,087 $ 23 $ 115,910 $ (104,787) $ 515 $ 11,661\nSale of common stock, net transactional costs 4,687,500 5 25,210 - - 25,215\nSale of common stock under At-the-market offering, net of transaction\nexpenses of $222 424,357 * 2,228 - - 2,228\nSale of subsidiary shares to non-controlling interest - - 7,124 - 3,468 10,592\nCommon stock issued for services 679,555 1 4,399 - - 4,400\nFair value of subsidiary shares issued to acquire research and development - - 1,051 - 248 1,299\nCommon stock issued upon conversion of Series C Preferred Stock at $3.75\nper share 29,334 * 110 - - 110\nCommon stock issued settlement of Series C Preferred Stock accrued\ndividends at $4.53 per share 15,516 * 70 - - 70\nCommon stock issued upon cashless exercise of warrants 12,840 * - - - -\nCommon stock issued upon cashless exercise of options 160,743 * - - - -\nCommon stock issued upon exercise of options at an average of $4.64 per\nshare 586,825 1 2,721 - - 2,722\nCommon stock issued upon exercise of warrants at an average of $3.88 per\nshare 542,646 1 2,089 - - 2,090\nCommon stock issued in exchange for subsidiary shares 83,055 * 24 - (24) -\nFair value of subsidiary shares issued to acquire research and development\nfrom Trek Therapeutics, PBC - - 2,439 - 735 3,174\nStock based compensation 219,334 * 17,983 - 2,782 20,765\nPreferred stock dividend - - (14) - - (14)\nNet loss - - - (52,218) (6,922) (59,140)\nBalance, December 31, 2020 30,764,792 $ 31 $ 181,344 $ (157,005) $ 802 $ 25,172\n*- less than $1\nF-6\nTable of Contents\nBIOSIG TECHNOLOGIES, INC.\nCONSOLIDATED STATEMENT OF CHANGES IN EQUITY\nYEARS ENDED DECEMBER 31, 2021 AND 2020\n(In Thousands, Except Par Value and Share Amounts)\nAdditional Non-\nCommon stock Paid in Accumulated controlling\nShares Amount Capital Deficit Interest Total\nBalance, December 31, 2020 30,764,792 $ 31 $ 181,344 $ (157,005) $ 802 $ 25,172\nCommon stock issued for services 1,124,341 1 3,974 - - 3,975\nCommon stock issued upon exercise of options at $2.96 per share 9,375 * 28 - - 28\nSale of common stock, net transactional costs of $995 2,500,000 3 9,001 - - 9,004\nSale of common stock under At-the-market offering, net of transaction\nexpenses of $40 251,720 * 1,300 - - 1,300\nChange in fair value of modified options - - 313 - 8 321\nStock based compensation 916,952 1 5,176 - 348 5,525\nPreferred stock dividend - - (9) - - (9)\nNet loss - - - (31,917) (939) (32,856)\nBalance, December 31, 2021 35,567,180 36 201,127 (188,922) 219 12,460\n*- less than $1\nSee the accompanying notes to the consolidated financial statements.\nF-7\nTable of Contents\nBIOSIG TECHNOLOGIES, INC.\nCONSOLIDATED STATEMENTS OF CASH FLOWS\n(In Thousands, Except Par Value and Share Amounts)\nYear ended December 31,\n2021 2020\nCASH FLOWS FROM OPERATING ACTIVITIES:\nNet loss $ (32,856) $ (59,140)\nAdjustments to reconcile net loss to cash used in operating activities:\nDepreciation and amortization 198 94\nNon-cash lease expense 441 456\nEquity based compensation 9,500 25,165\nGain on settlement of debt (553) -\nChange in fair value of modified options 321 -\nFair value of subsidiary stock issued to acquire research and development from Trek Therapeutics, PBC - 3,174\nFair value of subsidiary stock issued to acquire research and development - 1,299\nChanges in operating assets and liabilities:\nInventory (1,114) (287)\nPrepaid expenses and other (50) (119)\nDeferred revenue 38 -\nDeposits 60 (18)\nAccounts payable and accrued expenses (1,988) 3,233\nOperating lease liabilities (396) (458)\nNet cash used in operating activities (26,399) (26,601)\nCASH FLOWS FROM INVESTING ACTIVITIES:\nPurchase of property and equipment (542) (87)\nNet cash used in investing activity (542) (87)\nCASH FLOWS FROM FINANCING ACTIVITIES:\nProceeds from sale of common stock, net of issuance costs 9,004 25,215\nProceeds from sale subsidiary stock to non-controlling interest, net of issuance costs - 10,592\nProceeds from sale of common stock under a At-the-market offering, net of issuance costs 1,300 2,228\nProceeds from exercise of options 28 2,722\nProceeds from exercise of warrants - 2,090\nNet cash provided by financing activities 10,332 42,847\nNet (decrease) increase in cash and cash equivalents (16,609) 16,159\nCash, beginning of the year 28,268 12,109\nCash, end of the year $ 11,659 $ 28,268\nSupplemental disclosures of cash flow information:\nCash paid during the period for interest $ - $ -\nCash paid during the period for income taxes $ - $ -\nNoncash investing and financing activities:\nCommon stock issued upon conversion of Series C Preferred Stock and accrued dividends $ - $ 180\nDividend payable on preferred stock charged to additional paid in capital $ 9 $ 14\nRecord right-to-use assets and related lease liability $ 800 $ 2\nSee the accompanying notes to the consolidated financial statements.\nF-8\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nNOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION\nBusiness and organization\nBioSig Technologies, Inc. was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware\nin 2011. The Company is principally devoted to improving the standard care in electrophysiology with our PURE EP System’s enhanced signal acquisition, digital signal\nprocessing, and analysis during ablation of cardiac arrhythmias. The Company has generated minimal revenue to date and consequently its operations are subject to all risks\ninherent in business enterprises in early commercialization stage.\nOn November 7, 2018, the Company formed a subsidiary under the laws of the State of Delaware originally under the name of NeuroClear Technologies, Inc. which was\nrenamed to ViralClear Pharmaceuticals, Inc. (“ViralClear”) in March 2020. The subsidiary was established to pursue additional applications of the PURE EP™ signal\nprocessing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that\nshowed potential for the treatment of COVID-19. Since late 2020, ViralClear has been realigned with its original objective of pursuing additional applications of the PURE\nEP™ signal processing technology outside of cardiac electrophysiology.\nIn 2019 and 2020, ViralClear sold an aggregate of 1,965,240 shares of its common stock to investors for net proceeds of $15.6 million and issued an aggregate of 894,869\nshares of its common stock in connection with acquiring assets and with know-how agreements. As of December 31, 2021, the Company had a majority interest in\nViralClear of 68.44%.\nOn July 2, 2020, the Company formed an additional subsidiary, NeuroClear Technologies, Inc., a Delaware corporation.\nCOVID-19\nOn March 11, 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (COVID-19) outbreak, which has led to a global health\nemergency. The full public-health impact of the ongoing pandemic is currently indeterminable and rapidly evolving, and the related health crisis has adversely affected and\nmay continue to adversely affect the global economy, resulting in delaying to our commercialization objectives of the PURE EP Systems into 2022.\nNOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS\nAs of December 31, 2021, the Company had cash of $11.7 million and working capital of $11.3 million. The Company raised $10.3 million through the sale of common\nstock. Subsequent to December 31, 2021, the Company raised approximately $3 million from the sale of common stock and warrants. During the year ended December 31,\n2021, the Company used net cash in operating activities of $26.4 million. These conditions raise substantial doubt about the Company’s ability to continue as a going\nconcern.\nThe Company’s primary source of operating funds since inception has been cash proceeds from sale of of common and preferred stock. The Company has experienced net\nlosses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future.\nThe Company’s plans include the continued commercialization of the PURE EP System and other applications of our core technology and raising capital through the sale of\nadditional equity securities, debt or capital inflows from strategic partnerships. The Company’s strategic shift from a focus on technology development to commercialization\nwill allow the Company to significantly reduce operating expenses.\nThe Company will require additional financing to fund future operations. Further, although the Company began commercial operations; there is no assurance that the\nCompany will be able to generate sufficient cash flow to fund operations. In addition, there can be no assurance that the Company’s continuing research and development\nwill be successfully completed or that any additional products will be commercially viable.\nAccordingly, the accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a\ngoing concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the\nconsolidated financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment\nthat might result from the outcome of this uncertainty.\nF-9\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nNOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES\nA summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows.\nPrincipals of consolidation\nThe accompanying consolidated financial statements include the accounts of BioSig Technologies, Inc. and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc.,\nand wholly owned subsidiary, NeuroClear Technologies, Inc. herein referred to as the “Company” or “BioSig”. All significant intercompany accounts and transactions have\nbeen eliminated in consolidation.\nUse of Estimates\nThe preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported\namounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and\nexpenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, fair value of acquired assets, stock-based\ncompensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.\nRevenue Recognition\nThe Company derives its revenue primarily from the sale of its medical device, the PURE EP™ System, and well as related support and maintenance services and software\nupgrades in connection with the system.\nThe Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (“ASC 606”). The core\nprinciple of ASC 606 is that an entity recognizes revenue to depict\nthe transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or\nservices.\nThe Company determines revenue recognition through the following five steps:\n●Identify the contract with the customer;\n●Identify the performance obligations in the contract;\n●Determine the transaction price;\n●Allocate the transaction price to the performance obligation in the contract; and\n●Recognize revenue when, or as, the performance obligations are satisfied.\nPerformance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. If the\nCompany determines that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied.\nOnce the PURE EP system is delivered, installed, and accepted by the customer, our performance obligation is recognized. Support, maintenance, and software upgrades are\nperformance obligations over a defined period and are recognized ratably over the contractual service period. Customers typically purchase these services with the initial\nsale of the PURE EP System and do not have the right to terminate their contracts unless we fail to perform material obligations.\nThe Company may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single\nobjective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services\npromised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance\nobligation and the timing of revenue recognition related to those arrangements.\nF-10\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nThe Company records accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the\ncontractual arrangement. Unbilled receivables, if any, include amounts related to the Company’s contractual right to consideration for completed performance obligations\nnot yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on\nan individual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the\ncustomer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue.\nThe Company’s unconditional right to consideration for goods and services transferred to the customer is included in accounts receivable, net (if any) in the Company’s\nconsolidated balance sheet.\nThere are no contract liabilities for the year ended December 31, 2020.\nA reconciliation of contract liabilities with customers for the year ended December 31, 2021, are presented below:\nBalance at Consideration Recognized in Balance at\nDecember 31, 2020 Received Revenue December 31, 2021\n(000’s) (000’s) (000’s) (000’s)\nProduct revenue $ - $ 414 $ (414) $ -\nService revenue - 64 (27) 37\nTotal $ - $ 478 $ (441) $ 37\nThe table below summarizes our deferred revenue as of December 31, 2021 and 2020:\nDecember 31, December 31,\n2021 2020\n(000’s) (000’s)\nDeferred revenue-current $ 32 $ -\nDeferred revenue-noncurrent 5 -\nTotal deferred revenue $ 37 $ -\nThe Company had two customers which accounted for approximately 68% and 32% of their revenue in the year ended December 31, 2021.\nThe Company utilized one contract manufacturer for the manufacture and supply of the Pure EP system for the years ended December 31, 2021 and 2020.\nCost of Goods Sold\nCost of goods sold consists primarily of the delivered cost of our medical device(s) sold.\nAllowance for Doubtful Accounts\nThe Company adjusts accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for doubtful accounts for estimated\nlosses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon historical collection experience, financial condition of\nthe client and the status of any open or unresolved issues with the client preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve\nopen issues related to unpaid receivables. The allowance for doubtful accounts was $0 at December 31, 2021 and 2020. The Company believes that its reserve is adequate,\nhowever results may differ in future periods. For the year ended December 31, 2021 and 2020, bad debt expense totaled $0.\nF-11\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nFair Value of Financial Instruments\nAccounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The\ncarrying value of cash, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these\ninstruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements\ntogether with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of\nfinancial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.\nThe Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and ASC 825-10, which permits\nentities to choose to measure many financial instruments and certain other items at fair value.\nConcentrations of Credit Risk\nFinancial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The\nCompany places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At\nDecember 31, 2021 and 2020, deposits in excess of FDIC limits were $11.2 million and $27.8 million, respectively.\nInventory\nThe inventory is comprised of work in process and finished goods available for sale and are stated at the lower of cost or net realizable value using specific identification\nmethod for serial numbered inventory and first-in, first-out method for all other inventory for valuation. The inventory at December 31, 2021 and 2020 were $1.9 million\nand $0.8 million, respectively, comprised of finished goods.\nPrepaid Expenses and Vendor Deposits\nPrepaid expenses and vendor deposits are comprised of prepaid insurance, operating expenses and other prepayments.\nLeases\nThe Company determines if a contractual arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating\nlease liabilities, and noncurrent operating lease liabilities on the Company’s consolidated balance sheet. The Company evaluates and classifies leases as operating or finance\nleases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-\ncancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is\nreasonably certain and failure to exercise such option which result in an economic penalty. All the Company’s real estate leases are classified as operating leases. ROU\nassets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising\nfrom the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease\nterm.\nThe lease payments included in the present value are fixed lease payments. As most of the Company’s leases do not provide an implicit rate, the Company estimates its\ncollateralized incremental borrowing rate, based on information available at the commencement date, in determining the present value of lease payments. The Company\napplies the portfolio approach in applying discount rates to its classes of leases. The operating lease ROU assets include any payments made before the commencement\ndate. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company does not currently have subleases. The Company does not\ncurrently have residual value guarantees or restrictive covenants in its leases.\nF-12\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nProperty and Equipment\nProperty and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise\ndisposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from\ndisposition, is reflected in earnings.\nImpairment of Long-lived Assets\nThe Company recognizes an impairment of long-lived assets used in operations, other than goodwill, when events or circumstances indicate that the asset might be impaired\nand the estimated undiscounted cash flows to be generated by those assets over their remaining lives are less than the carrying amount of those items. The net carrying value\nof assets not recoverable is reduced to fair value, which is typically calculated using the discounted cash flow method. The Company did not recognize and record any\nimpairments of long-lived assets used in operations during the years ended December 31, 2021 and 2020.\nResearch and Development Costs\nThe Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC\n730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are\nexpensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved.\nCompany-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and\ndevelopment expenses of $5.6 million and $18.1 million for the year ended December 31, 2021 and 2020, respectively.\nAcquisition of Intellectual Property\nIntellectual property acquired are accounted for under the acquisition method of accounting. This method requires the recording of acquired assets, including separately\nidentifiable intangible assets, and assumed liabilities at their acquisition date fair values. Any excess consideration transferred over fair value is allocated on a relative fair\nvalue basis to the identifiable net assets.\nThe acquired intellectual property from the Trek acquisition was considered unproven compounds, the success of which was uncertain at the time of the acquisition.\nAccordingly, the fair value of the consideration paid was charged as acquired research and development to current period operations.\nNet Income (loss) Per Common Share\nThe Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common\nshare is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share, if presented,\nwould include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if\nconverted” methods as applicable.\nThe computation of basic and diluted loss per share as of December 31, 2021 and 2020 excludes potentially dilutive securities when their inclusion would be anti-dilutive,\nor if their exercise prices were greater than the average market price of the common stock during the period.\nPotentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:\nDecember 31, December 31,\n2021 2020\nSeries C convertible preferred stock 83,468 47,578\nOptions to purchase common stock 4,568,484 3,568,497\nWarrants to purchase common stock 818,910 1,446,200\nRestricted stock units to acquire common stock 141,250 218,334\nTotals 5,612,112 5,280,609\nF-13\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nStock Based Compensation\nThe Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The\nfair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.\nIncome Taxes\nThe Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets\nand liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate\napplicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability\nduring each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance\nis required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the\nprovision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported\nfor financial accounting and tax purposes in different periods.\nPatents, Net\nThe Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with\nthe application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research\nand development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line\nmethod over the lesser of the legal patent term or the estimated life of the product of 20 years. During the year ended December 31, 2021 and 2020, the Company recorded\namortization of $19,006 and $19,005 to current period operations, respectively.\nWarranty\nThe Company generally warrants its products to be free from material defects and to conform to material specifications for a period of up to two (2) years. Warranty\nexpense is estimated based primarily on historical experience and is reflected in the consolidated financial statements.\nNon-controlling Interest\nThe Company’s non-controlling interest represents the non-controlling shareholders ownership interests related to the Company’s subsidiary, ViralClear. The Company\nreports its non-controlling interest in subsidiaries as a separate component of equity in the consolidated balance sheets and reports both net loss attributable to the non-\ncontrolling interest and net loss attributable to the Company’s common shareholders on the face of the consolidated statements of operations. The Company’s equity interest\nin ViralClear is 68.44% and the non-controlling stockholders’ interest is 31.56% as of December 31, 2021. This is reflected in the consolidated statements of changes in\nequity.\nSegment Information\nOperating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating\ndecision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the\nmaterial financial information related to the Company’s principal operating segments. (See Note 12 – Segment Reporting).\nF-14\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nRecent Accounting Pronouncements\nIn June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”),\nwhich requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss\nimpairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-\nthan-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in\nthe amortized cost basis of the securities. ASU 2016-13 was effective for annual periods, and interim periods within those annual periods, beginning after December 15,\n2019. Early adoption was permitted, including adoption in any interim period.\nIn February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to\nSEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), which\namended the effective date of the original pronouncement for smaller reporting companies. ASC 2016-13 and its amendments will be effective for annual and interim\nperiods beginning after December 15, 2022 for smaller reporting companies. The Company is currently assessing the impact the adoption of this new standard will have on\nits consolidated financial statements and related disclosures.\nThere were other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are\nnot expected to a have a material impact on the Company’s financial position, results of operations or cash flows.\nNOTE 4 – PROPERTY AND EQUIPMENT\nProperty and equipment as of December 31, 2021 and 2020 is summarized as follows:\nDecember 31, December 31,\n2021 2020\n(000’s) (000’s)\nComputer equipment $ 383 $ 234\nFurniture and fixtures 88 75\nManufacturing equipment 286 34\nTesting/Demo equipment 145 96\nLeasehold improvements 79 -\nTotal 981 439\nLess accumulated depreciation (329) (150)\nProperty and equipment, net $ 652 $ 289\nProperty and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. Leasehold improvements are\ndepreciated over the related expected lease term. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the\nrespective accounts and the net difference less any amount realized from disposition, is reflected in earnings.\nDepreciation expense was $179,136 and $74,527 for years ended December 31, 2021 and 2020, respectively.\nNOTE 5 – RIGHT TO USE ASSETS AND LEASE LIABILITY\nOperating leases:\nOn February 10, 2021 the Company entered into a Sixth Amendment to the Office Lease at 12424 Wilshire Blvd in Los Angeles dated August 9, 2011 – it is the Fourth\nExtended Term with respect to Suite 745 and the Expansion Term with respect to Suite 740 which is from July 1, 2021 until June 30, 2022 with a fixed monthly rent equal\nto $13,702 (down from $16,289); and the security deposit will be reduced by $5,448 so that the balance remaining shall be $27,404.\nF-15\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nThe Company determined that the Sixth Amendment was a lease modification and accordingly reassessed the lease classification, remeasured the lease liability and adjusted\nthe right-to-use asset. At February 10, 2021 the Company removed the remaining right-to-use net assets of $60,881 and related lease liability of $63,076 and recorded right-\nto-use assets and related lease liability of $217,903.\nOn August 2, 2021, the Company exercised its option to extend its Rochester, Minnesota lease of approximately 1,400 square feet of office space for two additional years\nexpiring on October 31, 2023 with a fixed monthly rate of $3,513, increasing to $3,618 for the second year.\nThe Company determined that the lease option exercised was a lease modification and accordingly reassessed the lease classification, remeasured the lease liability and\nadjusted the right-to-use asset. On August 2, 2021 the Company removed the remaining right-to-use net assets of $10,247 and related lease liability of $10,400 and recorded\nright-to-use assets and related lease liability of $89,629. At the lease modification date, the Company estimated the lease liability and the right of use assets at present value\nusing the Company’s estimated incremental borrowing rate of 6.5%.\nOn August 3, 2021, the Company entered into a sublease agreement whereby the Company leased approximately 6,590 square feet of office space at 55 Greens Farms\nRoad, Westport, Connecticut commencing September 1, 2021 and expiring December 31, 2024 (40 months) at the initial rate beginning January 1, 2022 of $14,828 with\nescalating payments. In connection with the lease, the Company paid a security deposit of $14,232. There is no option to extend the lease past its initial term. At the lease\ncommencement date, the Company estimated the lease liability and right-to-use assets at present value using the Company’s incremental borrowing rate of 6.5% and\ndetermined their initial present values, at inception, of $492,876. In conjunction with the lease, the Company terminated, without penalty, the sublease at 54 Wilton Road,\nWestport, CT effective September 4, 2021 and removed the remaining right-to-use assets of $36,756 and related lease liability of $37,625 with a credit to rent expense of\n$868 relating to the lease termination.\nAs of December 31, 2021, the Company had outstanding five leases with aggregate payments of $32,143 per month, expiring through December 31, 2024.\nRight to use assets is summarized below:\nDecember 31, December 31,\n2021 2020\n(000’s) (000’s)\nRight to use assets, net $ 803 $ 1,087\nLess accumulated amortization (199) (781)\nRight to use assets, net $ 604 $ 306\nDuring the years ended December 31, 2021 and 2020, the Company recorded $479,746 and $492,844 as lease expense to current period operations, respectively.\nLease liability is summarized below:\nDecember 31, December 31,\n2021 2020\n(000’s) (000’s)\nTotal lease liability $ 656 $ 314\nLess: short term portion (283) (313)\nLong term portion $ 373 $ 1\nF-16\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nMaturity analysis under these lease agreements are as follows (000’s):\nYear ended December 31, 2022 $ 304\nYear ended December 31, 2023 221\nYear ended December 31, 2024 191\nTotal 716\nLess: Present value discount (60)\nLease liability $ 656\nLease expense for the year ended December 31, 2021 and 2020 was comprised of the following:\nDecember 31, December 31,\n2021 2020\n(000’s) (000’s)\nOperating lease expense $ 441 $ 456\nShort-term lease expense 39 35\nVariable lease expense - 2\nTotal $ 480 $ 493\nNOTE 6 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES\nAccounts payable and accrued expenses at December 31, 2021 and 2020 consist of the following:\nDecember 31, December 31,\n2021 2020\n(000’s) (000’s)\nAccrued accounting and legal $ 204 $ 177\nAccrued reimbursements and travel 56 56\nAccrued consulting 264 256\nAccrued research and development expenses 367 3,127\nAccrued product purchases 1 30\nAccrued marketing 38 -\nAccrued office and other 84 127\nAccrued payroll 552 936\nAccrued settlement related to arbitration 613 13\n$ 2,179 $ 4,722\nNOTE 7 – SERIES C 9% CONVERTIBLE PREFERRED STOCK\nSeries C 9% Convertible Preferred Stock\nOn January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”).\nF-17\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nThe Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled\nto dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013\nand are cumulative. The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis but may not vote the Series C\nPreferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares\nof common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion\nor exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of\nshares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.\nAs a result of an amendment to the conversion price of our Series C Preferred Stock, the conversion price effective as of December 31, 2020 was $3.75 per share, subject to\ncertain reset provisions. On December 12, 2021, the conversion price was reset to $2.27 per share. The effect was de minimis.\nThe Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of (a) 120% of the stated value of\n$1,000 or (b) the product of (I) the variable weighted average price of our common stock on the trading day immediately preceding the date of the triggering event and (II)\nthe stated value divided by the then conversion price or (ii) in shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by\n75%. As of December 31, 2021 and 2020, the aggregate stated value of our Series C Preferred Stock was $105,000. The triggering events include our being subject to a\njudgment of greater than $100,000 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred Stock occur, the holders of\nour Series C Preferred Stock may demand redemption, an obligation the Company may not have the ability to meet at the time of such demand. The Company will be\nrequired to pay interest on any amounts remaining unpaid after the required redemption of our Series C Preferred Stock, at a rate equal to the lesser of 18% per annum or the\nmaximum rate permitted by applicable law. Accordingly, the Company has classified the Series C Preferred Stock as a mezzanine obligation in the accompanying\nconsolidated balance sheets.\nThe Company issued an aggregate of 44,850 shares of its common stock in exchange for 110 shares of the Company’s Series C Preferred stock (stated value of $110,000)\nand $70,341 accrued dividends for the year ended December 31, 2020.\nSeries C Preferred Stock issued and outstanding totaled 105 as of December 31, 2021 and 2020. As of December 31, 2021 and 2020, the Company has accrued $81,667 and\n$72,517 dividends payable on the Series C Preferred Stock.\nNOTE 8 – STOCKHOLDER EQUITY\nShareholder rights plan\nOn July 14, 2020, our board of directors adopted a stockholder rights plan (the “Rights Plan”) and declared a dividend of one preferred share purchase right for each\noutstanding share of BioSig’s common stock to stockholders of record on July 27, 2020, and one right will be issued for each new share of common stock issued thereafter.\nEach right will initially trade with common stock, and will allow its holder to purchase from BioSig one one-thousandth of a share of Series F Junior Participating Preferred\nstock, par value $0.001 per share, for an exercise price of $50.00, once the rights become exercisable. In the event that a person or group acquires beneficial ownership of\n12% or more of BioSig’s then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than such person or members of such\ngroup) to purchase additional shares of BioSig’s common stock having a market value of two times the exercise price of the right. In addition, at any time after a person or\ngroup acquires 12% or more of BioSig’s outstanding common stock (unless such person or group acquires 50% or more), the Board may exchange one share of BioSig’s\ncommon stock for each outstanding right (other than rights owned by such person or group, which would have become void). The Rights Plan could make it more difficult\nfor a third party to acquire control of BioSig or a large block of our common stock without the approval of our board of directors. The rights expired on July 13, 2021.\nF-18\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nPreferred stock\nThe Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of December 31, 2021 and 2020, the Company has designated 200 shares of\nSeries A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E\nPreferred Stock and 200,000 shares of Series F Preferred Stock. As of December 31, 2021, and 2020, there were no outstanding shares of Series A, Series B, Series D,\nSeries E and Series F preferred stock.\nCommon stock\nBioSig Technologies, Inc.\nThe Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of December 31, 2021 and 2020, the Company had 35,567,180 and\n30,764,792 shares issued and outstanding, respectively.\nDuring the year ended December 31, 2020, the Company issued an aggregate of 219,334 shares of its common stock for vested restricted stock units as stock-based\ncompensation.\nOn February 25, 2020, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,500,000 shares of common stock\nfor aggregate proceeds of $9,052,331, net of $947,669 in expenses.\nOn June 24, 2020, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,187,500 shares of common stock for\naggregate proceeds of $16,161,980, net of $1,338,020 in expenses.\nDuring the year ended December 31, 2020, the Company issued 679,555 shares of common stock for services at a fair value of $4,399,533 ($6.47 per share).\nDuring the year ended December 31, 2020, the Company issued 542,646 shares of common stock in exchange for proceeds of $2,088,997 from the exercise of warrants.\nDuring the year ended December 31, 2020, the Company issued 586,825 shares of common stock in exchange for proceeds of $2,722,012 from the exercise of options.\nDuring the year ended December 31, 2020, the Company issued 12,840 shares of common stock in exchange for the exercise of 37,841 cashless exercises of warrants.\nDuring the year ended December 31, 2020, the Company issued 160,743 shares of common stock in exchange for the exercise of 616,398 cashless exercises of options.\nDuring the year ended December 31, 2020, the Company issued 83,055 shares of common stock in exchange for 80,958 previously issued ViralClear shares (see below).\nIn January 2021, the Company issued an aggregate of 658,868 shares of its common stock for services at a fair value previously recorded in 2020 of $2,658,224.\nOn July 2, 2021, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,500,000 shares of common stock for\naggregate proceeds of $9,004,033, net of $995,966 in expenses.\nDuring the year ended December 31, 2021, the Company issued 1,124,341 shares of common stock for services at a fair value of $3,975,451.\nDuring the year ended December 31, 2021, the Company issued 9,375 shares of common stock in exchange for proceeds of $27,750 from the exercise of options.\nF-19\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nDuring the year ended December 31, 2021, the Company issued an aggregate of 258,084 shares of its common stock for vested restricted stock units.\nAt-The-Market Sale Agreement\nAugust 28, 2020, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with Jefferies LLC to act as the Company’s sales agent and/or\nprincipal (“Jefferies” or the “Agent”), with respect to the issuance and sale of up to $45.0 million of the Company’s shares of common stock from time to time in an at-the-\nmarket offering.\nUpon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Jefferies may sell the Shares by any method permitted by law deemed\nto be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Company may sell the common stock in\namounts and at times to be determined by the Company from time to time subject to the terms and conditions of the Sales Agreement, but it has no obligation to sell any of\nthe shares under the Sales Agreement. The Company or Jefferies may suspend or terminate the offering of shares upon notice to the other party and subject to other\nconditions. Jefferies will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal\nlaw, rules and regulations and the rules of Nasdaq.\nThe Company paid Agent a commission equal to 3.0% of the gross proceeds from the sale of the shares pursuant to the Sales Agreement. The Company has also agreed to\nprovide Jefferies with customary indemnification and contribution rights.\nThe offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Sales Agreement or (ii) termination\nof the Sales Agreement in accordance with its terms.\nThe common stock was sold and issued pursuant the Company’s shelf registration statement on Form S-3, which was previously declared effective by the Securities and\nExchange Commission, and a related prospectus.\nFrom August 28, 2020 through December 31, 2020, the Company sold 424,357 shares of its common stock through the Sales Agreement for net proceeds of $2,228,000,\nafter transactional costs of $222,397.\nFrom January 15, 2021 through February 16, 2021, the Company sold 251,720 shares of its common stock through the Open Market Sales Agreement for net proceeds of\n$1,300,135, after transactional costs of $40,365.\nOn March 25, 2021, the Company delivered written notice to Jefferies to terminate the Sales Agreement effective as of April 8, 2021, pursuant to Section 7(b)(i) thereof.\nThe Company was not subject to any termination penalties related to the termination of the Sales Agreement.\nViralClear Pharmaceuticals, Inc.\nOn May 20, 2020, ViralClear and the Company entered into a securities purchase agreement, pursuant to which ViralClear agreed to sell in a private placement transaction\nan aggregate of 1,068,550 shares of ViralClear’s common stock at $10.00 per share, for an aggregate consideration of $10,592,075. This private placement closed on May\n20, 2020.\nThe Company was party to certain 2019 purchase agreements between ViralClear and the private placement investors with respect to a provision in each securities purchase\nagreement which provides that in the event that (i) ViralClear common stock is not listed on a national securities exchange by October 31, 2020, or (ii) a change of control\n(as defined in each securities purchase agreement) of ViralClear occurs, whichever is earlier, at the option of the holder of ViralClear common stock, each share of\nViralClear common stock may be exchanged into 0.9 of a share our common stock if the ViralClear common stock subject to the share exchange was purchased in the\nAugust or September 2019 private placements, or 1.1 shares of our common stock if the ViralClear common stock subject to the share exchange was purchased in the\nprivate placement closed in October 2019 through December 2019. In November and December 2020, the Company issued an aggregate of 83,055 shares of its common\nstock in exchange for 80,958 previously issued shares of ViralClear pursuant with 2019 purchase agreements.\nF-20\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nNOTE 9 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS\nBioSig Technologies, Inc.\n2012 Equity Incentive Plan\nOn October 19, 2012, the Board of Directors of BioSig Technologies, Inc. approved the 2012 Equity Incentive Plan (“the “Plan”) and terminated the Long-Term Incentive\nPlan (the “2011 Plan”). The Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 14,474,450 (as\namended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company. Under the terms of the Plan the Company may issue\nIncentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a\ncommittee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.\nHowever, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more\nstockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in\nabsence of such quoted market price, by the administrator in good faith.\nAdditionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten\nyears. There are 3,048,522 shares remaining available for future issuance of awards under the terms of the Plan as of December 31, 2021.\nDuring the years ended December 31, 2021 and 2020, the Company granted an aggregate of 1,818,000 and 1,070,000 (net of 50,000 canceled) options to officers, directors,\nand key consultants.\nDuring the years ended December 31, 2021 and 2020, the Company issued an aggregate of 1,185,872 and 634,517 stock grants to officers, employees and key consultants\nunder the plan. See Note 8.\nOptions\nOption valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option\nmodel with a volatility figure derived from historical stock prices of the Company. The Company accounts for the expected life of options using the based on the contractual\nlife of options for non-employees.\nFor employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in\nthe accounting standards codification.\nThe following table presents information related to stock options at December 31, 2021:\nOptions Outstanding Options Exercisable\nWeighted\nAverage Exercisable\nExercise Number of Remaining Life Number of\nPrice Options In Years Options\n$ Under 3.00 1,035,375 9.5 560,000\n3.00-3.99 587,466 6.5 387,466\n4.00-4.99 1,762,916 6.2 1,151,545\n5.00-5.99 156,132 7.1 119,464\n6.00-6.99 591,542 5.0 478,846\n7.00-7.99 191,720 6.9 177,138\nOver 8.00 243,333 6.3 197,351\n4,568,484 6.9 3,071,810\nF-21\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nA summary of the stock option activity and related information for the Plan for the two years ended December 31, 2021 is as follows:\nWeighted-Average\nWeighted-Average Remaining Aggregate\nShares Exercise Price Contractual Term Intrinsic Value\nOutstanding at January 1, 2020 3,980,804 $ 5.58 6.3 $ 3,130,791\nGrants 1,120,000 $ 4.98 10.0 -\nExercised (1,203,223) $ 5.08\nForfeited/expired (329,084) $ 5.19\nOutstanding at December 31, 2020 3,568,497 $ 5.59 7.0 $ 110,961\nGrants 1,818,000 $ 3.69 10.0 $ -\nExercised (9,375) $ 2.96\nForfeited/expired (808,638) $ 6.19\nOutstanding at December 31, 2021 4,568,484 $ 4.57 6.9 $ -\nExercisable at December 31, 2021 3,071,810 $ 4.83 6.0 $ -\nThe aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of BioSig\nTechnologies, Inc. of $2.23 as of December 31, 2021, which would have been received by the option holders had those option holders exercised their options as of that date.\nOn January 10, 2020, BioSig Technologies, Inc. granted 60,000 options to purchase the company stock in connection with the services rendered at the exercise price of\n$6.00 per share for a term of ten years with quarterly vesting beginning March 31, 2020 for three years.\nOn March 24, 2020, BioSig Technologies, Inc. granted 100,000 options to purchase the company stock in connection with the services rendered at the exercise price of\n$2.96 per share for a term of ten years with 25,000 vesting immediately and 75,000 quarterly vesting beginning June 30, 2020 for two years.\nOn March 31, 2020, BioSig Technologies, Inc. granted 50,000 options to purchase the company stock in connection with the services rendered at the exercise price of $3.73\nper share for a term of ten years with vesting quarterly vesting beginning June 30, 2020 for three years. On August 12, 2020, this option was cancelled and a was replaced\nfor a restricted stock award for 50,000 shares.\nOn April 14, 2020, BioSig Technologies, Inc. granted an aggregate of 625,000 options to purchase the company stock to directors and an employee. The options are\nexercisable at $4.66 per share for ten years and fully vested and exercisable at the date of grant. On April 14, 2020, BioSig Technologies, Inc. granted an aggregate of\n90,000 options to purchase shares of its common stock to employees. The options are exercisable at $4.66 per share for ten years and vest quarterly over three years.\nOn May 20, 2020, BioSig Technologies, Inc. granted an aggregate of 65,000 options to purchase the company stock to consultants and an employee. The options are\nexercisable at $10.49 per share for ten years with 40,000 fully vested and exercisable at the date of grant and 25,000 options vesting quarterly over three years.\nOn August 26, 2020, BioSig Technologies, Inc. granted an aggregate of 25,000 options to purchase the company stock to three employees at the exercise price of $7.57 per\nshare for a term of ten years with one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning November 26, 2021 for two years.\nOn October 9, 2020, BioSig Technologies, Inc. granted an aggregate of 105,000 options to purchase the company stock to three employees at the exercise price of $5.03 per\nshare for a term of ten years with one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning January 9, 2022 for two years.\nF-22\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nOn January 12, 2021, BioSig Technologies, Inc. granted 387,500 options to purchase the company stock in connection with the services rendered at the exercise price of\n$4.23 per share for a term of ten years with one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning January 12, 2022 for two\nyears.\nOn February 16, 2021, BioSig Technologies, Inc. granted 102,000 options to purchase the company stock in connection with the services rendered at the exercise price of\n$4.97 per share for a term of ten years with one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning February 16, 2022 for two\nyears.\nOn April 9, 2021, BioSig Technologies, Inc. granted 90,000 options to purchase the company stock in connection with the services rendered at the exercise price of $4.38\nper share for a term of ten years with one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning April 9, 2022 for two years.\nOn April 13, 2021, BioSig Technologies, Inc. granted 25,000 options to purchase the company stock in connection with the services rendered at the exercise price of $4.42\nper share for a term of ten years with one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning April 13, 2022 for two years.\nOn May 18, 2021, BioSig Technologies, Inc. granted 150,000 options to purchase the company stock in connection with the services rendered at the exercise price of $3.20\nper share for a term of ten years with one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning May 18, 2022 for two years.\nOn August 3, 2021, BioSig Technologies, Inc. granted an aggregated of 75,000 options to purchase shares of its common stock to three employees. The options are\nexercisable at $3.61 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal\nquarterly installments over the following two years.\nOn August 31, 2021, BioSig Technologies, Inc. granted an aggregated of 47,500 options to purchase shares of its common stock to three employees. The options are\nexercisable at $2.98 per share for ten years with immediate vesting.\nOn September 17, 2021, BioSig Technologies, Inc. granted an aggregated of 40,000 options to purchase shares of its common stock to two employees. The options are\nexercisable at $2.99 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal\nquarterly installments over the following two years.\nOn October 4, 2021, BioSig Technologies, Inc. granted 50,000 options to purchase shares of its common stock to a newly appointed Board member. The options are\nexercisable at $2.89 per share for ten years with half immediate vesting and half vesting on September 20, 2022.\nOn December 15, 2021, BioSig Technologies, Inc. granted an aggregate of 351,000 options to purchase shares of its common stock to two employees. The options are\nexercisable at $2.58 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal\nquarterly installments over the following two years.\nOn December 28, 2021, BioSig Technologies, Inc. granted an aggregate of 425,000 options to purchase shares of its common stock with as compensation to the Company’s\nBoard of Directors. The options are exercisable at $2.44 per share with immediate vesting. Also, on December 28, 2021, BioSig Technologies issued 75,000 options to\npurchase shares of its common stock to a consultant. The options are exercisable at $2.44 per share with 25,000 options vested immediately and 50,000 options vesting on\nthe one-year anniversary.\nThe following assumptions were used in determining the fair value of options during the years ended December 31, 2021 and 2020:\n2021 2020\nRisk-free interest rate 0.77% - 1.49% 0.42% to 1.83%\nDividend yield 0% 0%\nStock price volatility 82.50% to 95.98% 86.51% to 93.43%\nExpected life 5 – 10 years 5-10 years\nWeighted average grant date fair value $ 2.55 $ 4.03\nF-23\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nOn June 28, 2021, in connection with the exit of two members of the Company’s board of directors, the Company extended the life of 145,000 previously issued director\noptions from the contractual 90 days from termination of service to the earlier of the initial life or June 28, 2023. The change in estimated fair value of the modified options\nof $182,514 was charged to current period operations.\nThe following assumptions were used in determining the change in fair value of the modified options at June 28, 2021:\nRisk-free interest rate 0.05% - 0.25%\nDividend yield 0%\nStock price volatility 88.57%\nExpected life 0.25 – 2 years\nOn June 30, 2021, in connection with the resignation of a member of the Company’s board of directors, the Company entered into a one-year consulting contract and\nextended the life of 221,240 previously issued director options from the contractual 90 days from termination of service to the earlier of the initial life or two years after\nservice contract completion. The change in estimated fair value of the modified options of $111,402 was charged to current period operations.\nThe following assumptions were used in determining the change in fair value of the modified options on June 30, 2021:\nRisk-free interest rate 0.06% - 0.46%\nDividend yield 0%\nStock price volatility 88.59%\nExpected life 0.59 – 3 years\nThe fair value of all options vesting during the year ended December 31, 2021 and 2020 of $3,357,274 and $5,217,761, respectively, was charged to current period\noperations. Unrecognized compensation expense of $3,655,519 at December 31, 2021 will be expensed in future periods.\nWarrants\nThe following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at December 31, 2021:\nExercise Number Expiration\nPrice Outstanding Date\n$ 4.80 250,000 February 2025 to July 2026\n$ 6.16 568,910 November 2027\n818,910\nOn February 25, 2020, BioSig Technologies, Inc. issued warrants to purchase 125,000 shares of its common stock at $4.80 per share, expiring on February 21, 2025, for\nplacement agent services in connection with the sale of the company’s common stock.\nOn July 7, 2021, BioSig Technologies, Inc. issued warrants to purchase 125,000 shares of its common stock at $4.80 per share, expiring on July 2, 2026, for placement\nagent services in connection with the sale of the company’s common stock.\nF-24\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nA summary of the warrant activity for the two years ended December 31, 2021 is as follows:\nWeighted-Average\nWeighted-Average Remaining Aggregate\nShares Exercise Price Contractual Term Intrinsic Value\nOutstanding at January 1, 2020 2,744,718 $ 5.40 2.2 $ 3,410,763\nIssued 125,000 $ 4.80 4.2 -\nExercised (580,487) $ 3.89\nExpired (843,031) $ 6.29\nOutstanding at December 31, 2020 1,446,200 $ 5.44 3.3 $ 1,500\nIssued 125,000 $ 4.80 5.0\nExpired (752,290) $ 5.00 - -\nOutstanding at December 31, 2021 818,910 $ 5.74 5.3 $ -\nVested and expected to vest at December 31, 2021 818,910 $ 5.74 5.3 $ -\nExercisable at December 31, 2021 818,910 $ 5.74 5.3 $ -\nThe aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the company’s stock price of\n$2.23 of December 31, 2021, which would have been received by the option holders had those option holders exercised their options as of that date.\nRestricted Stock Units\nThe following table summarizes the restricted stock activity for the two years ended December 31, 2021:\nRestricted shares issued as of January 1, 2020 262,668\nGranted 175,000\nVested and issued (219,334)\nRestricted shares issued as of December 31, 2020 218,334\nGranted 301,000\nVested and issued (258,084)\nForfeited (120,000)\nVested restricted shares as of December 31, 2021 -\nUnvested restricted shares as of December 31, 2021 141,250\nIn 2020, the Company granted an aggregate of 175,000 restricted stock grants for services with vesting from one year to three years from grant date.\nOn January 4, 2021, the Company granted 220,000 restricted stock units for services with 105,000 vesting one-third on the one-year anniversary and two-thirds vesting\nquarterly thereafter beginning January 4, 2022 for two years and with 115,000 vesting quarterly for one year.\nOn March 8, 2021 the Company granted 31,000 restricted stock units for services vesting on August 31, 2021.\nOn June 1, 2021, in connection with the termination of an employee, the Company accelerated vesting of 30,000 previously granted restricted stock units from a three-year\nperiod to fully vested. The change in vesting of the modified restricted stock unit resulted in a $109,725 charge to current period operations.\nF-25\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nOn June 30, 2021, in connection with the resignation of a member of the Company’s board of directors, the Company accelerated vesting of 50,000 previously granted\nrestricted stock units from a three-year period to fully vested. The change in vesting of the modified restricted stock unit resulted in a $232,375 charge to current period\noperations.\nOn August 14, 2021 the Company granted 50,000 restricted stock units for services vesting quarterly for one year.\nStock based compensation expense related to restricted stock grants was $950,281 and $1,151,676 for the year ended December 31, 2021 and 2020, respectively. As of\nDecember 31, 2021, the stock-based compensation relating to restricted stock of $286,417 remains unamortized.\nViralClear Pharmaceuticals, Inc.\n2019 Long-Term Incentive Plan\nOn September 24, 2019, ViralClear’s Board of Directors approved the 2019 Long-Term Incentive Plan (as subsequently amended, the “ViralClear Plan”). The ViralClear\nPlan was approved by BioSig as ViralClear’s majority stockholder. The ViralClear Plan provides for the issuance of options, stock appreciation rights, restricted stock and\nrestricted stock units to purchase up to 4,000,000 shares of ViralClear’s common stock to officers, directors, employees and consultants of the ViralClear. Under the terms of\nthe ViralClear Plan, ViralClear may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of ViralClear only and nonstatutory options. The\nBoard of Directors of ViralClear or a committee thereof administers the ViralClear Plan and determines the exercise price, vesting and expiration period of the grants under\nthe ViralClear Plan.\nHowever, the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more\nstockholder and 100% of fair market value for a grantee who is not 10% stockholder. The fair market value of the common stock is determined based on the quoted market\nprice or in absence of such quoted market price, by the administrator in good faith.\nAdditionally, the vesting period of the grants under the ViralClear Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more\nthan ten years. There are 2,330,750 shares remaining available for future issuance of awards under the terms of the ViralClear Plan.\nViralClear Options\nA summary of the stock option activity and related information for the ViralClear Plan for the two years ended December 31, 2021 is as follows:\nWeighted-Average\nWeighted-Average Remaining\nShares Exercise Price Contractual Term\nOutstanding at January 1, 2020 575,000 $ 5.00 9.3\nGrants 1,599,173 $ 5.31 9.6\nForfeited/expired (646,507) $ 5.77\nOutstanding at December 31, 2020 1,527,666 $ 5.00 4.0\nExercised (550,000) $ 5.00\nForfeited/expired (852,666) $ 5.00\nOutstanding at December 31, 2021 125,000 $ 5.00 7.2\nExercisable at December 31, 2021 83,331 $ 5.00 6.6\nF-26\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nThe following table presents information related to stock options at December 31, 2021:\nOptions Outstanding Options Exercisable\nWeighted\nAverage Exercisable\nExercise Number of Remaining Life Number of\nPrice Options In Years Options\n$ 5.00 125,000 7.2 83,331\nThe fair value of the stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock\nprices of comparable entities with the market value of stock price based on recent sales. The Company accounts for the expected life of options in accordance with the\n“simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the\nimplied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.\nIn 2020, ViralClear granted an aggregate of 1,599,173 options to purchase shares with an exercise price of $5.00 to $10.00 for ten years with 1,278,999 vested immediately,\n120,174 quarterly over one year and 200,000 quarterly over two years.\nThe following assumptions were used in determining the change in fair value of the ViralClear options for the year ended December 31, 2020:\nRisk-free interest rate 0.36% to 0.52%\nDividend yield 0%\nStock price volatility 125.16% to 126.03%\nExpected life 5 – 6 years\nWeighted average grant date fair value $ 4.51\nOn July 1, 2021, ViralClear issued 206,250 shares of its common stock in exchange for the cashless exercise of 550,000 options previously granted on October 16, 2019.\nOn June 30, 2021, in connection with the resignation of a member of the Company’s board of directors, the Company entered into a one-year consulting contract and\nextended the life of 25,000 previously issued director options from the contractual 90 days from termination of service to the earlier of the initial life or two years after\nservice contract completion. The change in estimated fair value of the modified options of $26,577 was charged to current period operations.\nThe following assumptions were used in determining the change in fair value of the modified options at June 30, 2021:\nRisk-free interest rate 0.07% - 0.46%\nDividend yield 0%\nStock price volatility 88.59%\nExpected life 1.25 - 3 years\nThe fair value of all options vesting during the years ended December 31, 2021 and 2020 of $146,083 and $5,873,376, respectively, was charged to current period\noperations. Unrecognized compensation expense of $182,604 at December 31, 2021 will be expensed in future periods.\nWarrants (ViralClear)\nThe following table presents information related to warrants (ViralClear) at December 31, 2021:\nExercise Number Expiration\nPrice Outstanding Date\n$ 5.00 473,772 November 2027\n10.00 6,575 May 2025\n480,347\nF-27\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nOn May 20, 2020, ViralClear issued warrants to purchase 6,575 shares of its common stock at $10.00 per share, expiring on May 20, 2025, for placement agent services in\nconnection with the sale of ViralClear’s common stock.\nRestricted stock units (ViralClear)\nThe following table summarizes the restricted stock activity for the two years ended December 31, 2021:\nRestricted shares outstanding at January 1, 2020: 40,000\nGranted 1,380,716\nRestricted shares outstanding at December 31, 2020: 1,420,716\nIssued (40,000)\nForfeited (62,037)\nTotal restricted shares outstanding at December 31, 2021: 1,318,679\nComprised of:\nVested restricted shares as of December 31, 2021 678,679\nUnvested restricted shares as of December 31, 2021 640,000\nTotal 1,318,679\nOn March 25, 2020, ViralClear granted an aggregate of 338,000 restricted stock units to two ViralClear board members for services vesting immediately.\nOn March 30, 2020, ViralClear granted an aggregate of 960,000 restricted stock units to ViralClear board members and employees for services with 320,000 vesting\nimmediately, and 640,000 vesting upon ViralClear meeting certain milestones.\nOn July 13, 2020, ViralClear granted 82,716 restricted stock units to a consultant for services with vesting monthly over one year from date of grant.\nStock based compensation expense related to restricted stock unit grants of ViralClear was $904,112 and $5,893,320 for the years ended December 31, 2021 and 2020,\nrespectively. As of December 31, 2021, the stock-based compensation relating to restricted stock of $186,047 remains unamortized.\nNOTE 10 – NON-CONTROLLING INTEREST\nOn November 7, 2018, the Company formed a subsidiary, now known as ViralClear, to pursue additional applications of the PURE EP™ signal processing technology\noutside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that showed potential for the\ntreatment of COVID-19. Since late 2020, ViralClear has been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing\ntechnology outside of cardiac electrophysiology.\nOn March 24, 2020, ViralClear entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Trek Therapeutics, PBC (“Trek”), a related party; an entity\ncontrolled by a member of the Company’s board of directors. Pursuant to the Asset Purchase Agreement, Trek sold to ViralClear all right, title and interest of Trek and its\naffiliates to certain assets (the “Purchased Assets”). As consideration for the Purchased Assets, ViralClear agreed to pay Trek in upfront and milestone payments a\ncombination of cash, shares of ViralClear’s common stock, which common stock may equal up to 10% of ViralClear’s outstanding equity, and sublicense fees in the event\nViralClear sublicenses the Purchased Assets. On March 30, 2020, pursuant to the Asset Purchase Agreement, ViralClear paid $350,000 in cash and issued 634,910 shares of\nViralClear’s common stock valued at $3,174,550 to Trek. In addition, in the event of sublicensing, sale, transfer, assignment or similar transaction, ViralClear agreed to pay\nTrek 10% of the consideration received.\nAs part of the Purchased Assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding certain formulas and\ncompounds usage. The agreement, as amended on September 2, 2020, calls for milestone payments upon marketing authorization (as defined) in any first and second\ncountry of $10 million and $5 million, respectively, in addition to 6% royalty payments.\nF-28\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nThe common stock issued, and cash paid was accounted for as acquired research and development.\nOn April 8, 2020, ViralClear entered into a know-how license agreement (the “Agreement”) with Mayo Foundation for Medical Education and Research (“Mayo”). In\nconnection with the Agreement, ViralClear issued to Mayo 259,959 shares of ViralClear’s common stock, par value $0.001 per share.\nOn May 20, 2020, ViralClear entered into securities purchase agreements with investors pursuant to which the Company issued 1,068,550 shares of its common stock for\naggregate proceeds of $10,592,075, net of $93,425 in expenses.\nIn November and December 2020, the Company issued an aggregate of 83,055 shares of its common stock in exchange for 80,958 previously issued shares of ViralClear\npursuant with 2019 purchase agreements.\nOn April 1, 2021, ViralClear issued an aggregate of 40,000 shares of its common stock in exchange for vested restricted stock units.\nOn July 1, 2021, ViralClear issued an aggregate of 206,250 shares of its common stock in exchange for the cashless exercise of 550,000 previously issued options.\nAs of December 31, 2021, the Company had a majority interest in ViralClear of 68.4%.\nA reconciliation of the ViralClear Pharmaceuticals, Inc. non-controlling loss attributable to the Company:\nNet loss attributable to the non-controlling interest for the year ended December 31, 2021 (000’s):\nNet loss $ (3,077)\nAverage Non-controlling interest percentage of profit/losses 30.44%\nNet loss attributable to the non-controlling interest $ (939)\nNet loss attributable to the non-controlling interest for the year ended December 31, 2020 (000’s):\nNet loss $ (28,372)\nAverage Non-controlling interest percentage of profit/losses 24.40%\nNet loss attributable to the non-controlling interest $ (6,922)\nThe following table summarizes the changes in non-controlling interest for the two years ended December 31, 2021 (000’s):\nBalance, January 1, 2020 $ 515\nAllocation of equity to non-controlling interest due to equity-based compensation issued 2,782\nAllocation of equity to non-controlling interest due to sale of common stock 3,468\nAllocation of equity to non-controlling interest due to issuance of equity to acquire Trek and research and development 983\nAllocation of equity from non-controlling interest due to parent reacquiring shares shareholders (24)\nNet loss attributable to non-controlling interest (6,922)\nBalance, December 31, 2020 802\nAllocation of equity to non-controlling interest due to equity-based compensation issued 348\nAllocation of equity to non-controlling interest to due change in fair value of modified option 8\nNet loss attributable to non-controlling interest (939)\nBalance, December 31, 2021 $ 219\nF-29\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nNOTE 11 — COMMITMENTS AND CONTINGENCIES\nOperating leases\nSee Note 5 for operating lease discussion\nLicensing agreements\n2017 Know-How License Agreement\nOn March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was\ngranted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording,\nelectrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale. The agreement expires in ten years from the effective date.\nThe Company is obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined.\nPatent and Know-How License Agreement – EP Software Agreement\nOn November 20, 2019, the Company entered into a patent and know-how license agreement (the “EP Software Agreement”) with Mayo Foundation for Medical Education\nand Research (“Mayo”). The EP Software Agreement grants to the Company an exclusive worldwide license, with the right to sublicense, within the field of\nelectrophysiology software and under certain patent rights as described in the EP Software Agreement (the “Patent Rights”), to make, have made, use, offer for sale, sell and\nimport licensed products and a non-exclusive license to the Company to use the research and development information, materials, technical data, unpatented inventions,\ntrade secrets, know-how and supportive information of Mayo to develop, make, have made, use, offer for sale, sell, and import licensed products. The EP Software\nAgreement will expire upon the later of either (a) the expiration of the Patent Rights or (b) the 10th anniversary of the date of the first commercial sale of a licensed product,\nunless earlier terminated by Mayo for the Company’s failure to cure a material breach of the EP Software Agreement, the Company’s or a sublicensee’s commencement of\nany action or proceedings against Mayo or its affiliates other than for an uncured material breach of the EP Software Agreement by Mayo, or insolvency of the Company.\nIn connection with the EP Software Agreement, the Company issued to Mayo an 8-year warrant (the “EP Software Warrant”) to purchase 284,455 shares of the Company’s\ncommon stock at an exercise price of $6.16. The EP Software Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective\nregistration statement registering or a current prospectus available for the resale of the shares underlying the EP Software Warrant. The Company agreed to pay Mayo an\nupfront consideration of $25,000. The Company also agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to\nthird parties and sublicense income received by the Company and to make milestone payments of up to $625,000 in aggregate.\nAmended and Restated Patent and Know-How License Agreement – Tools Agreement\nOn November 20, 2019, the Company entered into an amended and restated patent and know-how license agreement (the “Tools Agreement”) with Mayo. The Tools\nAgreement contains terms of license grant substantially identical to the EP Software Agreement, although it is for different patent rights and covers the field of\nelectrophysiology systems.\nIn connection with the Tools Agreement, the Company issued to Mayo an 8-year warrant (the “Tools Warrant”) to purchase 284,455 shares of the Company’s common stock\nat an exercise price of $6.16. The Tools Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration statement\nregistering or a current prospectus available for the resale of the shares underlying the Tools Warrant. The Company agreed to pay Mayo an upfront consideration of\n$100,000. The Company also agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to third parties and\nsublicense income received by the Company and to make milestone payments of up to $550,000 in aggregate. In June 2021, patent rights were issued (“Valid Claim”) as\ndefined whereby the Company paid milestone one of $75,000.\nF-30\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nViralClear Patent and Know-How License Agreement\nOn November 20, 2019, the Company’s majority-owned subsidiary, ViralClear, entered into a patent and know-how license agreement (the “ViralClear Agreement”) with\nMayo. The ViralClear Agreement contains terms of license grant substantially identical to the EP Software Agreement and the Tools Agreement, although it is for different\npatent rights and covers the field of stimulation and electroporation for hypotension/syncope management, renal and non-renal denervation for hypertension treatment, and\nfor use in treatment of arrhythmias in the autonomic nervous system.\nIn connection with the ViralClear Agreement, ViralClear issued to Mayo an 8-year warrant (the “ViralClear Warrant”) to purchase 473,772 shares of ViralClear’s common\nstock at an exercise price of $5.00 per share. The ViralClear Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration\nstatement registering or a current prospectus available for the resale of the shares underlying the ViralClear Warrant. ViralClear agreed to pay Mayo an upfront\nconsideration of $50,000. ViralClear also agreed to make earned royalty payments to Mayo in connection with ViralClear’s sales of the licensed products to third parties and\nsublicense income received by the Company and to make milestone payments of up to $700,000 in aggregate. In June 2021, patent rights were issued (“Valid Claim”) as\ndefined whereby the Company paid milestone one of $75,000.\nTrek Therapeutics, PBC\nIn the event of sublicensing, sale, transfer, assignment or similar transaction, ViralClear agreed to pay Trek 10% of the consideration received.\nAs part of the acquired assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding certain formulas and\ncompounds usage. The agreement calls for milestone payments upon marketing authorization (as amended and defined with respect of product in a particular jurisdiction in\nthe territory, the receipt of all approvals from the relevant regulatory authority necessary to market and sell such product in any such jurisdiction, excluding any pricing\napproval or reimbursement authorization) in any first and second country of $10 million and $5 million, respectively, in addition to 6% royalty payments.\nDefined Contribution Plan\nEffective January 1, 2019, the Company established a qualified defined contribution plan (the “401(k) Plan”) pursuant to Section 401(k) of the Code, whereby all eligible\nemployees may participate. Participants may elect to defer a percentage of their annual pretax compensation to the 401(k) plan, subject to defined limitations. The Company\nis required to make contributions to the 401(k) Plan equal to 3 percent of each participant’s eligible compensation, subject to limitations under the Code. For the year ended\nDecember 31, 2021 and 2020, the Company charged operations $252,452 and $170,317, respectively, for contributions under the 401(k) Plan.\nPurchase commitments\nAs of December 31, 2021, the Company had aggregate purchase commitments of approximately $1,443,398 for future services or products, some of which are subject to\nmodification or cancellations.\nLitigation\nAurigene Pharmaceutical Services LTD vs. ViralClear Pharmaceuticals Inc. and BioSig Technologies, Inc.\nOn January 8, 2021, Aurigene Pharmaceutical Services, LTD (“Aurigene”) filed a complaint with the United States District Court for the District of Connecticut claiming\nthe Company is in default of certain milestone payments for manufacturing and services under contracts dated June 23, 2020 and July 16, 2020 in aggregate amount of\n$1,530,000.\nOn September 23, 2021, the Company entered into a settlement agreement with Aurigene for a sum of $1,000,000 payable in three installments of $400,000, $300,000, and\n$300,000 on September 30, 2021, December 31, 2021 and March 31, 2022, respectively, with no admission or concession by either party. Balance due under the settlement\nis $600,000 as of December 31, 2021.\nIn connection with the settlement, the Company recognized $553,000 gain on settlement of debt in the current period operations as the full amount was previously accrued.\nF-31\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nThe Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or\nsettlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of\noperations or liquidity.\nNOTE 12 – SEGMENT REPORTING\nIn accordance with ASC 280-10, the Company reports segment information based on the “management” approach. The management approach designates the internal\nreporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has three reportable\nsegments: BioSig Technologies, Inc. (parent), NeuroClear Technologies, Inc. and ViralClear Pharmaceuticals, Inc.\nInformation concerning the operations of the Company’s reportable segments is as follows:\n2021 2020\nRevenues (from external customers)\nBioSig $ 441 $ -\nViralClear - -\nNeuroClear - -\n$ 441 $ -\nOperating Expenses\nBioSig $ 30,016 $ 30,756\nViralClear 3,630 28,387\nNeuroClear 7 41\n$ 33,653 $ 59,184\nIncome (loss) from operations\nBioSig $ (29,772) $ (30,727)\nViralClear (3,077) (28,372)\nNeuroClear (7) (41)\n$ (32,856) $ (59,140)\nTotal Assets\nBioSig $ 13,595 $ 24,764\nViralClear 1,924 5,622\nNeuroClear - -\n$ 15,519 $ 30,386\nNOTE 13 – RELATED PARTY TRANSACTIONS\nAccrued expenses related primarily to travel reimbursements, director fees and accrued compensation due related parties as of December 31, 2021 and 2020 was $86,208\nand $317,000, respectively.\nF-32\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nOn March 30, 2020, the Company’s subsidiary, ViralClear entered into an engagement agreement with Weild & Co, a FINRA-registered broker-dealer controlled by a\nmember of the Company’s board of directors to act as ViralClear’s non-exclusive agent to provide investment banking and financial advisory services to assist ViralClear in\na potential financing transaction for an initial term of 9 months.\nIn connection with the engagement agreement, ViralClear agreed to pay Weild & Co a 5% cash and a 5% warrant or other securities of the aggregate subscriptions placed by\nWeild & Co. No costs have been incurred as of the date of this filing. No cash or warrant fees have been paid under this agreement.\nAs described in Note 11, on March 24, 2020, ViralClear entered into the Asset Purchase Agreement with Trek Therapeutics, PBC, an entity controlled by a former member\nof the Company’s board of directors. Pursuant to the Asset Purchase Agreement, Trek sold to ViralClear all right, title and interest of Trek and its affiliates to certain assets.\nAs consideration for the Purchased Assets, ViralClear agreed to pay Trek in upfront and milestone payments a combination of cash, shares of ViralClear’s common stock.\nIn 2020, ViralClear issued an aggregate of 1,138,000 restricted stock units for shares in ViralClear’s common stock to board members and an officer.\nIn 2020, ViralClear granted an aggregate of 746,507 options to purchase ViralClear’s common stock to members of ViralClear’s board of directors.\nOn August 12, 2020, the Company cancelled the grant from March 31, 2020 to a board member for 50,000 options to purchase the Company’s common stock at an exercise\nprice of $3.73 and granted the board member 50,000 shares of common stock at a cost basis of $7.10 per share for his assistance with ViralClear. The granted shares vested\nimmediately.\nIn 2020, the Company issued an aggregate of 175,000 shares of the Company’s common stock, 100,000 restricted stock units and 675,000 options to purchase the\nCompany’s common stock to officers and directors.\nIn 2020, the Company issued an aggregate of 4,030 shares of the Company’s common stock to a board member and an officer for the cashless exercise of options.\nOn January 5, 2021, the Company issued an aggregate of 450,000 shares of common stock to officers of the Company as part of annual compensation.\nOn June 28, 2021, in connection with the departure of two board members, the Company extended for up to two years 125,000 and 50,000 previously granted options that\nwould normally expire 90 days after leaving service.\nOn June 30, 2021, in connection with the resignation of a board member, the Company entered into a one-year consulting contract and extended for up to two years from\nend of contract service: 240,000 previously granted Company options, 25,000 previously granted ViralClear options and 329,000 previously issued ViralClear restricted\nstock units; all of which would normally expire 90 days after leaving service. In addition, the Company accelerated to fully vested previously issued restricted stock units\nand issued 50,000 shares of the Company’s common stock in settlement.\nOn October 4, 2021, the Company granted a new board member 50,000 options to acquire the Company’s common stock at an exercise price of $2.89 for joining the\nCompany’s Board of Directors. The options are exercisable for ten years with half vested immediately and half on September 20, 2022.\nOn December 28, 2021, the Company granted an aggregate of 425,000 options to acquire the company’s common stock at an exercise price of $2.44 for ten years and\nvesting immediately to the Company’s existing Board of Directors as compensation for the 2021 year.\nDuring the years ended December 31, 2021 and 2020, the Company’s Chief Financial Officer guaranteed issued corporate credit cards for no consideration.\nF-33\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nNOTE 14 – INCOME TAXES\nAt December 31, 2021, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $116,000,000, expiring in the year\n2039, that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the\nopinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes\nin the Company’s ownership, the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in future\nyears based on an assessment of earnings sufficient to fully utilize these potential tax benefits. During the year ended December 31, 2021, the Company has increased the\nvaluation allowance by $6,470,000 from $24,700,000 to $31,170,000. We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related\nmeasurement model for uncertain tax positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in\na tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities.\nTax position that meet the more likely than not threshold is then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater\nthan 50% likely of being realized upon ultimate settlement. The Company had no tax positions relating to open income tax returns that were considered to be uncertain.\nThe Company is required to file income tax returns in the U.S. Federal various State jurisdictions. The Company is no longer subject to income tax examinations by tax\nauthorities for tax years ending before December 31, 2015.\nThe effective rate differs from the statutory rate of 21% as of December 31, 2021 and 2020 due to the following:\nDecember 31, December 31,\n2021 2020\nStatutory rate on pre-tax book loss 21.00% (21.00)%\nStock based compensation 0.0% 8.10%\nFair value of warrant to acquire research and development 0.0% 1.59%\nOther (1.3)% 0.03%\nValuation allowance (19.7)% 11.28%\n0.00% 0.00%\nThe Company’s deferred taxes as of December 31, 2021 and 2020 consist of the following:\nDecember 31, December 31,\n2021 2020\nNon-Current deferred tax asset:\nNet operating loss carry-forwards $ 24,308,000 $ 19,900,000\nStock based compensation 6,862,000 4,800,000\nValuation allowance (31,170,000) (24,700,000)\nNet non-current deferred tax asset $ - $ -\nF-34\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nNOTE 15 – FAIR VALUE MEASUREMENT\nThe Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the\nprice that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When\ndetermining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most\nadvantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk,\ntransfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and\nminimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:\nLevel 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.\nAll items required to be recorded or measured on a recurring basis are based upon level 3 inputs.\nTo the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In\ncertain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value\nhierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.\nThe carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term\nmaturity.\nAs of December 31, 2021, and 2020, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures.\nAs of December 31, 2021, and 2020, the Company did not have any derivative instruments that were designated as hedges.\nThere were no derivative and warrant liabilities as of December 31, 2021 and 2020.\nNOTE 16 – SUBSEQUENT EVENTS\nEquity financing:\nOn March 22, 2022, the Company closed a registered direct offering (the “Offering”) of an aggregate of 2,613,130 shares of our common stock, at an offering price of $1.15\nper share and (ii) warrants to purchase up to 2,613,130 shares of our common stock, at an exercise price of $1.40 per share, that will become exercisable six months after the\ndate of issuance and will expire three and one-half years following the date of issuance, for gross proceeds of approximately $3.0 million before the deduction of fees and\noffering expenses.\nThe common stock and warrants were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-251859) (the “Shelf Registration\nStatement”), previously filed with the SEC on December 31, 2020, and declared effective by the SEC on January 12, 2021, and a prospectus supplement, dated March 21,\n2022, to the Shelf Registration Statement, filed with the SEC on March 22, 2022.\nEquity transactions:\nOn January 3, 2022, the Company issued an aggregate of 75,000 shares of its common stock for services previously granted and accrued on December 29, 2021 valued at\n$167,250.\nOn January 4, 2022, the Company issued an aggregate of 53,749 shares of its common stock for previously issued vested restricted stock units.\nOn January 27, 2022, The Company issued an aggregate of 40,000 shares of its common stock for services valued at $72,800.\nF-35\nTable of Contents\nBIOSIG TECHNOLOGIES INC.\nNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\nDECEMBER 31, 2021\nOn February 1, 2022, the Company issued a 25,000 restricted stock unit to a consultant for services rendered with 12,500 shares vesting immediately and 12,500 shares\nvesting upon completion of certain milestones valued at $56,750. The vested shares of 12,500 were issued on February 1, 2022.\nOn February 15, 2022, the Company issued 12,500 shares of its common stock for a previously issued restricted stock units.\nOn February 7, 2022, the Company granted an aggregate of 250,000 options to purchase shares of its common stock to consultants. The options are exercisable at $1.72 per\nshare for ten years with (i) 100,000 options vesting in equal quarterly installments over one year, and (ii) 150,000 options vesting 50% at grant date and 50% upon milestone\nof $7 million revenue.\nOn February 17, 2022, the Company granted 30,000 options to purchase shares of its common stock to a consultant. The options are exercisable at $1.58 per share for ten\nyears vesting in equal quarterly installments over one year.\nOn February 17, 2022, the Company granted an aggregate of 36,000 options to purchase shares of its common stock to two employees. The options are exercisable at $1.58\nper share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments\nover the following two years.\nIn March 2022, the Company issued a 25,000 restricted stock unit to a consultant for services rendered. The restricted stock unit vests quarterly over one year and valued at\n$56,750.\nOn March 15, 2022, BioSig granted an aggregate of 70,000 options to purchase shares of its common stock to three employees. The options are exercisable at $1.28 per\nshare for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over\nthe following two years.\nOn March 21, 2022, the Company issued 50,000 shares of its common stock to an officer for services valued at $70,000.\nOn March 30, 2022, the Company granted 350,000 options to purchase shares of its common stock an employee. The options are exercisable at $1.30 per share for ten years\nwith one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two\nyears.\nF-36\nTable of Contents\nITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE\nNone.\nITEM 9A. CONTROLS AND PROCEDURES\nManagement’s evaluation of disclosure controls and procedures.\nOur management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and\nprocedures pursuant to Rule 13a-15(e) under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management recognizes that any\ncontrols and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the\ndesign of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the\nbenefits of possible controls and procedures relative to their costs.\nBased on management’s evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are designed at\na reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the\nExchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and\ncommunicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.\nManagement’s report on internal control over financial reporting.\nOur management is responsible for establishing and maintaining adequate internal control over financial reporting for our company. Internal control over financial\nreporting is defined in Rule 13a-15(f) and 15d-15(f) promulgated under the Exchange Act, as a process designed by, or under the supervision of, a company’s principal\nexecutive and principal financial officer and effected by the our board of directors, management and other personnel, to provide reasonable assurance regarding the\nreliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes\nthose policies and procedures that:\n(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;\n(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted\naccounting principles, and that receipts and expenditures of the company are being made in accordance with authorizations of management and directors of the\ncompany; and\n(3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a\nmaterial effect on the financial statements.\nBecause of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness\nto future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or\nprocedures may deteriorate. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of\nachieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible enhancements to controls and procedures.\nWe conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in Internal Control — Integrated Framework\n(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our principal executive officer and principal financial\nofficer conclude that, at December 31, 2021, our internal control over financial reporting was effective.\n56\nTable of Contents\nChanges in Internal Control over Financial Reporting\nThere were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2021, that have materially affected, or\nare reasonably likely to materially affect, our internal control over financial reporting.\nITEM 9B – OTHER INFORMATION\nNone.\nITEM 9C – DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS\nNot applicable.\n57\nTable of Contents\nPART III\nITEM 10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE\nThe information required by this item is incorporated by reference to the 2022 Proxy Statement to be filed within 120 days after the end of the year ended\nDecember 31, 2021.\nITEM 11 - EXECUTIVE COMPENSATION\nThe information required by this item is incorporated by reference to the 2022 Proxy Statement to be filed within 120 days after the end of the year ended\nDecember 31, 2021.\nITEM 12 – SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS\nThe information required by this item is incorporated by reference to the 2022 Proxy Statement to be filed within 120 days after the end of the year ended\nDecember 31, 2021.\nITEM 13 – CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE\nThe information required by this item is incorporated by reference to the 2022 Proxy Statement to be filed within 120 days after the end of the year ended\nDecember 31, 2021.\nITEM 14 – PRINCIPAL ACCOUNTING FEES AND SERVICES\nThe information required by this item is incorporated by reference to the 2022 Proxy Statement to be filed within 120 days after the end of the year ended\nDecember 31, 2021.\n58\nTable of Contents\nPART IV\nITEM 15 – EXHIBITS, FINANCIAL STATEMENT SCHEDULES\nThe following documents are filed as part of this report:\n(1) Financial Statements\nThe following financial statements are included herein:\nReport of Independent Registered Public Accounting Firm (PCAOB ID 711)\nConsolidated Balance Sheets as of December 31, 2021, and 2020\nConsolidated Statements of Operations for the years ended December 31, 2021, and 2020\nConsolidated Statement of Changes in Equity for the Years ended December 31, 2021 and 2020\nConsolidated Statements of Cash Flows for the years ended December 31, 2021, and 2020\nNotes to Consolidated Financial Statements\n(2) Financial Statement Schedules\nNone.\n(3) Exhibits\nExhibit No. Description\n3.1 Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form S-1 filed\non July 22, 2013)\n3.2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to\nExhibit 3.2 to the Form S-1 filed on July 22, 2013)\n3.3 Certificate of Second Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by\nreference to Exhibit 3.3 to the Form S-1 filed on July 22, 2013)\n3.4 Certificate of Third Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by\nreference to Exhibit 3.5 to the Form S-1/A filed on January 21, 2014)\n3.5 Certificate of Fourth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by\nreference to Exhibit 3.6 to the Form S-1/A filed on March 28, 2014)\n3.6 Certificate of Fifth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by\nreference to Exhibit 3.1 to the Form 8-K filed on August 21, 2014)\n3.7 Certificate of Sixth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by\nreference to Exhibit 3.1 to the Form 8-K filed on November 25, 2016)\n3.8 Certificate of Seventh Amendment to the Amended and Restated Certificate of BioSig Technologies, Inc. (incorporated by reference to Exhibit\n3.1 to the Form 8-K filed on September 10, 2018)\n3.9 Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit\n3.1 to the Form 8-K filed on November 9, 2017)\n3.10 Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit\n3.1 to the Form 8-K filed on February 16, 2018)\n3.11 Certificate of Designations of Series F Junior Participating Preferred Stock of BioSig Technologies, Inc. (incorporated by reference to Exhibit\n3.1 to the Form 8-K filed on July 17, 2020)\n3.12 Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to the Exhibit 3.1 to the Form 8-K filed on September\n27, 2019)\n3.13 Amendment No. 1 to Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K\nfiled on October 22, 2019)\n4.1* Description of Securities.\n59\nTable of Contents\n4.2 Form of Underwriter Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on February 24, 2020)\n4.3 Form of Underwriter Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on July 2, 2021)\n10.1+ BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form S-1 filed on July 22, 2013)\n10.2+ Form of Stock Option Agreement under the 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Form S-1 filed on July\n22, 2013)\n10.3+ Amendment No. 1 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.27 to the Form S-1/A\nfiled on March 28, 2014)\n10.4+ Form of Restricted Stock Award Agreement under the 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Form 8-K\nfiled on September 5, 2014)\n10.5+ Amendment No. 2 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the Form S-8 filed\non April 17, 2015)\n10.6+ Amendment No. 3 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.41 to the Form S-1\nfiled on May 20, 2015)\n10.7+ Amendment No. 4 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Form 8-K filed\non May 29, 2015)\n10.8+ Amendment No. 5 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed\non November 25, 2016)\n10.9 Form of Warrant used in connection with the April 30, 2018 private placement (incorporated by reference to Exhibit 10.2 to the Form 8-K filed\non May 1, 2018).\n10.10+ Amendment No. 6 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed\non July 30, 2018)\n10.11 Form of Series B Common Stock Purchase Warrant in connection with the July 30, 2018 private placement (incorporated by reference to\nExhibit 10.3 to the Form 8-K filed on August 16, 2018)\n10.12 Securities Purchase Agreement dated as of March 12, 2019, by and between BioSig Technologies, Inc. and certain purchasers set forth therein\n(incorporated by reference to Exhibit 10.1 to the Form 8-K filed on March 14, 2019)\n10.13 Form of Securities Purchase Agreement dated as of August 5, 2019, by and between NeuroClear Technologies, Inc. and certain purchasers set\nforth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on August 5, 2019)\n10.14 Form of Securities Purchase Agreement dated as of September 5, 2019, by and between NeuroClear Technologies, Inc. and certain purchasers\nset forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on September 5, 2019)\n10.15 Patent License Agreement, dated September 12, 2019, by and between Mayo Foundation for Medical Education and Research and BioSig\nTechnologies, Inc. (incorporated by reference to Exhibit 10.3 to the Form 10-Q filed on October 23, 2019)\n10.16 Form of Securities Purchase Agreement dated as of October 21, 2019, by and between NeuroClear Technologies, Inc. and certain purchasers set\nforth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on October 24, 2019)\n10.17+ Amendment No. 7 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed\non November 20, 2019)\n10.18 Form of Securities Purchase Agreement dated as of December 31, 2019, by and between BioSig Technologies, Inc. and certain purchasers set\nforth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on December 31, 2019)\n10.19 Common Stock Purchase Warrant of BioSig Technologies, Inc., dated November 20, 2019, issued to Mayo Foundation for Medical Education\nand Research (EP Software Warrant)\n10.20 Common Stock Purchase Warrant of BioSig Technologies, Inc., dated November 20, 2019, issued to Mayo Foundation for Medical Education\nand Research (Tools Warrant)\n10.21 Common Stock Purchase Warrant of NeuroClear Technologies, Inc., dated November 20, 2019, issued to Mayo Clinic Ventures\n10.22+ Amendment No. 8 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed\non June 30, 2020)\n10.23 Form of Securities Purchase Agreement dated June 24, 2020 by and between BioSig Technologies, Inc. and certain purchasers set forth therein\n(incorporated by reference to Exhibit 10.1 to the Form 8-K filed on June 26, 2020)\n10.24+ Ninth Amendment to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed\non June 29, 2021).\n60\nTable of Contents\n21.1 Subsidiary List of BioSig Technologies, Inc. (incorporated by reference to Exhibit 21.1 to the Form 10-K filed on March 15, 2021).\n23.1* Consent of Friedman LLP\n31.01* Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the\nSarbanes-Oxley Act of 2002.\n31.02* Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the\nSarbanes-Oxley Act of 2002.\n32.01** Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of\nthe Sarbanes-Oxley Act of 2002.\n101 INS* Inline XBRL Instance Document\n101 SCH* Inline XBRL Taxonomy Extension Schema Document\n101 CAL* Inline XBRL Taxonomy Calculation Linkbase Document\n101 LAB* Inline XBRL Taxonomy Labels Linkbase Document\n101 PRE* Inline XBRL Taxonomy Presentation Linkbase Document\n101 DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document\n104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n* Filed herewith.\n** Furnished herewith.\n+ Indicates a management contract or compensatory plan.\nITEM 16 – FORM 10-K SUMMARY\nNone.\n61\nTable of Contents\nSIGNATURES\nIn accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\nBIOSIG TECHNOLOGIES, INC.\nDate: March 31, 2022 By: /s/ KENNETH L. LONDONER\nKenneth L. Londoner\nChief Executive Officer and Executive Chairman (Principal Executive\nOfficer)\nDate: March 31, 2022 By: /s/ STEVEN CHAUSSY\nSteven Chaussy\nChief Financial Officer (Principal Financial Officer and Principal\nAccounting Officer)\nPursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the\ncapacities and on the dates indicated.\nName Position Date\n/s/ DONALD E. FOLEY Director March 31, 2022\nDonald E. Foley\n/s/ PATRICK J. GALLAGHER Director March 31, 2022\nPatrick J. Gallagher\n/s/ JAMES BARRY PhD Director March 31, 2022\nJames Barry, PhD\n/s/ ANTHONY ZOOK Director March 31, 2022\nAnthony Zook\n/s/ DAVID WEILD IV Director March 31, 2022\nDavid Weild IV\n/s/ SAMUEL E. NAVARRO Director March 31, 2022\nSamuel E. Navarro\n62\n(cid:0)(cid:3)\n(cid:0)( (cid:0); (cid:0)+ (cid:0), (cid:0)% (cid:0), (cid:0)7 (cid:0)(cid:3)(cid:0)(cid:23) (cid:0)(cid:17)(cid:0)(cid:20)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)( (cid:0)6 (cid:0)& (cid:0)5 (cid:0), (cid:0)3 (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)& (cid:0)8 (cid:0)5 (cid:0), (cid:0)7 (cid:0), (cid:0)( (cid:0)6 (cid:0)(cid:3)(cid:0)5 (cid:0)( (cid:0)* (cid:0), (cid:0)6 (cid:0)7 (cid:0)( (cid:0)5 (cid:0)( (cid:0)’ (cid:0)(cid:3)(cid:0)3 (cid:0)8 (cid:0)5 (cid:0)6 (cid:0)8 (cid:0)$ (cid:0)1 (cid:0)7 (cid:0)(cid:3)(cid:0)7 (cid:0)2 (cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)& (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)7 (cid:0)+ (cid:0)( (cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)& (cid:0)8 (cid:0)5 (cid:0), (cid:0)7 (cid:0), (cid:0)( (cid:0)6 (cid:0)(cid:3)(cid:0)( (cid:0); (cid:0)& (cid:0)+ (cid:0)$ (cid:0)1 (cid:0)* (cid:0)( (cid:0)(cid:3)(cid:0)$ (cid:0)& (cid:0)7 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:23)\n(cid:0)(cid:3)\n(cid:0)$ (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)6 (cid:0)L(cid:0)J (cid:0)(cid:3)(cid:0)7 (cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)O(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U (cid:0)S (cid:0)R (cid:0)U (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)‡ (cid:0)Z (cid:0)H (cid:0)(cid:15)(cid:0)· (cid:0)(cid:3)(cid:0)‡ (cid:0)R (cid:0)X (cid:0)U (cid:0)· (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)‡ (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)· (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:19) (cid:0)(cid:17)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H\n(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U (cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)I(cid:0)R (cid:0)U(cid:0)H (cid:0)J (cid:0)R (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)V (cid:0)F (cid:0)U (cid:0)L(cid:0)S (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)D (cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)P (cid:0)P (cid:0)D (cid:0)U (cid:0)\\ (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)T (cid:0)X (cid:0)D (cid:0)O(cid:0)L(cid:0)I(cid:0)L(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3) (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)U(cid:0)H (cid:0)W(cid:0)\\ (cid:0)(cid:3) (cid:0)E (cid:0)\\ (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)R (cid:0)X (cid:0)U (cid:0)(cid:3) (cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)F (cid:0)H (cid:0)U (cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)F (cid:0)R (cid:0)U (cid:0)S (cid:0)R (cid:0)U (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)D (cid:0)V\n(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)‡ (cid:0)$ (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U (cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)R (cid:0)U (cid:0)S (cid:0)R (cid:0)U (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)· (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:16)(cid:0)O(cid:0)D (cid:0)Z (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)‡ (cid:0)% (cid:0)\\ (cid:0)(cid:16)(cid:0)O(cid:0)D (cid:0)Z (cid:0)V (cid:0)· (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)X (cid:0)U (cid:0)U(cid:0)H (cid:0)Q (cid:0)W(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)S (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W(cid:0)V\n(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U (cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)R (cid:0)U (cid:0)S (cid:0)R (cid:0)U (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)L(cid:0)Q (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)$ (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U (cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)D (cid:0)S (cid:0)L(cid:0)W(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N\n(cid:0)(cid:3)\n(cid:0): (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)S (cid:0)L(cid:0)W(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:19) (cid:0)(cid:17)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)‡ (cid:0)E (cid:0)O(cid:0)D (cid:0)Q (cid:0)N (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)H (cid:0)F (cid:0)N (cid:0)· (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:25) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)% (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)&\n(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:23) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)’ (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)( (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)) (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:17)\n(cid:0)$ (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:28) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:23) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:24) (cid:0)(cid:28) (cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:24) (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)% (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)’ (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)( (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0))\n(cid:0)- (cid:0)X (cid:0)Q (cid:0)L(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)3 (cid:0)D (cid:0)U(cid:0)W(cid:0)L(cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G\n(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Y (cid:0)D (cid:0)L(cid:0)O(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)U(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)O(cid:0)L(cid:0)F (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)D (cid:0)Z (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U\n(cid:0)V (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)8 (cid:0)Q (cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)R (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)H (cid:0)N (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)D (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)& (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)W(cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)+ (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R\n(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)D (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)F (cid:0)O(cid:0)D (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)J (cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Y (cid:0)D (cid:0)L(cid:0)O(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)S (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:17)(cid:0)(cid:3)(cid:0): (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)\n(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)W(cid:0)L(cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)U(cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)( (cid:0)Y (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)I(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)W(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)W(cid:0)X (cid:0)U(cid:0)H\n(cid:0)G (cid:0)L(cid:0)V (cid:0)S (cid:0)R (cid:0)V (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)U(cid:0)H (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)S (cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)W(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)U(cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)\n(cid:0)F (cid:0)D (cid:0)S (cid:0)L(cid:0)W(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)( (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)L(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)[ (cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)H (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)L(cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V\n(cid:0)F (cid:0)X (cid:0)P (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)R (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)J (cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)I(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)W(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)O(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V\n(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)P (cid:0)D (cid:0)L(cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)P (cid:0)L(cid:0)Q (cid:0)R (cid:0)U(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)H (cid:0)O(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)M(cid:0)R (cid:0)U(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)L(cid:0)U(cid:0)P (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)Z (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)D (cid:0)Z (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)+ (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)S (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)F (cid:0)U(cid:0)L(cid:0)S (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)G (cid:0)H (cid:0)P (cid:0)S (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)Q (cid:0)N (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)6 (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)T (cid:0)X (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)V (cid:0)R (cid:0)O(cid:0)X (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)D (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)H (cid:0)W(cid:0)V\n(cid:0)O(cid:0)H (cid:0)J (cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Y (cid:0)D (cid:0)L(cid:0)O(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)L(cid:0)E (cid:0)X (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)E (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)$ (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)% (cid:0)\\ (cid:0)(cid:16)(cid:0)O(cid:0)D (cid:0)Z (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)O(cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)I(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)7 (cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)I(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)I(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)H (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)G (cid:0)U(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:25) (cid:0)(cid:28) (cid:0)(cid:3)(cid:0)( (cid:0)D (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)8 (cid:0)Q (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)% (cid:0)O(cid:0)Y (cid:0)G (cid:0)(cid:17)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)6 (cid:0)X (cid:0)L(cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:20) (cid:0)(cid:23) (cid:0)(cid:15)\n(cid:0)6 (cid:0)D (cid:0)O(cid:0)W(cid:0)(cid:3)(cid:0)/ (cid:0)D (cid:0)N (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)8 (cid:0)7 (cid:0)(cid:3)(cid:0)(cid:27) (cid:0)(cid:23) (cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)2 (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0)D (cid:0)V (cid:0)G (cid:0)D (cid:0)T (cid:0)(cid:3)(cid:0)& (cid:0)D (cid:0)S (cid:0)L(cid:0)W(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)N (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)\\ (cid:0)P (cid:0)E (cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)‡ (cid:0)% (cid:0)6 (cid:0)* (cid:0)0 (cid:0)(cid:17)(cid:0)·\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)3 (cid:0)U (cid:0)H (cid:0)I(cid:0)H (cid:0)U (cid:0)U (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)F (cid:0)U(cid:0)L(cid:0)E (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)D (cid:0)Z (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)U(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)U(cid:0)R (cid:0)P (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H\n(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)P (cid:0)R (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)V (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3) (cid:0)( (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)V (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3) (cid:0)V (cid:0)K (cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3) (cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)Q (cid:0)X (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)Y (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)S (cid:0)R (cid:0)Z (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:15)\n(cid:0)T (cid:0)X (cid:0)D (cid:0)O(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)Y (cid:0)L(cid:0)O(cid:0)H (cid:0)J (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:15)\n(cid:0)O(cid:0)L(cid:0)T (cid:0)X (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)S (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0),(cid:0)V (cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:18)(cid:0)R (cid:0)U\n(cid:0)O(cid:0)L(cid:0)T (cid:0)X (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)Q (cid:0)L(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)O(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)6 (cid:0)H (cid:0)U (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U (cid:0)H (cid:0)I(cid:0)H (cid:0)U (cid:0)U (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N\n(cid:0)(cid:3)\n(cid:0)( (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)Q (cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)(cid:28) (cid:0)(cid:8) (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)H (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)8 (cid:0)Q (cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G\n(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)U(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)D (cid:0)W(cid:0)L(cid:0)V (cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:16)(cid:0)L(cid:0)Q (cid:0)(cid:16)(cid:0)N (cid:0)L(cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:17)\n(cid:0)6 (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)F (cid:0)X (cid:0)P (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)S (cid:0)D (cid:0)\\ (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3) (cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)Q (cid:0)F (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:17)(cid:0)(cid:3) (cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)V (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)& (cid:0)(cid:3) (cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3) (cid:0)Z (cid:0)H (cid:0)U(cid:0)H\n(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:26) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)$ (cid:0)X (cid:0)J (cid:0)X (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:23) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)F (cid:0)U(cid:0)L(cid:0)S (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)I(cid:0)O(cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0),(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:11)(cid:0)L(cid:0)(cid:12) (cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)R (cid:0)X (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)O(cid:0)L(cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)K\n(cid:0)(cid:3)\n(cid:0)W(cid:0)U(cid:0)D (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)O(cid:0)L(cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:15)\n(cid:0)(cid:3)\n(cid:0)(cid:11)(cid:0)L(cid:0)L(cid:0)(cid:12) (cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)O(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)O(cid:0)L(cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V\n(cid:0)(cid:3)\n(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)O(cid:0)H (cid:0)Q (cid:0)G (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)\\ (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)O(cid:0)L(cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:15)\n(cid:0)(cid:3)\n(cid:0)(cid:11)(cid:0)L(cid:0)L(cid:0)L(cid:0)(cid:12) (cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Y (cid:0)D (cid:0)L(cid:0)O(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)X (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)U(cid:0)Y (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G\n(cid:0)(cid:3)\n(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)\n(cid:0)(cid:3)\n(cid:0)(cid:11)(cid:0)L(cid:0)Y (cid:0)(cid:12) (cid:0)Z (cid:0)H (cid:0)(cid:3) (cid:0)I(cid:0)D (cid:0)L(cid:0)O(cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)R (cid:0)E (cid:0)V (cid:0)H (cid:0)U(cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)S (cid:0)H (cid:0)U(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)Q (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)Z (cid:0)D (cid:0)U(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)\\ (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)Z (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)E (cid:0)U(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3) (cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3) (cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H\n(cid:0)V (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)F (cid:0)K (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)U(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)Y (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)O(cid:0)D (cid:0)F (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)(cid:3)\n(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)O(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)U(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)O(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)U(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)X (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19)\n(cid:0)F (cid:0)D (cid:0)O(cid:0)H (cid:0)Q (cid:0)G (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)\\ (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)Z (cid:0)U(cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)O(cid:0)L(cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:15)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)Y (cid:0)(cid:12) (cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)Y (cid:0)L(cid:0)(cid:12) (cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)Q (cid:0)N (cid:0)U(cid:0)X (cid:0)S (cid:0)W(cid:0)F (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)P (cid:0)L(cid:0)O(cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)U(cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)M(cid:0)X (cid:0)G (cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U\n(cid:0)(cid:3)\n(cid:0)(cid:11)(cid:0)Y (cid:0)L(cid:0)L(cid:0)(cid:12) (cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)M(cid:0)X (cid:0)G (cid:0)J (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)E (cid:0)L(cid:0)W(cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)D (cid:0)L(cid:0)Q (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)J (cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)M(cid:0)X (cid:0)G (cid:0)J (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)P (cid:0)D (cid:0)L(cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)Y (cid:0)D (cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)E (cid:0)R (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)U\n(cid:0)(cid:3) (cid:0)X (cid:0)Q (cid:0)V (cid:0)W(cid:0)D (cid:0)\\ (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:23) (cid:0)(cid:24) (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)O(cid:0)H (cid:0)Q (cid:0)G (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)\\ (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)G (cid:0)H (cid:0)H (cid:0)P (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)L(cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)&\n(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)J (cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)L(cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)L(cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:8) (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0),(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)T (cid:0)X (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)D (cid:0)L(cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)T (cid:0)X (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)H\n(cid:0)S (cid:0)O(cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)U(cid:0)X (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)S (cid:0)D (cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)H (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)U(cid:0)D (cid:0)Q (cid:0)N (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)Q (cid:0)L(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O\n(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)V (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)$ (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)R (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)Q (cid:0)X (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U\n(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:21) (cid:0)(cid:17)(cid:0)(cid:21) (cid:0)(cid:26) (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)U(cid:0)V (cid:0)K (cid:0)L(cid:0)S (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)F (cid:0)U(cid:0)L(cid:0)E (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)O(cid:0)R (cid:0)Z (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)D (cid:0)W(cid:0)F (cid:0)K (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)W(cid:0)L(cid:0)(cid:16)\n(cid:0)G (cid:0)L(cid:0)O(cid:0)X (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)W(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:16)(cid:0)O(cid:0)L(cid:0)Q (cid:0)N (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)F (cid:0)K (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:21) (cid:0)(cid:17)(cid:0)(cid:21) (cid:0)(cid:26) (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U\n(cid:0)F (cid:0)X (cid:0)V (cid:0)W(cid:0)R (cid:0)P (cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)W(cid:0)L(cid:0)(cid:16)(cid:0)G (cid:0)L(cid:0)O(cid:0)X (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)W(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0),(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:16)(cid:0)O(cid:0)L(cid:0)Q (cid:0)N (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)Y (cid:0)R (cid:0)U(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)&\n(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)H (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)Y (cid:0)D (cid:0)O(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:16)(cid:0)O(cid:0)L(cid:0)Q (cid:0)N (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)\n(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)H (cid:0)P (cid:0)S (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)J (cid:0)H (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:16)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G\n(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)U(cid:0)V (cid:0)K (cid:0)L(cid:0)S (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)U(cid:0)V (cid:0)K (cid:0)L(cid:0)S (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)(cid:23) (cid:0)(cid:17)(cid:0)(cid:28) (cid:0)(cid:28) (cid:0)(cid:8) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)O(cid:0)O(cid:0)R (cid:0)Z (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:17)(cid:0)(cid:28) (cid:0)(cid:28) (cid:0)(cid:8) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)O(cid:0)O(cid:0)R (cid:0)Z (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U\n(cid:0)H (cid:0)[ (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)H (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)U(cid:0)V (cid:0)K (cid:0)L(cid:0)S (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)L(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:16)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Q (cid:0)X (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)O(cid:0)F (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)I(cid:0)I(cid:0)H (cid:0)U(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:17)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)W\n(cid:0)O(cid:0)H (cid:0)D (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)(cid:25) (cid:0)(cid:26) (cid:0)(cid:8) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)L(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)X (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)L(cid:0)L(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U\n(cid:0)G (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)Q (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\\n(cid:0)F (cid:0)O(cid:0)D (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)U(cid:0)D (cid:0)Q (cid:0)N (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)Q (cid:0)L(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)Z (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)L(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)G (cid:0)H (cid:0)P (cid:0)S (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)L(cid:0)E (cid:0)X (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)H (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)T (cid:0)X (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)H (cid:0)O(cid:0)D (cid:0)Z (cid:0)D (cid:0)U (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)Q (cid:0)W(cid:0)L(cid:0)(cid:16)(cid:0)7 (cid:0)D (cid:0)N (cid:0)H (cid:0)R (cid:0)Y (cid:0)H (cid:0)U (cid:0)(cid:3)(cid:0)/ (cid:0)D (cid:0)Z (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)3 (cid:0)U (cid:0)R (cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U (cid:0)(cid:3)(cid:0)$ (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U (cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0), (cid:0)Q (cid:0)F (cid:0)R (cid:0)U (cid:0)S (cid:0)R (cid:0)U (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)% (cid:0)\\ (cid:0)(cid:16)(cid:0)O(cid:0)D (cid:0)Z (cid:0)V\n(cid:0)(cid:3)\n(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:22) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)O(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)* (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)D (cid:0)Z (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)J (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)E (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)W(cid:0)Z (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q\n(cid:0)W(cid:0)K (cid:0)U(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)F (cid:0)D (cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:1)(cid:148) (cid:0)S (cid:0)U(cid:0)L(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)H (cid:0)L(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)E (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U\n(cid:0)(cid:3)\n(cid:0)E (cid:0)H (cid:0)F (cid:0)R (cid:0)P (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:1)(cid:148) (cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)X (cid:0)P (cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)F (cid:0)R (cid:0)P (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)D (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)(cid:27) (cid:0)(cid:24) (cid:0)(cid:8) (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)V (cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\\n(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)P (cid:0)S (cid:0)O(cid:0)R (cid:0)\\ (cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)S (cid:0)O(cid:0)D (cid:0)Q (cid:0)V (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)R (cid:0)U\n(cid:0)(cid:3)\n(cid:1)(cid:148) (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)H (cid:0)T (cid:0)X (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)P (cid:0)E (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)E (cid:0)\\ (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)E (cid:0)\\ (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)I(cid:0)I(cid:0)L(cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)D\n(cid:0)(cid:3)\n(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)¶(cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)H (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)D (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)(cid:25) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:18)(cid:0)(cid:22) (cid:0)(cid:8) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)‡ (cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)E (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)· (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)W(cid:0)Z (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W\n(cid:0)P (cid:0)D (cid:0)M(cid:0)R (cid:0)U(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)L(cid:0)G (cid:0)L(cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)R (cid:0)I(cid:0)(cid:29)(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)U(cid:0)J (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)V (cid:0)D (cid:0)O(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)U(cid:0)W(cid:0)J (cid:0)D (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)I(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)S (cid:0)R (cid:0)V (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)V (cid:0)R (cid:0)O(cid:0)X (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)D (cid:0)V (cid:0)V (cid:0)H (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)J (cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:8) (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)H (cid:0)L(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)J (cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)H (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)J (cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)W(cid:0)H\n(cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)I(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:30)(cid:0)(cid:3) (cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)Z (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)F (cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)R (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3) (cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)U(cid:0)V (cid:0)K (cid:0)L(cid:0)S (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)F (cid:0)O(cid:0)D (cid:0)V (cid:0)V (cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)V (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H\n(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)L(cid:0)G (cid:0)L(cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)L(cid:0)S (cid:0)W(cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)H (cid:0)I(cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)R (cid:0)D (cid:0)Q (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)J (cid:0)X (cid:0)D (cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)H (cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)H (cid:0)I(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)G\n(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)L(cid:0)G (cid:0)L(cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0),(cid:0)Q (cid:0)(cid:3) (cid:0)J (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:22) (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)(cid:3) (cid:0)‡ (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)· (cid:0)(cid:3) (cid:0)D (cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)E (cid:0)H (cid:0)Q (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3) (cid:0)R (cid:0)Z (cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:8) (cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)P (cid:0)R (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)X (cid:0)W(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)Y (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H\n(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)L(cid:0)O(cid:0)L(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)O(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)‡ (cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)U(cid:0)· (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)U(cid:0)R (cid:0)D (cid:0)G (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W\n(cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)X (cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)L(cid:0)O(cid:0)L(cid:0)D (cid:0)W(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)R (cid:0)F (cid:0)L(cid:0)D (cid:0)W(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)H (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)P (cid:0)P (cid:0)H (cid:0)G (cid:0)L(cid:0)D (cid:0)W(cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)V (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)U(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)Z (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\\n(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)S (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)S (cid:0)R (cid:0)V (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)U(cid:0)L(cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:22) (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)O(cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)Q (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:22) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)’ (cid:0)H (cid:0)O(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)* (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)D (cid:0)Z (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)D (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)K (cid:0)H (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\\n(cid:0)P (cid:0)R (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)2 (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)$ (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)% (cid:0)\\ (cid:0)(cid:16)(cid:0)O(cid:0)D (cid:0)Z (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:22) (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:22) (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)O(cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)U(cid:0)J (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)D (cid:0)N (cid:0)H (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)W(cid:0)H (cid:0)P (cid:0)S (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)R (cid:0)X (cid:0)U(cid:0)D (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)W(cid:0)H (cid:0)P (cid:0)S (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H\n(cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)X (cid:0)Q (cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)L(cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)R (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)Y (cid:0)D (cid:0)L(cid:0)O(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)3 (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)$ (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)% (cid:0)\\ (cid:0)(cid:16)(cid:0)O(cid:0)D (cid:0)Z (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)O(cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)R (cid:0)X (cid:0)U(cid:0)D (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)Y (cid:0)R (cid:0)O(cid:0)Y (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)R (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q\n(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3) (cid:0)P (cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)Z (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)H (cid:0)P (cid:0)L(cid:0)X (cid:0)P (cid:0)(cid:3) (cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)L(cid:0)U(cid:0)(cid:3) (cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)V (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)X (cid:0)U\n(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)Z (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)H (cid:0)P (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)L(cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)I(cid:0)R (cid:0)U(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)P (cid:0)R (cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U\n(cid:0)$ (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)% (cid:0)\\ (cid:0)(cid:16)(cid:0)O(cid:0)D (cid:0)Z (cid:0)V (cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:1)(cid:148) (cid:0)G (cid:0)R (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)X (cid:0)P (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)I(cid:0)R (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)R (cid:0)Z (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)M(cid:0)R (cid:0)U(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)H (cid:0)O(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)(cid:3)\n(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)H (cid:0)O(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)O(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)\\ (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)R (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:12)(cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:1)(cid:148) (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)H (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)O(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)L(cid:0)U(cid:0)P (cid:0)D (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)F (cid:0)U(cid:0)H (cid:0)W(cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:1)(cid:148) (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)R (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)V (cid:0)K (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)S (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U\n(cid:0)(cid:3)\n(cid:0)P (cid:0)H (cid:0)H (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)P (cid:0)X (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)O(cid:0)\\ (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0), (cid:0)Q (cid:0)G (cid:0)H (cid:0)P (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)’ (cid:0)L(cid:0)U (cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U (cid:0)V\n(cid:0)(cid:3)\n(cid:0)3 (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:23) (cid:0)(cid:24) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)O(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)* (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)D (cid:0)Z (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)R (cid:0)Z (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)H (cid:0)P (cid:0)Q (cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)D (cid:0)L(cid:0)Q (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)M(cid:0)X (cid:0)G (cid:0)J (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)\n(cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)W(cid:0)W(cid:0)O(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)X (cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Q (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)U(cid:0)G (cid:0)(cid:16)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)U(cid:0)L(cid:0)Y (cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)D (cid:0)L(cid:0)Q (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)X (cid:0)D (cid:0)O(cid:0)O(cid:0)\\\n(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)W(cid:0)W(cid:0)O(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)U(cid:0)L(cid:0)Y (cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)J (cid:0)R (cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)Q (cid:0)H (cid:0)U\n(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)O(cid:0)L(cid:0)H (cid:0)Y (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)S (cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)U(cid:0)L(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)H (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)G (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)O(cid:0)L(cid:0)H (cid:0)Y (cid:0)H\n(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)X (cid:0)D (cid:0)O(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)O(cid:0)D (cid:0)Z (cid:0)I(cid:0)X (cid:0)O(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)6 (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:1)(cid:148) (cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)M(cid:0)R (cid:0)U(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)R (cid:0)U(cid:0)X (cid:0)P (cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:1)(cid:148) (cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)M(cid:0)R (cid:0)U(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)R (cid:0)U(cid:0)X (cid:0)P\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:1)(cid:148) (cid:0)L(cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)H (cid:0)S (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)J (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)V (cid:0)H (cid:0)O(cid:0)(cid:30)(cid:0)(cid:3)(cid:0)R (cid:0)U\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:1)(cid:148) (cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)M(cid:0)R (cid:0)U(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)H (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)R (cid:0)U(cid:0)X (cid:0)P (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0): (cid:0)L(cid:0)W(cid:0)K (cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)X (cid:0)U(cid:0)W(cid:0)(cid:3) (cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)D (cid:0)O(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)K (cid:0)R (cid:0)Z (cid:0)H (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)Q (cid:0)R (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)G (cid:0)H (cid:0)P (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3) (cid:0)E (cid:0)H (cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)U(cid:0)L(cid:0)Y (cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)G (cid:0)M(cid:0)X (cid:0)G (cid:0)J (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)O(cid:0)L(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H\n(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)O(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)* (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)D (cid:0)Z (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)H (cid:0)P (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)I(cid:0)X (cid:0)O(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)U(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)Z (cid:0)L(cid:0)V (cid:0)H\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)U(cid:0)L(cid:0)Y (cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)U(cid:0)G (cid:0)(cid:16)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)O(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)* (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)D (cid:0)Z (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)H (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)X (cid:0)D (cid:0)O(cid:0)V (cid:0)¶(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)O(cid:0)W(cid:0)L(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)L(cid:0)Y (cid:0)L(cid:0)G (cid:0)X (cid:0)D (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)H (cid:0)P (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)H (cid:0)G (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)8 (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)O(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)* (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)D (cid:0)Z (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)H (cid:0)P (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)D (cid:0)Z (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)Q (cid:0)(cid:16)(cid:0)H (cid:0)[ (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R\n(cid:0)S (cid:0)X (cid:0)E (cid:0)O(cid:0)L(cid:0)F (cid:0)(cid:3)(cid:0)S (cid:0)R (cid:0)O(cid:0)L(cid:0)F (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)H (cid:0)P (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)\\ (cid:0)R (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)D (cid:0)Z (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Y (cid:0)R (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)H (cid:0)G\n(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)Z (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)/ (cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)3 (cid:0)H (cid:0)U (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)’ (cid:0)L(cid:0)U (cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U (cid:0)V\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)’ (cid:0)H (cid:0)O(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)* (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)/ (cid:0)D (cid:0)Z (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)O(cid:0)L(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)D\n(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)H (cid:0)W(cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)P (cid:0)D (cid:0)J (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)E (cid:0)U(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)G (cid:0)X (cid:0)F (cid:0)L(cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)+ (cid:0)R (cid:0)Z (cid:0)H (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)2 (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)$ (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)F (cid:0)N (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)H (cid:0)W(cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)P (cid:0)D (cid:0)J (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U\n(cid:0)E (cid:0)U(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)G (cid:0)X (cid:0)F (cid:0)L(cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)O(cid:0)O(cid:0)H (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)O(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)* (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)D (cid:0)Z (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)V (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)3 (cid:0)R (cid:0)V (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0), (cid:0)Q (cid:0)G (cid:0)H (cid:0)P (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U (cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V\n(cid:0)(cid:3)\n(cid:0),(cid:0)Q (cid:0)V (cid:0)R (cid:0)I(cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)H (cid:0)P (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)L(cid:0)V (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)O(cid:0)L(cid:0)Q (cid:0)J\n(cid:0)X (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)L(cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)V (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)L(cid:0)Q (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)H (cid:0)P (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)D (cid:0)L(cid:0)Q (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)E (cid:0)O(cid:0)L(cid:0)F (cid:0)(cid:3)(cid:0)S (cid:0)R (cid:0)O(cid:0)L(cid:0)F (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)I(cid:0)R (cid:0)U(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)H (cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)F (cid:0)H (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)( (cid:0); (cid:0)+ (cid:0), (cid:0)% (cid:0), (cid:0)7 (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:17)(cid:0)(cid:20)\n(cid:0)(cid:3)\n(cid:0)& (cid:0)2 (cid:0)1 (cid:0)6 (cid:0)( (cid:0)1 (cid:0)7 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0), (cid:0)1 (cid:0)’ (cid:0)( (cid:0)3 (cid:0)( (cid:0)1 (cid:0)’ (cid:0)( (cid:0)1 (cid:0)7 (cid:0)(cid:3)(cid:0)5 (cid:0)( (cid:0)* (cid:0), (cid:0)6 (cid:0)7 (cid:0)( (cid:0)5 (cid:0)( (cid:0)’ (cid:0)(cid:3)(cid:0)3 (cid:0)8 (cid:0)% (cid:0)/ (cid:0), (cid:0)& (cid:0)(cid:3)(cid:0)$ (cid:0)& (cid:0)& (cid:0)2 (cid:0)8 (cid:0)1 (cid:0)7 (cid:0), (cid:0)1 (cid:0)* (cid:0)(cid:3)(cid:0)) (cid:0), (cid:0)5 (cid:0)0\n(cid:0)(cid:3)\n(cid:0): (cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)R (cid:0)U(cid:0)S (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)I(cid:0)H (cid:0)U(cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)6 (cid:0)(cid:16)(cid:0)(cid:22) (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)) (cid:0)L(cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0)R (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:16)(cid:0)(cid:21) (cid:0)(cid:24) (cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:24) (cid:0)(cid:28) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:16)(cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:23) (cid:0)(cid:23) (cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:16)(cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:25) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:16)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:23) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:16)(cid:0)(cid:21) (cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:24) (cid:0)(cid:27) (cid:0)(cid:22)\n(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:16)(cid:0)(cid:21) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:21) (cid:0)(cid:28) (cid:0)(cid:27) (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)6 (cid:0)(cid:16)(cid:0)(cid:27) (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)) (cid:0)L(cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0)R (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:16)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:27) (cid:0)(cid:27) (cid:0)(cid:19) (cid:0)(cid:26) (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)6 (cid:0)L(cid:0)J (cid:0)(cid:3)(cid:0)7 (cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U\n(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)F (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:20) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)H (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)2 (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)O(cid:0)D (cid:0)Q (cid:0)D (cid:0)W(cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)D (cid:0)J (cid:0)U(cid:0)D (cid:0)S (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)L(cid:0)V (cid:0)W(cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)W(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)X (cid:0)E (cid:0)W\n(cid:0)F (cid:0)R (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)J (cid:0)R (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)Q (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0)) (cid:0)U (cid:0)L(cid:0)H (cid:0)G (cid:0)P (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)/ (cid:0)3\n(cid:0)(cid:3)\n(cid:0)0 (cid:0)D (cid:0)U(cid:0)O(cid:0)W(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)1 (cid:0)H (cid:0)Z (cid:0)(cid:3)(cid:0)- (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)\\ (cid:0)(cid:3)\n(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:21)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)( (cid:0); (cid:0)+ (cid:0), (cid:0)% (cid:0), (cid:0)7 (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)(cid:19) (cid:0)(cid:20)\n(cid:0)(cid:3)\n(cid:0)& (cid:0)( (cid:0)5 (cid:0)7 (cid:0), (cid:0)) (cid:0), (cid:0)& (cid:0)$ (cid:0)7 (cid:0), (cid:0)2 (cid:0)1\n(cid:0)(cid:3)\n(cid:0),(cid:0)(cid:15)(cid:0)(cid:3)(cid:0). (cid:0)H (cid:0)Q (cid:0)Q (cid:0)H (cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)/ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)/ (cid:0)R (cid:0)Q (cid:0)G (cid:0)R (cid:0)Q (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:20) (cid:0)(cid:17) (cid:0),(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)H (cid:0)Z (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)6 (cid:0)L(cid:0)J (cid:0)(cid:3)(cid:0)7 (cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)(cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:17) (cid:0)% (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)W(cid:0)U(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)P (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)N (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V\n(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)L(cid:0)U(cid:0)F (cid:0)X (cid:0)P (cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)L(cid:0)V (cid:0)O(cid:0)H (cid:0)D (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:22) (cid:0)(cid:17) (cid:0)% (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O\n(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)O(cid:0)R (cid:0)Z (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:23) (cid:0)(cid:17) (cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0),(cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)R (cid:0)Q (cid:0)V (cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)L(cid:0)V (cid:0)K (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)L(cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W\n(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)H (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)G (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)H (cid:0)(cid:12)(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)G (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12) (cid:0)’ (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)S (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R\n(cid:0)H (cid:0)Q (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)L(cid:0)G (cid:0)L(cid:0)D (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)R (cid:0)V (cid:0)H\n(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)L(cid:0)F (cid:0)X (cid:0)O(cid:0)D (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)S (cid:0)D (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)E (cid:0)(cid:12) (cid:0)’ (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U\n(cid:0)V (cid:0)X (cid:0)S (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)U(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)L(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)S (cid:0)D (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U\n(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)S (cid:0)R (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)J (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)F (cid:0)(cid:12) (cid:0)( (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)G (cid:0)(cid:12) (cid:0)’ (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)F (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)X (cid:0)U(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R\n(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:24) (cid:0)(cid:17) (cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0),(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V\n(cid:0)D (cid:0)X (cid:0)G (cid:0)L(cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)G (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)Y (cid:0)D (cid:0)O(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)Q (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:12)(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12) (cid:0)$ (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)F (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)D (cid:0)N (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H\n(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)P (cid:0)P (cid:0)D (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)E (cid:0)(cid:12) (cid:0)$ (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)U(cid:0)D (cid:0)X (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)H (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)Y (cid:0)R (cid:0)O(cid:0)Y (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)P (cid:0)S (cid:0)O(cid:0)R (cid:0)\\ (cid:0)H (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)R (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V\n(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:29)(cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:21) (cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0). (cid:0)( (cid:0)1 (cid:0)1 (cid:0)( (cid:0)7 (cid:0)+ (cid:0)(cid:3)(cid:0)/ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)/ (cid:0)2 (cid:0)1 (cid:0)’ (cid:0)2 (cid:0)1 (cid:0)( (cid:0)5 (cid:0)(cid:3)\n(cid:0). (cid:0)H (cid:0)Q (cid:0)Q (cid:0)H (cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)/ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)/ (cid:0)R (cid:0)Q (cid:0)G (cid:0)R (cid:0)Q (cid:0)H (cid:0)U (cid:0)(cid:3)\n(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U (cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)( (cid:0); (cid:0)+ (cid:0), (cid:0)% (cid:0), (cid:0)7 (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)(cid:19) (cid:0)(cid:21)\n(cid:0)(cid:3)\n(cid:0)& (cid:0)( (cid:0)5 (cid:0)7 (cid:0), (cid:0)) (cid:0), (cid:0)& (cid:0)$ (cid:0)7 (cid:0), (cid:0)2 (cid:0)1\n(cid:0)(cid:3)\n(cid:0),(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)D (cid:0)X (cid:0)V (cid:0)V (cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:20) (cid:0)(cid:17) (cid:0),(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)H (cid:0)Z (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)6 (cid:0)L(cid:0)J (cid:0)(cid:3)(cid:0)7 (cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)(cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:17) (cid:0)% (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)W(cid:0)U(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)P (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)N (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V\n(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)L(cid:0)U(cid:0)F (cid:0)X (cid:0)P (cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)L(cid:0)V (cid:0)O(cid:0)H (cid:0)D (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:22) (cid:0)(cid:17) (cid:0)% (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O\n(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)O(cid:0)R (cid:0)Z (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:23) (cid:0)(cid:17) (cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0),(cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)R (cid:0)Q (cid:0)V (cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)L(cid:0)V (cid:0)K (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)L(cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W\n(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)H (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)G (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)H (cid:0)(cid:12)(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)G (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12) (cid:0)’ (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)S (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R\n(cid:0)H (cid:0)Q (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)L(cid:0)G (cid:0)L(cid:0)D (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)R (cid:0)V (cid:0)H\n(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)L(cid:0)F (cid:0)X (cid:0)O(cid:0)D (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)S (cid:0)D (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)E (cid:0)(cid:12) (cid:0)’ (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U\n(cid:0)V (cid:0)X (cid:0)S (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)U(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)L(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)S (cid:0)D (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U\n(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)S (cid:0)R (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)J (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:30)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)F (cid:0)(cid:12) (cid:0)( (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)G (cid:0)(cid:12) (cid:0)’ (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)F (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)X (cid:0)U(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R\n(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:24) (cid:0)(cid:17) (cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0),(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V\n(cid:0)D (cid:0)X (cid:0)G (cid:0)L(cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)G (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)R (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)Y (cid:0)D (cid:0)O(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)Q (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:12)(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12) (cid:0)$ (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)F (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)D (cid:0)N (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H\n(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)P (cid:0)P (cid:0)D (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)E (cid:0)(cid:12) (cid:0)$ (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)U(cid:0)D (cid:0)X (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)H (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)Y (cid:0)R (cid:0)O(cid:0)Y (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)P (cid:0)S (cid:0)O(cid:0)R (cid:0)\\ (cid:0)H (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)R (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V\n(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:29)(cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:21) (cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0)6 (cid:0)7 (cid:0)( (cid:0)9 (cid:0)( (cid:0)1 (cid:0)(cid:3)(cid:0)& (cid:0)+ (cid:0)$ (cid:0)8 (cid:0)6 (cid:0)6 (cid:0)< (cid:0)(cid:3)\n(cid:0)6 (cid:0)W(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)D (cid:0)X (cid:0)V (cid:0)V (cid:0)\\ (cid:0)(cid:3)\n(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U (cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)( (cid:0); (cid:0)+ (cid:0), (cid:0)% (cid:0), (cid:0)7 (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:21) (cid:0)(cid:17)(cid:0)(cid:19) (cid:0)(cid:20)\n(cid:0)(cid:3)\n(cid:0)& (cid:0)( (cid:0)5 (cid:0)7 (cid:0), (cid:0)) (cid:0), (cid:0)& (cid:0)$ (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)6 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)& (cid:0)+ (cid:0), (cid:0)( (cid:0)) (cid:0)(cid:3)(cid:0)( (cid:0); (cid:0)( (cid:0)& (cid:0)8 (cid:0)7 (cid:0), (cid:0)9 (cid:0)( (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)) (cid:0), (cid:0)& (cid:0)( (cid:0)5 (cid:0)(cid:3)(cid:0)$ (cid:0)1 (cid:0)’ (cid:0)(cid:3)(cid:0)& (cid:0)+ (cid:0), (cid:0)( (cid:0)) (cid:0)(cid:3)(cid:0)) (cid:0), (cid:0)1 (cid:0)$ (cid:0)1 (cid:0)& (cid:0), (cid:0)$ (cid:0)/ (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)) (cid:0), (cid:0)& (cid:0)( (cid:0)5\n(cid:0)3 (cid:0)8 (cid:0)5 (cid:0)6 (cid:0)8 (cid:0)$ (cid:0)1 (cid:0)7 (cid:0)(cid:3)(cid:0)7 (cid:0)2\n(cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:3)(cid:0)8 (cid:0)(cid:17)(cid:0)6 (cid:0)(cid:17)(cid:0)& (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)& (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:15)\n(cid:0)$ (cid:0)6 (cid:0)(cid:3)(cid:0)$ (cid:0)’ (cid:0)2 (cid:0)3 (cid:0)7 (cid:0)( (cid:0)’ (cid:0)(cid:3)(cid:0)3 (cid:0)8 (cid:0)5 (cid:0)6 (cid:0)8 (cid:0)$ (cid:0)1 (cid:0)7 (cid:0)(cid:3)(cid:0)7 (cid:0)2\n(cid:0)6 (cid:0)( (cid:0)& (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)7 (cid:0)+ (cid:0)( (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)5 (cid:0)% (cid:0)$ (cid:0)1 (cid:0)( (cid:0)6 (cid:0)(cid:16)(cid:0)2 (cid:0); (cid:0)/ (cid:0)( (cid:0)< (cid:0)(cid:3)(cid:0)$ (cid:0)& (cid:0)7 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21)\n(cid:0)(cid:3)\n(cid:0),(cid:0)(cid:15)(cid:0)(cid:3)(cid:0). (cid:0)H (cid:0)Q (cid:0)Q (cid:0)H (cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)/ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)/ (cid:0)R (cid:0)Q (cid:0)G (cid:0)R (cid:0)Q (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:3)(cid:0)8 (cid:0)(cid:17)(cid:0)6 (cid:0)(cid:17)(cid:0)& (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)R (cid:0)S (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)D (cid:0)U(cid:0)E (cid:0)D (cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:16)(cid:0)2 (cid:0)[ (cid:0)O(cid:0)H (cid:0)\\ (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)6 (cid:0)L(cid:0)J (cid:0)(cid:3)(cid:0)7 (cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)F (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:20) (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)O(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)G (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V\n(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)6 (cid:0)L(cid:0)J (cid:0)(cid:3)(cid:0)7 (cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)% (cid:0)\\ (cid:0)(cid:29) (cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0). (cid:0)( (cid:0)1 (cid:0)1 (cid:0)( (cid:0)7 (cid:0)+ (cid:0)(cid:3)(cid:0)/ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)/ (cid:0)2 (cid:0)1 (cid:0)’ (cid:0)2 (cid:0)1 (cid:0)( (cid:0)5\n(cid:0)’ (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:29)(cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:21) (cid:0)1 (cid:0)D (cid:0)P (cid:0)H (cid:0)(cid:29) (cid:0). (cid:0)H (cid:0)Q (cid:0)Q (cid:0)H (cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)/ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)/ (cid:0)R (cid:0)Q (cid:0)G (cid:0)R (cid:0)Q (cid:0)H (cid:0)U\n(cid:0)(cid:3) (cid:0)7 (cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)(cid:29) (cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U\n(cid:0)(cid:3)\n(cid:0),(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)D (cid:0)X (cid:0)V (cid:0)V (cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:3)(cid:0)8 (cid:0)(cid:17)(cid:0)6 (cid:0)(cid:17)(cid:0)& (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)R (cid:0)S (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)D (cid:0)U(cid:0)E (cid:0)D (cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:16)(cid:0)2 (cid:0)[ (cid:0)O(cid:0)H (cid:0)\\ (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)% (cid:0)L(cid:0)R (cid:0)6 (cid:0)L(cid:0)J (cid:0)(cid:3)(cid:0)7 (cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)F (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:20) (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)O(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)G (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V\n(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)6 (cid:0)L(cid:0)J (cid:0)(cid:3)(cid:0)7 (cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)% (cid:0)\\ (cid:0)(cid:29) (cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0)6 (cid:0)7 (cid:0)( (cid:0)9 (cid:0)( (cid:0)1 (cid:0)(cid:3)(cid:0)& (cid:0)+ (cid:0)$ (cid:0)8 (cid:0)6 (cid:0)6 (cid:0)<\n(cid:0)’ (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:29)(cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:21) (cid:0)1 (cid:0)D (cid:0)P (cid:0)H (cid:0)(cid:29) (cid:0)6 (cid:0)W(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)D (cid:0)X (cid:0)V (cid:0)V (cid:0)\\\n(cid:0)(cid:3) (cid:0)7 (cid:0)L(cid:0)W(cid:0)O(cid:0)H (cid:0)(cid:29) (cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)"
        }
      ]
    },
    {
      "section_name": "Investor Presentation",
      "links": [
        {
          "title": "Download",
          "url": "https://d1io3yog0oux5.cloudfront.net/_e03c9e0dc1d812508ee764d49a549930/biosigtech/db/338/3217/pdf/Corporate+Presentation_Feb+7+2024_for+website+%28pdf%29.pdf",
          "content": "Corporate Presentation\nFebruary 2024 | Nasdaq: BSGM\nBioSig Forward-Looking Statements\nThis presentation contains forward-looking statements including statements that address activities, events, or developments that BioSig\nexpects, believes, or anticipates will or may occur in the future, such as predictions of financial performance, approvals, and launches by\nBioSig of new products, market acceptance of BioSig’s products, market and procedure projections, financing plans, and related\ndocuments. Forward-looking statements are based on BioSig’s experience and perception of current conditions, trends, expected future\ndevelopments, and other factors it believes are appropriate under the circumstances and are subject to numerous risks and\nuncertainties, many of which are beyond BioSig’s control.\nThese risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products,\nBioSig’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances\nand approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and\ntrain doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing\nBioSig’s products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products\nand procedures or BioSig’s ability to effectively react to other risks and uncertainties described from time to time in BioSig’s SEC filings,\nsuch as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government\nregulation, negative publicity, current worldwide economic conditions, and share price volatility.\nBioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless\nrequired by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future\nevents, or otherwise.\n2\nReimagining What’s Possible\nin Cardiac Care\nWe are a medical technology company focused\non deciphering and animating the body’s\nelectrical signals, starting with heart rhythms.\n3\nThe Market Dynamics\nCurrent market Procedural need\n33.5M people worldwide live with atrial Better intracardiac signal quality could lead\nfibrillation. Medicines, widely prescribed, to improved success rates and ablation\nare not curative and have side effects. efficacy. Poor signal quality leads to more\nThere’s an unmet need for alternative time in expensive EP labs. More precise\ntreatments, like catheter ablations. signals are needed to diagnose and treat\narrhythmias.\nCost Escalation Cost-saving solution\n$7B is invested by hospitals each year on Our strategy is to deliver superior signal\ncapital equipment and high-cost catheters. quality and contribute to greater\nThe cost of delivering high-quality care to procedural efficacy. Our subscription\npatients requires doing more with less—\nmodel removes the burden of ownership\nincreasing pressure on physicians to find\nand maintenance for hospitals.\nways to improve procedural workflow.\n1. Chudzik, R., Distel, D., Stoneman, L., Thording, L. Why Hospital Leaders Should Look to Cardiology for Sustained Future Reprocessing Savings. (2018, April 25). Innovative Health.\nhttps://blog.innovative-health.com/blog/why-hospital-leaders-should-look-to-cardiology-for-sustained-future-reprocessing-savings.\n4\nThe Consequence of Poor Signals\nLab Noise and Poor Signal Clarity\nPoor signal quality\n• Despite the important progress that has been made in the\ndiagnosis and treatment of cardiac arrhythmias over the last\n35 years, noise from the lab environment substantially\ninterferes with the conventional system’s ability to process\nand visualize intracardiac signals – resulting in blind spots\nand loss of relevant data.\nRising cost of care\nThe Toll of Inefficiency\n• Signal weakness can introduce misleading information,\ncontributing to greater time spent in expensive lab environments.\nInefficiencies\nMore stress on patient and physician.\n5\nOur Solution\nWith the PURE EP Platform, we preserve the\nvalue of cardiac signals and deliver clear,\nactionable insights for today’s Electrophysiologists.\n6\nPreserving Full-Spectrum Signal Insights with PURE EP\nConventional signal pathway\nPartial\nsignal display\nVariable Analog\nInstrumental High-pass Low-pass Notch Fixed gain\ngain digital\namplifier filter filter Filter amplifier\namplifier converter\nCatheters\nLoss of information through hardware-based process\nPURE EP signal pathway Full-spectrum\nsignal insights\nInstrumentation Anti-aliasing Analog digital\namplifier filter converter\nCatheters\nPURE EP MSU PURE EP software\n7\nCardiac Signal Insights with Unprecedented Clarity & Precision\nConventional system\n8\nSource:BioSigSpotlightCases\nClinical Data Supports Faster Diagnosis & Economic Value\nPURE EP 2.0 STUDY PURE 2.0 SUB - STUDY\nImproved Workflow, Time Cost Savings*\nSignal Clarity & Relevance*\nTo determine the difference in procedural times when\nIn a multi-center, randomized prospective study,\ncomparing ablations guided by PURE EP ’s\nPURE EP ’s signals were compared to conventional\nelectrocardiogram (EGM) visualization to the\nrecording and mapping systems signals:\nconventional system:\nof PURE EP signals rated superior in quality\n75% PURE EP led to a mean procedure time reduction of:\n11.3\nminutes\nof the time, physicians were more confident in\ndifferentiating signal components with\n83%\nGiven that the mean cost of operating room time is\nPURE EP\napproximately $37 per minute3, PURE EP\ndemonstrated potential cost savings of approximately:\nof the time, PURE EP produced superior, small,\n$418.10\nper procedure\n73% fractionated signals of clinical significance\n1. Chudzik, R., Al-Ahmad A, Knight B, Tzou W, et al.Evaluation of a novel cardiac signal processing system for electrophysiology procedures: the PURE EP 2.0. study. J Cardiovasc Electrophysiol. 2021;32(11):2915-\n2922. Epub 2021 Oct 1. DOI: 10.1111/jce.15250\n2. Gallinghouse, G. Joseph; Natale, Andrea; Al-Ahmad, Amin; Della Roca, Domenico Giovanni; Jones, Sterling; Firmstone, Samantha; Lewen, Jason. (2022). Time of Redo Atrial Fibrillation Ablation Procedures with 9\nPURE EP Recording System for ECG/EGM Visualization: A Randomized Study. Paper presented atAPHRS 2022 Singapore: The 15thAPHRS Scientific Session [PP-069-2-AF (55)]. Identifier:NCT04964440\n3. Chudzik, R., Distel, D., Stoneman, L., Thording, L. Why Hospital Leaders Should Look to Cardiology for Sustained Future Reprocessing Savings. (2018, April 25). Innovative Health. https://blog.innovative-\nhealth.com/blog/why-hospital-leaders-should-look-to-cardiology-for-sustained-future-reprocessing-savings\nClinical Data Supporting Procedural Accuracy & Ablation Time\nAbstract 1 Abstract 2 Abstract 3\nUnipolar Signal Feasibility of Unipolar Comparison of Unipolar\nModification-Guided Signal Guided Ablation in Electrogram Monitoring\nRadiofrequency Ablation Creating Contiguous during Radiofrequency\nLines of Conduction Ablation in Viable and\nBlock: A Proof-of- Ablated Myocardium:\nConcept Study Loss of the S-component\nReduced time of Maintained accuracy Enhanced precision in\nablation by 2/3 in lesion lesion placement\nwith real-time, tissue- spacing to successfully by differentiating between\nspecific feedback vs. block arrhythmia-causing healthy and scarred\nCleveland Clinic researchers\nsurrogate markers electrical impulses tissue\npresented 3 abstracts at HRS 2023\nfeaturing our PURE EP Platform\nvs. the conventional Ablation Index\n1. Yavin, H. D., Wazni, O. M.,Tabaja, C.,Koch, Z.,Younis, A.,Hussein, A. A., Nakagawa, H., Santangeli, P., Saliba, W. I.,Esposito-Tanaka, C., Bhargava, M., Sroubek, J.(May 2023).Unipolar Signal\nModification-Guided Radiofrequency Ablation.Heart Rhythm 2023, New Orleans, LA. https://doi.org/10.1016/j.hrthm.2023.03.576\n2. Esposito-Tanaka, C.,Wazni, O. M., Koch, Z.,Younis, A., Santangeli, P., Tabaja, C., Sroubek, J., Yavin, H. D.(May 2023).Feasibility of Unipolar Signal Guided Ablation in Creating Contiguous Lines of\n10\nConduction Block: A Proof-of-Concept Study. Heart Rhythm 2023, New Orleans, LA. PO-03-037.https://doi.org/10.1016/j.hrthm.2023.03.985\n3. Yavin, H. D., Koch, Z.,Younis, A.,Santangeli, P. Tabaja, C.,Sroubek, J., Esposito-Tanaka, C.,Wazni, O. M.Calibri).Comparison of Unipolar Electrogram Monitoring during Radiofrequency Ablation in\nViable and Ablated Myocardium: Loss of the S-component.Heart Rhythm 2023, New Orleans, LA.https://doi.org/10.1016/j.hrthm.2023.03.576\nIntegrating into EP Labs for Improved Efficiency\n11\nHaving high-quality, better signals makes a\ndifference in almost every case. Since we installed\nthe system in our lab, the efficiency in which we\noperate has significantly improved.\n~Dhanunjaya DJ Lakkireddy, MD\nKansas City Heart Rhythm Institute, Overland Park, KS\nComplex AF Case Study Utilizing a New Standard in Signal Processing\nPURE EP — Commercial History\nVersion 7 Software Subscription Model Reimbursement Code Market Release +\nRelease Early Adoption Implementation Distribution Partnership\n• Impactful clinical\n• Tiered pricing model • Implementation of • NFT rollout\nsoftware\ncurrent CPT code for • Supportive Clinical\n• Revenue generation\n• 20 mins of time savings* use during ablations data\nfor hospital\n• Near Field Tracking • Adds to procedure • Continued Product\n• First customer sales\n(NFT) Algorithm revenues Upgrades\n• 66% reduction in (RF)\n• Secure distribution\nablation time\npartnership.\nAUGUST 2023 NOVEMBER 2023 DECEMBER 2023 JANUARY 2024\n*Estimated\n13\nPURE EP - New Novel Software Features\nAutomatic Tachycardia Characterization (ATC)\nNear Field Tracking is a unique algorithm for\nAlerts electrophysiologists to heart conduction patterns\nassessing lesion efficiency and increases my\nthat may be difficult to detect with the naked eye or that\nprocedural efficiency and confidence . . .\nmight warrant further evaluation.\nThis revolutionary feature has become a\ncritical tool during all my complex cases.\nNear Field Tracking (NFT)\nMonitors changes in the local unipolar electrogram to\nprovide real-time tissue feedback that assists Hicham El Masry,\nMD, FHRS, Cardiac Electrophysiologist\nelectrophysiologists as they make their final\nMayo Clinic Arizona\ndeterminations between healthy and scarred tissue for\nlesion placement during an ablation.\n14\nA Strong, Well-Protected Patent Portfolio\n100+\n35 30 35+\nPatents\nIssued and Issued Patent\nallowed utility design & applications\ngranted/allowed/\npatents utility patents pending\npending\n15\nProprietary & Confidential\nGrowing into an Expanding Global Market\n14.4 million Catheter ablation EP labs\nAmericans suffer is fast becoming a are growing\nfrom cardiac first-line therapy to meet demand\narrhythmias\nAtrial Fibrillation is Global ablation Estimated:\n$1.6\nthe most common procedures:\narrhythmia affecting: ~3,425 EP labs in\nbillion\n~1.5 million in 2022\nU.S.\n~6.1 million people in ~8.4% CAGR\nthe U.S. and growing\ntotal global\n~3,915 EP labs\nComplex ablation\naddressable market\n~33.5 million people outside the U.S.\nprocedures:\nworldwide\n~13.5% projected\nCAGR\nSource: MarketWatch Global Electrophysiology Device Market Could Exceed $12.2 Billion By 2026. Definitive Healthcare, U.S. News & World Report, Newsweek, and BioSig estimates\n16\nLeading with Strong Industry Experience\nKen Londoner Steve Buhaly Fred Hrkac\nFounder, Chairman, Chief Financial Officer Executive Vice President,\nChief Executive Officer, Director\nDirector\nEndicott Management Qorvo; Longview Fibre; Biosense Webster; Boston\nPartners; J & W Seligman Planar System Scientific\n& Co.; Visiting Professor,\nColumbia University\n17\nWhy BioSig Now?\nDisruptive and novel technology Flexible pricing model\nOur technology saves procedural time and improves Supports recurring revenue and continuous\nworkflow efficiency in an environment where the innovation.\ntechnology has not changed meaningfully in 25+ years.\nSubstantial and growing global market Reimbursement\nGlobal EP market is growing by 11.2% and expected to Addition of CPT code for physician and hospital\nreach $16B by 2028. reimbursement.\nStrong clinical data pipeline Well-protected IP portfolio\nPublished/ongoing clinical studies supporting 100+ Worldwide fundamental patents\ncommercialization. granted/allowed.\nShift to Distribution Partnership\nNew focus on sourcing distribution partner(s) to support the\nsales & distribution of PURE EP .\nSource: Global Market Insights Inc. March 08, 2022\n18\nContact us\nAndy Ballou\nVP of Investor Relations aballou@biosigtech.com\n203-409-5444, x133\nBioSig Technologies, Inc.\n55 Greens Farms Road\nWestport, CT 06880\nwww.biosig.com\n19"
        }
      ]
    }
  ]
}